Maladie,Sponsor,Statut,Titre,URL
Lung Cancer,Information provided by AstraZeneca (Responsible Party),Active,Study Details | NCT05817110 | Validating Artificial Intelligence Effectiveness Defined Lung Nodule Malignancy Score in Patients With Pulmonary Nodule. | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT05817110?cond=Lung%20Cancer&viewType=Card&page=1&rank=1
Lung Cancer,"Information provided by University Health Network, Toronto",Terminated,Study Details | NCT00188656 | Computed Tomography (CT) in Head and Neck Patients | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00188656?cond=Lung%20Cancer&viewType=Card&page=1&rank=2
Lung Cancer,"Information provided by Tingting Li, Shanghai Chest Hospital (Responsible Party)",Recruiting,Study Details | NCT07117539 | Impact of Different Lung Isolation Devices on Pharyngolaryngeal Injuries After Pulmonary Resection | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT07117539?cond=Lung%20Cancer&viewType=Card&page=1&rank=3
Lung Cancer,"Information provided by Fatma Alzahraa, Ain Shams University (Responsible Party)",Completed,Study Details | NCT06479798 | Accuracy of Convex Probe EBUS-TBNA Versus FDG,https://clinicaltrials.gov/study/NCT06479798?cond=Lung%20Cancer&viewType=Card&page=1&rank=4
Lung Cancer,Information provided by City of Hope Medical Center (Responsible Party),Completed,Study Details | NCT02345798 | Video,https://clinicaltrials.gov/study/NCT02345798?cond=Lung%20Cancer&viewType=Card&page=1&rank=5
Lung Cancer,"Information provided by Oncology Specialties, Alabama",Terminated,Study Details | NCT00232128 | Protocol for Radiofrequency Ablation of Pulmonary Neoplasms | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00232128?cond=Lung%20Cancer&viewType=Card&page=1&rank=6
Lung Cancer,Information provided by University Hospitals Bristol and Weston NHS Foundation Trust (Responsible Party),Completed,Study Details | NCT01621698 | Study of Use of Paravertebral Blocks for Pain Relief in Video Assisted Lung Surgery | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01621698?cond=Lung%20Cancer&viewType=Card&page=1&rank=7
Lung Cancer,Information provided by University Hospital Southampton NHS Foundation Trust (Responsible Party),Recruiting,Study Details | NCT02013063 | Single Pulmonary Nodule Investigation | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02013063?cond=Lung%20Cancer&viewType=Card&page=1&rank=8
Lung Cancer,Information provided by Universitaire Ziekenhuizen KU Leuven (Responsible Party),Completed,Study Details | NCT01451359 | Endobronchial Valves in Persistent Air Leak | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01451359?cond=Lung%20Cancer&viewType=Card&page=1&rank=9
Lung Cancer,"Information provided by Hecheng Li M.D., Ph.D, Ruijin Hospital (Responsible Party)",Recruiting,Study Details | NCT03010033 | Effect of Pulmonary Rehabilitation on Perioperative Outcomes in Smoker Patients With Lung Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03010033?cond=Lung%20Cancer&viewType=Card&page=1&rank=10
Lung Cancer,"Information provided by Hecheng Li M.D., Ph.D, Ruijin Hospital (Responsible Party)",Completed,Study Details | NCT03134534 | Robot,https://clinicaltrials.gov/study/NCT03134534?cond=Lung%20Cancer&viewType=Card&page=2&rank=11
Lung Cancer,"Information provided by Ethicon, Inc. (Responsible Party)",Completed,Study Results | NCT04889989 | Microwave Ablation in Chinese Patients With Lung Tumors | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT04889989?cond=Lung%20Cancer&viewType=Card&page=2&rank=12&tab=results
Lung Cancer,"Information provided by Ethicon, Inc. (Responsible Party)",Terminated,Study Details | NCT04889989 | Microwave Ablation in Chinese Patients With Lung Tumors | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT04889989?cond=Lung%20Cancer&viewType=Card&page=2&rank=12
Lung Cancer,"Information provided by Shahbaz Ahmad, University of Lahore (Responsible Party)",Recruiting,"Study Details | NCT05118347 | Effects of Buteyko Breathing Technique Versus Incentive Spirometer on Breath Holding Time, Cardiopulmonary Endurance and Quality of Life in Patients With Post Lung Tumor Resection | ClinicalTrials.gov",https://clinicaltrials.gov/study/NCT05118347?cond=Lung%20Cancer&viewType=Card&page=2&rank=13
Lung Cancer,Information provided by National Taiwan University Hospital (Responsible Party),Completed,Study Details | NCT03881410 | The Efficacy of Shear-wave Elastography,https://clinicaltrials.gov/study/NCT03881410?cond=Lung%20Cancer&viewType=Card&page=2&rank=14
Lung Cancer,Information provided by Japan Clinical Oncology Group,Completed,Study Details | NCT00128037 | Trial of Pre,https://clinicaltrials.gov/study/NCT00128037?cond=Lung%20Cancer&viewType=Card&page=2&rank=15
Lung Cancer,"Information provided by Fuda Cancer Hospital, Guangzhou (Responsible Party)",Completed,Study Details | NCT02430597 | Irreversible Electroporation(IRE) For Unresectable Hilus Pulmonis Neoplasms | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02430597?cond=Lung%20Cancer&viewType=Card&page=2&rank=16
Lung Cancer,Information provided by Hopital Foch (Responsible Party),Completed,Study Details | NCT02853188 | Measure of Plasma Tissue Factor to Predict a Venous Thromboembolism in Primitive Cancer of Lung | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02853188?cond=Lung%20Cancer&viewType=Card&page=2&rank=17
Lung Cancer,Information provided by Dacima Consulting (Responsible Party),Recruiting,Study Details | NCT06934499 | Tunisian Lung Cancer Study | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT06934499?cond=Lung%20Cancer&viewType=Card&page=2&rank=18
Lung Cancer,Information provided by Affiliated Cancer Hospital & Institute of Guangzhou Medical University (Responsible Party),Recruiting,Study Details | NCT06531850 | Prospective Study of Serum Marker LncRNA RP5,https://clinicaltrials.gov/study/NCT06531850?cond=Lung%20Cancer&viewType=Card&page=2&rank=19
Lung Cancer,Information provided by Region Stockholm (Responsible Party),Recruiting,Study Details | NCT06322329 | RealMove (Lung): Assessing Tumour Motion With Dynamic MRI | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT06322329?cond=Lung%20Cancer&viewType=Card&page=2&rank=20
Lung Cancer,"Information provided by Michel Chalhoub, Northwell Health (Responsible Party)",Completed,Study Details | NCT01734980 | Endobronchial Ultrasound Transbronchial Needle Aspiration Using Needle Suction Versus No Suction | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01734980?cond=Lung%20Cancer&viewType=Card&page=3&rank=21
Lung Cancer,"Information provided by Haruhiko Fukuda, Japan Clinical Oncology Group (Responsible Party)",Completed,Study Details | NCT00132639 | Study of Preoperative Docetaxel or Cisplatin (CDDP) + Docetaxel for C-stage IB-II Non,https://clinicaltrials.gov/study/NCT00132639?cond=Lung%20Cancer&viewType=Card&page=3&rank=22
Lung Cancer,"Information provided by Nanospectra Biosciences, Inc. (Responsible Party)",Terminated,Study Details | NCT01679470 | Efficacy Study of AuroLase Therapy in Subjects With Primary and/or Metastatic Lung Tumors | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01679470?cond=Lung%20Cancer&viewType=Card&page=3&rank=23
Lung Cancer,Information provided by The University of Texas Health Science Center at San Antonio (Responsible Party),Completed,Study Details | NCT04717804 | 4D CBCT and Intrafractional Imaging for the Determination of the Most Representative 4D Simulation Planning Technique for Lung SBRT Technique Patients | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT04717804?cond=Lung%20Cancer&viewType=Card&page=3&rank=24
Lung Cancer,"Information provided by University Hospital, Tours",Terminated,Study Details | NCT00241267 | Bronchial Ultrasonography Via a Fibrescope: Pilot Study in Tumoral Disease | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00241267?cond=Lung%20Cancer&viewType=Card&page=3&rank=25
Lung Cancer,Information provided by Impact Biotech Ltd (Responsible Party),Recruiting,Study Details | NCT05918783 | Padeliporfin VTP Using Robotic Assisted Bronchoscopy in Peripheral Lung Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT05918783?cond=Lung%20Cancer&viewType=Card&page=3&rank=26
Lung Cancer,"Information provided by Centre Hospitalier Universitaire, Amiens (Responsible Party)",Completed,Study Details | NCT03645915 | GLUT1: A Novel Tool re fl Ecting Proliferative Activity of Lung Neuroendocrine Tumors | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03645915?cond=Lung%20Cancer&viewType=Card&page=3&rank=27
Lung Cancer,"Information provided by E.C. Boerma, Frisius Medisch Centrum (Responsible Party)",Recruiting,Study Details | NCT05545085 | Thoracoscopic Laser Speckle Contrast Imaging for Segment Resections | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT05545085?cond=Lung%20Cancer&viewType=Card&page=3&rank=28
Lung Cancer,"Information provided by Galvanize Therapeutics, Inc. (Responsible Party)",Completed,Study Details | NCT05890872 | Aliya™ Pulsed Electric Fields (PEF) for Advanced Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT05890872?cond=Lung%20Cancer&viewType=Card&page=3&rank=29
Lung Cancer,Information provided by Abramson Cancer Center at Penn Medicine (Responsible Party),Completed,Study Details | NCT02559349 | Gut Microbiota And Radiotherapy | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02559349?cond=Lung%20Cancer&viewType=Card&page=3&rank=30
Lung Cancer,"Information provided by Michael Brun Andersen, Copenhagen University Hospital at Herlev (Responsible Party)",Recruiting,Study Details | NCT06440616 | Benefit of Spectral Information in Patients Suspected for Lung Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT06440616?cond=Lung%20Cancer&viewType=Card&page=4&rank=31
Lung Cancer,Information provided by Merck Sharp & Dohme LLC (Responsible Party),Recruiting,Study Details | NCT06788912 | Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER,https://clinicaltrials.gov/study/NCT06788912?cond=Lung%20Cancer&viewType=Card&page=4&rank=32
Lung Cancer,"Information provided by Zhou Chengzhi, Guangzhou Institute of Respiratory Disease (Responsible Party)",Recruiting,Study Details | NCT05826483 | Almonertinib in the First,https://clinicaltrials.gov/study/NCT05826483?cond=Lung%20Cancer&viewType=Card&page=4&rank=33
Lung Cancer,Information provided by European Institute of Oncology (Responsible Party),Recruiting,Study Details | NCT05974475 | MONDRIAN: Multi-omics Integrative Modelling for Stereotactic Body Radiotherapy in Early-stage Non,https://clinicaltrials.gov/study/NCT05974475?cond=Lung%20Cancer&viewType=Card&page=4&rank=34
Lung Cancer,Information provided by Weill Medical College of Cornell University (Responsible Party),Completed,Study Results | NCT01783236 | Analgesic Efficacy of Intravenous Acetaminophen After Video,https://clinicaltrials.gov/study/NCT01783236?cond=Lung%20Cancer&viewType=Card&page=4&rank=35&tab=results
Lung Cancer,Information provided by Weill Medical College of Cornell University (Responsible Party),Completed,Study Details | NCT01783236 | Analgesic Efficacy of Intravenous Acetaminophen After Video,https://clinicaltrials.gov/study/NCT01783236?cond=Lung%20Cancer&viewType=Card&page=4&rank=35
Lung Cancer,"Information provided by Sei Won Lee, Asan Medical Center (Responsible Party)",Inconnu,Study Details | NCT05414188 | Beneficial Effect of Pulmonary Rehabilitation in Lung Cancer Patients Receiving Radiation Therapy | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT05414188?cond=Lung%20Cancer&viewType=Card&page=4&rank=36
Lung Cancer,"Information provided by University Hospital, Toulouse (Responsible Party)",Completed,Study Details | NCT03293433 | Quantification of microRNAs in Diagnosis of Pulmonary Nodules | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03293433?cond=Lung%20Cancer&viewType=Card&page=4&rank=37
Lung Cancer,"Information provided by Mohamed Salama, Otto Wagner Hospital (Responsible Party)",Recruiting,Study Details | NCT04778826 | Immune Response Following Lobectomy Along With or Without Bilateral Transcervical Mediastinal Lymphadenectomy | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT04778826?cond=Lung%20Cancer&viewType=Card&page=4&rank=38
Lung Cancer,"Information provided by Barbara C. Brocki, Aalborg University Hospital (Responsible Party)",Completed,Study Details | NCT01048762 | Multidisciplinary Rehabilitation After Cancer Pulmonis Operation | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01048762?cond=Lung%20Cancer&viewType=Card&page=4&rank=39
Lung Cancer,"Information provided by Hecheng Li M.D., Ph.D, Ruijin Hospital (Responsible Party)",Recruiting,Study Details | NCT04973293 | Preoperative Sintilimab Combined With Bevacizumab and Chemotherapy for Resectable Non,https://clinicaltrials.gov/study/NCT04973293?cond=Lung%20Cancer&viewType=Card&page=4&rank=40
Lung Cancer,"Information provided by Professor Alex MOLASIOTIS, The Hong Kong Polytechnic University (Responsible Party)",Completed,Study Details | NCT03834116 | Resistance Inspiratory Muscle Training for Patients With Thoracic Malignancies | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03834116?cond=Lung%20Cancer&viewType=Card&page=5&rank=41
Lung Cancer,Information provided by Peking University First Hospital (Responsible Party),Inconnu,Study Details | NCT05840094 | Multimodalitic Imaging in the N,https://clinicaltrials.gov/study/NCT05840094?cond=Lung%20Cancer&viewType=Card&page=5&rank=42
Lung Cancer,"Information provided by In-Jae, Oh, MD, Chonnam National University Hospital (Responsible Party)",Completed,Study Details | NCT04059887 | Evaluation of Blood TMB for the Efficacy of Atezolizumab [BUDDY] | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT04059887?cond=Lung%20Cancer&viewType=Card&page=5&rank=43
Lung Cancer,Information provided by Yale University (Responsible Party),Completed,Study Results | NCT03352245 | Feasibility of an Activity Regimen in Patients With Advanced Stage Lung Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03352245?cond=Lung%20Cancer&viewType=Card&page=5&rank=44&tab=results
Lung Cancer,Information provided by Yale University (Responsible Party),Completed,Study Details | NCT03352245 | Feasibility of an Activity Regimen in Patients With Advanced Stage Lung Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03352245?cond=Lung%20Cancer&viewType=Card&page=5&rank=44
Lung Cancer,"Information provided by Menghua Tao, Henry Ford Health System (Responsible Party)",Recruiting,Study Details | NCT07064395 | Bright Light Therapy on Sleep Health in Lung Cancer Patients | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT07064395?cond=Lung%20Cancer&viewType=Card&page=5&rank=45
Lung Cancer,Information provided by Peking Union Medical College Hospital (Responsible Party),Inconnu,Study Details | NCT07023068 | ⁶⁸Ga,https://clinicaltrials.gov/study/NCT07023068?cond=Lung%20Cancer&viewType=Card&page=5&rank=46
Lung Cancer,Information provided by Guangdong Association of Clinical Trials (Responsible Party),Terminated,Study Details | NCT02985203 | Oral Navelbine and Cisplatin Followed by Metronomic Oral Navelbine in Non,https://clinicaltrials.gov/study/NCT02985203?cond=Lung%20Cancer&viewType=Card&page=5&rank=47
Lung Cancer,"Information provided by Liu Zhishun, Guang'anmen Hospital of China Academy of Chinese Medical Sciences (Responsible Party)",Recruiting,Study Details | NCT06926140 | Acupuncture Combined With PD-1/PD,https://clinicaltrials.gov/study/NCT06926140?cond=Lung%20Cancer&viewType=Card&page=5&rank=48
Lung Cancer,"Information provided by Chris Goodman, London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's (Responsible Party)",Inconnu,Study Details | NCT06794125 | An Evaluation of Dose,https://clinicaltrials.gov/study/NCT06794125?cond=Lung%20Cancer&viewType=Card&page=5&rank=49
Lung Cancer,"Information provided by Everest Detection, Inc. (Responsible Party)",Inconnu,Study Details | NCT06816121 | Identification and Validation of Blood-Based Biomarkers for Early Detection of Asymptomatic Lung Cancer in High,https://clinicaltrials.gov/study/NCT06816121?cond=Lung%20Cancer&viewType=Card&page=5&rank=50
Lung Cancer,Information provided by Integro Theranostics (Responsible Party),Active,"Study Details | NCT06713564 | A Single Dose, Open-Label, Dose-escalation Study of the Safety and Imaging Characteristics of LS301",https://clinicaltrials.gov/study/NCT06713564?cond=Lung%20Cancer&viewType=Card&page=6&rank=51
Lung Cancer,Information provided by Fuzhou General Hospital (Responsible Party),Inconnu,Study Details | NCT06772363 | SERS,https://clinicaltrials.gov/study/NCT06772363?cond=Lung%20Cancer&viewType=Card&page=6&rank=52
Lung Cancer,Information provided by Peking University Cancer Hospital & Institute (Responsible Party),Inconnu,Study Details | NCT06674252 | A Study on the Improvement of Postoperative Symptoms and Survival Benefits of Modified Bufei Decoction in Elderly Patients With Lung Cancer Undergoing Radical Surgery | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT06674252?cond=Lung%20Cancer&viewType=Card&page=6&rank=53
Lung Cancer,"Information provided by Akhil Patel, George Washington University (Responsible Party)",Recruiting,Study Details | NCT06810375 | Erector Spinae Versus Intercostal Nerve Blocks With Liposomal Bupivacaine for Analgesia in Thoracic Surgery | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT06810375?cond=Lung%20Cancer&viewType=Card&page=6&rank=54
Lung Cancer,"Information provided by Jiayuan Sun, Shanghai Chest Hospital (Responsible Party)",Recruiting,Study Details | NCT07045532 | Assessment the Effectiveness of BTVA in COPD and Ablation in Pulmonary Nodules by Pulmonary MRI | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT07045532?cond=Lung%20Cancer&viewType=Card&page=6&rank=55
Lung Cancer,Information provided by AstraZeneca,Completed,Study Results | NCT00344773 | First,https://clinicaltrials.gov/study/NCT00344773?cond=Lung%20Cancer&viewType=Card&page=6&rank=56&tab=results
Lung Cancer,Information provided by AstraZeneca,Completed,Study Details | NCT00344773 | First,https://clinicaltrials.gov/study/NCT00344773?cond=Lung%20Cancer&viewType=Card&page=6&rank=56
Lung Cancer,"Information provided by Piotr Palaczyński, Medical University of Silesia (Responsible Party)",Completed,Study Details | NCT03749512 | NLCR in Prediction of the Grade of Lung Tumor. | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03749512?cond=Lung%20Cancer&viewType=Card&page=6&rank=57
Lung Cancer,"Information provided by Shanghai Youhe Medical Technology Co., Ltd. (Responsible Party)",Recruiting,Study Details | NCT04447482 | ENB Vs. Conventional Bronchoscopy With Fluoroscopy for Safe and Effective Biopsy of Pulmonary Lesions | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT04447482?cond=Lung%20Cancer&viewType=Card&page=6&rank=58
Lung Cancer,"Information provided by Per thor Straten, Herlev Hospital (Responsible Party)",Active,Study Details | NCT04263467 | High Intensity Aerobic Exercise Training and Immune Cell Mobilization in Patients With Lung Cancer (HI AIM) | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT04263467?cond=Lung%20Cancer&viewType=Card&page=6&rank=59
Lung Cancer,Information provided by Seoul National University Bundang Hospital (Responsible Party),Recruiting,Study Details | NCT07102589 | SWEEP: Shuttle Walking Test for Exercise Evaluation in Pulmonary Resection | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT07102589?cond=Lung%20Cancer&viewType=Card&page=6&rank=60
Lung Cancer,Information provided by Rarecells Diagnostics SAS (Responsible Party),Recruiting,Study Details | NCT06546007 | Rarecells Molecular Biomarkers for Early Detection of Lung Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT06546007?cond=Lung%20Cancer&viewType=Card&page=7&rank=61
Lung Cancer,"Information provided by Zeynep Kızılcık Ozkan, Trakya University (Responsible Party)",Completed,Study Details | NCT05915221 | Effect of SMS Use on Postoperative Respiratory and Cough Exercise Compliance | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT05915221?cond=Lung%20Cancer&viewType=Card&page=7&rank=62
Lung Cancer,Information provided by Chang Gung Memorial Hospital (Responsible Party),Completed,Study Details | NCT04974632 | Mobile 3D C,https://clinicaltrials.gov/study/NCT04974632?cond=Lung%20Cancer&viewType=Card&page=7&rank=63
Lung Cancer,Information provided by Institut de Cancérologie de la Loire (Responsible Party),Recruiting,Study Details | NCT02696863 | Plan for Systematic Identification of Lung Cancers of Occupational Origin: Implementation Study | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02696863?cond=Lung%20Cancer&viewType=Card&page=7&rank=64
Lung Cancer,Information provided by RenJi Hospital (Responsible Party),Inconnu,Study Details | NCT05745506 | Effect of Sleep Disorder on the Development of Lung Tumors | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT05745506?cond=Lung%20Cancer&viewType=Card&page=7&rank=65
Lung Cancer,Information provided by Wake Forest University Health Sciences (Responsible Party),Completed,Study Results | NCT03861091 | Prophylactic Risedronate for Patients With Peripheral Lung Tumors Treated With SBRT | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03861091?cond=Lung%20Cancer&viewType=Card&page=7&rank=66&tab=results
Lung Cancer,Information provided by Wake Forest University Health Sciences (Responsible Party),Completed,Study Details | NCT03861091 | Prophylactic Risedronate for Patients With Peripheral Lung Tumors Treated With SBRT | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03861091?cond=Lung%20Cancer&viewType=Card&page=7&rank=66
Lung Cancer,Information provided by National Taiwan University Hospital (Responsible Party),Completed,Study Details | NCT06542055 | Compare the Effects of Preoperative Pulmonary Rehabilitation Exercises on Postoperative Anxiety and Muscle Strength | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT06542055?cond=Lung%20Cancer&viewType=Card&page=7&rank=67
Lung Cancer,Information provided by Washington University School of Medicine (Responsible Party),Completed,Study Details | NCT06236516 | One Fraction Simulation-Free Treatment With CT,https://clinicaltrials.gov/study/NCT06236516?cond=Lung%20Cancer&viewType=Card&page=7&rank=68
Lung Cancer,Information provided by National Taiwan University Hospital,Completed,Study Details | NCT01388803 | The Depth of Right Bronchial Blocker Placement in Taiwanese in Video,https://clinicaltrials.gov/study/NCT01388803?cond=Lung%20Cancer&viewType=Card&page=7&rank=69
Lung Cancer,"Information provided by Qian Chu, Tongji Hospital (Responsible Party)",Recruiting,Study Details | NCT04888429 | Camrelizumab Plus Famitinib as Treatment in Patient With Advanced or Metastatic Pulmonary Sarcomatoid Carcinoma | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT04888429?cond=Lung%20Cancer&viewType=Card&page=7&rank=70
Lung Cancer,"Information provided by CSA Medical, Inc. (Responsible Party)",Completed,Study Details | NCT02483052 | RejuvenAir Lobectomy for Safety and Histology | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02483052?cond=Lung%20Cancer&viewType=Card&page=8&rank=71
Lung Cancer,"Information provided by Ernest Scalzetti, State University of New York - Upstate Medical University (Responsible Party)",Withdrawn,Study Details | NCT00638625 | Correlation of X,https://clinicaltrials.gov/study/NCT00638625?cond=Lung%20Cancer&viewType=Card&page=8&rank=72
Lung Cancer,"Information provided by Maxwell. T. Vergo, Dartmouth-Hitchcock Medical Center (Responsible Party)",Completed,"Study Details | NCT02575898 | Feasibility of a Creative Writing Intervention in an Advanced Cancer Population: A Single Arm, Consecutive Cohort Study | ClinicalTrials.gov",https://clinicaltrials.gov/study/NCT02575898?cond=Lung%20Cancer&viewType=Card&page=8&rank=73
Lung Cancer,"Information provided by Yu Zhang, PhD, Guangdong Provincial People's Hospital (Responsible Party)",Completed,Study Details | NCT07100444 | Spinal Metastasis as the First Presentation of Lung Malignancy: Clinical Characteristics and Postoperative Survival | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT07100444?cond=Lung%20Cancer&viewType=Card&page=8&rank=74
Lung Cancer,Information provided by Washington University School of Medicine (Responsible Party),Inconnu,Study Details | NCT07146568 | Evaluating the Implementation and Effectiveness of the Pink and Pearl Campaign on Lung Cancer Screening at Christian Hospital | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT07146568?cond=Lung%20Cancer&viewType=Card&page=8&rank=75
Lung Cancer,Information provided by Washington University School of Medicine (Responsible Party),Recruiting,Study Details | NCT06898333 | Implementation and Effectiveness of the BJC,https://clinicaltrials.gov/study/NCT06898333?cond=Lung%20Cancer&viewType=Card&page=8&rank=76
Lung Cancer,"Information provided by Hyun Joo Ahn, Samsung Medical Center (Responsible Party)",Completed,Study Details | NCT02331056 | Could the Stroke Volume Variation Predict a Fluid Responsiveness in Thoracotomy? | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02331056?cond=Lung%20Cancer&viewType=Card&page=8&rank=77
Lung Cancer,Information provided by Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau (Responsible Party),Inconnu,Study Details | NCT06157957 | Cancer Screening Smoking Cessation AND Respiratory Assessment | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT06157957?cond=Lung%20Cancer&viewType=Card&page=8&rank=78
Lung Cancer,Information provided by Merck Sharp & Dohme LLC (Responsible Party),Recruiting,Study Details | NCT06780098 | Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER,https://clinicaltrials.gov/study/NCT06780098?cond=Lung%20Cancer&viewType=Card&page=8&rank=79
Lung Cancer,"Information provided by Fabien Maldonado, Vanderbilt-Ingram Cancer Center (Responsible Party)",Recruiting,Study Details | NCT06638398 | Biomarker Platform (Virtual Nodule Clinic) for the Management of Indeterminate Pulmonary Nodules | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT06638398?cond=Lung%20Cancer&viewType=Card&page=8&rank=80
Lung Cancer,"Information provided by Hecheng Li M.D., Ph.D, Ruijin Hospital (Responsible Party)",Withdrawn,Study Details | NCT04529603 | The Efficacy of Intraoperative Pulmonary Nodules Localization Guided by Virtual Reality Technology | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT04529603?cond=Lung%20Cancer&viewType=Card&page=9&rank=81
Lung Cancer,"Information provided by Guanghong Zhou, Sichuan Provincial People's Hospital (Responsible Party)",Recruiting,Study Details | NCT06419114 | Exploration of Optical Coherence Tomography,https://clinicaltrials.gov/study/NCT06419114?cond=Lung%20Cancer&viewType=Card&page=9&rank=82
Lung Cancer,"Information provided by phenoMapper, LLC (Responsible Party)",Recruiting,Study Details | NCT06158971 | Feasibility Study of the Microwave Ablation System for Lung Tissue Ablation | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT06158971?cond=Lung%20Cancer&viewType=Card&page=9&rank=83
Lung Cancer,Information provided by Hospital Israelita Albert Einstein (Responsible Party),Completed,Study Details | NCT05081674 | Brazilian Lung Immunotherapy Study | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT05081674?cond=Lung%20Cancer&viewType=Card&page=9&rank=84
Lung Cancer,"Information provided by Christophe Dooms, MD, PhD, KU Leuven (Responsible Party)",Recruiting,Study Details | NCT02906280 | RCT Comparing 19Ga vs 22Ga EBUS,https://clinicaltrials.gov/study/NCT02906280?cond=Lung%20Cancer&viewType=Card&page=9&rank=85
Lung Cancer,Information provided by University of Sydney (Responsible Party),Inconnu,Study Details | NCT06159660 | Ventilation Using Radiographic Examination: Functional Lung Imaging Techniques for the Reduction of Toxicity in Functional Avoidance Radiation Therapy | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT06159660?cond=Lung%20Cancer&viewType=Card&page=9&rank=86
Lung Cancer,"Information provided by Pedro Machado, Instituto Politécnico de Leiria (Responsible Party)",Completed,Study Details | NCT05473052 | Home,https://clinicaltrials.gov/study/NCT05473052?cond=Lung%20Cancer&viewType=Card&page=9&rank=87
Lung Cancer,"Information provided by Pedro Machado, Instituto Politécnico de Leiria (Responsible Party)",Completed,Study Details | NCT05469425 | Home,https://clinicaltrials.gov/study/NCT05469425?cond=Lung%20Cancer&viewType=Card&page=9&rank=88
Lung Cancer,Information provided by European Lung Cancer Working Party (Responsible Party),Recruiting,Study Details | NCT03368820 | Cardiovascular Morbidities and Lung Cancer Treatment: a Prospective Registry | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03368820?cond=Lung%20Cancer&viewType=Card&page=9&rank=89
Lung Cancer,Information provided by M.D. Anderson Cancer Center (Responsible Party),Completed,Study Details | NCT04995172 | Feasibility of Mobile-CT,https://clinicaltrials.gov/study/NCT04995172?cond=Lung%20Cancer&viewType=Card&page=9&rank=90
Lung Cancer,Information provided by M.D. Anderson Cancer Center (Responsible Party),Completed,Study Details | NCT05046067 | Feasibility Study of Anatomical Modeling for Image Guided Thoracic Surgery | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT05046067?cond=Lung%20Cancer&viewType=Card&page=10&rank=91
Lung Cancer,Information provided by Kaiser Permanente (Responsible Party),Completed,Study Details | NCT05059132 | Inspiratory Muscle Training and Behavioral Support to Alleviate Dyspnea and Promote Walking in Lung Cancer Survivors: A Pilot Study | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT05059132?cond=Lung%20Cancer&viewType=Card&page=10&rank=92
Lung Cancer,"Information provided by PrECOG, LLC. (Responsible Party)",Completed,Study Results | NCT02713828 | Study of Glembatumumab Vedotin in gpNMB,https://clinicaltrials.gov/study/NCT02713828?cond=Lung%20Cancer&viewType=Card&page=10&rank=93&tab=results
Lung Cancer,"Information provided by PrECOG, LLC. (Responsible Party)",Terminated,Study Details | NCT02713828 | Study of Glembatumumab Vedotin in gpNMB,https://clinicaltrials.gov/study/NCT02713828?cond=Lung%20Cancer&viewType=Card&page=10&rank=93
Lung Cancer,"Information provided by Yihao Zhu, Sichuan Cancer Hospital and Research Institute (Responsible Party)",Inconnu,Study Details | NCT06258954 | Effect of 3D,https://clinicaltrials.gov/study/NCT06258954?cond=Lung%20Cancer&viewType=Card&page=10&rank=94
Lung Cancer,Information provided by Alliance for Clinical Trials in Oncology (Responsible Party),Completed,Study Details | NCT00899782 | Collection and Storage of Blood and Tissue Samples From Patients Who Are Undergoing Surgery For Lung Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00899782?cond=Lung%20Cancer&viewType=Card&page=10&rank=95
Lung Cancer,Information provided by Rgene Corporation (Responsible Party),Inconnu,Study Details | NCT05764928 | Evaluate the Safety and Efficacy of BLEX 404 Oral Liquid Combined With Pemetrexed + Cisplatin Therapy | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT05764928?cond=Lung%20Cancer&viewType=Card&page=10&rank=96
Lung Cancer,"Information provided by Myung-Ju Ahn, Samsung Medical Center (Responsible Party)",Inconnu,"Study Details | NCT06830694 | Clinical Trial for Safety and Effectiveness Evaluation of Tarlatamab (AMG757) with Etoposide, Carboplatin and Atezolizumab in Transformed Small Cell Lung Cancer Patients from Adenocarcinoma After EGFR TKI Treatment | ClinicalTrials.gov",https://clinicaltrials.gov/study/NCT06830694?cond=Lung%20Cancer&viewType=Card&page=10&rank=97
Lung Cancer,Information provided by The University of Texas Health Science Center at San Antonio (Responsible Party),Recruiting,Study Details | NCT03655015 | Patient,https://clinicaltrials.gov/study/NCT03655015?cond=Lung%20Cancer&viewType=Card&page=10&rank=98
Lung Cancer,Information provided by Wake Forest University Health Sciences (Responsible Party),Completed,Study Details | NCT03741868 | Symptom Burden and Unmet Supportive Care Needs in Lung Cancer Patients Undergoing First or Second Line Immunotherapy | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03741868?cond=Lung%20Cancer&viewType=Card&page=10&rank=99
Lung Cancer,"Information provided by Mereo BioPharma (OncoMed Pharmaceuticals, Inc.) (Responsible Party)",Completed,"Study Results | NCT02259582 | A Study of Carboplatin, Pemetrexed Plus Placebo vs Carboplatin, Pemetrexed Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With Non-Squamous Non",https://clinicaltrials.gov/study/NCT02259582?cond=Lung%20Cancer&viewType=Card&page=10&rank=100&tab=results
Lung Cancer,"Information provided by Mereo BioPharma (OncoMed Pharmaceuticals, Inc.) (Responsible Party)",Completed,"Study Details | NCT02259582 | A Study of Carboplatin, Pemetrexed Plus Placebo vs Carboplatin, Pemetrexed Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With Non-Squamous Non",https://clinicaltrials.gov/study/NCT02259582?cond=Lung%20Cancer&viewType=Card&page=10&rank=100
Lung Cancer,Information provided by Baptist Health South Florida (Responsible Party),Withdrawn,Study Details | NCT04917224 | Study of LUNG Stereotactic Adaptive Ablative Radiotherapy | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT04917224?cond=Lung%20Cancer&viewType=Card&page=11&rank=101
Lung Cancer,"Information provided by Matthew T. Freedman, MD, Georgetown University (Responsible Party)",Completed,Study Results | NCT01261507 | Reader Study of DeltaView™ Chest Radiograph Software | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01261507?cond=Lung%20Cancer&viewType=Card&page=11&rank=102&tab=results
Lung Cancer,"Information provided by Matthew T. Freedman, MD, Georgetown University (Responsible Party)",Completed,Study Details | NCT01261507 | Reader Study of DeltaView™ Chest Radiograph Software | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01261507?cond=Lung%20Cancer&viewType=Card&page=11&rank=102
Lung Cancer,"Information provided by Per Reidar Woldbæk, Oslo University Hospital (Responsible Party)",Recruiting,Study Details | NCT03070626 | Preoperative Loading With Carbohydrates in Lung Cancer Surgery | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03070626?cond=Lung%20Cancer&viewType=Card&page=11&rank=103
Lung Cancer,"Information provided by Ju-Wei Mu, Cancer Institute and Hospital, Chinese Academy of Medical Sciences (Responsible Party)",Recruiting,"Study Details | NCT02992353 | Single-port, Two-port Versus Three-port VATS on Non",https://clinicaltrials.gov/study/NCT02992353?cond=Lung%20Cancer&viewType=Card&page=11&rank=104
Lung Cancer,"Information provided by Jeremy Harris, University of California, Irvine (Responsible Party)",Completed,Study Details | NCT05555342 | A Novel Method for Treating Lung Met w/Combo of Electric Fields & Rad Therapy: A Single,https://clinicaltrials.gov/study/NCT05555342?cond=Lung%20Cancer&viewType=Card&page=11&rank=105
Lung Cancer,Information provided by National Taiwan University Hospital (Responsible Party),Recruiting,Study Details | NCT03469323 | Effects of Succinylcholine on Nonintubated Thoracoscopic Surgery | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03469323?cond=Lung%20Cancer&viewType=Card&page=11&rank=106
Lung Cancer,Information provided by VA Office of Research and Development (Responsible Party),Recruiting,Study Details | NCT02984761 | Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02984761?cond=Lung%20Cancer&viewType=Card&page=11&rank=107
Lung Cancer,"Information provided by Oliver Jonas, Brigham and Women's Hospital (Responsible Party)",Completed,Study Details | NCT03972228 | Microdevice for Evaluating Drug Response in Site in Lung Lesions | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03972228?cond=Lung%20Cancer&viewType=Card&page=11&rank=108
Lung Cancer,"Information provided by Galvanize Therapeutics, Inc. (Responsible Party)",Terminated,Study Details | NCT04773275 | A Clinical Evaluation of the Aliya™ System in Late Stage Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT04773275?cond=Lung%20Cancer&viewType=Card&page=11&rank=109
Lung Cancer,"Information provided by Mia Elhidsi, MD, Fakultas Kedokteran Universitas Indonesia (Responsible Party)",Inconnu,Study Details | NCT06102369 | The Role of Narrow Band Imaging (NBI) Bronchoscopy in Detecting Bronchial Squamous Dysplasia in Lung Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT06102369?cond=Lung%20Cancer&viewType=Card&page=11&rank=110
Lung Cancer,Information provided by Spanish Lung Cancer Group (Responsible Party),Completed,Study Details | NCT01814163 | Observational Post,https://clinicaltrials.gov/study/NCT01814163?cond=Lung%20Cancer&viewType=Card&page=12&rank=111
Lung Cancer,Information provided by National Taiwan University Hospital (Responsible Party),Recruiting,Study Details | NCT04056273 | Assess the Use of rEBUS With a Guide Sheath to Increase Transbronchial Lung Biopsy Yield Rate | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT04056273?cond=Lung%20Cancer&viewType=Card&page=12&rank=112
Lung Cancer,"Information provided by Jiangsu ShengDiYa Medicine Co., Ltd. (Responsible Party)",Inconnu,"Study Details | NCT02852798 | Apatinib Combined With Docetaxel Monotherapy as Second-line Therapy of Advanced EGFR WT, Non",https://clinicaltrials.gov/study/NCT02852798?cond=Lung%20Cancer&viewType=Card&page=12&rank=113
Lung Cancer,Information provided by Zhejiang Cancer Hospital (Responsible Party),Recruiting,Study Details | NCT01635400 | Study of Relationship Between UGT1A1 Gene Polymorphism and Toxicity and Efficacy of Irinotecan in Small Cell Lung Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01635400?cond=Lung%20Cancer&viewType=Card&page=12&rank=114
Lung Cancer,Information provided by University of Hull (Responsible Party),Completed,Study Details | NCT05404022 | Feasibility Trial of a Personalised Nutrition and Activity Programme for People With Lung Cancer Over 65 Years | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT05404022?cond=Lung%20Cancer&viewType=Card&page=12&rank=115
Lung Cancer,"Information provided by Department of Radiation Oncology, University of Maryland, Baltimore (Responsible Party)",Completed,Study Details | NCT00780611 | Investigating the Improvement in 4D CT Images Using AV Biofeedback | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00780611?cond=Lung%20Cancer&viewType=Card&page=12&rank=116
Lung Cancer,Information provided by Broncus Technologies,Recruiting,Study Details | NCT01067755 | Evaluation of the LungPoint Virtual Bronchoscopic Navigation (VBN) System | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01067755?cond=Lung%20Cancer&viewType=Card&page=12&rank=117
Lung Cancer,"Information provided by Ernest Scalzetti, State University of New York - Upstate Medical University (Responsible Party)",Completed,Study Details | NCT00638352 | False/Negative Rate of Lung Percutaneous Needle Biopsy | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00638352?cond=Lung%20Cancer&viewType=Card&page=12&rank=118
Lung Cancer,Information provided by Hellenic Cooperative Oncology Group (Responsible Party),Completed,Study Details | NCT01218529 | Lapatinib and WBRT for Patients With Brain Metastases From Lung or Breast Tumors | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01218529?cond=Lung%20Cancer&viewType=Card&page=12&rank=119
Lung Cancer,"Information provided by Sara Pai, MD, PhD, Massachusetts General Hospital (Responsible Party)",Recruiting,Study Details | NCT06412172 | The Natural History and Biological Study of Pulmonary Recurrent Respiratory Papillomatosis (pRRP) | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT06412172?cond=Lung%20Cancer&viewType=Card&page=12&rank=120
Lung Cancer,"Information provided by University Hospital, Brest",Completed,Study Details | NCT00295672 | Oral Vinorelbine and Cisplatin and Concurrent Radiotherapy After Induction Chemotherapy in Locally Advanced NSCLC. | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00295672?cond=Lung%20Cancer&viewType=Card&page=13&rank=121
Lung Cancer,Information provided by Hoffmann-La Roche (Responsible Party),Completed,Study Results | NCT01161173 | An Observational Study of Tarceva (Erlotinib) in Routine Daily Clinical Practice as Second Line Treatment in Patients With Non,https://clinicaltrials.gov/study/NCT01161173?cond=Lung%20Cancer&viewType=Card&page=13&rank=122&tab=results
Lung Cancer,Information provided by Hoffmann-La Roche (Responsible Party),Completed,Study Details | NCT01161173 | An Observational Study of Tarceva (Erlotinib) in Routine Daily Clinical Practice as Second Line Treatment in Patients With Non,https://clinicaltrials.gov/study/NCT01161173?cond=Lung%20Cancer&viewType=Card&page=13&rank=122
Lung Cancer,Information provided by C. R. Bard (Responsible Party),Completed,Study Results | NCT01394978 | NeoMend ProGEL™ Pleural Air Leak Sealant Post,https://clinicaltrials.gov/study/NCT01394978?cond=Lung%20Cancer&viewType=Card&page=13&rank=123&tab=results
Lung Cancer,Information provided by C. R. Bard (Responsible Party),Completed,Study Details | NCT01394978 | NeoMend ProGEL™ Pleural Air Leak Sealant Post,https://clinicaltrials.gov/study/NCT01394978?cond=Lung%20Cancer&viewType=Card&page=13&rank=123
Lung Cancer,Information provided by Technische Universität Dresden (Responsible Party),Active,Study Details | NCT05470595 | A Single-arm Trial of Atezolizumab/Platinum/Etoposide for the Treatment of Advanced Large,https://clinicaltrials.gov/study/NCT05470595?cond=Lung%20Cancer&viewType=Card&page=13&rank=124
Lung Cancer,"Information provided by Jiayuan Sun, Shanghai Chest Hospital (Responsible Party)",Completed,Study Details | NCT03537378 | Hybrid APC Therapy in Early Central Lung Neoplasms | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03537378?cond=Lung%20Cancer&viewType=Card&page=13&rank=125
Lung Cancer,"Information provided by Fuda Cancer Hospital, Guangzhou (Responsible Party)",Completed,Study Details | NCT02333474 | Safety and Efficacy of Mix Vaccine in Lung Carcinoma Patient | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02333474?cond=Lung%20Cancer&viewType=Card&page=13&rank=126
Lung Cancer,"Information provided by LI Junling, Chinese Academy of Medical Sciences (Responsible Party)",Recruiting,Study Details | NCT01969955 | Nab-paclitaxel as Second,https://clinicaltrials.gov/study/NCT01969955?cond=Lung%20Cancer&viewType=Card&page=13&rank=127
Lung Cancer,Information provided by Abramson Cancer Center at Penn Medicine (Responsible Party),Recruiting,Study Details | NCT06955468 | Evaluating a Bidirectional Priming Intervention for Goals-of,https://clinicaltrials.gov/study/NCT06955468?cond=Lung%20Cancer&viewType=Card&page=13&rank=128
Lung Cancer,"Information provided by Ozal Adiyeke, Başakşehir Çam & Sakura City Hospital (Responsible Party)",Completed,Study Details | NCT06964698 | Optimizing Post,https://clinicaltrials.gov/study/NCT06964698?cond=Lung%20Cancer&viewType=Card&page=13&rank=129
Lung Cancer,"Information provided by Marc Fortin, Institut universitaire de cardiologie et de pneumologie de Québec, University Laval (Responsible Party)",Inconnu,Study Details | NCT06950515 | General Anesthesia vs Conscious Sedation for Radial Endobronchial Ultrasound | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT06950515?cond=Lung%20Cancer&viewType=Card&page=13&rank=130
Lung Cancer,Information provided by Mirati Therapeutics Inc. (Responsible Party),Recruiting,Study Details | NCT05853575 | Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21) | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT05853575?cond=Lung%20Cancer&viewType=Card&page=14&rank=131
Lung Cancer,"Information provided by Qiong Zhao, Zhejiang University (Responsible Party)",Inconnu,Study Details | NCT02009605 | Icotinib in Previously Treated Non/Light,https://clinicaltrials.gov/study/NCT02009605?cond=Lung%20Cancer&viewType=Card&page=14&rank=132
Lung Cancer,"Information provided by Guangzhou FineImmune Biotechnology Co., LTD. (Responsible Party)",Recruiting,"Study Details | NCT06942143 | An Open-label, Phase I Clinical Trial of Super1 TCR-T in NY-ESO-1",https://clinicaltrials.gov/study/NCT06942143?cond=Lung%20Cancer&viewType=Card&page=14&rank=133
Lung Cancer,Information provided by Chang Gung Memorial Hospital (Responsible Party),Completed,Study Details | NCT03395964 | Comparison of Preoperative CT Scan Guided and Intraoperative Hybrid DynaCT Scan,https://clinicaltrials.gov/study/NCT03395964?cond=Lung%20Cancer&viewType=Card&page=14&rank=134
Lung Cancer,"Information provided by Hsin-Yuan Fang, China Medical University Hospital (Responsible Party)",Inconnu,Study Details | NCT06397807 | Postoperative Pain Management on Patients Undergoing Lung Tumor Resection | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT06397807?cond=Lung%20Cancer&viewType=Card&page=14&rank=135
Lung Cancer,Information provided by Regina Elena Cancer Institute (Responsible Party),Recruiting,Study Details | NCT06254196 | Clinical Trial of Telenursing for Monitoring Supportive Care Needs in Patients With Lung Cancer and Melanoma Candidates for the First Prescription of Targeted Therapies | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT06254196?cond=Lung%20Cancer&viewType=Card&page=14&rank=136
Lung Cancer,Information provided by Shanghai Zhongshan Hospital (Responsible Party),Inconnu,Study Details | NCT06530667 | Broadband Collaborative Pulse Ablation Instrument Treating Malignant Pulmonary Nodules | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT06530667?cond=Lung%20Cancer&viewType=Card&page=14&rank=137
Lung Cancer,Information provided by Latin American Cooperative Oncology Group (Responsible Party),Completed,Study Details | NCT04230408 | Intensified Chemo-immuno-radiotherapy With Durvalumab for Stage III Non,https://clinicaltrials.gov/study/NCT04230408?cond=Lung%20Cancer&viewType=Card&page=14&rank=138
Lung Cancer,"Information provided by Univ.-Prof. Dr. Marcus Hacker, Medical University of Vienna (Responsible Party)",Recruiting,Study Details | NCT05912465 | Predicting Lung Cancer,https://clinicaltrials.gov/study/NCT05912465?cond=Lung%20Cancer&viewType=Card&page=14&rank=139
Lung Cancer,Information provided by Centre Leon Berard (Responsible Party),Recruiting,Study Details | NCT06393816 | FIRST-NEC (GFPC 01-2022),https://clinicaltrials.gov/study/NCT06393816?cond=Lung%20Cancer&viewType=Card&page=14&rank=140
Lung Cancer,Information provided by Chang Gung Memorial Hospital,Completed,Study Details | NCT00922155 | Diagnosis of Lung Lesions by Endobronchial Ultrasound With an Alternative Guide Sheath | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00922155?cond=Lung%20Cancer&viewType=Card&page=15&rank=141
Lung Cancer,"Information provided by Hecheng Li M.D., Ph.D, Ruijin Hospital (Responsible Party)",Recruiting,Study Details | NCT04982900 | Treatment of EGFR-TKI for Residual Lesions of Multiple Synchronous Ground,https://clinicaltrials.gov/study/NCT04982900?cond=Lung%20Cancer&viewType=Card&page=15&rank=142
Lung Cancer,Information provided by Oncology Center of Biochemical Education And Research (Responsible Party),Completed,Study Details | NCT06049966 | Atezolizumab in Large Cell Neuroendocrine Carcinoma | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT06049966?cond=Lung%20Cancer&viewType=Card&page=15&rank=143
Lung Cancer,Information provided by Centre Leon Berard (Responsible Party),Completed,Study Details | NCT02013297 | Study of SBRT Efficacy on Intra and Extra,https://clinicaltrials.gov/study/NCT02013297?cond=Lung%20Cancer&viewType=Card&page=15&rank=144
Lung Cancer,"Information provided by Jianxing He, The First Affiliated Hospital of Guangzhou Medical University (Responsible Party)",Recruiting,Study Details | NCT04026841 | The Efficacy of PD-1 Antibody Sintilimab on Early,https://clinicaltrials.gov/study/NCT04026841?cond=Lung%20Cancer&viewType=Card&page=15&rank=145
Lung Cancer,Information provided by AstraZeneca (Responsible Party),Inconnu,Study Details | NCT07143110 | LUNG,https://clinicaltrials.gov/study/NCT07143110?cond=Lung%20Cancer&viewType=Card&page=15&rank=146
Lung Cancer,"Information provided by Kübra Kılıç, Hacettepe University (Responsible Party)",Completed,"Study Details | NCT04431921 | Assessment of Functional Capacity, Pain, Cognitive and Respiratory Functions in Lung Cancer Survivors | ClinicalTrials.gov",https://clinicaltrials.gov/study/NCT04431921?cond=Lung%20Cancer&viewType=Card&page=15&rank=147
Lung Cancer,Information provided by RenJi Hospital (Responsible Party),Recruiting,Study Details | NCT03795155 | Prospective Genomics Initiative on Multiple Synchronous Lung Cancer (PGI,https://clinicaltrials.gov/study/NCT03795155?cond=Lung%20Cancer&viewType=Card&page=15&rank=148
Lung Cancer,"Information provided by Menssana Research, Inc. (Responsible Party)",Completed,Study Details | NCT00639067 | Breath Test for Early Detection of Lung Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00639067?cond=Lung%20Cancer&viewType=Card&page=15&rank=149
Lung Cancer,Information provided by KA Imaging Inc. (Responsible Party),Recruiting,Study Details | NCT03528733 | Feasibility of Multi,https://clinicaltrials.gov/study/NCT03528733?cond=Lung%20Cancer&viewType=Card&page=15&rank=150
Lung Cancer,"Information provided by Doğa Ulcay, Maltepe University (Responsible Party)",Completed,Study Details | NCT05879354 | Active Cycle of Breathing Techniques on Respiratory Distress Symptom Cluster | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT05879354?cond=Lung%20Cancer&viewType=Card&page=16&rank=151
Lung Cancer,Information provided by Assistance Publique - Hôpitaux de Paris (Responsible Party),Recruiting,Study Details | NCT05977803 | Contribution of the CEST Sequence in the Characterization of Radionecrosis of Brain Metastases of Pulmonary Origin | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT05977803?cond=Lung%20Cancer&viewType=Card&page=16&rank=152
Lung Cancer,"Information provided by Evelyn Arana, DrPH, Rutgers, The State University of New Jersey (Responsible Party)",Recruiting,Study Details | NCT07165691 | TELEhealth Shared Decision,https://clinicaltrials.gov/study/NCT07165691?cond=Lung%20Cancer&viewType=Card&page=16&rank=153
Lung Cancer,"Information provided by Mateusz Polaczek, National Institute for Tuberculosis and Lung Diseases, Poland (Responsible Party)",Inconnu,Study Details | NCT04036721 | Coorticosteroid Regimen in Patients With Anti-PD-1/PD,https://clinicaltrials.gov/study/NCT04036721?cond=Lung%20Cancer&viewType=Card&page=16&rank=154
Lung Cancer,Information provided by AstraZeneca (Responsible Party),Inconnu,Study Details | NCT07109154 | DeniLA: Comprehensive Demographics and Clinical Profile of NSCLC Patients: Analyzing Guideline-Concordant Care in First,https://clinicaltrials.gov/study/NCT07109154?cond=Lung%20Cancer&viewType=Card&page=16&rank=155
Lung Cancer,"Information provided by Young-Chul Kim, Chonnam National University Hospital (Responsible Party)",Completed,Study Details | NCT02498860 | Efficacy and Safety of Adjuvant Pemetrexed Plus Cisplatin for Adenocarcinoma of Lung | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02498860?cond=Lung%20Cancer&viewType=Card&page=16&rank=156
Lung Cancer,Information provided by Novartis (Novartis Pharmaceuticals) (Responsible Party),Completed,Study Results | NCT01563354 | 3-arm Trial to Evaluate Pasireotide LAR/Everolimus Alone/in Combination in Patients With Lung/Thymus NET,https://clinicaltrials.gov/study/NCT01563354?cond=Lung%20Cancer&viewType=Card&page=16&rank=157&tab=results
Lung Cancer,Information provided by Novartis (Novartis Pharmaceuticals) (Responsible Party),Completed,Study Details | NCT01563354 | 3-arm Trial to Evaluate Pasireotide LAR/Everolimus Alone/in Combination in Patients With Lung/Thymus NET,https://clinicaltrials.gov/study/NCT01563354?cond=Lung%20Cancer&viewType=Card&page=16&rank=157
Lung Cancer,"Information provided by Hecheng Li M.D., Ph.D, Ruijin Hospital (Responsible Party)",Completed,Study Details | NCT04211051 | Safety and Feasibility of Pulmonary Surgery Marker System in the Intraoperative Localization of Small Pulmonary Nodules | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT04211051?cond=Lung%20Cancer&viewType=Card&page=16&rank=158
Lung Cancer,Information provided by Trans Tasman Radiation Oncology Group (Responsible Party),Completed,Study Details | NCT00351598 | Lung Tumour Volume Database | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00351598?cond=Lung%20Cancer&viewType=Card&page=16&rank=159
Lung Cancer,"Information provided by Pei-Hung Liao, National Taipei University of Nursing and Health Sciences (Responsible Party)",Active,Study Details | NCT06259461 | Machine Learning to Construct an Association Model for Lung Cancer and Environmental Hormone | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT06259461?cond=Lung%20Cancer&viewType=Card&page=16&rank=160
Lung Cancer,Non spécifié,Inconnu,Study Details | NCT06195657 | | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT06195657?cond=Lung%20Cancer&viewType=Card&page=17&rank=161
Lung Cancer,"Information provided by Liu Jui Fang, Chang Gung Memorial Hospital (Responsible Party)",Completed,Study Results | NCT02757092 | The Impacts of Pulmonary Rehabilitation Therapy on Patients After Thoracic Surgery | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02757092?cond=Lung%20Cancer&viewType=Card&page=17&rank=162&tab=results
Lung Cancer,"Information provided by Liu Jui Fang, Chang Gung Memorial Hospital (Responsible Party)",Completed,Study Details | NCT02757092 | The Impacts of Pulmonary Rehabilitation Therapy on Patients After Thoracic Surgery | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02757092?cond=Lung%20Cancer&viewType=Card&page=17&rank=162
Lung Cancer,Information provided by First People's Hospital of Hangzhou (Responsible Party),Recruiting,Study Details | NCT07207278 | Multi Omics Molecular Characteristics and Immunophenotyping of Lung Signet Ring Cell Carcinoma | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT07207278?cond=Lung%20Cancer&viewType=Card&page=17&rank=163
Lung Cancer,"Information provided by LVHUA WANG, Cancer Institute and Hospital, Chinese Academy of Medical Sciences (Responsible Party)",Inconnu,Study Details | NCT05904015 | The Study of Envafolimab Combined With Concurrent Chemoradiotherapy In LS,https://clinicaltrials.gov/study/NCT05904015?cond=Lung%20Cancer&viewType=Card&page=17&rank=164
Lung Cancer,"Information provided by zhuhao, RenJi Hospital (Responsible Party)",Inconnu,Study Details | NCT05850702 | Attenuation of the Hemodynamic Response to Double,https://clinicaltrials.gov/study/NCT05850702?cond=Lung%20Cancer&viewType=Card&page=17&rank=165
Lung Cancer,Information provided by Peking Union Medical College Hospital (Responsible Party),Recruiting,Study Details | NCT05543954 | 68Ga-FAPI,https://clinicaltrials.gov/study/NCT05543954?cond=Lung%20Cancer&viewType=Card&page=17&rank=166
Lung Cancer,"Information provided by Giuseppe Colucci MD, Gruppo Oncologico Italia Meridionale (Responsible Party)",Active,Study Details | NCT01303926 | Quality of Life Comparison in Advanced Non,https://clinicaltrials.gov/study/NCT01303926?cond=Lung%20Cancer&viewType=Card&page=17&rank=167
Lung Cancer,"Information provided by Anita Y. Kinney, PhD, RN, Rutgers, The State University of New Jersey (Responsible Party)",Recruiting,Study Details | NCT05491213 | TELESCOPE- TELEhealth Shared Decision,https://clinicaltrials.gov/study/NCT05491213?cond=Lung%20Cancer&viewType=Card&page=17&rank=168
Lung Cancer,"Information provided by Auris Health, Inc. (Responsible Party)",Withdrawn,Study Details | NCT05426213 | A Study of Robot,https://clinicaltrials.gov/study/NCT05426213?cond=Lung%20Cancer&viewType=Card&page=17&rank=169
Lung Cancer,Information provided by NovaRx Corporation,Completed,Study Details | NCT01058785 | Phase II Study of Lucanix™ in Patients With Stages II-IV Non,https://clinicaltrials.gov/study/NCT01058785?cond=Lung%20Cancer&viewType=Card&page=17&rank=170
Lung Cancer,"Information provided by Ethicon, Inc. (Responsible Party)",Completed,Study Results | NCT05299606 | POWER Study (Prospective Transbronchial Microwave + Robotic,https://clinicaltrials.gov/study/NCT05299606?cond=Lung%20Cancer&viewType=Card&page=18&rank=171&tab=results
Lung Cancer,"Information provided by Ethicon, Inc. (Responsible Party)",Terminated,Study Details | NCT05299606 | POWER Study (Prospective Transbronchial Microwave + Robotic,https://clinicaltrials.gov/study/NCT05299606?cond=Lung%20Cancer&viewType=Card&page=18&rank=171
Lung Cancer,Information provided by Johnson & Johnson Enterprise Innovation Inc. (Responsible Party),Completed,Study Details | NCT05231278 | Confocal Laser Endomicroscopy Nodule Localization by Robotic Bronchoscopy | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT05231278?cond=Lung%20Cancer&viewType=Card&page=18&rank=172
Lung Cancer,Information provided by The First People's Hospital of Lianyungang (Responsible Party),Recruiting,Study Details | NCT05203276 | Envafolimab Combined With Endostar in the First,https://clinicaltrials.gov/study/NCT05203276?cond=Lung%20Cancer&viewType=Card&page=18&rank=173
Lung Cancer,"Information provided by Fuda Cancer Hospital, Guangzhou (Responsible Party)",Completed,Study Details | NCT02744664 | Cryotherapy Combine Icotinib for Advanced NSCLC Treatment | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02744664?cond=Lung%20Cancer&viewType=Card&page=18&rank=174
Lung Cancer,"Information provided by Jian Zhang, Air Force Military Medical University, China (Responsible Party)",Inconnu,Study Details | NCT02666755 | Novel Detection System for Lung Cancer Curative Effect Monitoring | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02666755?cond=Lung%20Cancer&viewType=Card&page=18&rank=175
Lung Cancer,"Information provided by Jin Hyoung Kang, Seoul St. Mary's Hospital (Responsible Party)",Recruiting,Study Details | NCT05326425 | Lazertinib in Patients With NSCLC With Asymptomatic or Mild Symptomatic Brain Metastases After Failure of EGFR TKI. | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT05326425?cond=Lung%20Cancer&viewType=Card&page=18&rank=176
Lung Cancer,Information provided by Jules Bordet Institute (Responsible Party),Recruiting,Study Details | NCT04726358 | ProCaLung: Project on Cancer of the Lung | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT04726358?cond=Lung%20Cancer&viewType=Card&page=18&rank=177
Lung Cancer,"Information provided by Chang Chen, Shanghai Pulmonary Hospital, Shanghai, China (Responsible Party)",Recruiting,Study Details | NCT04775901 | Application of Three,https://clinicaltrials.gov/study/NCT04775901?cond=Lung%20Cancer&viewType=Card&page=18&rank=178
Lung Cancer,"Information provided by Jhingook Kim, MD, Samsung Medical Center (Responsible Party)",Recruiting,Study Details | NCT04922073 | Practical Usability of EGFR Mutation Detection in ctDNA From Resectable NSCLC | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT04922073?cond=Lung%20Cancer&viewType=Card&page=18&rank=179
Lung Cancer,"Information provided by Tim Lautenschlaeger, Indiana University (Responsible Party)",Terminated,Study Details | NCT02117440 | Functional Image and Molecular Markers to Predict Treatment Outcomes in Lung Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02117440?cond=Lung%20Cancer&viewType=Card&page=18&rank=180
Lung Cancer,Information provided by Pfizer (Responsible Party),Recruiting,Study Details | NCT04721106 | Korea Post Marketing Surveillance (PMS) Study of Vizimpro | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT04721106?cond=Lung%20Cancer&viewType=Card&page=19&rank=181
Lung Cancer,Information provided by Tang-Du Hospital (Responsible Party),Terminated,Study Details | NCT02277366 | Role of Bronchoscopy in Early Lung Cancer Screening of High Risk Population | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02277366?cond=Lung%20Cancer&viewType=Card&page=19&rank=182
Lung Cancer,"Information provided by Jian Zhang, Air Force Military Medical University, China (Responsible Party)",Recruiting,Study Details | NCT02320617 | Application of Diffusion Weighted MRI Versus CT in Evaluation of the Effect of Treating Lung Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02320617?cond=Lung%20Cancer&viewType=Card&page=19&rank=183
Lung Cancer,"Information provided by Shanghai Cancer Hospital, China (Responsible Party)",Recruiting,"Study Details | NCT04513301 | Efficacy and Safety of Sintilimab With or Without Radiotherapy in Patients With Recurrent or IV NSCLC (EGFR -, ALK -) After Failure of Platinum",https://clinicaltrials.gov/study/NCT04513301?cond=Lung%20Cancer&viewType=Card&page=19&rank=184
Lung Cancer,Information provided by The First Affiliated Hospital of Xiamen University (Responsible Party),Inconnu,Study Details | NCT04425135 | Camrelizumab Combined With Apatinib Mesylate and Standard Chemotherapy (Pemetrixed + Carboplatin) in Patients With Tyrosine Kinase Inhibitor Failure in ALK,https://clinicaltrials.gov/study/NCT04425135?cond=Lung%20Cancer&viewType=Card&page=19&rank=185
Lung Cancer,Information provided by Tianjin Medical University Second Hospital (Responsible Party),Inconnu,Study Details | NCT04486287 | Sintilimab After Stereotactic Ablation Brachytherapy for Refractory Oligometastatic Non,https://clinicaltrials.gov/study/NCT04486287?cond=Lung%20Cancer&viewType=Card&page=19&rank=186
Lung Cancer,"Information provided by Lu Shun, Shanghai Chest Hospital (Responsible Party)",Recruiting,Study Details | NCT04159337 | NGS-based Large,https://clinicaltrials.gov/study/NCT04159337?cond=Lung%20Cancer&viewType=Card&page=19&rank=187
Lung Cancer,Information provided by National Institutes of Health Clinical Center (CC),Terminated,"Study Details | NCT01313429 | Tumor Cell Vaccine for Patients Undergoing Surgery for Sarcomas, Melanomas, Germ Cell Tumors, or Malignancies That Have Metastasized to the Lungs, Pleura, or Mediastinum | ClinicalTrials.gov",https://clinicaltrials.gov/study/NCT01313429?cond=Lung%20Cancer&viewType=Card&page=19&rank=188
Lung Cancer,"Information provided by Baohui Han, Shanghai Chest Hospital (Responsible Party)",Recruiting,Study Details | NCT03975504 | China Lung Cancer Screening (CLUS) Study Version 2.0 | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03975504?cond=Lung%20Cancer&viewType=Card&page=19&rank=189
Lung Cancer,Information provided by First People's Hospital of Hangzhou (Responsible Party),Recruiting,Study Details | NCT03940404 | Anlotinib Therapy in Patients With Advanced Lung Cancer. | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03940404?cond=Lung%20Cancer&viewType=Card&page=19&rank=190
Lung Cancer,"Information provided by Jun Ni, Nantong University (Responsible Party)",Inconnu,Study Details | NCT04185467 | Lung Cancer Rehabilitation After Medical Treatment | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT04185467?cond=Lung%20Cancer&viewType=Card&page=20&rank=191
Lung Cancer,"Information provided by CHIH-HSI KUO, Chang Gung Memorial Hospital (Responsible Party)",Active,"Study Details | NCT00415337 | Endobronchial Ultrasound Guided Transbronchial Lung Biopsy With or Without Guide Sheath in Lung Tumors and the Analysis of Echoic Patterns of Lung Tumors and Mediastinal Lymph Nodes, and the Association Between Diagnostic Yield of Transbronchial Lung Biopsy and EBUS Echoic Features. | ClinicalTrials.gov",https://clinicaltrials.gov/study/NCT00415337?cond=Lung%20Cancer&viewType=Card&page=20&rank=192
Lung Cancer,Information provided by Samsung Medical Center (Responsible Party),Active,"Study Details | NCT03705546 | The Impact of Physical Activity on the Postoperative Symptoms, Complications, and Quality of Life Among Lung Cancer | ClinicalTrials.gov",https://clinicaltrials.gov/study/NCT03705546?cond=Lung%20Cancer&viewType=Card&page=20&rank=193
Lung Cancer,"Information provided by Juan LI, Central South University (Responsible Party)",Completed,Study Details | NCT06746948 | Dyadic Psychological Stress Among Lung Cancer Patient,https://clinicaltrials.gov/study/NCT06746948?cond=Lung%20Cancer&viewType=Card&page=20&rank=194
Lung Cancer,"Information provided by Bai Chunxue, Chinese Alliance Against Lung Cancer (Responsible Party)",Completed,Study Details | NCT01928836 | Risk Stratification of Patients Using the Lung Cancer Biomarker Panel in China | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01928836?cond=Lung%20Cancer&viewType=Card&page=20&rank=195
Lung Cancer,"Information provided by Jiangsu HengRui Medicine Co., Ltd. (Responsible Party)",Terminated,Study Details | NCT03666728 | A Study of SHR-1210 in Combination With BP102 in Subjects With Non,https://clinicaltrials.gov/study/NCT03666728?cond=Lung%20Cancer&viewType=Card&page=20&rank=196
Lung Cancer,Information provided by Innovent Biologics (Suzhou) Co. Ltd. (Responsible Party),Completed,Study Results | NCT03607539 | Efficacy and Safety Evaluation of Sintilimab in Patients With Advanced or Metastatic Non,https://clinicaltrials.gov/study/NCT03607539?cond=Lung%20Cancer&viewType=Card&page=20&rank=197&tab=results
Lung Cancer,Information provided by Innovent Biologics (Suzhou) Co. Ltd. (Responsible Party),Completed,Study Details | NCT03607539 | Efficacy and Safety Evaluation of Sintilimab in Patients With Advanced or Metastatic Non,https://clinicaltrials.gov/study/NCT03607539?cond=Lung%20Cancer&viewType=Card&page=20&rank=197
Lung Cancer,Information provided by Beijing Tongren Hospital (Responsible Party),Recruiting,Study Details | NCT03357094 | Pulmonary Ventilation/Perfusion Imaging for the Prediction of Postoperative Residual Pulmonary Function | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03357094?cond=Lung%20Cancer&viewType=Card&page=20&rank=198
Lung Cancer,"Information provided by Dr. Nir Peled MD, PhD, Sheba Medical Center (Responsible Party)",Recruiting,Study Details | NCT01527461 | Identifying Unique Scent Signature of Lung Cancer Through Body Odor | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01527461?cond=Lung%20Cancer&viewType=Card&page=20&rank=199
Lung Cancer,Information provided by University of Bristol (Responsible Party),Completed,Study Details | NCT03521375 | VIdeo Assisted Thoracoscopic Lobectomy Versus Conventional Open LobEcTomy for Lung Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03521375?cond=Lung%20Cancer&viewType=Card&page=20&rank=200
Lung Cancer,Information provided by National Institutes of Health Clinical Center (CC) (National Cancer Institute (NCI)) (Responsible Party),Recruiting,"Study Details | NCT00242723 | Evaluation of Cell Changes in Blood and Tissue in Cancers of the Lung, Esophagus and Lung Lining | ClinicalTrials.gov",https://clinicaltrials.gov/study/NCT00242723?cond=Lung%20Cancer&viewType=Card&page=21&rank=201
Lung Cancer,Information provided by Pfizer (Responsible Party),Completed,Study Results | NCT03220230 | Validation of Molecular Diagnostic Thecnologies for Lung Cancer Patients. | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03220230?cond=Lung%20Cancer&viewType=Card&page=21&rank=202&tab=results
Lung Cancer,Information provided by Pfizer (Responsible Party),Completed,Study Details | NCT03220230 | Validation of Molecular Diagnostic Thecnologies for Lung Cancer Patients. | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03220230?cond=Lung%20Cancer&viewType=Card&page=21&rank=202
Lung Cancer,"Information provided by Shenzhen Gene Health Bio Tech Co., Ltd. (Responsible Party)",Recruiting,Study Details | NCT03081741 | Circulating Tumor DNA in Surgical Lung Cancer Patients | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03081741?cond=Lung%20Cancer&viewType=Card&page=21&rank=203
Lung Cancer,Information provided by University of Pennsylvania (Responsible Party),Completed,Study Details | NCT01335893 | Intraoperative Imaging of Thoracic Malignancies With Indocyanine Green | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01335893?cond=Lung%20Cancer&viewType=Card&page=21&rank=204
Lung Cancer,"Information provided by Chang Chen, Shanghai Pulmonary Hospital, Shanghai, China (Responsible Party)",Completed,Study Details | NCT03325907 | Transthoracic Needle Biopsy Using 3D Printed Navigational Template: A Phase I Feasibility Trial | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03325907?cond=Lung%20Cancer&viewType=Card&page=21&rank=205
Lung Cancer,"Information provided by Simon Reuter, Naestved Hospital (Responsible Party)",Terminated,Study Details | NCT03272087 | Rational Approach to a Unilateral Pleural Effusion | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03272087?cond=Lung%20Cancer&viewType=Card&page=21&rank=206
Lung Cancer,Information provided by IRCCS Sacro Cuore Don Calabria di Negrar (Responsible Party),Terminated,Study Details | NCT03137576 | Erector Spinae Plane Block Versus Paravertebral Block During Non,https://clinicaltrials.gov/study/NCT03137576?cond=Lung%20Cancer&viewType=Card&page=21&rank=207
Lung Cancer,"Information provided by Ju-Wei Mu, Cancer Institute and Hospital, Chinese Academy of Medical Sciences (Responsible Party)",Recruiting,Study Details | NCT02933294 | Uniportal Versus Triportal Thoracoscopic Lobectomy and Sublobectomy for Early Stage Lung Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02933294?cond=Lung%20Cancer&viewType=Card&page=21&rank=208
Lung Cancer,Information provided by Wissenschaftliches Institut Bethanien e.V (Responsible Party),Completed,Study Details | NCT03017183 | Detection of Heterogeneity in Central Lung Cancer - EBUS,https://clinicaltrials.gov/study/NCT03017183?cond=Lung%20Cancer&viewType=Card&page=21&rank=209
Lung Cancer,Information provided by Wake Forest University Health Sciences (Responsible Party),Completed,Study Details | NCT02962115 | Development and Pilot Testing of a Clinical Informatics Lung Cancer Screening Intervention | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02962115?cond=Lung%20Cancer&viewType=Card&page=21&rank=210
Lung Cancer,"Information provided by Haiquan Chen, Fudan University (Responsible Party)",Recruiting,Study Details | NCT03380468 | Adjuvant Chemotherapy for High Risk Stage I Lung Adenocarcinoma | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03380468?cond=Lung%20Cancer&viewType=Card&page=22&rank=211
Lung Cancer,"Information provided by Michael Frass, Medical University of Vienna (Responsible Party)",Completed,Study Results | NCT01509612 | Additive Homeopathy in Cancer Patients | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01509612?cond=Lung%20Cancer&viewType=Card&page=22&rank=212&tab=results
Lung Cancer,"Information provided by Michael Frass, Medical University of Vienna (Responsible Party)",Completed,Study Details | NCT01509612 | Additive Homeopathy in Cancer Patients | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01509612?cond=Lung%20Cancer&viewType=Card&page=22&rank=212
Lung Cancer,"Information provided by Yi-Long Wu, Guangdong Association of Clinical Trials (Responsible Party)",Recruiting,Study Details | NCT03046316 | Local Therapy in Advanced NSCLC With Non,https://clinicaltrials.gov/study/NCT03046316?cond=Lung%20Cancer&viewType=Card&page=22&rank=213
Lung Cancer,"Information provided by Chen Liang_An, Chinese PLA General Hospital (Responsible Party)",Recruiting,Study Details | NCT02701231 | Low-frequency Rotating Magnetic System Combined With Systemic Anti,https://clinicaltrials.gov/study/NCT02701231?cond=Lung%20Cancer&viewType=Card&page=22&rank=214
Lung Cancer,Information provided by Wissenschaftliches Institut Bethanien e.V (Responsible Party),Completed,Study Results | NCT02855281 | Sensitivity of PDL-1-analysis From Pleural Effusion in Non,https://clinicaltrials.gov/study/NCT02855281?cond=Lung%20Cancer&viewType=Card&page=22&rank=215&tab=results
Lung Cancer,Information provided by Wissenschaftliches Institut Bethanien e.V (Responsible Party),Completed,Study Details | NCT02855281 | Sensitivity of PDL-1-analysis From Pleural Effusion in Non,https://clinicaltrials.gov/study/NCT02855281?cond=Lung%20Cancer&viewType=Card&page=22&rank=215
Lung Cancer,"Information provided by Jamie Studts, University of Kentucky (Responsible Party)",Completed,Study Details | NCT02790866 | Development and Feasibility Testing of a Lung Cancer Screening Decision Aid | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02790866?cond=Lung%20Cancer&viewType=Card&page=22&rank=216
Lung Cancer,Non spécifié,Inconnu,Study Details | NCT02790190 | | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02790190?cond=Lung%20Cancer&viewType=Card&page=22&rank=217
Lung Cancer,"Information provided by Simon Reuter, Naestved Hospital (Responsible Party)",Terminated,Study Details | NCT02834455 | Rational Approach to a Unilateral Pleural Effusion2 | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02834455?cond=Lung%20Cancer&viewType=Card&page=22&rank=218
Lung Cancer,"Information provided by Swaroop Revannasiddaiah, Swami Rama Cancer Hospital and Research Institute (Responsible Party)",Inconnu,Study Details | NCT01947062 | Metronomic Cyclophosphamide in Combination With Standard Chemotherapy for Squamous Cell Lung Carcinoma | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01947062?cond=Lung%20Cancer&viewType=Card&page=22&rank=219
Lung Cancer,"Information provided by Gitte Fredberg Persson, Rigshospitalet, Denmark (Responsible Party)",Completed,Study Details | NCT02540499 | Deep Inspiration Breath Hold as Primary Strategy for Locally Advanced Lung Cancer Radiotherapy | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02540499?cond=Lung%20Cancer&viewType=Card&page=22&rank=220
Lung Cancer,"Information provided by University Hospital, Limoges (Responsible Party)",Completed,Study Details | NCT02531737 | Nintedanib (Vargatef®) Plus Docetaxel in Second Line of Treatment in Patients With Lung Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02531737?cond=Lung%20Cancer&viewType=Card&page=23&rank=221
Lung Cancer,"Information provided by Jun Wang, Peking University People's Hospital (Responsible Party)",Recruiting,Study Details | NCT02740400 | A Comparison Between EBUS-GS and CT,https://clinicaltrials.gov/study/NCT02740400?cond=Lung%20Cancer&viewType=Card&page=23&rank=222
Lung Cancer,"Information provided by Shadia Jalal, Indiana University (Responsible Party)",Recruiting,Study Details | NCT02630615 | Circulating Tumor Cells (CTC) in Lung Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02630615?cond=Lung%20Cancer&viewType=Card&page=23&rank=223
Lung Cancer,Information provided by Tang-Du Hospital (Responsible Party),Recruiting,Study Details | NCT02518802 | Pemetrexed Combined With Synchronous Gefitinib as Adjuvent Therapy in Patient With EGFR Mutant Lung Adenocarcinoma | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02518802?cond=Lung%20Cancer&viewType=Card&page=23&rank=224
Lung Cancer,Information provided by Centre Hospitalier Universitaire de Nice (Responsible Party),Completed,Study Details | NCT02372448 | Multicenter Validation of the Sensitivity of Theranostic ALK Rearrangement Detection by FISH Analysis and Prevalence of Escaping Mutations in Circulating Tumor Cells for the Non,https://clinicaltrials.gov/study/NCT02372448?cond=Lung%20Cancer&viewType=Card&page=23&rank=225
Lung Cancer,"Information provided by Raffit Hassan, M.D., National Institutes of Health Clinical Center (CC) (Responsible Party)",Completed,Study Results | NCT02839681 | Anti,https://clinicaltrials.gov/study/NCT02839681?cond=Lung%20Cancer&viewType=Card&page=23&rank=226&tab=results
Lung Cancer,"Information provided by Raffit Hassan, M.D., National Institutes of Health Clinical Center (CC) (Responsible Party)",Terminated,Study Details | NCT02839681 | Anti,https://clinicaltrials.gov/study/NCT02839681?cond=Lung%20Cancer&viewType=Card&page=23&rank=226
Lung Cancer,Information provided by Xijing Hospital,Recruiting,Study Details | NCT00657423 | Impact of Endostar Combined With Chemotherapy on the Angiogenesis of Advanced Non,https://clinicaltrials.gov/study/NCT00657423?cond=Lung%20Cancer&viewType=Card&page=23&rank=227
Lung Cancer,"Information provided by Eva Boysen Hansen, Aarhus University Hospital (Responsible Party)",Active,Study Details | NCT02284633 | Blood Sample Monitoring of Patients With EGFR Mutated Lung Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02284633?cond=Lung%20Cancer&viewType=Card&page=23&rank=228
Lung Cancer,Information provided by National Taiwan University Hospital (Responsible Party),Recruiting,Study Details | NCT02393664 | Effects of Nonintubated Versus Intubated General Anesthesia on Recovery After Thoracoscopic Lung Resection | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02393664?cond=Lung%20Cancer&viewType=Card&page=23&rank=229
Lung Cancer,Information provided by University of Arkansas (Responsible Party),Withdrawn,Study Details | NCT02264236 | Vaccination of Advanced,https://clinicaltrials.gov/study/NCT02264236?cond=Lung%20Cancer&viewType=Card&page=23&rank=230
Lung Cancer,"Information provided by Wei Qin, Xidian University (Responsible Party)",Recruiting,Study Details | NCT02469493 | The Effect and Mechanism of Electroacupuncture on Acute Chemotherapy,https://clinicaltrials.gov/study/NCT02469493?cond=Lung%20Cancer&viewType=Card&page=24&rank=231
Lung Cancer,Information provided by Boehringer Ingelheim (Responsible Party),Terminated,Study Details | NCT02199886 | Dose-escalation Study of BIBH 1 in Patients With Non,https://clinicaltrials.gov/study/NCT02199886?cond=Lung%20Cancer&viewType=Card&page=24&rank=232
Lung Cancer,Information provided by National Taiwan University Hospital,Recruiting,Study Details | NCT00172575 | Differentiation of Malig. & Ben. Solitary Pulm. Nodules & Prediction of Clin. Outcome Using Perfus. Analysis of DCEMRI | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00172575?cond=Lung%20Cancer&viewType=Card&page=24&rank=233
Lung Cancer,Information provided by McMaster University (Responsible Party),Completed,Study Details | NCT02149576 | Does Intense Regimented Surveillance Improve the Rates of Therapeutic Re,https://clinicaltrials.gov/study/NCT02149576?cond=Lung%20Cancer&viewType=Card&page=24&rank=234
Lung Cancer,Non spécifié,Inconnu,Study Details | NCT02030444 | | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02030444?cond=Lung%20Cancer&viewType=Card&page=24&rank=235
Lung Cancer,Information provided by National Taiwan University Hospital (Responsible Party),Completed,Study Details | NCT02123173 | Hemodynamic Changes During One Lung Ventilation in Non-intubated Vedio,https://clinicaltrials.gov/study/NCT02123173?cond=Lung%20Cancer&viewType=Card&page=24&rank=236
Lung Cancer,Information provided by European Lung Cancer Working Party (Responsible Party),Active,Study Details | NCT02484872 | Has Inflammation a Significant Implication in Lung Cancer Evolution? | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02484872?cond=Lung%20Cancer&viewType=Card&page=24&rank=237
Lung Cancer,Information provided by Nova Scotia Health Authority (Responsible Party),Recruiting,Study Details | NCT06354959 | Prehab for Lung and Esophageal Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT06354959?cond=Lung%20Cancer&viewType=Card&page=24&rank=238
Lung Cancer,"Information provided by Johnny Moons, University Hospital, Gasthuisberg (Responsible Party)",Completed,Study Details | NCT02031809 | Multicentric Study VATS Major Introperative Complications | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02031809?cond=Lung%20Cancer&viewType=Card&page=24&rank=239
Lung Cancer,"Information provided by University Hospital, Caen (Responsible Party)",Inconnu,Study Details | NCT01687647 | Sputum Cytometry Analysis in Lung Cancer Screening After Professional Asbestos Exposure | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01687647?cond=Lung%20Cancer&viewType=Card&page=24&rank=240
Lung Cancer,"Information provided by University of Colorado, Denver (Responsible Party)",Recruiting,Study Details | NCT01580982 | Molecular Analysis of Oncogenes and Resistance Mechanisms in Lung Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01580982?cond=Lung%20Cancer&viewType=Card&page=25&rank=241
Lung Cancer,"Information provided by University of Colorado, Denver (Responsible Party)",Recruiting,Study Details | NCT01585675 | Specimen Banking From Patients With Lung Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01585675?cond=Lung%20Cancer&viewType=Card&page=25&rank=242
Lung Cancer,"Information provided by Young Joo Min, Ulsan University Hospital (Responsible Party)",Inconnu,Study Details | NCT01775943 | Efficacy of EGFR TKIs in Patients With Rare EGFR,https://clinicaltrials.gov/study/NCT01775943?cond=Lung%20Cancer&viewType=Card&page=25&rank=243
Lung Cancer,"Information provided by Oscar Gerardo Arrieta Rodríguez MD, Instituto Nacional de Cancerologia de Mexico (Responsible Party)",Completed,Study Details | NCT01631565 | Early Incorporation of Patient and Family to Attention and Care Program in Oncology Versus Standard of Care | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01631565?cond=Lung%20Cancer&viewType=Card&page=25&rank=244
Lung Cancer,Information provided by University Medical Center Groningen (Responsible Party),Inconnu,Study Details | NCT06809946 | Feasibility of Fluorescence Imaging with Bevacizumab,https://clinicaltrials.gov/study/NCT06809946?cond=Lung%20Cancer&viewType=Card&page=25&rank=245
Lung Cancer,"Information provided by Dennis Wigle, Mayo Clinic (Responsible Party)",Terminated,Study Details | NCT01622621 | Stereotactic Body Radiotherapy (SBRT) Versus Sublobar Resection for High-Risk Patients Non,https://clinicaltrials.gov/study/NCT01622621?cond=Lung%20Cancer&viewType=Card&page=25&rank=246
Lung Cancer,Information provided by Norwegian University of Science and Technology (Responsible Party),Completed,Study Details | NCT01413737 | Postoperative Results of Surgical Treatment of Lung Cancer After 30 Days | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01413737?cond=Lung%20Cancer&viewType=Card&page=25&rank=247
Lung Cancer,"Information provided by University of California, San Francisco (Responsible Party)",Withdrawn,Study Details | NCT01684696 | Virtual Intervention for Lung Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01684696?cond=Lung%20Cancer&viewType=Card&page=25&rank=248
Lung Cancer,Information provided by Boehringer Ingelheim (Responsible Party),Completed,Study Results | NCT01466660 | LUX,https://clinicaltrials.gov/study/NCT01466660?cond=Lung%20Cancer&viewType=Card&page=25&rank=249&tab=results
Lung Cancer,Information provided by Boehringer Ingelheim (Responsible Party),Completed,Study Details | NCT01466660 | LUX,https://clinicaltrials.gov/study/NCT01466660?cond=Lung%20Cancer&viewType=Card&page=25&rank=249
Lung Cancer,"Information provided by Filiz Oezkan, University Hospital, Essen (Responsible Party)",Recruiting,Study Details | NCT02157857 | One Step Nucleic Acid Amplification in Endobronchial Ultrasound,https://clinicaltrials.gov/study/NCT02157857?cond=Lung%20Cancer&viewType=Card&page=25&rank=250
Lung Cancer,Information provided by Duke University (Responsible Party),Completed,Study Details | NCT00673283 | Early Detection of Lung Cancer Via Bi,https://clinicaltrials.gov/study/NCT00673283?cond=Lung%20Cancer&viewType=Card&page=26&rank=251
Lung Cancer,Information provided by Sanofi (Responsible Party),Completed,Study Details | NCT01266512 | Concurrent Chemoradiotherapy Using Intensity Modulated Radiotherapy (IMRT) & Docetaxel-cisplatin (or Carboplatin) Followed by Adjuvant Chemotherapy for Inoperable Stage III Non-small,https://clinicaltrials.gov/study/NCT01266512?cond=Lung%20Cancer&viewType=Card&page=26&rank=252
Lung Cancer,"Information provided by Cai Li, First Affiliated Hospital, Sun Yat-Sen University (Responsible Party)",Completed,Study Details | NCT01307085 | Effect of Remote Ischemic Preconditioning on Lung Injury After Pulmonary Resection | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01307085?cond=Lung%20Cancer&viewType=Card&page=26&rank=253
Lung Cancer,Information provided by Proton Collaborative Group (Responsible Party),Active,Study Details | NCT01770418 | A Phase I/II Study of Hypofractionated Proton Therapy for Stage II-III Non,https://clinicaltrials.gov/study/NCT01770418?cond=Lung%20Cancer&viewType=Card&page=26&rank=254
Lung Cancer,Information provided by Sanofi (Responsible Party),Completed,Study Details | NCT01038661 | Tax First,https://clinicaltrials.gov/study/NCT01038661?cond=Lung%20Cancer&viewType=Card&page=26&rank=255
Lung Cancer,Information provided by Sanofi,Completed,Study Details | NCT00826852 | Weekly Docetaxel and Four Weekly Carboplatin in Non-small Cell Lung Cancer Carbo,https://clinicaltrials.gov/study/NCT00826852?cond=Lung%20Cancer&viewType=Card&page=26&rank=256
Lung Cancer,"Information provided by André Änghede Haraldsson, Region Skane (Responsible Party)",Inconnu,Study Details | NCT05844761 | Real,https://clinicaltrials.gov/study/NCT05844761?cond=Lung%20Cancer&viewType=Card&page=26&rank=257
Lung Cancer,"Information provided by Hospital Authority, Hong Kong",Completed,Study Details | NCT00563420 | Early Lung Cancer Detection in Patients With Sputum Cytology and Autofluorescence Bronchoscopy in People at High Risk of Lung Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00563420?cond=Lung%20Cancer&viewType=Card&page=26&rank=258
Lung Cancer,"Information provided by Hospital Authority, Hong Kong",Recruiting,Study Details | NCT00563160 | Study of Efficacy of Induction Chemotherapy With Gemcitabine and Carboplatin for Operable Non-small,https://clinicaltrials.gov/study/NCT00563160?cond=Lung%20Cancer&viewType=Card&page=26&rank=259
Lung Cancer,Information provided by Oncolytics Biotech (Responsible Party),Completed,Study Details | NCT00998192 | A Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Squamous Cell Carcinoma of the Lung | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00998192?cond=Lung%20Cancer&viewType=Card&page=26&rank=260
Lung Cancer,Information provided by National Institutes of Health Clinical Center (CC) (National Cancer Institute (NCI)) (Responsible Party),Completed,"Study Details | NCT00482118 | Smoky Coal Exposure, Genetic Susceptibility, and Lung Cancer in Non",https://clinicaltrials.gov/study/NCT00482118?cond=Lung%20Cancer&viewType=Card&page=27&rank=261
Lung Cancer,Information provided by Eli Lilly and Company (Responsible Party),Completed,Study Results | NCT00497770 | An Observational Study of the Ethnic Impact of Patients Undergoing Second (2nd) Line Treatment for Non,https://clinicaltrials.gov/study/NCT00497770?cond=Lung%20Cancer&viewType=Card&page=27&rank=262&tab=results
Lung Cancer,Information provided by Eli Lilly and Company (Responsible Party),Completed,Study Details | NCT00497770 | An Observational Study of the Ethnic Impact of Patients Undergoing Second (2nd) Line Treatment for Non,https://clinicaltrials.gov/study/NCT00497770?cond=Lung%20Cancer&viewType=Card&page=27&rank=262
Lung Cancer,"Information provided by David Schrump, M.D., National Cancer Institute (NCI) (Responsible Party)",Completed,"Study Results | NCT02054104 | Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum | ClinicalTrials.gov",https://clinicaltrials.gov/study/NCT02054104?cond=Lung%20Cancer&viewType=Card&page=27&rank=263&tab=results
Lung Cancer,"Information provided by David Schrump, M.D., National Cancer Institute (NCI) (Responsible Party)",Terminated,"Study Details | NCT02054104 | Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum | ClinicalTrials.gov",https://clinicaltrials.gov/study/NCT02054104?cond=Lung%20Cancer&viewType=Card&page=27&rank=263
Lung Cancer,Information provided by National Institutes of Health Clinical Center (CC) (National Cancer Institute (NCI)) (Responsible Party),Completed,"Study Details | NCT00339859 | DNA Repair, p53 and Apoptosis Phenotypes in Lung Cancer | ClinicalTrials.gov",https://clinicaltrials.gov/study/NCT00339859?cond=Lung%20Cancer&viewType=Card&page=27&rank=264
Lung Cancer,Information provided by Eli Lilly and Company,Completed,Study Results | NCT00356525 | Chemotherapy Treatment in Re,https://clinicaltrials.gov/study/NCT00356525?cond=Lung%20Cancer&viewType=Card&page=27&rank=265&tab=results
Lung Cancer,Information provided by Eli Lilly and Company,Terminated,Study Details | NCT00356525 | Chemotherapy Treatment in Re,https://clinicaltrials.gov/study/NCT00356525?cond=Lung%20Cancer&viewType=Card&page=27&rank=265
Lung Cancer,Information provided by Assistance Publique - Hôpitaux de Paris (Responsible Party),Completed,Study Details | NCT00805077 | Pulmonary Surgery and Protective Mechanical Ventilation | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00805077?cond=Lung%20Cancer&viewType=Card&page=27&rank=266
Lung Cancer,"Information provided by Rune Matthiesen, Universidade Nova de Lisboa (Responsible Party)",Recruiting,Study Details | NCT04887545 | Immune- and Microenvironment,https://clinicaltrials.gov/study/NCT04887545?cond=Lung%20Cancer&viewType=Card&page=27&rank=267
Lung Cancer,Information provided by Sanofi,Completed,Study Details | NCT00174629 | GILT Docetaxel - Non,https://clinicaltrials.gov/study/NCT00174629?cond=Lung%20Cancer&viewType=Card&page=27&rank=268
Lung Cancer,"Information provided by Yuhchyau Chen, University of Rochester (Responsible Party)",Completed,Study Details | NCT00178230 | Circulating Cytokines as Predictors of Radiation Induced Pulmonary Toxicity | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00178230?cond=Lung%20Cancer&viewType=Card&page=27&rank=269
Lung Cancer,Information provided by Sanofi,Completed,Study Details | NCT00258739 | Docetaxel in Non Small Cell Lung Cancer (NSCLC) | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00258739?cond=Lung%20Cancer&viewType=Card&page=27&rank=270
Lung Cancer,"Information provided by University Hospital, Basel, Switzerland (Responsible Party)",Completed,"Study Details | NCT00558350 | Systemic, Intrapulmonary and Pleural Inflammatory Reaction in Patients Undergoing Thoracic Surgery | ClinicalTrials.gov",https://clinicaltrials.gov/study/NCT00558350?cond=Lung%20Cancer&viewType=Card&page=28&rank=271
Lung Cancer,Information provided by Sanofi,Completed,Study Details | NCT00174772 | Pulmonart: Docetaxel - Non,https://clinicaltrials.gov/study/NCT00174772?cond=Lung%20Cancer&viewType=Card&page=28&rank=272
Lung Cancer,Information provided by Pfizer,Withdrawn,"Study Details | NCT00090701 | A Phase 2, Open-Label, Multicenter Study of the GARFT Inhibitor in Patients With Metastatic Non",https://clinicaltrials.gov/study/NCT00090701?cond=Lung%20Cancer&viewType=Card&page=28&rank=273
Lung Cancer,Information provided by AHS Cancer Control Alberta (Responsible Party),Completed,Study Details | NCT00123747 | Study of 18F-Fluorodeoxyglucose (FluGlucoScan) in Patients Receiving a Treatment Planning Study of 3 Dimensional Conformal Radiation Therapy Guided by Breath Held CT and PET Imaging for Patients With Non,https://clinicaltrials.gov/study/NCT00123747?cond=Lung%20Cancer&viewType=Card&page=28&rank=274
Lung Cancer,Information provided by Eli Lilly and Company,Completed,Study Details | NCT00071136 | Pemetrexed and Gemcitabine in Patients With Advanced Non,https://clinicaltrials.gov/study/NCT00071136?cond=Lung%20Cancer&viewType=Card&page=28&rank=275
Lung Cancer,Information provided by Pfizer,Completed,"Study Details | NCT00050830 | A Phase 2, Randomized, Open-Label Study Of Single Agent CI-1033 In Patients With Advanced Non",https://clinicaltrials.gov/study/NCT00050830?cond=Lung%20Cancer&viewType=Card&page=28&rank=276
Lung Cancer,Information provided by Pfizer,Completed,Study Details | NCT00074854 | A Clinical Efficacy Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR,https://clinicaltrials.gov/study/NCT00074854?cond=Lung%20Cancer&viewType=Card&page=28&rank=277
Lung Cancer,Information provided by Eli Lilly and Company,Completed,Study Details | NCT00051506 | ALIMTA(Pemetrexed)/Cisplatin and ALIMTA(Pemetrexed)/Carboplatin in Extensive Stage Small Cell Lung Cancer. | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00051506?cond=Lung%20Cancer&viewType=Card&page=28&rank=278
Lung Cancer,"Information provided by Neal Edward Dunlap, University of Louisville (Responsible Party)",Recruiting,Study Details | NCT01871454 | Safety of Pentoxifylline and Vitamin E With Stereotactic Ablative Radiotherapy (SABR) in Non,https://clinicaltrials.gov/study/NCT01871454?cond=Lung%20Cancer&viewType=Card&page=28&rank=279
Lung Cancer,"Information provided by Dong Wook Shin, Samsung Medical Center (Responsible Party)",Recruiting,Study Details | NCT05078918 | Comprehensive Care Program for Their Return to Normal Life Among Lung Cancer Survivors | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT05078918?cond=Lung%20Cancer&viewType=Card&page=28&rank=280
Lung Cancer,"Information provided by University Hospital, Brest (Responsible Party)",Recruiting,Study Details | NCT03175861 | Modeling of the Response to Hypofractionated Stereotactic Pulmonary Irradiation | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03175861?cond=Lung%20Cancer&viewType=Card&page=29&rank=281
Lung Cancer,Non spécifié,Inconnu,Study Details | NCT05676788 | | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT05676788?cond=Lung%20Cancer&viewType=Card&page=29&rank=282
Lung Cancer,"Information provided by Taipei Veterans General Hospital, Taiwan (Responsible Party)",Recruiting,Study Details | NCT05875870 | Effects of Bright,https://clinicaltrials.gov/study/NCT05875870?cond=Lung%20Cancer&viewType=Card&page=29&rank=283
Lung Cancer,Information provided by Royal Marsden NHS Foundation Trust (Responsible Party),Completed,Study Details | NCT02587455 | Pembrolizumab and Palliative Radiotherapy in Lung | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02587455?cond=Lung%20Cancer&viewType=Card&page=29&rank=284
Lung Cancer,Information provided by Centre Hospitalier Universitaire de Besancon (Responsible Party),Completed,"Study Details | NCT02862288 | Preliminary Study of Microwave Tumoral Ablation Performances for the Treatment of Pulmonary, Renal and Bone Neoplasia. | ClinicalTrials.gov",https://clinicaltrials.gov/study/NCT02862288?cond=Lung%20Cancer&viewType=Card&page=29&rank=285
Lung Cancer,"Information provided by Hecheng Li M.D., Ph.D, Ruijin Hospital (Responsible Party)",Active,Study Details | NCT04945928 | Safety and Feasibility of Surgery After Conversion Therapy for Locally Advanced and Advanced NSCLC | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT04945928?cond=Lung%20Cancer&viewType=Card&page=29&rank=286
Lung Cancer,"Information provided by Jerod L Stapleton, PhD, University of Kentucky (Responsible Party)",Recruiting,Study Details | NCT05857995 | Precision Lung Cancer Survivorship Care Intervention | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT05857995?cond=Lung%20Cancer&viewType=Card&page=29&rank=287
Lung Cancer,Information provided by Grupo Espanol de Tumores Neuroendocrinos (Responsible Party),Completed,Study Results | NCT03095274 | Durvalumab (MEDI4736) Plus Tremelimumab for Advanced Neuroendocrine Neoplasms of Gastroenteropancreatic or Lung Origin | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03095274?cond=Lung%20Cancer&viewType=Card&page=29&rank=288&tab=results
Lung Cancer,Information provided by Grupo Espanol de Tumores Neuroendocrinos (Responsible Party),Completed,Study Details | NCT03095274 | Durvalumab (MEDI4736) Plus Tremelimumab for Advanced Neuroendocrine Neoplasms of Gastroenteropancreatic or Lung Origin | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03095274?cond=Lung%20Cancer&viewType=Card&page=29&rank=288
Lung Cancer,"Information provided by Wael Hanna, St. Joseph's Healthcare Hamilton (Responsible Party)",Completed,Study Details | NCT03849040 | The Use of Artificial Intelligence to Predict Cancerous Lymph Nodes for Lung Cancer Staging During Ultrasound Imaging | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03849040?cond=Lung%20Cancer&viewType=Card&page=29&rank=289
Lung Cancer,"Information provided by Chen Liang_An, Chinese PLA General Hospital (Responsible Party)",Recruiting,Study Details | NCT02965300 | The Value of VOCs Analysis in Exhaled Breath for Pulmonary Benign and Malignant Lesion Diagnosis | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02965300?cond=Lung%20Cancer&viewType=Card&page=29&rank=290
Lung Cancer,"Information provided by Hecheng Li M.D., Ph.D, Ruijin Hospital (Responsible Party)",Completed,Study Details | NCT03516500 | Trial of Identifying the Lung Intersegmental Plane by Iron Sucrose Injection Staining | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03516500?cond=Lung%20Cancer&viewType=Card&page=30&rank=291
Lung Cancer,"Information provided by SK Medical (Beijing) Co., Ltd. (Responsible Party)",Completed,Study Details | NCT02050100 | Biomarkers for Diagnosis of Lung Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02050100?cond=Lung%20Cancer&viewType=Card&page=30&rank=292
Lung Cancer,Information provided by McMaster University (Responsible Party),Completed,Study Details | NCT02793713 | EBUS Score Validation for Malignancy | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02793713?cond=Lung%20Cancer&viewType=Card&page=30&rank=293
Lung Cancer,Information provided by National Taiwan University Hospital (Responsible Party),Recruiting,Study Details | NCT03144622 | 18F,https://clinicaltrials.gov/study/NCT03144622?cond=Lung%20Cancer&viewType=Card&page=30&rank=294
Lung Cancer,Information provided by Maastricht University Medical Center (Responsible Party),Active,Study Details | NCT02931942 | Changing Over Time of Ascorbic Acid After Chemotherapy | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02931942?cond=Lung%20Cancer&viewType=Card&page=30&rank=295
Lung Cancer,Information provided by L'hôpital Nord-Ouest - Villefranche Villefranche sur Saône (Responsible Party),Completed,Study Details | NCT06832592 | Supportive Care Needs of Bronchial Cancer Patients in Active Treatment: A Descriptive Study in Outpatient Oncology | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT06832592?cond=Lung%20Cancer&viewType=Card&page=30&rank=296
Lung Cancer,Information provided by Assistance Publique - Hôpitaux de Paris (Responsible Party),Terminated,Study Details | NCT03090880 | Prophylaxis of Venous Thromboembolism in Advanced Lung Cancer (PROVE) | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03090880?cond=Lung%20Cancer&viewType=Card&page=30&rank=297
Lung Cancer,Information provided by Tianjin Medical University Cancer Institute and Hospital (Responsible Party),Recruiting,Study Details | NCT06775678 | Spatial Fragmentation Combined With Low-dose Radiotherapy for Immunotherapy Combined With Chemotherapy-resistant Locally Advanced or Advanced Non,https://clinicaltrials.gov/study/NCT06775678?cond=Lung%20Cancer&viewType=Card&page=30&rank=298
Lung Cancer,Information provided by IRCCS Sacro Cuore Don Calabria di Negrar (Responsible Party),Completed,Study Details | NCT03134729 | PATHOS Study Pain Assessment in Thoracic Oncologic Surgery | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03134729?cond=Lung%20Cancer&viewType=Card&page=30&rank=299
Lung Cancer,Information provided by Latin American Cooperative Oncology Group (Responsible Party),Active,"Study Details | NCT05299125 | Amivantamab, Lazertinib, and Pemetrexed for First-line Treatment of Recurrent/Metastatic Non",https://clinicaltrials.gov/study/NCT05299125?cond=Lung%20Cancer&viewType=Card&page=30&rank=300
Breast Cancer,Information provided by photonamic GmbH & Co. KG (Responsible Party),Terminated,Study Details | NCT01110954 | Fluorescence,https://clinicaltrials.gov/study/NCT01110954?cond=Breast%20Cancer&viewType=Card&page=1&rank=1
Breast Cancer,Information provided by Centre Jean Perrin (Responsible Party),Terminated,Study Details | NCT01522300 | Etude Tomos- Apport de la Tomosynthèse Dans le Bilan d'Extension locorégional préthérapeutique d'Une Tumeur du Sein : Recherche de multicentricité Tomos Study,https://clinicaltrials.gov/study/NCT01522300?cond=Breast%20Cancer&viewType=Card&page=1&rank=2
Breast Cancer,"Information provided by Helio Carrara, University of Sao Paulo (Responsible Party)",Inconnu,Study Details | NCT03777852 | Emotional Evaluation and Reconstructed Breast Satisfaction | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03777852?cond=Breast%20Cancer&viewType=Card&page=1&rank=3
Breast Cancer,Information provided by Tianjin Medical University Cancer Institute and Hospital (Responsible Party),Recruiting,"Study Details | NCT05781633 | The Efficacy and Safety of Eutideron, Etoposide, and Bevacizumab in Patients With Brain Metastases From Breast Cancer. | ClinicalTrials.gov",https://clinicaltrials.gov/study/NCT05781633?cond=Breast%20Cancer&viewType=Card&page=1&rank=4
Breast Cancer,"Information provided by Institut National de la Santé Et de la Recherche Médicale, France (Responsible Party)",Completed,Study Details | NCT01531036 | 3D Breast Ultrasound Elastography in Patients Under Neoadjuvant Chemotherapy | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01531036?cond=Breast%20Cancer&viewType=Card&page=1&rank=5
Breast Cancer,"Information provided by Jun Zhang, Fudan University (Responsible Party)",Completed,Study Details | NCT05408676 | Comparison of Dexamethasone Alone vs in Combination With Pericardium 6 (P6) Electrical Stimulation or Granisetron in the Prevention of Postoperative Nausea and Vomiting in Patients Undergoing Breast Cancer Surgery | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT05408676?cond=Breast%20Cancer&viewType=Card&page=1&rank=6
Breast Cancer,"Information provided by David Garcia Cinca, Hospital Clinic of Barcelona (Responsible Party)",Inconnu,Study Details | NCT04301375 | Omission of Surgery and Sentinel Lymph Node Dissection in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti- HER2,https://clinicaltrials.gov/study/NCT04301375?cond=Breast%20Cancer&viewType=Card&page=1&rank=7
Breast Cancer,Information provided by US Oncology Research (Responsible Party),Terminated,"Study Details | NCT02229149 | Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre",https://clinicaltrials.gov/study/NCT02229149?cond=Breast%20Cancer&viewType=Card&page=1&rank=8
Breast Cancer,"Information provided by Jin Seok Ahn, MD, Samsung Medical Center (Responsible Party)",Completed,Study Details | NCT04678544 | Cooling Cap Trial to Prevent Permanent Chemotherapy,https://clinicaltrials.gov/study/NCT04678544?cond=Breast%20Cancer&viewType=Card&page=1&rank=9
Breast Cancer,"Information provided by Guniz M.Koksal, Istanbul University (Responsible Party)",Completed,Study Details | NCT03204708 | Open Technique Interpectoral Catheter for Postoperative Analgesia in Modified Radical Mastectomy | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03204708?cond=Breast%20Cancer&viewType=Card&page=1&rank=10
Breast Cancer,"Information provided by Hao Wang, Sichuan Provincial People's Hospital (Responsible Party)",Completed,Study Details | NCT05976620 | Clinical Study of 18F-FAPI,https://clinicaltrials.gov/study/NCT05976620?cond=Breast%20Cancer&viewType=Card&page=2&rank=11
Breast Cancer,"Information provided by Eduardo Barbieri, Instituto Brasileiro de Controle do Cancer (Responsible Party)",Recruiting,Study Details | NCT05665920 | Efficacy and Safety of Ultra_HYPofractionated RadiotHerapy in Women With BrEast CaNcer Receiving Regional Nodal Radiation vs Nodal Moderate Hypofractionated Radiotherapy | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT05665920?cond=Breast%20Cancer&viewType=Card&page=2&rank=12
Breast Cancer,"Information provided by JIAN WEN, The Fourth Affiliated Hospital of China Medical University (Responsible Party)",Inconnu,Study Details | NCT06994416 | A Novel Fluorescent Ductal Needle for Localization and Sampling of High,https://clinicaltrials.gov/study/NCT06994416?cond=Breast%20Cancer&viewType=Card&page=2&rank=13
Breast Cancer,Information provided by Thomas Jefferson University (Responsible Party),Recruiting,Study Details | NCT05408260 | A Study to Compare the Effectiveness of Two Types of Ultrasound Technologies in Women Who Have Had Breast Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT05408260?cond=Breast%20Cancer&viewType=Card&page=2&rank=14
Breast Cancer,"Information provided by Estefania Toledo, University of Navarra (Responsible Party)",Active,Study Details | NCT04174391 | Lifestyles and Breast Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT04174391?cond=Breast%20Cancer&viewType=Card&page=2&rank=15
Breast Cancer,"Information provided by Liu Qiang, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (Responsible Party)",Recruiting,Study Details | NCT07095023 | Neoadjuvant Oral Paclitaxel Plus Subcutaneous Pertuzumab/Trastuzumab in Patients With HER2,https://clinicaltrials.gov/study/NCT07095023?cond=Breast%20Cancer&viewType=Card&page=2&rank=16
Breast Cancer,"Information provided by Juergen Debus, University Hospital Heidelberg (Responsible Party)",Recruiting,Study Details | NCT06954623 | Partial Breast Re,https://clinicaltrials.gov/study/NCT06954623?cond=Breast%20Cancer&viewType=Card&page=2&rank=17
Breast Cancer,"Information provided by National University Hospital, Singapore",Recruiting,Study Details | NCT00941408 | Biomarker Study of Breast Tumors | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00941408?cond=Breast%20Cancer&viewType=Card&page=2&rank=18
Breast Cancer,"Information provided by Kun Wang, Guangdong Provincial People's Hospital (Responsible Party)",Inconnu,Study Details | NCT06825949 | A Clinical Study to Explore the Efficacy and Safety of Hyperbaric Oxygen in the Neoadjuvant Treatment of Hormone Receptor Positive Breast Cancer Patients | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT06825949?cond=Breast%20Cancer&viewType=Card&page=2&rank=19
Breast Cancer,"Information provided by Kun Wang, Guangdong Provincial People's Hospital (Responsible Party)",Inconnu,Study Details | NCT06825975 | A Phase II Single-Arm Clinical Study to Explore the Efficacy and Safety of Hyperbaric Oxygen in the Neoadjuvant Treatment of Triple,https://clinicaltrials.gov/study/NCT06825975?cond=Breast%20Cancer&viewType=Card&page=2&rank=20
Breast Cancer,"Information provided by Kun Wang, Guangdong Provincial People's Hospital (Responsible Party)",Recruiting,Study Details | NCT06811870 | A Phase II Single,https://clinicaltrials.gov/study/NCT06811870?cond=Breast%20Cancer&viewType=Card&page=3&rank=21
Breast Cancer,"Information provided by Kun Wang, Guangdong Provincial People's Hospital (Responsible Party)",Inconnu,Study Details | NCT06819501 | Hyperbaric Oxygen Therapy for Peripheral Neuropathy Due to Paclitaxel Analogs | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT06819501?cond=Breast%20Cancer&viewType=Card&page=3&rank=22
Breast Cancer,"Information provided by Second Affiliated Hospital, School of Medicine, Zhejiang University (Responsible Party)",Completed,Study Details | NCT06172270 | Sub,https://clinicaltrials.gov/study/NCT06172270?cond=Breast%20Cancer&viewType=Card&page=3&rank=23
Breast Cancer,Information provided by Institut Rafael (Responsible Party),Completed,"Study Details | NCT06662864 | Study on Sleep, Lifestyle and Quality of Life in Women With Breast Cancer | ClinicalTrials.gov",https://clinicaltrials.gov/study/NCT06662864?cond=Breast%20Cancer&viewType=Card&page=3&rank=24
Breast Cancer,Information provided by Chang Gung Memorial Hospital (Responsible Party),Inconnu,"Study Details | NCT07034248 | Electrochemical Biosensor Based on Lectin-functionalized Nitrogen, Sulfur",https://clinicaltrials.gov/study/NCT07034248?cond=Breast%20Cancer&viewType=Card&page=3&rank=25
Breast Cancer,Information provided by Peking Union Medical College Hospital (Responsible Party),Recruiting,Study Details | NCT03347864 | 68Ga-NOTA,https://clinicaltrials.gov/study/NCT03347864?cond=Breast%20Cancer&viewType=Card&page=3&rank=26
Breast Cancer,Information provided by Institut Bergonié (Responsible Party),Withdrawn,Study Details | NCT01827969 | Feasibility Study of Ablathermy Focused Ultrasound (USF) of Breast Tumors Before Mastectomy | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01827969?cond=Breast%20Cancer&viewType=Card&page=3&rank=27
Breast Cancer,"Information provided by Andrzej Krol, State University of New York - Upstate Medical University (Responsible Party)",Completed,Study Details | NCT00639171 | Evaluate the Use of the Magnetic Resonance Spectroscopy in Determining if the Breast Tumor is Benign or Malignant | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00639171?cond=Breast%20Cancer&viewType=Card&page=3&rank=28
Breast Cancer,"Information provided by Beckman Laser Institute and Medical Center, University of California, Irvine (Responsible Party)",Withdrawn,Study Details | NCT02340468 | Breast Tumor Oxygenation During Exercise | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02340468?cond=Breast%20Cancer&viewType=Card&page=3&rank=29
Breast Cancer,Information provided by Aegera Therapeutics,Terminated,Study Details | NCT00558545 | A Phase 1,https://clinicaltrials.gov/study/NCT00558545?cond=Breast%20Cancer&viewType=Card&page=3&rank=30
Breast Cancer,Information provided by UNICANCER (Responsible Party),Completed,Study Details | NCT04132960 | Study of DS,https://clinicaltrials.gov/study/NCT04132960?cond=Breast%20Cancer&viewType=Card&page=4&rank=31
Breast Cancer,Information provided by Regina Elena Cancer Institute (Responsible Party),Recruiting,Study Details | NCT05858762 | Artificial Intelligence for Automated Diagnosis of Breast Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT05858762?cond=Breast%20Cancer&viewType=Card&page=4&rank=32
Breast Cancer,Information provided by Eastern Cooperative Oncology Group (Responsible Party),Completed,Study Results | NCT05076266 | COVID,https://clinicaltrials.gov/study/NCT05076266?cond=Breast%20Cancer&viewType=Card&page=4&rank=33&tab=results
Breast Cancer,Information provided by Eastern Cooperative Oncology Group (Responsible Party),Terminated,Study Details | NCT05076266 | COVID,https://clinicaltrials.gov/study/NCT05076266?cond=Breast%20Cancer&viewType=Card&page=4&rank=33
Breast Cancer,"Information provided by Paul L. Carson Ph.D, University of Michigan (Responsible Party)",Completed,Study Details | NCT00721903 | Three Dimensional (3D) Ultrasound in Predicting Response to Breast Cancer Therapies | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00721903?cond=Breast%20Cancer&viewType=Card&page=4&rank=34
Breast Cancer,Information provided by Region Skane (Responsible Party),Recruiting,Study Details | NCT06857669 | Clinical Explorative Optical Breast Investigations | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT06857669?cond=Breast%20Cancer&viewType=Card&page=4&rank=35
Breast Cancer,"Information provided by LuZhe Sun, The University of Texas Health Science Center at San Antonio (Responsible Party)",Completed,Study Results | NCT02642094 | Aging Mammary Stem Cells and Breast Cancer Prevention | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02642094?cond=Breast%20Cancer&viewType=Card&page=4&rank=36&tab=results
Breast Cancer,"Information provided by LuZhe Sun, The University of Texas Health Science Center at San Antonio (Responsible Party)",Terminated,Study Details | NCT02642094 | Aging Mammary Stem Cells and Breast Cancer Prevention | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02642094?cond=Breast%20Cancer&viewType=Card&page=4&rank=36
Breast Cancer,Information provided by Pontificia Universidad Catolica de Chile (Responsible Party),Recruiting,Study Details | NCT04948983 | The Effect of a Patient Decision Aids for Breast Cancer Screening | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT04948983?cond=Breast%20Cancer&viewType=Card&page=4&rank=37
Breast Cancer,"Information provided by University Hospital, Tours",Completed,Study Details | NCT00243698 | A Pilot Study Evaluation of the Efficacy of SonoVue to Detect and Characterise Breast Lesions | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00243698?cond=Breast%20Cancer&viewType=Card&page=4&rank=38
Breast Cancer,"Information provided by Andréa Dias Reis, Universidade Estadual Paulista Júlio de Mesquita Filho (Responsible Party)",Completed,Study Details | NCT03494400 | Aerobic Training in Treatment for Breast Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03494400?cond=Breast%20Cancer&viewType=Card&page=4&rank=39
Breast Cancer,"Information provided by Michele Tedeschi, Istituto Clinico Humanitas (Responsible Party)",Terminated,Study Details | NCT02375048 | Randomized Study on Postmenopausal Women With Early Stage Breast Cancer: WBI Versus APBI | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02375048?cond=Breast%20Cancer&viewType=Card&page=4&rank=40
Breast Cancer,Information provided by AB-CT - Advanced Breast-CT GmbH (Responsible Party),Recruiting,Study Details | NCT05989022 | Comparison of Low,https://clinicaltrials.gov/study/NCT05989022?cond=Breast%20Cancer&viewType=Card&page=5&rank=41
Breast Cancer,"Information provided by Sara Tolaney, MD, Dana-Farber Cancer Institute (Responsible Party)",Completed,Study Results | NCT00542451 | Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2,https://clinicaltrials.gov/study/NCT00542451?cond=Breast%20Cancer&viewType=Card&page=5&rank=42&tab=results
Breast Cancer,"Information provided by Sara Tolaney, MD, Dana-Farber Cancer Institute (Responsible Party)",Completed,Study Details | NCT00542451 | Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2,https://clinicaltrials.gov/study/NCT00542451?cond=Breast%20Cancer&viewType=Card&page=5&rank=42
Breast Cancer,Information provided by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (Responsible Party),Completed,Study Results | NCT03863522 | Automated Method for Breast Cancer Detection | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03863522?cond=Breast%20Cancer&viewType=Card&page=5&rank=43&tab=results
Breast Cancer,Information provided by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (Responsible Party),Terminated,Study Details | NCT03863522 | Automated Method for Breast Cancer Detection | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03863522?cond=Breast%20Cancer&viewType=Card&page=5&rank=43
Breast Cancer,Information provided by Mayo Clinic (Responsible Party),Recruiting,Study Details | NCT04692818 | 3D Ultrasound Breast Imaging | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT04692818?cond=Breast%20Cancer&viewType=Card&page=5&rank=44
Breast Cancer,"Information provided by National University Hospital, Singapore",Active,Study Details | NCT01247467 | Analysis of Prognostic and Predictive Genomic Signatures Using Archival Paraffin-embedded Breast Tumor,https://clinicaltrials.gov/study/NCT01247467?cond=Breast%20Cancer&viewType=Card&page=5&rank=45
Breast Cancer,"Information provided by Megha Garg, University of Missouri-Columbia (Responsible Party)",Completed,Study Results | NCT03684408 | Radiofrequency Chip for Localization of Non,https://clinicaltrials.gov/study/NCT03684408?cond=Breast%20Cancer&viewType=Card&page=5&rank=46&tab=results
Breast Cancer,"Information provided by Megha Garg, University of Missouri-Columbia (Responsible Party)",Completed,Study Details | NCT03684408 | Radiofrequency Chip for Localization of Non,https://clinicaltrials.gov/study/NCT03684408?cond=Breast%20Cancer&viewType=Card&page=5&rank=46
Breast Cancer,"Information provided by Beckman Laser Institute and Medical Center, University of California, Irvine (Responsible Party)",Withdrawn,Study Details | NCT02725658 | Monitoring and Predicting Breast Cancer Neoadjuvant Chemotherapy Response Using DOSI | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02725658?cond=Breast%20Cancer&viewType=Card&page=5&rank=47
Breast Cancer,Information provided by Institut Paoli-Calmettes (Responsible Party),Recruiting,Study Details | NCT02869607 | Institut Paoli Calmettes Breast Cancer Database | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02869607?cond=Breast%20Cancer&viewType=Card&page=5&rank=48
Breast Cancer,Information provided by Siemens Healthcare QT (Responsible Party),Completed,Study Details | NCT02608281 | Evaluation of Diagnostic Accuracy of Contrast Enhanced Dual Energy Mammography Imaging in Comparison to CE,https://clinicaltrials.gov/study/NCT02608281?cond=Breast%20Cancer&viewType=Card&page=5&rank=49
Breast Cancer,"Information provided by National University Hospital, Singapore",Active,Study Details | NCT01247480 | Analysis of Prognostic and Predictive Genomic Signatures Using Archival Paraffin,https://clinicaltrials.gov/study/NCT01247480?cond=Breast%20Cancer&viewType=Card&page=5&rank=50
Breast Cancer,Information provided by Koning Corporation (Responsible Party),Completed,Study Details | NCT01952717 | PMA Required Pivotal Multi-reader Multi,https://clinicaltrials.gov/study/NCT01952717?cond=Breast%20Cancer&viewType=Card&page=6&rank=51
Breast Cancer,"Information provided by Virginia G. Kaklamani, The University of Texas Health Science Center at San Antonio (Responsible Party)",Withdrawn,"Study Details | NCT02396433 | Combination of Carboplatin, Eribulin Mesylate, and E7449 in BRCA",https://clinicaltrials.gov/study/NCT02396433?cond=Breast%20Cancer&viewType=Card&page=6&rank=52
Breast Cancer,"Information provided by Kathy Miller, Indiana University School of Medicine (Responsible Party)",Completed,Study Results | NCT02595372 | Inhibiting Fatty Acid Synthase to Improve Efficacy of Neoadjuvant Chemotherapy | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02595372?cond=Breast%20Cancer&viewType=Card&page=6&rank=53&tab=results
Breast Cancer,"Information provided by Kathy Miller, Indiana University School of Medicine (Responsible Party)",Completed,Study Details | NCT02595372 | Inhibiting Fatty Acid Synthase to Improve Efficacy of Neoadjuvant Chemotherapy | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02595372?cond=Breast%20Cancer&viewType=Card&page=6&rank=53
Breast Cancer,Information provided by Novian Health Inc. (Responsible Party),Recruiting,Study Details | NCT03463954 | Confirmatory Clinical Evaluation of Novilase® Laser Therapy for Focal Destruction of Malignant Breast Tumors | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03463954?cond=Breast%20Cancer&viewType=Card&page=6&rank=54
Breast Cancer,"Information provided by Mark L. Venturi, MD FACS, National Center for Plastic Surgery, Virginia (Responsible Party)",Completed,Study Details | NCT01372917 | Evaluating AlloMax in Immediate Expander,https://clinicaltrials.gov/study/NCT01372917?cond=Breast%20Cancer&viewType=Card&page=6&rank=55
Breast Cancer,Information provided by University of Arkansas (Responsible Party),Completed,Study Results | NCT00571987 | Pilot Study of Radiofrequency Ablation of Breast Cancer Lumpectomy Sites to Decrease Re,https://clinicaltrials.gov/study/NCT00571987?cond=Breast%20Cancer&viewType=Card&page=6&rank=56&tab=results
Breast Cancer,Information provided by University of Arkansas (Responsible Party),Completed,Study Details | NCT00571987 | Pilot Study of Radiofrequency Ablation of Breast Cancer Lumpectomy Sites to Decrease Re,https://clinicaltrials.gov/study/NCT00571987?cond=Breast%20Cancer&viewType=Card&page=6&rank=56
Breast Cancer,Information provided by Centre Hospitalier Emile Roux (Responsible Party),Recruiting,"Study Details | NCT04794075 | Therapeutic Education and Nursing Support Program for Supportive Care, in Patients Treated With Hormone Therapy for Non",https://clinicaltrials.gov/study/NCT04794075?cond=Breast%20Cancer&viewType=Card&page=6&rank=57
Breast Cancer,Information provided by University of Arkansas (Responsible Party),Active,Study Details | NCT00572481 | Axillary Reverse Mapping | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00572481?cond=Breast%20Cancer&viewType=Card&page=6&rank=58
Breast Cancer,"Information provided by Dr Rajendra A. Badwe, Tata Memorial Centre (Responsible Party)",Completed,Study Details | NCT00193778 | Assessing Impact of Loco,https://clinicaltrials.gov/study/NCT00193778?cond=Breast%20Cancer&viewType=Card&page=6&rank=59
Breast Cancer,Information provided by NeuTec Pharma,Completed,Study Details | NCT00217815 | Preliminary Study of Mycograb and Docetaxel in Advanced Breast Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00217815?cond=Breast%20Cancer&viewType=Card&page=6&rank=60
Breast Cancer,"Information provided by Dr Rajendra A. Badwe, Tata Memorial Centre (Responsible Party)",Terminated,Study Details | NCT00128362 | Sentinel Node Biopsy and Axillary Sampling in Operable Breast Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00128362?cond=Breast%20Cancer&viewType=Card&page=7&rank=61
Breast Cancer,Information provided by M.D. Anderson Cancer Center (Responsible Party),Active,Study Details | NCT03429907 | An Early Stress,https://clinicaltrials.gov/study/NCT03429907?cond=Breast%20Cancer&viewType=Card&page=7&rank=62
Breast Cancer,Breath Gas Analysis for the Diagnosis of Breast Cancer,Terminated,Study Details | NCT01105468 | Breath Gas Analysis for the Diagnosis of Breast Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01105468?cond=Breast%20Cancer&viewType=Card&page=7&rank=63
Breast Cancer,"Information provided by Ping Liang, Chinese PLA General Hospital (Responsible Party)",Recruiting,Study Details | NCT02860104 | Ultrasound Guided Percutaneous Microwave Ablation for Breast Lesions | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02860104?cond=Breast%20Cancer&viewType=Card&page=7&rank=64
Breast Cancer,"Information provided by Valentina Hoyos, Baylor College of Medicine (Responsible Party)",Inconnu,Study Details | NCT06251544 | TRAIL-R2 and HER2 Bi,https://clinicaltrials.gov/study/NCT06251544?cond=Breast%20Cancer&viewType=Card&page=7&rank=65
Breast Cancer,"Information provided by Fengxi Su, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (Responsible Party)",Recruiting,Study Details | NCT01503905 | Neoadjuvant Chemotherapy for Operable Premenopausal Breast Cancer Patients | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01503905?cond=Breast%20Cancer&viewType=Card&page=7&rank=66
Breast Cancer,"Information provided by SANA AHUJA, Vardhman Mahavir Medical College And Safdarjung Hospital (Responsible Party)",Completed,Study Details | NCT06433804 | Clinicopathological Parameters of HER2 Low Breast Cancers | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT06433804?cond=Breast%20Cancer&viewType=Card&page=7&rank=67
Breast Cancer,Information provided by Washington University School of Medicine (Responsible Party),Active,Study Details | NCT04067726 | RANKL Inhibition and Mammographic Breast Density | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT04067726?cond=Breast%20Cancer&viewType=Card&page=7&rank=68
Breast Cancer,"Information provided by HiberCell, Inc. (Responsible Party)",Completed,Study Details | NCT05159778 | Phase 2 Study of Imprime PGG and Pembrolizumab in Patients With HR+/HER2,https://clinicaltrials.gov/study/NCT05159778?cond=Breast%20Cancer&viewType=Card&page=7&rank=69
Breast Cancer,Information provided by RenJi Hospital (Responsible Party),Inconnu,Study Details | NCT03022864 | Accurate Diagnosis System for Postoperative Chronic Pain Based on fMRI | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03022864?cond=Breast%20Cancer&viewType=Card&page=7&rank=70
Breast Cancer,"Information provided by Eduardo Barbieri, Instituto Brasileiro de Controle do Cancer (Responsible Party)",Recruiting,"Study Details | NCT04669873 | Accelerated Partial Breast Irradiation Versus Standard or Hypofractionated Whole-Breast Irradiation, in Early Breast Cancer, After Breast",https://clinicaltrials.gov/study/NCT04669873?cond=Breast%20Cancer&viewType=Card&page=8&rank=71
Breast Cancer,Information provided by Pfizer (Responsible Party),Active,Study Details | NCT04654208 | Swedish Ibrance Registries Insights (SIRI) | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT04654208?cond=Breast%20Cancer&viewType=Card&page=8&rank=72
Breast Cancer,Information provided by Pulsion Medical Systems SE,Inconnu,Study Details | NCT01395706 | ICG Fluorescence Technique for the Detection of Sentinel Lymph Nodes | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01395706?cond=Breast%20Cancer&viewType=Card&page=8&rank=73
Breast Cancer,Information provided by Institut Curie (Responsible Party),Completed,Study Details | NCT04327063 | MIRs 04 : Interpectoral Nerve Block With Ropivacaine Versus Placebo Before Breast Cancer Surgery | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT04327063?cond=Breast%20Cancer&viewType=Card&page=8&rank=74
Breast Cancer,Information provided by Peking Union Medical College Hospital (Responsible Party),Inconnu,Study Details | NCT04825444 | Clinical Study of Vascular Imaging Evaluation of Computed Tomography Photoacoustic Breast Imaging System | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT04825444?cond=Breast%20Cancer&viewType=Card&page=8&rank=75
Breast Cancer,"Information provided by Daiichi Sankyo (Daiichi Sankyo Taiwan Ltd., a Daiichi Sankyo Company) (Responsible Party)",Completed,Study Results | NCT03368196 | DS,https://clinicaltrials.gov/study/NCT03368196?cond=Breast%20Cancer&viewType=Card&page=8&rank=76&tab=results
Breast Cancer,"Information provided by Daiichi Sankyo (Daiichi Sankyo Taiwan Ltd., a Daiichi Sankyo Company) (Responsible Party)",Completed,Study Details | NCT03368196 | DS,https://clinicaltrials.gov/study/NCT03368196?cond=Breast%20Cancer&viewType=Card&page=8&rank=76
Breast Cancer,"Information provided by Stefanie A. Woodard, University of Alabama at Birmingham (Responsible Party)",Active,Study Details | NCT04340180 | Evaluating the Performance of AI in Evaluating Breast MRI Performed With Dose Reduction | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT04340180?cond=Breast%20Cancer&viewType=Card&page=8&rank=77
Breast Cancer,Information provided by AryoGen Pharmed Co. (Responsible Party),Completed,Study Results | NCT03425656 | Comparing Efficacy and Safety of AryoGen Pharmed Biosimilar Trastuzumab (AryoTrust) Versus Herceptin® in Breast Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03425656?cond=Breast%20Cancer&viewType=Card&page=8&rank=78&tab=results
Breast Cancer,Information provided by AryoGen Pharmed Co. (Responsible Party),Completed,Study Details | NCT03425656 | Comparing Efficacy and Safety of AryoGen Pharmed Biosimilar Trastuzumab (AryoTrust) Versus Herceptin® in Breast Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03425656?cond=Breast%20Cancer&viewType=Card&page=8&rank=78
Breast Cancer,"Information provided by Daiichi Sankyo (Daiichi Sankyo Co., Ltd.) (Responsible Party)",Completed,Study Results | NCT03366428 | Phase 1 Study to Evaluate the Effect of DS-8201a on the QT/QTc Interval and Pharmacokinetics in HER2,https://clinicaltrials.gov/study/NCT03366428?cond=Breast%20Cancer&viewType=Card&page=8&rank=79&tab=results
Breast Cancer,"Information provided by Daiichi Sankyo (Daiichi Sankyo Co., Ltd.) (Responsible Party)",Completed,Study Details | NCT03366428 | Phase 1 Study to Evaluate the Effect of DS-8201a on the QT/QTc Interval and Pharmacokinetics in HER2,https://clinicaltrials.gov/study/NCT03366428?cond=Breast%20Cancer&viewType=Card&page=8&rank=79
Breast Cancer,Information provided by Institut fuer Frauengesundheit (Responsible Party),Completed,Study Details | NCT03289819 | Neoadjuvant Pembrolizumab(Pbr)/Nab,https://clinicaltrials.gov/study/NCT03289819?cond=Breast%20Cancer&viewType=Card&page=8&rank=80
Breast Cancer,Information provided by Pfizer (Responsible Party),Completed,Study Results | NCT03159195 | Ibrance Real World Insights | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03159195?cond=Breast%20Cancer&viewType=Card&page=9&rank=81&tab=results
Breast Cancer,Information provided by Pfizer (Responsible Party),Completed,Study Details | NCT03159195 | Ibrance Real World Insights | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03159195?cond=Breast%20Cancer&viewType=Card&page=9&rank=81
Breast Cancer,"Information provided by National University Hospital, Singapore",Recruiting,Study Details | NCT00698477 | Chemotherapy on Methylation Patterns in Breast Tumor Tissue Correlating With Clinical Response and Outcomes | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00698477?cond=Breast%20Cancer&viewType=Card&page=9&rank=82
Breast Cancer,Information provided by Rabin Medical Center (Responsible Party),Completed,Study Details | NCT02495363 | Analgesic Effects of Ultrasound Guided PEC Blocks on Analgesic Opioid Consumption of Cancer Surgery Patients | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02495363?cond=Breast%20Cancer&viewType=Card&page=9&rank=83
Breast Cancer,Information provided by Institut Curie (Responsible Party),Completed,Study Details | NCT02408393 | MIRs03: Paravertebral Block With Ropivacaine Before Breast Cancer Surgery | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02408393?cond=Breast%20Cancer&viewType=Card&page=9&rank=84
Breast Cancer,"Information provided by AKANIST PIYAPANT, MD.,FRCST., National Cancer Institute, Thailand (Responsible Party)",Completed,Study Details | NCT01943032 | Discordant Hormonal Status of Breast Cancer. | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01943032?cond=Breast%20Cancer&viewType=Card&page=9&rank=85
Breast Cancer,"Information provided by AKANIST PIYAPANT, MD.,FRCST., National Cancer Institute, Thailand (Responsible Party)",Completed,Study Details | NCT01935739 | Discordant HER2/Neu Status of Breast Cancer. | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01935739?cond=Breast%20Cancer&viewType=Card&page=9&rank=86
Breast Cancer,Information provided by Pierre Fabre Medicament (Responsible Party),Completed,Study Results | NCT01953003 | Phase III Study of Vinflunine Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01953003?cond=Breast%20Cancer&viewType=Card&page=9&rank=87&tab=results
Breast Cancer,Information provided by Pierre Fabre Medicament (Responsible Party),Completed,Study Details | NCT01953003 | Phase III Study of Vinflunine Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01953003?cond=Breast%20Cancer&viewType=Card&page=9&rank=87
Breast Cancer,"Information provided by Erwei Song, M.D., Ph.D., Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (Responsible Party)",Withdrawn,Study Details | NCT02376413 | Oncoplastic Breast-conserving Surgery in Non,https://clinicaltrials.gov/study/NCT02376413?cond=Breast%20Cancer&viewType=Card&page=9&rank=88
Breast Cancer,"Information provided by Jun Zhu, Peking University (Responsible Party)",Recruiting,Study Details | NCT02905916 | The Efficacy and Safety of PEG-rhG,https://clinicaltrials.gov/study/NCT02905916?cond=Breast%20Cancer&viewType=Card&page=9&rank=89
Breast Cancer,"Information provided by Mohamed Ahmed Mansour, Kasr El Aini Hospital (Responsible Party)",Completed,Study Details | NCT03030677 | Establishing Technique for PECS2 Catheter Insertion | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03030677?cond=Breast%20Cancer&viewType=Card&page=9&rank=90
Breast Cancer,"Information provided by XU Zhi, Peking University (Responsible Party)",Recruiting,Study Details | NCT01668238 | Detection of Benign and Malignant Thyroid and Breast Tumors by Fourier Transform Infrared Spectrometry | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01668238?cond=Breast%20Cancer&viewType=Card&page=10&rank=91
Breast Cancer,Information provided by Institut Paoli-Calmettes (Responsible Party),Recruiting,Study Details | NCT03667417 | Genetic Predisposition to Breast and Ovarian Cancer: Prospective Study of BRCAx Gene Mutation | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03667417?cond=Breast%20Cancer&viewType=Card&page=10&rank=92
Breast Cancer,"Information provided by Matthew S. Rosen, Ph.D., Massachusetts General Hospital (Responsible Party)",Inconnu,Study Details | NCT05486520 | Low,https://clinicaltrials.gov/study/NCT05486520?cond=Breast%20Cancer&viewType=Card&page=10&rank=93
Breast Cancer,"Information provided by Carrie Hruska, Mayo Clinic (Responsible Party)",Completed,Study Details | NCT01588834 | Histology of Functional Density in Premenopausal Breast | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01588834?cond=Breast%20Cancer&viewType=Card&page=10&rank=94
Breast Cancer,"Information provided by Lixin Jiang, RenJi Hospital (Responsible Party)",Inconnu,Study Details | NCT06185855 | A Simplified Approach to Predicting the Malignancy of Breast Lesions: Nomogram in Ultrasonography | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT06185855?cond=Breast%20Cancer&viewType=Card&page=10&rank=95
Breast Cancer,Information provided by Olive Healthcare (Responsible Party),Completed,Study Details | NCT06597175 | Evaluating Investigational Medical Device for Breast Tumor Diagnosis Using Diffusion Optical Spectroscopy | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT06597175?cond=Breast%20Cancer&viewType=Card&page=10&rank=96
Breast Cancer,"Information provided by Carrie Hruska, Mayo Clinic (Responsible Party)",Completed,Study Details | NCT01240278 | Histology of Functional Density in Postmenopausal Breast | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01240278?cond=Breast%20Cancer&viewType=Card&page=10&rank=97
Breast Cancer,Information provided by AstraZeneca (Responsible Party),Completed,Study Details | NCT01711502 | Epidemiology and Management of Metastatic Breast Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01711502?cond=Breast%20Cancer&viewType=Card&page=10&rank=98
Breast Cancer,"Information provided by Kaisa Fritzell, Karolinska Institutet (Responsible Party)",Recruiting,"Study Details | NCT05512260 | Development, Implementation and Evaluation of an Individual Decision Aid in Swedish Cancer Screening Programs | ClinicalTrials.gov",https://clinicaltrials.gov/study/NCT05512260?cond=Breast%20Cancer&viewType=Card&page=10&rank=99
Breast Cancer,Information provided by National Institutes of Health Clinical Center (CC),Completed,Study Details | NCT00001496 | Establishment of Normal Breast Epithelial Cell Lines From Patients at High Risk for Breast Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00001496?cond=Breast%20Cancer&viewType=Card&page=10&rank=100
Breast Cancer,"Information provided by Nippon Kayaku Co., Ltd. (Responsible Party)",Completed,Study Results | NCT01644890 | A Phase III Study of NK105 in Patients With Breast Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01644890?cond=Breast%20Cancer&viewType=Card&page=11&rank=101&tab=results
Breast Cancer,"Information provided by Nippon Kayaku Co., Ltd. (Responsible Party)",Completed,Study Details | NCT01644890 | A Phase III Study of NK105 in Patients With Breast Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01644890?cond=Breast%20Cancer&viewType=Card&page=11&rank=101
Breast Cancer,Information provided by Alaunos Therapeutics (Responsible Party),Completed,Study Results | NCT01703754 | Adenoviral Vector Monotherapy or Combination With Chemotherapy in Subjects With Recurrent/Metastatic Breast Cancer. | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01703754?cond=Breast%20Cancer&viewType=Card&page=11&rank=102&tab=results
Breast Cancer,Information provided by Alaunos Therapeutics (Responsible Party),Terminated,Study Details | NCT01703754 | Adenoviral Vector Monotherapy or Combination With Chemotherapy in Subjects With Recurrent/Metastatic Breast Cancer. | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01703754?cond=Breast%20Cancer&viewType=Card&page=11&rank=102
Breast Cancer,Information provided by Seagen Inc. (Responsible Party),Completed,Study Details | NCT01983501 | A Study of Tucatinib (ONT-380) Combined With Ado-trastuzumab Emtansine (T,https://clinicaltrials.gov/study/NCT01983501?cond=Breast%20Cancer&viewType=Card&page=11&rank=103
Breast Cancer,Information provided by Washington University School of Medicine (Responsible Party),Completed,Study Details | NCT03262831 | Mindful Movement in Women Receiving Adjuvant or Neoadjuvant Therapy for Breast Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03262831?cond=Breast%20Cancer&viewType=Card&page=11&rank=104
Breast Cancer,"Information provided by Winnie Chee, IMU University, Malaysia (Responsible Party)",Completed,Study Details | NCT04400552 | Perioperative Oral Nutrition Supplementation in Malnourished Surgical Cancer Patients | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT04400552?cond=Breast%20Cancer&viewType=Card&page=11&rank=105
Breast Cancer,Information provided by Washington University School of Medicine (Responsible Party),Withdrawn,"Study Details | NCT03285607 | MCS110 Combined With Neoadjuvant Doxorubicin, Cyclophosphamide, and Weekly Paclitaxel in Patients With Hormone-Receptor Positive and HER2",https://clinicaltrials.gov/study/NCT03285607?cond=Breast%20Cancer&viewType=Card&page=11&rank=106
Breast Cancer,Information provided by Avera McKennan Hospital & University Health Center (Responsible Party),Completed,Study Results | NCT02472353 | Use of Metformin to Reduce Cardiac Toxicity in Breast Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02472353?cond=Breast%20Cancer&viewType=Card&page=11&rank=107&tab=results
Breast Cancer,Information provided by Avera McKennan Hospital & University Health Center (Responsible Party),Terminated,Study Details | NCT02472353 | Use of Metformin to Reduce Cardiac Toxicity in Breast Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02472353?cond=Breast%20Cancer&viewType=Card&page=11&rank=107
Breast Cancer,"Information provided by Mary E. Charlson, MD, Weill Medical College of Cornell University (Responsible Party)",Completed,Study Details | NCT00248911 | The Effect Of Meditation On Quality Of Life In Women With Breast Cancer And Other Gynecological Cancers | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00248911?cond=Breast%20Cancer&viewType=Card&page=11&rank=108
Breast Cancer,"Information provided by Paul L. Carson Ph.D, University of Michigan (Responsible Party)",Completed,Study Details | NCT01807754 | Simulated Screening Study for Breast Imaging | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01807754?cond=Breast%20Cancer&viewType=Card&page=11&rank=109
Breast Cancer,Information provided by Institut Claudius Regaud (Responsible Party),Recruiting,Study Details | NCT07195344 | Study Aiming to Compare the Plasma Exposure of the Payload (Free-DXd) in Patients Treated by T,https://clinicaltrials.gov/study/NCT07195344?cond=Breast%20Cancer&viewType=Card&page=11&rank=110
Breast Cancer,"Information provided by Sonya Reid, Vanderbilt-Ingram Cancer Center (Responsible Party)",Recruiting,Study Details | NCT05693766 | Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT05693766?cond=Breast%20Cancer&viewType=Card&page=12&rank=111
Breast Cancer,"Information provided by Miroslav Župčić, University Hospital Dubrava (Responsible Party)",Active,Study Details | NCT02004834 | Levobupivacaine and Lidocaine for Paravertebral Block Causes Greater Hemodynamic Oscillations Than Levobupivacaine | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02004834?cond=Breast%20Cancer&viewType=Card&page=12&rank=112
Breast Cancer,Information provided by US Oncology Research (Responsible Party),Completed,Study Details | NCT02229136 | Miracle Mouthwash Plus Hydrocortisone vs Prednisolone Mouth Rinse for Mouth Sores Caused by Everolimus | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02229136?cond=Breast%20Cancer&viewType=Card&page=12&rank=113
Breast Cancer,Information provided by Washington University School of Medicine (Responsible Party),Recruiting,Study Details | NCT06981208 | ChatGPT & Surgeon Synergy: Redefining Breast Reconstruction Consultations for Enhanced Patient Engagement and Satisfaction | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT06981208?cond=Breast%20Cancer&viewType=Card&page=12&rank=114
Breast Cancer,Information provided by Weill Medical College of Cornell University (Responsible Party),Active,Study Details | NCT02755896 | Trial to Compare Radiation Fibrosis With Five Versus Three Fractions | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02755896?cond=Breast%20Cancer&viewType=Card&page=12&rank=115
Breast Cancer,Information provided by Washington University School of Medicine (Responsible Party),Completed,Study Details | NCT05716542 | Prehabilitation to Revolutionize Oncology: Telehealth Exercise for Cognitive Triumphs (The PROTECT Trial) | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT05716542?cond=Breast%20Cancer&viewType=Card&page=12&rank=116
Breast Cancer,Information provided by Washington University School of Medicine (Responsible Party),Recruiting,Study Details | NCT05972343 | COOL-IT-PRO: Cryoablation of Breast Cancer in Non,https://clinicaltrials.gov/study/NCT05972343?cond=Breast%20Cancer&viewType=Card&page=12&rank=117
Breast Cancer,Information provided by Washington University School of Medicine (Responsible Party),Recruiting,"Study Details | NCT05837455 | NeoTAILOR: ABiomarker-directed Approach to Guide Neoadjuvant Therapy for Patients With Stage II/III ER-positive, HER2",https://clinicaltrials.gov/study/NCT05837455?cond=Breast%20Cancer&viewType=Card&page=12&rank=118
Breast Cancer,Information provided by AstraZeneca (Responsible Party),Terminated,Study Details | NCT01596530 | Evaluation of Drug Activity in Women With Breast Cancer and no Previous Herceptin Treatment | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01596530?cond=Breast%20Cancer&viewType=Card&page=12&rank=119
Breast Cancer,Information provided by Washington University School of Medicine (Responsible Party),Recruiting,"Study Details | NCT04968964 | Treatment Monitoring of Patients Receiving CDK 4/6 Inhibitors for Hormone Receptor (HR) Positive, HER2 Negative Metastatic Breast Cancer (MBC) With or Without the Addition of DiviTum® Serum Thymidine Kinase 1 (TK1) Activity Testing | ClinicalTrials.gov",https://clinicaltrials.gov/study/NCT04968964?cond=Breast%20Cancer&viewType=Card&page=12&rank=120
Breast Cancer,"Information provided by Isabel Blancas, Hospital Clinico Universitario San Cecilio (Responsible Party)",Completed,Study Results | NCT01509625 | Retrospective Study Assessment Treatment Response Faslodex®( 500 mg) | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01509625?cond=Breast%20Cancer&viewType=Card&page=13&rank=121&tab=results
Breast Cancer,"Information provided by Isabel Blancas, Hospital Clinico Universitario San Cecilio (Responsible Party)",Completed,Study Details | NCT01509625 | Retrospective Study Assessment Treatment Response Faslodex®( 500 mg) | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01509625?cond=Breast%20Cancer&viewType=Card&page=13&rank=121
Breast Cancer,Information provided by Maxigen Biotech Inc. (Responsible Party),Recruiting,Study Details | NCT07209020 | HealiAid Collagen Wound Dressing in Patients Undergoing Breast Tumor Surgery | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT07209020?cond=Breast%20Cancer&viewType=Card&page=13&rank=122
Breast Cancer,"Information provided by Samuel Achilefu, University of Texas Southwestern Medical Center (Responsible Party)",Completed,Study Results | NCT02807597 | Real,https://clinicaltrials.gov/study/NCT02807597?cond=Breast%20Cancer&viewType=Card&page=13&rank=123&tab=results
Breast Cancer,"Information provided by Samuel Achilefu, University of Texas Southwestern Medical Center (Responsible Party)",Terminated,Study Details | NCT02807597 | Real,https://clinicaltrials.gov/study/NCT02807597?cond=Breast%20Cancer&viewType=Card&page=13&rank=123
Breast Cancer,"Information provided by Instituto Nacional de Cancer, Brazil (Responsible Party)",Recruiting,Study Details | NCT04861220 | Surgical Pre,https://clinicaltrials.gov/study/NCT04861220?cond=Breast%20Cancer&viewType=Card&page=13&rank=124
Breast Cancer,"Information provided by University Hospital, Toulouse (Responsible Party)",Inconnu,Study Details | NCT05949983 | Health Economic Evaluation of an Adapted Physical Activity Program for Women With Breast Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT05949983?cond=Breast%20Cancer&viewType=Card&page=13&rank=125
Breast Cancer,"Information provided by Ping Liang, Chinese PLA General Hospital (Responsible Party)",Recruiting,Study Details | NCT03286413 | Comparison of Microwave Ablation With Cryoablation for Breast Tumor | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03286413?cond=Breast%20Cancer&viewType=Card&page=13&rank=126
Breast Cancer,"Information provided by Paul L. Carson Ph.D, University of Michigan (Responsible Party)",Completed,Study Details | NCT00859261 | Two Dimensional (2D) Silicon Transducer,https://clinicaltrials.gov/study/NCT00859261?cond=Breast%20Cancer&viewType=Card&page=13&rank=127
Breast Cancer,Information provided by Yonsei University (Responsible Party),Completed,Study Details | NCT04440995 | The Effects of Perioperative PECS Block During Robotic Breast Surgery and Breast Reconstruction | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT04440995?cond=Breast%20Cancer&viewType=Card&page=13&rank=128
Breast Cancer,Information provided by EXoPERT (Responsible Party),Recruiting,Study Details | NCT06672302 | A Prospective Study to Develop and Clinically Validate an in Vitro Diagnostic Medical Device That Uses Blood to Classify Patients At High Risk for Breast Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT06672302?cond=Breast%20Cancer&viewType=Card&page=13&rank=129
Breast Cancer,Information provided by US Oncology Research (Responsible Party),Active,Study Details | NCT03379428 | Trial of Ibrutinib Plus Trastuzumab in HER2,https://clinicaltrials.gov/study/NCT03379428?cond=Breast%20Cancer&viewType=Card&page=13&rank=130
Breast Cancer,Information provided by Kaiser Permanente (Responsible Party),Completed,Study Details | NCT02302196 | Autologous Fat Grafting of the Breast in Women With Post Lumpectomy Contour Defects | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02302196?cond=Breast%20Cancer&viewType=Card&page=14&rank=131
Breast Cancer,"Information provided by Shelley Johns, Indiana University (Responsible Party)",Completed,Study Details | NCT02611544 | Investigation of Three Approaches to Address Fear of Recurrence Among Breast Cancer Survivors | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02611544?cond=Breast%20Cancer&viewType=Card&page=14&rank=132
Breast Cancer,"Information provided by Ceren Yalniz, University of Alabama at Birmingham (Responsible Party)",Recruiting,Study Details | NCT06294574 | Improved Successful Retrieval Rate of HydroMARK Plus Breast Biopsy Site Marker in Comparison to HydroMARK as Well as Improved Surgeon Satisfaction | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT06294574?cond=Breast%20Cancer&viewType=Card&page=14&rank=133
Breast Cancer,"Information provided by Irene Cantarero Villanueva, Universidad de Granada (Responsible Party)",Completed,Study Details | NCT04583124 | Adjusting the Dose of Therapeutic Exercise to Prevent Neurotoxicity Due to Anticancer Treatment (ATENTO) | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT04583124?cond=Breast%20Cancer&viewType=Card&page=14&rank=134
Breast Cancer,"Information provided by Prof. dr. Mira Meeús, Universiteit Antwerpen (Responsible Party)",Recruiting,Study Details | NCT05507034 | Identifying Biomarkers for Chronic Pain After Breast Cancer Treatment. | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT05507034?cond=Breast%20Cancer&viewType=Card&page=14&rank=135
Breast Cancer,Information provided by Mayo Clinic (Responsible Party),Recruiting,Study Details | NCT06058650 | Molecular Breast Imaging Guidance for Breast Biopsy for Patients With Breast Abnormalities | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT06058650?cond=Breast%20Cancer&viewType=Card&page=14&rank=136
Breast Cancer,"Information provided by Irene Cantarero Villanueva, Universidad de Granada (Responsible Party)",Recruiting,Study Details | NCT04652609 | Preventing Chemotherapy,https://clinicaltrials.gov/study/NCT04652609?cond=Breast%20Cancer&viewType=Card&page=14&rank=137
Breast Cancer,"Information provided by Marlid Cruz Ramos, Instituto Nacional de Cancerologia de Mexico (Responsible Party)",Recruiting,"Study Details | NCT06090747 | Improving Lifestyle Behavior by ""Joven, Fuerte y Saludable"" Multidisciplinary Program. | ClinicalTrials.gov",https://clinicaltrials.gov/study/NCT06090747?cond=Breast%20Cancer&viewType=Card&page=14&rank=138
Breast Cancer,"Information provided by Shelley Johns, Indiana University (Responsible Party)",Completed,Study Details | NCT05364450 | Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT05364450?cond=Breast%20Cancer&viewType=Card&page=14&rank=139
Breast Cancer,Information provided by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (Responsible Party),Inconnu,Study Details | NCT05862610 | The Study of Trilaciclib Combined With Chemotherapy On The Neoadjuvant Therapy of TNBC | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT05862610?cond=Breast%20Cancer&viewType=Card&page=14&rank=140
Breast Cancer,"Information provided by Etienne El Helou, Dr Etienne El Helou (Responsible Party)",Completed,Study Details | NCT05604677 | Factor Influencing Breast Surgery Type Decision,https://clinicaltrials.gov/study/NCT05604677?cond=Breast%20Cancer&viewType=Card&page=15&rank=141
Breast Cancer,"Information provided by Rubén Martín Payo, University of Oviedo (Responsible Party)",Completed,Study Results | NCT04396665 | Breast Cancer: Feasibility of an Educational Intervention | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT04396665?cond=Breast%20Cancer&viewType=Card&page=15&rank=142&tab=results
Breast Cancer,"Information provided by Rubén Martín Payo, University of Oviedo (Responsible Party)",Completed,Study Details | NCT04396665 | Breast Cancer: Feasibility of an Educational Intervention | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT04396665?cond=Breast%20Cancer&viewType=Card&page=15&rank=142
Breast Cancer,Information provided by Centre Henri Becquerel (Responsible Party),Inconnu,Study Details | NCT06056414 | Study of Anxiety After a Session of Energy Resonance by Cutaneous Stimulation | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT06056414?cond=Breast%20Cancer&viewType=Card&page=15&rank=143
Breast Cancer,"Information provided by Ruth O'Regan, Emory University (Responsible Party)",Completed,Study Results | NCT01194908 | Re,https://clinicaltrials.gov/study/NCT01194908?cond=Breast%20Cancer&viewType=Card&page=15&rank=144&tab=results
Breast Cancer,"Information provided by Ruth O'Regan, Emory University (Responsible Party)",Terminated,Study Details | NCT01194908 | Re,https://clinicaltrials.gov/study/NCT01194908?cond=Breast%20Cancer&viewType=Card&page=15&rank=144
Breast Cancer,"Information provided by Anne Fleischer, University of Cincinnati (Responsible Party)",Completed,Study Details | NCT05868187 | CanRestoreFunction Cancer,https://clinicaltrials.gov/study/NCT05868187?cond=Breast%20Cancer&viewType=Card&page=15&rank=145
Breast Cancer,"Information provided by Yongsheng Wang, Shandong Cancer Hospital and Institute (Responsible Party)",Recruiting,Study Details | NCT03024463 | The Multi,https://clinicaltrials.gov/study/NCT03024463?cond=Breast%20Cancer&viewType=Card&page=15&rank=146
Breast Cancer,Information provided by Celltrion (Responsible Party),Completed,Study Results | NCT02162667 | Efficacy and Safety Evaluating Study of CT,https://clinicaltrials.gov/study/NCT02162667?cond=Breast%20Cancer&viewType=Card&page=15&rank=147&tab=results
Breast Cancer,Information provided by Celltrion (Responsible Party),Completed,Study Details | NCT02162667 | Efficacy and Safety Evaluating Study of CT,https://clinicaltrials.gov/study/NCT02162667?cond=Breast%20Cancer&viewType=Card&page=15&rank=147
Breast Cancer,"Information provided by Dr. Evelyn Moninkhof, UMC Utrecht (Responsible Party)",Recruiting,Study Details | NCT06480513 | Cancer Of the BReast Asanas Study (COBRA) | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT06480513?cond=Breast%20Cancer&viewType=Card&page=15&rank=148
Breast Cancer,Information provided by Mayo Clinic (Responsible Party),Active,Study Details | NCT05889988 | A Study of Ado-trastuzumab Emtansine (T-DM1)-Induced Peripheral Neuropathy in HER2,https://clinicaltrials.gov/study/NCT05889988?cond=Breast%20Cancer&viewType=Card&page=15&rank=149
Breast Cancer,"Information provided by Kyung-Hun Lee, Seoul National University Hospital (Responsible Party)",Recruiting,Study Details | NCT06928818 | Trastuzumab Emtansine(T-DM1) After Trastuzumab Deruxtecan(T-DXd) in HER2,https://clinicaltrials.gov/study/NCT06928818?cond=Breast%20Cancer&viewType=Card&page=15&rank=150
Breast Cancer,"Information provided by Dr. med. Petra Voiss, Universität Duisburg-Essen (Responsible Party)",Completed,Study Details | NCT03874598 | Effectiveness of Ear Acupuncture to Improve Insomnia in Women With Breast Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03874598?cond=Breast%20Cancer&viewType=Card&page=16&rank=151
Breast Cancer,"Information provided by Camila Giro, Instituto Brasileiro de Controle do Cancer (Responsible Party)",Active,Study Details | NCT05050890 | Prognostic Value of Circulating Tumor DNA Dosing in Patients in Neoadjuvant Breast Neoplasia | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT05050890?cond=Breast%20Cancer&viewType=Card&page=16&rank=152
Breast Cancer,"Information provided by Angela N Fellner PhD CCRP, TriHealth Inc. (Responsible Party)",Terminated,Study Details | NCT02364960 | Targeted Intraoperative Therapy Registry at Bethesda North Hospital (TARGIT) | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02364960?cond=Breast%20Cancer&viewType=Card&page=16&rank=153
Breast Cancer,"Information provided by Nicole Look Hong, Sunnybrook Health Sciences Centre (Responsible Party)",Completed,Study Details | NCT04893421 | Magnetic Occult Lesion Localization Instrument (MOLLI) Guidance System for Breast Lesion Localization | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT04893421?cond=Breast%20Cancer&viewType=Card&page=16&rank=154
Breast Cancer,Information provided by Zhejiang Cancer Hospital (Responsible Party),Recruiting,Study Details | NCT03756064 | Neoadjuvant Study of Pyrotinib in Patients With HER2 Positive Breast Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03756064?cond=Breast%20Cancer&viewType=Card&page=16&rank=155
Breast Cancer,Information provided by Pfizer (Responsible Party),Active,Study Details | NCT06495164 | A Real,https://clinicaltrials.gov/study/NCT06495164?cond=Breast%20Cancer&viewType=Card&page=16&rank=156
Breast Cancer,"Information provided by Graziella di Grezia, Link Campus University (Responsible Party)",Inconnu,Study Details | NCT06843083 | Contrast Enhanced Mammography or Breast Magnetic Resonance: Which Choice for Optimal Diagnostic Performance? | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT06843083?cond=Breast%20Cancer&viewType=Card&page=16&rank=157
Breast Cancer,"Information provided by Graziella di Grezia, Link Campus University (Responsible Party)",Inconnu,Study Details | NCT06843096 | Contrast Enhanced Mammography in the Evaluation of Cancer of Unknown Primary Syndrome | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT06843096?cond=Breast%20Cancer&viewType=Card&page=16&rank=158
Breast Cancer,Information provided by United BioPharma (Responsible Party),Completed,"Study Details | NCT03013881 | A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of UB",https://clinicaltrials.gov/study/NCT03013881?cond=Breast%20Cancer&viewType=Card&page=16&rank=159
Breast Cancer,Information provided by Jonsson Comprehensive Cancer Center (Responsible Party),Completed,Study Details | NCT06090630 | MR Correlated Spectroscopic Imaging for Diagnosing Breast Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT06090630?cond=Breast%20Cancer&viewType=Card&page=16&rank=160
Breast Cancer,Information provided by AHS Cancer Control Alberta (Responsible Party),Terminated,Study Details | NCT00771381 | A Study to Determine the Value of 18F,https://clinicaltrials.gov/study/NCT00771381?cond=Breast%20Cancer&viewType=Card&page=17&rank=161
Breast Cancer,"Information provided by Graziella di Grezia, Link Campus University (Responsible Party)",Inconnu,Study Details | NCT06846814 | Second-Look Ultrasound Post Contrast,https://clinicaltrials.gov/study/NCT06846814?cond=Breast%20Cancer&viewType=Card&page=17&rank=162
Breast Cancer,"Information provided by Jinghua Zhao, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (Responsible Party)",Completed,Study Details | NCT06472700 | Endoscopic Extirpation of Benign Breast Tumors Using a Lateral Chest Wall Incision | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT06472700?cond=Breast%20Cancer&viewType=Card&page=17&rank=163
Breast Cancer,"Information provided by Osama Hussein, Mansoura University (Responsible Party)",Recruiting,Study Details | NCT04644848 | Ultrasonographic Axillary Localization | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT04644848?cond=Breast%20Cancer&viewType=Card&page=17&rank=164
Breast Cancer,"Information provided by Patryk Eisler, Karlstad Central Hospital (Responsible Party)",Completed,Study Details | NCT04824599 | Regional Anesthesia and Partial Mastectomy | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT04824599?cond=Breast%20Cancer&viewType=Card&page=17&rank=165
Breast Cancer,Information provided by Pierre Fabre Pharma GmbH (Responsible Party),Completed,Study Details | NCT04388384 | Real-life Pan-HER,https://clinicaltrials.gov/study/NCT04388384?cond=Breast%20Cancer&viewType=Card&page=17&rank=166
Breast Cancer,Information provided by Baylor Research Institute (Responsible Party),Recruiting,Study Details | NCT06517212 | Tirzepatide Weight Loss for MRD+ Early Breast Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT06517212?cond=Breast%20Cancer&viewType=Card&page=17&rank=167
Breast Cancer,"Information provided by University Hospital, Grenoble (Responsible Party)",Completed,"Study Details | NCT04444882 | Complications After Lumpectomy, Sentinel Node and Radiotherapy in Breast Cancer Patients and Physiotherapy Care | ClinicalTrials.gov",https://clinicaltrials.gov/study/NCT04444882?cond=Breast%20Cancer&viewType=Card&page=17&rank=168
Breast Cancer,Information provided by Seagen Inc. (Responsible Party),Completed,Study Details | NCT02025192 | A Study of Tucatinib (ONT,https://clinicaltrials.gov/study/NCT02025192?cond=Breast%20Cancer&viewType=Card&page=17&rank=169
Breast Cancer,"Information provided by Sara Mohamed Gamal Hassan, Assiut University (Responsible Party)",Completed,Study Details | NCT04083027 | Non,https://clinicaltrials.gov/study/NCT04083027?cond=Breast%20Cancer&viewType=Card&page=17&rank=170
Breast Cancer,Information provided by Wyeth is now a wholly owned subsidiary of Pfizer,Completed,Study Results | NCT00062751 | Study Evaluating Temsirolimus (CCI,https://clinicaltrials.gov/study/NCT00062751?cond=Breast%20Cancer&viewType=Card&page=18&rank=171&tab=results
Breast Cancer,Information provided by Wyeth is now a wholly owned subsidiary of Pfizer,Completed,Study Details | NCT00062751 | Study Evaluating Temsirolimus (CCI,https://clinicaltrials.gov/study/NCT00062751?cond=Breast%20Cancer&viewType=Card&page=18&rank=171
Breast Cancer,"Information provided by Nagwa Abd El-Sadek Ahmed, Sohag University (Responsible Party)",Inconnu,Study Details | NCT06134570 | ALDH1A1 Expression in Invasive Mammary Carcinoma | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT06134570?cond=Breast%20Cancer&viewType=Card&page=18&rank=172
Breast Cancer,"Information provided by Abida K. Sattar, MD, FACS, Aga Khan University (Responsible Party)",Recruiting,Study Details | NCT03939598 | Feasibility of Preoperative Tattooing of Percutaneously Biopsied Axillary Lymph Node: A Quasi Experimental Pilot Study | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03939598?cond=Breast%20Cancer&viewType=Card&page=18&rank=173
Breast Cancer,Information provided by MedSIR (Responsible Party),Completed,Study Details | NCT02056080 | Clinical Benefit of the Treatment With Trastuzumab in Combination With Lapatinib in Metastatic Breast Cancer HER2 Positive Patients Who Has Been Previously Treated With Trastuzumab and/or Lapatinib | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02056080?cond=Breast%20Cancer&viewType=Card&page=18&rank=174
Breast Cancer,Information provided by Umbria Bioengineering Technologies (Responsible Party),Recruiting,Study Details | NCT06291896 | A Clinical Investigation to Evaluate Microwave Imaging Via MammoWave® in a Population,https://clinicaltrials.gov/study/NCT06291896?cond=Breast%20Cancer&viewType=Card&page=18&rank=175
Breast Cancer,"Information provided by Vincent Vinh-Hung, University of Geneva, Switzerland (Responsible Party)",Active,Study Details | NCT01432002 | FDG,https://clinicaltrials.gov/study/NCT01432002?cond=Breast%20Cancer&viewType=Card&page=18&rank=176
Breast Cancer,Information provided by St. Olavs Hospital (Responsible Party),Completed,Study Details | NCT03761420 | Adjuvant Endocrine Therapy in Early Stage Breast Cancer: Adherence and Clinical Outcome | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03761420?cond=Breast%20Cancer&viewType=Card&page=18&rank=177
Breast Cancer,"Information provided by Hsin-Tien Hsu, Kaohsiung Medical University Chung-Ho Memorial Hospital (Responsible Party)",Completed,Study Details | NCT05576545 | Develop and Evaluate the Effectiveness of a Self-Care Smartphone Application on the Self,https://clinicaltrials.gov/study/NCT05576545?cond=Breast%20Cancer&viewType=Card&page=18&rank=178
Breast Cancer,"Information provided by Gerhard Andersson, Linkoeping University (Responsible Party)",Inconnu,Study Details | NCT03275727 | A Guided Internet-delivered Individually-tailored ACT,https://clinicaltrials.gov/study/NCT03275727?cond=Breast%20Cancer&viewType=Card&page=18&rank=179
Breast Cancer,Information provided by Institut fuer Frauengesundheit (Responsible Party),Active,Study Details | NCT05033756 | Comprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresectable or Metastatic HER2 Negative Breast Cancer and a Deleterious Germline Mutation or a Homologous Recombination Deficiency (COMPRENDO | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT05033756?cond=Breast%20Cancer&viewType=Card&page=18&rank=180
Breast Cancer,Information provided by Pfizer (Responsible Party),Completed,Study Details | NCT03445637 | Post Marketing Surveillance Study to Observe Safety and Efficacy of IBRANCE® | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03445637?cond=Breast%20Cancer&viewType=Card&page=19&rank=181
Breast Cancer,Information provided by Samsung Medical Center (Responsible Party),Active,Study Details | NCT03269981 | Randomized Study of Elective Regional Lymph Node Irradiation in N1 Breast Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03269981?cond=Breast%20Cancer&viewType=Card&page=19&rank=182
Breast Cancer,"Information provided by Michael O'Connor, Mayo Clinic (Responsible Party)",Withdrawn,Study Details | NCT03266562 | Estrogen Receptor Expression in Breast Cancer,https://clinicaltrials.gov/study/NCT03266562?cond=Breast%20Cancer&viewType=Card&page=19&rank=183
Breast Cancer,"Information provided by Wonshik Han, Seoul National University Hospital (Responsible Party)",Completed,Study Results | NCT03273426 | Prediction of pCR by Preoperative Biopsy in Breast Cancer With cCR After Neoadjuvant Chemotherapy. | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03273426?cond=Breast%20Cancer&viewType=Card&page=19&rank=184&tab=results
Breast Cancer,"Information provided by Wonshik Han, Seoul National University Hospital (Responsible Party)",Completed,Study Details | NCT03273426 | Prediction of pCR by Preoperative Biopsy in Breast Cancer With cCR After Neoadjuvant Chemotherapy. | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03273426?cond=Breast%20Cancer&viewType=Card&page=19&rank=184
Breast Cancer,Information provided by Cliniques universitaires Saint-Luc- Université Catholique de Louvain (Responsible Party),Completed,Study Details | NCT03330717 | Interventional Study on the Impact of the Hypnosis Used as Sedation or Relaxation in the Breast Oncologic Surgery | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03330717?cond=Breast%20Cancer&viewType=Card&page=19&rank=185
Breast Cancer,"Information provided by DİLEK YILDIRIM, Istanbul Aydın University (Responsible Party)",Active,Study Details | NCT05723237 | The Effect of Breast Cancer Screening Training | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT05723237?cond=Breast%20Cancer&viewType=Card&page=19&rank=186
Breast Cancer,"Information provided by Merck KGaA, Darmstadt, Germany (Responsible Party)",Completed,"Study Results | NCT00463788 | Cetuximab and Cisplatin in the Treatment of ""Triple Negative"" (Estrogen Receptor [ER] Negative, Progesterone Receptor [PgR] Negative, and Human Epidermal Growth Factor Receptor 2 [HER2] Negative) Metastatic Breast Cancer | ClinicalTrials.gov",https://clinicaltrials.gov/study/NCT00463788?cond=Breast%20Cancer&viewType=Card&page=19&rank=187&tab=results
Breast Cancer,"Information provided by Merck KGaA, Darmstadt, Germany (Responsible Party)",Completed,"Study Details | NCT00463788 | Cetuximab and Cisplatin in the Treatment of ""Triple Negative"" (Estrogen Receptor [ER] Negative, Progesterone Receptor [PgR] Negative, and Human Epidermal Growth Factor Receptor 2 [HER2] Negative) Metastatic Breast Cancer | ClinicalTrials.gov",https://clinicaltrials.gov/study/NCT00463788?cond=Breast%20Cancer&viewType=Card&page=19&rank=187
Breast Cancer,"Information provided by Katherine D. Crew, Columbia University (Responsible Party)",Completed,Study Details | NCT03069742 | Study of Web,https://clinicaltrials.gov/study/NCT03069742?cond=Breast%20Cancer&viewType=Card&page=19&rank=188
Breast Cancer,"Information provided by Kunwei Shen, Shanghai Jiao Tong University School of Medicine (Responsible Party)",Terminated,Study Details | NCT03295552 | Decitabine Plus Carboplatin in the Treatment of Metastatic TNBC | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03295552?cond=Breast%20Cancer&viewType=Card&page=19&rank=189
Breast Cancer,"Information provided by Instituto Nacional de Cancer, Brazil (Responsible Party)",Recruiting,Study Details | NCT03024580 | A Study Evaluating Megestrol Acetate Modulation in Hormone Receptor Positive Advanced Breast Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03024580?cond=Breast%20Cancer&viewType=Card&page=19&rank=190
Breast Cancer,Information provided by Palleos Healthcare GmbH (Responsible Party),Terminated,Study Details | NCT03220178 | Impact of eHealth,https://clinicaltrials.gov/study/NCT03220178?cond=Breast%20Cancer&viewType=Card&page=20&rank=191
Breast Cancer,Information provided by Evgen Pharma (Responsible Party),Completed,Study Details | NCT02970682 | SFX,https://clinicaltrials.gov/study/NCT02970682?cond=Breast%20Cancer&viewType=Card&page=20&rank=192
Breast Cancer,Information provided by BriaCell Therapeutics Corporation (Responsible Party),Completed,Study Results | NCT03066947 | SV-BR-1,https://clinicaltrials.gov/study/NCT03066947?cond=Breast%20Cancer&viewType=Card&page=20&rank=193&tab=results
Breast Cancer,Information provided by BriaCell Therapeutics Corporation (Responsible Party),Completed,Study Details | NCT03066947 | SV-BR-1,https://clinicaltrials.gov/study/NCT03066947?cond=Breast%20Cancer&viewType=Card&page=20&rank=193
Breast Cancer,"Information provided by Stephanie Santana Pinto, Federal University of Pelotas (Responsible Party)",Completed,Study Details | NCT03124095 | Combined Training Intervention for Women Who Underwent Primary Treatment for Breast Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03124095?cond=Breast%20Cancer&viewType=Card&page=20&rank=194
Breast Cancer,"Information provided by Jeannie Shen, Huntington Memorial Hospital (Responsible Party)",Recruiting,Study Details | NCT02913573 | Effect of Pectoral Nerve Block on Post,https://clinicaltrials.gov/study/NCT02913573?cond=Breast%20Cancer&viewType=Card&page=20&rank=195
Breast Cancer,Information provided by McMaster University (Responsible Party),Recruiting,Study Details | NCT02914197 | Giving Information on the Risks and Limitations of Mammography Screening (GIRLS) | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02914197?cond=Breast%20Cancer&viewType=Card&page=20&rank=196
Breast Cancer,Information provided by Eisai Inc. (Responsible Party),Completed,Study Results | NCT02513472 | Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple,https://clinicaltrials.gov/study/NCT02513472?cond=Breast%20Cancer&viewType=Card&page=20&rank=197&tab=results
Breast Cancer,Information provided by Eisai Inc. (Responsible Party),Completed,Study Details | NCT02513472 | Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple,https://clinicaltrials.gov/study/NCT02513472?cond=Breast%20Cancer&viewType=Card&page=20&rank=197
Breast Cancer,"Information provided by Kunwei Shen, Shanghai Jiao Tong University School of Medicine (Responsible Party)",Active,Study Details | NCT02455141 | Adjuvant Treatment of EC Followed by Taxane +/- Carboplatin in Triple,https://clinicaltrials.gov/study/NCT02455141?cond=Breast%20Cancer&viewType=Card&page=20&rank=198
Breast Cancer,Information provided by Stanford University (Responsible Party),Withdrawn,Study Details | NCT02432118 | Radiofrequency,https://clinicaltrials.gov/study/NCT02432118?cond=Breast%20Cancer&viewType=Card&page=20&rank=199
Breast Cancer,"Information provided by Hyo-Seok Na, Seoul National University Bundang Hospital (Responsible Party)",Completed,Study Details | NCT02561468 | The Preemptive Analgesic Efficacy of Nefopam | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02561468?cond=Breast%20Cancer&viewType=Card&page=20&rank=200
Breast Cancer,"Information provided by K.R. Charaghvandi, UMC Utrecht (Responsible Party)",Completed,Study Details | NCT02316561 | Single Dose Ablative Radiation Treatment for Early,https://clinicaltrials.gov/study/NCT02316561?cond=Breast%20Cancer&viewType=Card&page=21&rank=201
Breast Cancer,Information provided by University of Arkansas (Responsible Party),Withdrawn,Study Details | NCT02372305 | Comparison of FlexHD and Alloderm Outcomes in Breast Reconstructive Surgery | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02372305?cond=Breast%20Cancer&viewType=Card&page=21&rank=202
Breast Cancer,Information provided by Peking Union Medical College Hospital (Responsible Party),Recruiting,Study Details | NCT04429269 | A Comparative Study of Mammography and Ultrasound for Breast Cancer Screening and Early Diagnosis | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT04429269?cond=Breast%20Cancer&viewType=Card&page=21&rank=203
Breast Cancer,"Information provided by June Carroll, University of Toronto (Responsible Party)",Completed,Study Details | NCT00295529 | GenetiKiT: Evaluation of an Educational Intervention on the Delivery of Genetics Services by Family Physicians | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00295529?cond=Breast%20Cancer&viewType=Card&page=21&rank=204
Breast Cancer,"Information provided by Cianna Medical, Inc. (Responsible Party)",Inconnu,Study Details | NCT02370082 | SAVI SCOUT Clinical Evaluation Study | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02370082?cond=Breast%20Cancer&viewType=Card&page=21&rank=205
Breast Cancer,Information provided by Universitaire Ziekenhuizen KU Leuven (Responsible Party),Completed,Study Details | NCT03988777 | Magnetic Seed Localisation for Nonpalpable Breast Lesions | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03988777?cond=Breast%20Cancer&viewType=Card&page=21&rank=206
Breast Cancer,"Information provided by Julie Arsenault, Juravinski Cancer Center (Responsible Party)",Recruiting,Study Details | NCT02065960 | Feasibility Study of Stereotactic Body Radiotherapy for Early Breast Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02065960?cond=Breast%20Cancer&viewType=Card&page=21&rank=207
Breast Cancer,Information provided by Novartis (Novartis Pharmaceuticals) (Responsible Party),Completed,Study Details | NCT00107016 | Everolimus and Letrozole as Preoperative Therapy of Primary Breast Cancer in Post,https://clinicaltrials.gov/study/NCT00107016?cond=Breast%20Cancer&viewType=Card&page=21&rank=208
Breast Cancer,Information provided by Carebot s.r.o. (Responsible Party),Completed,Study Details | NCT06428799 | Evaluation of Carebot AI MMG Medical Device for Breast Lesion Detection and Density Assessment | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT06428799?cond=Breast%20Cancer&viewType=Card&page=21&rank=209
Breast Cancer,"Information provided by Brita Arver, Karolinska University Hospital (Responsible Party)",Completed,Study Details | NCT01859936 | Will Preoperative MRI Breast in Women Under 56 Years With Breast Cancer Change Primary Treatment | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01859936?cond=Breast%20Cancer&viewType=Card&page=21&rank=210
Breast Cancer,Information provided by Case Comprehensive Cancer Center (Responsible Party),Withdrawn,Study Details | NCT03261323 | Breast Reconstruction Following Breast Cancer in Very High Risk Patients | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03261323?cond=Breast%20Cancer&viewType=Card&page=22&rank=211
Breast Cancer,Information provided by Hellenic Cooperative Oncology Group (Responsible Party),Completed,Study Details | NCT01218529 | Lapatinib and WBRT for Patients With Brain Metastases From Lung or Breast Tumors | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01218529?cond=Breast%20Cancer&viewType=Card&page=22&rank=212
Breast Cancer,Information provided by Genta Incorporated (Responsible Party),Recruiting,Study Details | NCT01221870 | Tesetaxel as First,https://clinicaltrials.gov/study/NCT01221870?cond=Breast%20Cancer&viewType=Card&page=22&rank=213
Breast Cancer,Information provided by Tigris Pharmaceuticals,Terminated,Study Details | NCT01233947 | Study of AFP464 +/,https://clinicaltrials.gov/study/NCT01233947?cond=Breast%20Cancer&viewType=Card&page=22&rank=214
Breast Cancer,Information provided by Tigris Pharmaceuticals,Withdrawn,Study Details | NCT01015521 | Efficacy Study of Aminoflavone Prodrug to Treat Breast Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01015521?cond=Breast%20Cancer&viewType=Card&page=22&rank=215
Breast Cancer,Information provided by Pfizer,Completed,Study Results | NCT01061359 | Application Of Epirubicin Within A Neo,https://clinicaltrials.gov/study/NCT01061359?cond=Breast%20Cancer&viewType=Card&page=22&rank=216&tab=results
Breast Cancer,Information provided by Pfizer,Completed,Study Details | NCT01061359 | Application Of Epirubicin Within A Neo,https://clinicaltrials.gov/study/NCT01061359?cond=Breast%20Cancer&viewType=Card&page=22&rank=216
Breast Cancer,"Information provided by Dawn L. Hershman, Columbia University (Responsible Party)",Completed,Study Details | NCT00821288 | Post,https://clinicaltrials.gov/study/NCT00821288?cond=Breast%20Cancer&viewType=Card&page=22&rank=217
Breast Cancer,Information provided by Merck Sharp & Dohme LLC (Responsible Party),Completed,Study Results | NCT00779285 | Safety Study of CAELYX in Patients With Metastatic Breast Cancer Previously Treated With Anthracyclines (Study P04057)(TERMINATED) | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00779285?cond=Breast%20Cancer&viewType=Card&page=22&rank=218&tab=results
Breast Cancer,Information provided by Merck Sharp & Dohme LLC (Responsible Party),Terminated,Study Details | NCT00779285 | Safety Study of CAELYX in Patients With Metastatic Breast Cancer Previously Treated With Anthracyclines (Study P04057)(TERMINATED) | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00779285?cond=Breast%20Cancer&viewType=Card&page=22&rank=218
Breast Cancer,Information provided by Merck Sharp & Dohme LLC (Responsible Party),Completed,Study Details | NCT00779129 | A Study to Evaluate Safety and Efficacy of Caelyx in Combination With Cyclophosphamide in the Treatment of Metastatic Breast Cancer (P02948) | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00779129?cond=Breast%20Cancer&viewType=Card&page=22&rank=219
Breast Cancer,Information provided by Merck Sharp & Dohme LLC (Responsible Party),Completed,Study Results | NCT00687440 | A Study to Determine the Activity of Caelyx With Trastuzumab and Docetaxel in the Treatment of Metastatic Breast Cancer (Study P03679) | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00687440?cond=Breast%20Cancer&viewType=Card&page=22&rank=220&tab=results
Breast Cancer,Information provided by Merck Sharp & Dohme LLC (Responsible Party),Completed,Study Details | NCT00687440 | A Study to Determine the Activity of Caelyx With Trastuzumab and Docetaxel in the Treatment of Metastatic Breast Cancer (Study P03679) | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00687440?cond=Breast%20Cancer&viewType=Card&page=22&rank=220
Breast Cancer,Information provided by Merck Sharp & Dohme LLC (Responsible Party),Completed,Study Results | NCT00736333 | A Study to Evaluate Safety and Tolerability in Patients With Metastatic Breast Cancer Receiving Treatment With Caelyx (Study P04878)(COMPLETED) | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00736333?cond=Breast%20Cancer&viewType=Card&page=23&rank=221&tab=results
Breast Cancer,Information provided by Merck Sharp & Dohme LLC (Responsible Party),Completed,Study Details | NCT00736333 | A Study to Evaluate Safety and Tolerability in Patients With Metastatic Breast Cancer Receiving Treatment With Caelyx (Study P04878)(COMPLETED) | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00736333?cond=Breast%20Cancer&viewType=Card&page=23&rank=221
Breast Cancer,"Information provided by Bryan Schneider, MD, Hoosier Cancer Research Network (Responsible Party)",Completed,Study Results | NCT02101385 | Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02101385?cond=Breast%20Cancer&viewType=Card&page=23&rank=222&tab=results
Breast Cancer,"Information provided by Bryan Schneider, MD, Hoosier Cancer Research Network (Responsible Party)",Completed,Study Details | NCT02101385 | Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02101385?cond=Breast%20Cancer&viewType=Card&page=23&rank=222
Breast Cancer,Information provided by Merck Sharp & Dohme LLC (Responsible Party),Completed,Study Results | NCT00550771 | Phase II Trial to Compare the Safety of Two Chemotherapy Plus Trastuzumab Regimens as Adjuvant Therapy for HER2,https://clinicaltrials.gov/study/NCT00550771?cond=Breast%20Cancer&viewType=Card&page=23&rank=223&tab=results
Breast Cancer,Information provided by Merck Sharp & Dohme LLC (Responsible Party),Completed,Study Details | NCT00550771 | Phase II Trial to Compare the Safety of Two Chemotherapy Plus Trastuzumab Regimens as Adjuvant Therapy for HER2,https://clinicaltrials.gov/study/NCT00550771?cond=Breast%20Cancer&viewType=Card&page=23&rank=223
Breast Cancer,"Information provided by Jun Zhang, Fudan University (Responsible Party)",Completed,Study Details | NCT06143020 | Effect of ESPB on Postoperative Pain in Patients With Breast Cancer Implant Reconstruction | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT06143020?cond=Breast%20Cancer&viewType=Card&page=23&rank=224
Breast Cancer,Information provided by Bayer (Responsible Party),Completed,Study Details | NCT00313248 | Evaluation of a New Agent for Treatment of Advanced Stage Breast Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00313248?cond=Breast%20Cancer&viewType=Card&page=23&rank=225
Breast Cancer,Information provided by Accelerated Community Oncology Research Network (Responsible Party),Completed,Study Results | NCT00270894 | Neoadjuvant Chemotherapy + Herceptin in HER2 Positive Stage II,https://clinicaltrials.gov/study/NCT00270894?cond=Breast%20Cancer&viewType=Card&page=23&rank=226&tab=results
Breast Cancer,Information provided by Accelerated Community Oncology Research Network (Responsible Party),Completed,Study Details | NCT00270894 | Neoadjuvant Chemotherapy + Herceptin in HER2 Positive Stage II,https://clinicaltrials.gov/study/NCT00270894?cond=Breast%20Cancer&viewType=Card&page=23&rank=226
Breast Cancer,"Information provided by So-Youn Jung, National Cancer Center, Korea (Responsible Party)",Completed,Study Details | NCT02172989 | Clinical Application of Near,https://clinicaltrials.gov/study/NCT02172989?cond=Breast%20Cancer&viewType=Card&page=23&rank=227
Breast Cancer,Information provided by Achieve Life Sciences,Terminated,Study Details | NCT00251095 | Comparison of Safety and Efficacy of TOCOSOL(R) Paclitaxel Versus Taxol(R) for Treatment of Metastatic Breast Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00251095?cond=Breast%20Cancer&viewType=Card&page=23&rank=228
Breast Cancer,Information provided by University of Washington (Responsible Party),Completed,Study Details | NCT00194727 | Weekly Vinorelbine and Oral Capecitabine as Treatment for Stage IV Breast Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00194727?cond=Breast%20Cancer&viewType=Card&page=23&rank=229
Breast Cancer,Information provided by University of Washington,Completed,Study Details | NCT00194740 | Taxotere Plus Weekly Navelbine and G,https://clinicaltrials.gov/study/NCT00194740?cond=Breast%20Cancer&viewType=Card&page=23&rank=230
Breast Cancer,Information provided by University of Washington (Responsible Party),Completed,Study Details | NCT00194753 | Adjuvant Therapy for High-Risk Breast Cancer With Wkly Adriamycin & Oral Cytoxan With G,https://clinicaltrials.gov/study/NCT00194753?cond=Breast%20Cancer&viewType=Card&page=24&rank=231
Breast Cancer,Information provided by University of Iowa,Completed,Study Details | NCT00583739 | Yoga to Reduce Cancer Fatigue | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00583739?cond=Breast%20Cancer&viewType=Card&page=24&rank=232
Breast Cancer,Information provided by Norwegian Breast Cancer Group,Completed,Study Details | NCT00201435 | Weekly Taxol Plus Xeloda® vs Taxotere q3wk Plus Xeloda® in the Treatment of Metastatic BC | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00201435?cond=Breast%20Cancer&viewType=Card&page=24&rank=233
Breast Cancer,"Information provided by National University Hospital, Singapore (Responsible Party)",Recruiting,Study Details | NCT05035745 | Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START) | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT05035745?cond=Breast%20Cancer&viewType=Card&page=24&rank=234
Breast Cancer,"Information provided by Katherine D. Crew, Columbia University (Responsible Party)",Completed,Study Details | NCT01980823 | Pre,https://clinicaltrials.gov/study/NCT01980823?cond=Breast%20Cancer&viewType=Card&page=24&rank=235
Breast Cancer,Information provided by University Hospital Tuebingen (Responsible Party),Recruiting,Study Details | NCT06335108 | Postoperative Pain After Breast Surgery Under Tumescent Local Anaesthesia Versus General Anaesthesia ( TLA,https://clinicaltrials.gov/study/NCT06335108?cond=Breast%20Cancer&viewType=Card&page=24&rank=236
Breast Cancer,Information provided by UNICANCER (Responsible Party),Recruiting,Study Details | NCT06606730 | Personalizing the Use of Pembrolizumab for Patients Who Have a Strong Response in Early Triple Negative Breast Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT06606730?cond=Breast%20Cancer&viewType=Card&page=24&rank=237
Breast Cancer,"Information provided by Lise Worthen-Chaudhari, Ohio State University Comprehensive Cancer Center (Responsible Party)",Recruiting,Study Details | NCT06749210 | DAANCE FOR CHEMOTHERAPY,https://clinicaltrials.gov/study/NCT06749210?cond=Breast%20Cancer&viewType=Card&page=24&rank=238
Breast Cancer,"Information provided by Ping Liang, Chinese PLA General Hospital (Responsible Party)",Recruiting,Study Details | NCT04626986 | Comparison of Microwave Ablation With Breast Conserving Surgery for Breast Tumor | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT04626986?cond=Breast%20Cancer&viewType=Card&page=24&rank=239
Breast Cancer,Information provided by Washington University School of Medicine (Responsible Party),Terminated,Study Details | NCT02462200 | Shave Margins in Breast Conservation Therapy | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02462200?cond=Breast%20Cancer&viewType=Card&page=24&rank=240
Breast Cancer,Information provided by KK Women's and Children's Hospital (Responsible Party),Recruiting,Study Details | NCT04571307 | Cryotherapy in Breast B3 Lesions | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT04571307?cond=Breast%20Cancer&viewType=Card&page=25&rank=241
Breast Cancer,Information provided by University of Valencia (Responsible Party),Completed,Study Details | NCT05185752 | Comparative Analysis of Three Locoregional Anesthesia Methods in Breast Tumour Pathology Surgery | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT05185752?cond=Breast%20Cancer&viewType=Card&page=25&rank=242
Breast Cancer,Information provided by Haukeland University Hospital (Responsible Party),Active,Study Details | NCT02624973 | PErsonalized TREatment of High-risk MAmmary Cancer,https://clinicaltrials.gov/study/NCT02624973?cond=Breast%20Cancer&viewType=Card&page=25&rank=243
Breast Cancer,Information provided by Novian Health Inc. (Responsible Party),Active,"Study Details | NCT01478438 | A Multicenter ""Ablate and Resect"" Study of Novilase® Interstitial Laser Therapy for the Ablation of Small Breast Cancers | ClinicalTrials.gov",https://clinicaltrials.gov/study/NCT01478438?cond=Breast%20Cancer&viewType=Card&page=25&rank=244
Breast Cancer,Information provided by M.D. Anderson Cancer Center (Responsible Party),Recruiting,Study Details | NCT00477100 | Biospecimen and Medical Data Collection and Tumor Biopsy in Creating Research Tissue Registry in Patients With Inflammatory or Invasive Breast Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00477100?cond=Breast%20Cancer&viewType=Card&page=25&rank=245
Breast Cancer,Information provided by NSABP Foundation Inc (Responsible Party),Completed,Study Results | NCT02296801 | A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen,https://clinicaltrials.gov/study/NCT02296801?cond=Breast%20Cancer&viewType=Card&page=25&rank=246&tab=results
Breast Cancer,Information provided by NSABP Foundation Inc (Responsible Party),Completed,Study Details | NCT02296801 | A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen,https://clinicaltrials.gov/study/NCT02296801?cond=Breast%20Cancer&viewType=Card&page=25&rank=246
Breast Cancer,Information provided by Washington University School of Medicine (Responsible Party),Completed,Study Results | NCT03007979 | Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03007979?cond=Breast%20Cancer&viewType=Card&page=25&rank=247&tab=results
Breast Cancer,Information provided by Washington University School of Medicine (Responsible Party),Completed,Study Details | NCT03007979 | Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03007979?cond=Breast%20Cancer&viewType=Card&page=25&rank=247
Breast Cancer,Information provided by Washington University School of Medicine (Responsible Party),Completed,Study Results | NCT02907918 | Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab in Stage II,https://clinicaltrials.gov/study/NCT02907918?cond=Breast%20Cancer&viewType=Card&page=25&rank=248&tab=results
Breast Cancer,Information provided by Washington University School of Medicine (Responsible Party),Terminated,Study Details | NCT02907918 | Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab in Stage II,https://clinicaltrials.gov/study/NCT02907918?cond=Breast%20Cancer&viewType=Card&page=25&rank=248
Breast Cancer,"Information provided by Elisavet Paplomata, Emory University (Responsible Party)",Completed,Study Results | NCT00832338 | Trial Using Docetaxel Cytoxan in Breast Cancers With High Recurrence Scores | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00832338?cond=Breast%20Cancer&viewType=Card&page=25&rank=249&tab=results
Breast Cancer,"Information provided by Elisavet Paplomata, Emory University (Responsible Party)",Terminated,Study Details | NCT00832338 | Trial Using Docetaxel Cytoxan in Breast Cancers With High Recurrence Scores | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00832338?cond=Breast%20Cancer&viewType=Card&page=25&rank=249
Breast Cancer,"Information provided by JeeYeon Lee, Kyungpook National University Chilgok Hospital (Responsible Party)",Active,Study Details | NCT06622967 | KNUCH CadAI-B-1(KCB,https://clinicaltrials.gov/study/NCT06622967?cond=Breast%20Cancer&viewType=Card&page=25&rank=250
Breast Cancer,Information provided by AstraZeneca (Responsible Party),Completed,Study Details | NCT02733601 | Epidemiology of Breast Cancer in Women Based on Diagnosis Data From Oncologists and Breast Surgeons in Algeria | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02733601?cond=Breast%20Cancer&viewType=Card&page=26&rank=251
Breast Cancer,Information provided by Borstkanker Onderzoek Groep (Responsible Party),Active,Study Details | NCT05392608 | SEQUence of Endocrine Therapy in Advanced Luminal Breast Cancer (SEQUEL,https://clinicaltrials.gov/study/NCT05392608?cond=Breast%20Cancer&viewType=Card&page=26&rank=252
Breast Cancer,Information provided by The First Affiliated Hospital of Xinxiang Medical College (Responsible Party),Recruiting,Study Details | NCT05544123 | The Treatment Situation of Chinese County Population With Breast Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT05544123?cond=Breast%20Cancer&viewType=Card&page=26&rank=253
Breast Cancer,Information provided by University Medical Center Groningen (Responsible Party),Recruiting,Study Details | NCT05851053 | Breast Cancer Long,https://clinicaltrials.gov/study/NCT05851053?cond=Breast%20Cancer&viewType=Card&page=26&rank=254
Breast Cancer,"Information provided by Eileen Connolly, Columbia University (Responsible Party)",Active,Study Details | NCT03165487 | Comparison of the Breast Tumor Microenvironment | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03165487?cond=Breast%20Cancer&viewType=Card&page=26&rank=255
Breast Cancer,"Information provided by Dr Amit Goyal, University Hospitals of Derby and Burton NHS Foundation Trust (Responsible Party)",Recruiting,Study Details | NCT04109079 | Axillary Management in Breast Cancer Patients with Needle Biopsy Proven Nodal Metastases After Neoadjuvant Chemotherapy | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT04109079?cond=Breast%20Cancer&viewType=Card&page=26&rank=256
Breast Cancer,"Information provided by Gang Hu, Wuhan Children's Hospital (Responsible Party)",Completed,Study Details | NCT06970561 | Analysis of Recurrence of Intraductal Papilloma Treated With Vacuum,https://clinicaltrials.gov/study/NCT06970561?cond=Breast%20Cancer&viewType=Card&page=26&rank=257
Breast Cancer,Information provided by University of Texas at Austin (Responsible Party),Recruiting,Study Details | NCT06085313 | Cancer Pain Management Using a Web,https://clinicaltrials.gov/study/NCT06085313?cond=Breast%20Cancer&viewType=Card&page=26&rank=258
Breast Cancer,Information provided by Arbeitsgemeinschaft medikamentoese Tumortherapie (Responsible Party),Recruiting,Study Details | NCT03870620 | Metastatic Breast Cancer in Austria | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03870620?cond=Breast%20Cancer&viewType=Card&page=26&rank=259
Breast Cancer,Information provided by Smart Breast Corp. (Responsible Party),Inconnu,Study Details | NCT07114679 | Molecular Breast Imaging (MBI),https://clinicaltrials.gov/study/NCT07114679?cond=Breast%20Cancer&viewType=Card&page=26&rank=260
Breast Cancer,"Information provided by Murat Ferhat Ferhatoglu, Okan University (Responsible Party)",Inconnu,Study Details | NCT03596463 | Influence of Multidisciplinary Breast Tumor Board on Physician Decision | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03596463?cond=Breast%20Cancer&viewType=Card&page=27&rank=261
Breast Cancer,Information provided by Region Örebro County (Responsible Party),Active,Study Details | NCT04812652 | Digitally Distributed Yoga for Women Treated for Breast Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT04812652?cond=Breast%20Cancer&viewType=Card&page=27&rank=262
Breast Cancer,Information provided by The Swedish School of Sport and Health Sciences (Responsible Party),Completed,Study Details | NCT05729451 | Change in Cardiorespiratory Fitness and Breast Cancer Incidence and Mortality | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT05729451?cond=Breast%20Cancer&viewType=Card&page=27&rank=263
Breast Cancer,Information provided by University of Southern California (Responsible Party),Recruiting,Study Details | NCT06336928 | A Validation Study to Determine Concordance of Liquid Biopsy and Breast Cancer Diagnosis | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT06336928?cond=Breast%20Cancer&viewType=Card&page=27&rank=264
Breast Cancer,"Information provided by Rotem Sivan-Hoffmann, Meir Medical Center (Responsible Party)",Inconnu,Study Details | NCT05305937 | Implantation of CEST and CESL MRI Methods for Detection of Breast Tumors | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT05305937?cond=Breast%20Cancer&viewType=Card&page=27&rank=265
Breast Cancer,Information provided by University of Calgary (Responsible Party),Recruiting,Study Details | NCT06960291 | Sustainable Implementation of the EXCEL Exercise Oncology Program Across Canada | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT06960291?cond=Breast%20Cancer&viewType=Card&page=27&rank=266
Breast Cancer,Information provided by Universitaire Ziekenhuizen KU Leuven (Responsible Party),Recruiting,Study Details | NCT04200768 | FATLAS: Comprehensive Multi,https://clinicaltrials.gov/study/NCT04200768?cond=Breast%20Cancer&viewType=Card&page=27&rank=267
Breast Cancer,Information provided by M.D. Anderson Cancer Center (Responsible Party),Active,Study Details | NCT03162627 | Selumetinib and Olaparib in Solid Tumors | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03162627?cond=Breast%20Cancer&viewType=Card&page=27&rank=268
Breast Cancer,"Information provided by Shulian Wang, Cancer Institute and Hospital, Chinese Academy of Medical Sciences (Responsible Party)",Completed,Study Details | NCT07084519 | Hypofractionated vs Conventional RT After Prosthetic Breast Reconstruction | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT07084519?cond=Breast%20Cancer&viewType=Card&page=27&rank=269
Breast Cancer,Information provided by Integro Theranostics (Responsible Party),Active,Study Details | NCT05900986 | LS301-IT in Partial Mastectomy and Sentinel Lymph Node Biopsy (SLNB) for DCIS or Stage I,https://clinicaltrials.gov/study/NCT05900986?cond=Breast%20Cancer&viewType=Card&page=27&rank=270
Breast Cancer,Information provided by Mayo Clinic (Responsible Party),Recruiting,Study Details | NCT06217874 | Collection of Specimens and Clinical Data for Patients With Recurrent or Metastatic Breast Cancer or Male Breast Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT06217874?cond=Breast%20Cancer&viewType=Card&page=28&rank=271
Breast Cancer,Information provided by St. Olavs Hospital (Responsible Party),Inconnu,Study Details | NCT07180433 | Piloting 18F,https://clinicaltrials.gov/study/NCT07180433?cond=Breast%20Cancer&viewType=Card&page=28&rank=272
Breast Cancer,"Information provided by Koual Meriem, European Georges Pompidou Hospital (Responsible Party)",Completed,Study Details | NCT03788187 | Persistant Organics Pollutants in Breast Cancer. | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03788187?cond=Breast%20Cancer&viewType=Card&page=28&rank=273
Breast Cancer,"Information provided by Fredrik Strand, Karolinska University Hospital (Responsible Party)",Active,Study Details | NCT04778670 | Artificial Intelligence in Large,https://clinicaltrials.gov/study/NCT04778670?cond=Breast%20Cancer&viewType=Card&page=28&rank=274
Breast Cancer,"Information provided by Yvonne Wengstrom, Karolinska Institutet (Responsible Party)",Completed,Study Details | NCT05361018 | Sensorimotor Training Using Whole Body Vibration Exercise to Reduce Chemotherapy,https://clinicaltrials.gov/study/NCT05361018?cond=Breast%20Cancer&viewType=Card&page=28&rank=275
Breast Cancer,Information provided by Washington University School of Medicine (Responsible Party),Recruiting,Study Details | NCT05505643 | Cryoablation vs Lumpectomy in T1 Breast Cancers | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT05505643?cond=Breast%20Cancer&viewType=Card&page=28&rank=276
Breast Cancer,"Information provided by Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (Responsible Party)",Active,Study Details | NCT06499077 | Non,https://clinicaltrials.gov/study/NCT06499077?cond=Breast%20Cancer&viewType=Card&page=28&rank=277
Breast Cancer,"Information provided by Chin-Tsung Shen, Mackay Medical College (Responsible Party)",Completed,Study Details | NCT04602910 | Developing a Web-based Shared Decision,https://clinicaltrials.gov/study/NCT04602910?cond=Breast%20Cancer&viewType=Card&page=28&rank=278
Breast Cancer,Information provided by Peking University People's Hospital (Responsible Party),Inconnu,Study Details | NCT02318615 | Immediate Axillary Plasty With a Pedicled Muscle Flap for Breast Cancer Related Lymphedema Prevention | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02318615?cond=Breast%20Cancer&viewType=Card&page=28&rank=279
Breast Cancer,"Information provided by Nicholas Hing Yee Liang, Clinical Research Centre, Malaysia (Responsible Party)",Terminated,Study Details | NCT06293508 | mHealth Behavioural Intervention to Increase Breast Cancer Screening Rates Among Members of the Public | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT06293508?cond=Breast%20Cancer&viewType=Card&page=28&rank=280
Breast Cancer,"Information provided by Gabriele Martelli, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (Responsible Party)",Completed,Study Details | NCT04436809 | Sentinel Node Biopsy Alone or With Axillary Dissection After Primary Chemotherapy | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT04436809?cond=Breast%20Cancer&viewType=Card&page=29&rank=281
Breast Cancer,"Information provided by Igor Moraes Mariano, Federal University of Uberlandia (Responsible Party)",Completed,Study Details | NCT04479098 | Effects of Training and Detraining on Postmenopausal Breast Cancer Survivors | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT04479098?cond=Breast%20Cancer&viewType=Card&page=29&rank=282
Breast Cancer,"Information provided by Wang Ouchen, First Affiliated Hospital of Wenzhou Medical University (Responsible Party)",Recruiting,"Study Details | NCT06234137 | A Prospective, Open, Multicenter Single-arm Clinical Studie of Docetaxel, Carboplatin Combined With Inetetamab and Pyrotinib in the Treatment of Local-advanced HER2",https://clinicaltrials.gov/study/NCT06234137?cond=Breast%20Cancer&viewType=Card&page=29&rank=283
Breast Cancer,"Information provided by Xinhong Wu, PhD, Hubei Cancer Hospital (Responsible Party)",Inconnu,Study Details | NCT06258863 | Investigating the Effects of Different Incision Types on Aesthetic Outcomes and Incision,https://clinicaltrials.gov/study/NCT06258863?cond=Breast%20Cancer&viewType=Card&page=29&rank=284
Breast Cancer,Information provided by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (Responsible Party),Recruiting,Study Details | NCT06102018 | Diagnostic Biomarkers Exploration of Breast Cancer From Serum and Urine | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT06102018?cond=Breast%20Cancer&viewType=Card&page=29&rank=285
Breast Cancer,"Information provided by Lisle Nabell, University of Alabama at Birmingham (Responsible Party)",Completed,Study Results | NCT00530868 | Comparing Letrozole Given Alone to Letrozole Given With Avastin in Post,https://clinicaltrials.gov/study/NCT00530868?cond=Breast%20Cancer&viewType=Card&page=29&rank=286&tab=results
Breast Cancer,"Information provided by Lisle Nabell, University of Alabama at Birmingham (Responsible Party)",Completed,Study Details | NCT00530868 | Comparing Letrozole Given Alone to Letrozole Given With Avastin in Post,https://clinicaltrials.gov/study/NCT00530868?cond=Breast%20Cancer&viewType=Card&page=29&rank=286
Breast Cancer,Information provided by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (Responsible Party),Inconnu,Study Details | NCT06843681 | Trastuzumab Plus Taxane Neoadjuvant Therapy for HER2,https://clinicaltrials.gov/study/NCT06843681?cond=Breast%20Cancer&viewType=Card&page=29&rank=287
Breast Cancer,"Information provided by Li Huiping, Peking University Cancer Hospital & Institute (Responsible Party)",Recruiting,Study Details | NCT05969184 | Palbociclib Combine With Anti,https://clinicaltrials.gov/study/NCT05969184?cond=Breast%20Cancer&viewType=Card&page=29&rank=288
Breast Cancer,"Information provided by NantCell, Inc. (Responsible Party)",Completed,Study Results | NCT00626106 | QUILT,https://clinicaltrials.gov/study/NCT00626106?cond=Breast%20Cancer&viewType=Card&page=29&rank=289&tab=results
Breast Cancer,"Information provided by NantCell, Inc. (Responsible Party)",Completed,Study Details | NCT00626106 | QUILT,https://clinicaltrials.gov/study/NCT00626106?cond=Breast%20Cancer&viewType=Card&page=29&rank=289
Breast Cancer,"Information provided by William Read, Emory University (Responsible Party)",Completed,"Study Results | NCT01272141 | A Study of Lapatinib in Combination With Everolimus in Patients With Advanced, Triple Negative Breast Cancer | ClinicalTrials.gov",https://clinicaltrials.gov/study/NCT01272141?cond=Breast%20Cancer&viewType=Card&page=29&rank=290&tab=results
Breast Cancer,"Information provided by William Read, Emory University (Responsible Party)",Terminated,"Study Details | NCT01272141 | A Study of Lapatinib in Combination With Everolimus in Patients With Advanced, Triple Negative Breast Cancer | ClinicalTrials.gov",https://clinicaltrials.gov/study/NCT01272141?cond=Breast%20Cancer&viewType=Card&page=29&rank=290
Breast Cancer,Information provided by Hospices Civils de Lyon (Responsible Party),Completed,Study Details | NCT05574816 | Evaluation of the Diagnostic Performance of a Bra Prototype to Detect Breast Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT05574816?cond=Breast%20Cancer&viewType=Card&page=30&rank=291
Breast Cancer,"Information provided by Raphael do Nascimento Pereira, Universidade Metodista de Piracicaba (Responsible Party)",Completed,Study Details | NCT03826979 | PILATES METHOD ON THE UPPER LIMBS FUNCTIONALITY | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03826979?cond=Breast%20Cancer&viewType=Card&page=30&rank=292
Breast Cancer,Information provided by Rna Diagnostics Inc. (Responsible Party),Recruiting,Study Details | NCT03524430 | RNA Disruption Assay (RDA),https://clinicaltrials.gov/study/NCT03524430?cond=Breast%20Cancer&viewType=Card&page=30&rank=293
Breast Cancer,Information provided by MedSIR (Responsible Party),Completed,Study Results | NCT02061085 | Monotherapy With Eribulin In Her2 Negative Metastatic Breast Cancer as a First Line Treatment | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02061085?cond=Breast%20Cancer&viewType=Card&page=30&rank=294&tab=results
Breast Cancer,Information provided by MedSIR (Responsible Party),Completed,Study Details | NCT02061085 | Monotherapy With Eribulin In Her2 Negative Metastatic Breast Cancer as a First Line Treatment | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02061085?cond=Breast%20Cancer&viewType=Card&page=30&rank=294
Breast Cancer,"Information provided by Li Huiping, Peking University Cancer Hospital & Institute (Responsible Party)",Inconnu,"Study Details | NCT05577442 | Trastuzumab, Pyrotinib Combined With Dalpiciclib and Endocrine Therapy for HR +/HER2 + Advanced Breast Cancer | ClinicalTrials.gov",https://clinicaltrials.gov/study/NCT05577442?cond=Breast%20Cancer&viewType=Card&page=30&rank=295
Breast Cancer,"Information provided by Jun Zhang, Fudan University (Responsible Party)",Completed,Study Details | NCT05299021 | Serratus Anterior Plane Block for Modified Radical Mastectomy: Double-point VS Single,https://clinicaltrials.gov/study/NCT05299021?cond=Breast%20Cancer&viewType=Card&page=30&rank=296
Breast Cancer,"Information provided by International Cancer Research Group, United Arab Emirates (Responsible Party)",Completed,Study Details | NCT03447132 | Fulvestrant Versus Fulvestrant Plus Palbociclib in Operable Breast Cancer Responding to Fulvestrant | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03447132?cond=Breast%20Cancer&viewType=Card&page=30&rank=297
Breast Cancer,"Information provided by Wang Xiaojia, Zhejiang Cancer Hospital (Responsible Party)",Inconnu,"Study Details | NCT05480189 | Effect of Zoledronic Acid Treatment on Bone-related Events in Breast Cancer Patients With Bone Metastases: a Prospective, Multicenter, Real",https://clinicaltrials.gov/study/NCT05480189?cond=Breast%20Cancer&viewType=Card&page=30&rank=298
Breast Cancer,"Information provided by Tao Sun, Liaoning Cancer Hospital & Institute (Responsible Party)",Inconnu,Study Details | NCT05244993 | AK105 Plus Anlotinib Hydrochloride Combined With Albumin Paclitaxel as a First-line Therapy in Patients With Advanced Triple,https://clinicaltrials.gov/study/NCT05244993?cond=Breast%20Cancer&viewType=Card&page=30&rank=299
Breast Cancer,"Information provided by Ebtehal Mohamed Mahmoud Salah, Ain Shams University (Responsible Party)",Inconnu,Study Details | NCT05151224 | Circulating microRNA 21 Expression Level Before and After Neoadjuvant Systemic Therapy in Breast Carcinoma | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT05151224?cond=Breast%20Cancer&viewType=Card&page=30&rank=300
Pancreatic Cancer,"Information provided by Fuda Cancer Hospital, Guangzhou (Responsible Party)",Completed,Study Details | NCT02074046 | Safety Study of Cancer Stem Cell Vaccine to Treat Pancreatic Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02074046?cond=Pancreatic%20Cancer&viewType=Card&page=1&rank=1
Pancreatic Cancer,Information provided by RenJi Hospital (Responsible Party),Recruiting,Study Details | NCT06478225 | Evaluate the Safety and Efficacy of BGT007H Cell Therapy in Patients With Relapsed/Refractory Pancreatic Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT06478225?cond=Pancreatic%20Cancer&viewType=Card&page=1&rank=2
Pancreatic Cancer,"Information provided by Guopei Luo, Fudan University (Responsible Party)",Recruiting,Study Details | NCT07183280 | Multicentric Database for Solid Pseudopapillary Neoplasm of the Pancreas | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT07183280?cond=Pancreatic%20Cancer&viewType=Card&page=1&rank=3
Pancreatic Cancer,"Information provided by Anish Thomas, National Cancer Institute (NCI) (Responsible Party)",Completed,Study Results | NCT04896073 | Superenhancer Inhibitor Minnelide in Advanced Refractory Adenosquamous Carcinoma of the Pancreas (ASCP) | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT04896073?cond=Pancreatic%20Cancer&viewType=Card&page=1&rank=4&tab=results
Pancreatic Cancer,"Information provided by Anish Thomas, National Cancer Institute (NCI) (Responsible Party)",Completed,Study Details | NCT04896073 | Superenhancer Inhibitor Minnelide in Advanced Refractory Adenosquamous Carcinoma of the Pancreas (ASCP) | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT04896073?cond=Pancreatic%20Cancer&viewType=Card&page=1&rank=4
Pancreatic Cancer,Information provided by H. Lee Moffitt Cancer Center and Research Institute (Responsible Party),Terminated,Study Details | NCT01455311 | Evaluation of Image,https://clinicaltrials.gov/study/NCT01455311?cond=Pancreatic%20Cancer&viewType=Card&page=1&rank=5
Pancreatic Cancer,"Information provided by Alejandro Ruiz Velasco Santacruz, Tecnologico de Monterrey (Responsible Party)",Completed,Study Details | NCT04728750 | Laparoscopic Enucleation of Frantz's Tumor of the Pancreas | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT04728750?cond=Pancreatic%20Cancer&viewType=Card&page=1&rank=6
Pancreatic Cancer,Information provided by Duke University (Responsible Party),Completed,Study Results | NCT02318095 | Gemcitabine/Nab,https://clinicaltrials.gov/study/NCT02318095?cond=Pancreatic%20Cancer&viewType=Card&page=1&rank=7&tab=results
Pancreatic Cancer,Information provided by Duke University (Responsible Party),Completed,Study Details | NCT02318095 | Gemcitabine/Nab,https://clinicaltrials.gov/study/NCT02318095?cond=Pancreatic%20Cancer&viewType=Card&page=1&rank=7
Pancreatic Cancer,"Information provided by University Hospital, Strasbourg, France (Responsible Party)",Completed,Study Details | NCT05528614 | Evaluation of the Results of Simultaneous Pancreatic and Hepatic Resections for Metastatic Neuroendocrine Tumors. | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT05528614?cond=Pancreatic%20Cancer&viewType=Card&page=1&rank=8
Pancreatic Cancer,"Information provided by James Hebert, University of Vermont (Responsible Party)",Withdrawn,Study Details | NCT01526590 | Contrast Enhanced Endoscopic Ultrasound for Vascular Involvement in Pancreatic Lesions | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01526590?cond=Pancreatic%20Cancer&viewType=Card&page=1&rank=9
Pancreatic Cancer,"Information provided by Shyam Varadarajulu, University of Alabama at Birmingham (Responsible Party)",Completed,Study Details | NCT01501903 | Standard Versus Fanning Techniques for Endoscopic Ultrasound-Fine Needle Aspiration (EUS,https://clinicaltrials.gov/study/NCT01501903?cond=Pancreatic%20Cancer&viewType=Card&page=1&rank=10
Pancreatic Cancer,"Information provided by Anda Biopharmaceutical Development (Shenzhen) Co., Ltd. (Responsible Party)",Recruiting,Study Details | NCT03558945 | Clinical Trial on Personalized Neoantigen Vaccine for Pancreatic Tumor | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03558945?cond=Pancreatic%20Cancer&viewType=Card&page=2&rank=11
Pancreatic Cancer,Information provided by Institut Paoli-Calmettes (Responsible Party),Completed,Study Details | NCT01692873 | Prognostic and Predictive Biomarkers of Therapeutic Response in Pancreatic Tumors | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01692873?cond=Pancreatic%20Cancer&viewType=Card&page=2&rank=12
Pancreatic Cancer,"Information provided by Salvatore Paiella, MD, Universita di Verona (Responsible Party)",Completed,Study Details | NCT03788382 | Failure to Adjuvant Therapy After Pancreatic Resection for Pancreatic Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03788382?cond=Pancreatic%20Cancer&viewType=Card&page=2&rank=13
Pancreatic Cancer,"Information provided by Muhammad Beg, University of Texas Southwestern Medical Center (Responsible Party)",Completed,Study Results | NCT01838317 | A Phase II Study of Pioglitazone for Patients With Cancer of the Pancreas | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01838317?cond=Pancreatic%20Cancer&viewType=Card&page=2&rank=14&tab=results
Pancreatic Cancer,"Information provided by Muhammad Beg, University of Texas Southwestern Medical Center (Responsible Party)",Completed,Study Details | NCT01838317 | A Phase II Study of Pioglitazone for Patients With Cancer of the Pancreas | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01838317?cond=Pancreatic%20Cancer&viewType=Card&page=2&rank=14
Pancreatic Cancer,Information provided by University of Virginia (Responsible Party),Completed,Study Details | NCT01673334 | Evaluation of EUS-Guided 22 Gauge Core Biopsy Versus Fine,https://clinicaltrials.gov/study/NCT01673334?cond=Pancreatic%20Cancer&viewType=Card&page=2&rank=15
Pancreatic Cancer,"Information provided by TingBo Liang, Zhejiang University (Responsible Party)",Recruiting,Study Details | NCT06770439 | IBI343 Combined With Chemotherapy in Advanced Pancreatic Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT06770439?cond=Pancreatic%20Cancer&viewType=Card&page=2&rank=16
Pancreatic Cancer,Information provided by Tianjin Medical University Cancer Institute and Hospital (Responsible Party),Recruiting,Study Details | NCT06760364 | A Clinical Study of CHT102 in MSLN,https://clinicaltrials.gov/study/NCT06760364?cond=Pancreatic%20Cancer&viewType=Card&page=2&rank=17
Pancreatic Cancer,Information provided by H. Lee Moffitt Cancer Center and Research Institute (Responsible Party),Active,Study Details | NCT06519097 | Study of IPMN Progression Prevention With Tocotrienol (SIPP,https://clinicaltrials.gov/study/NCT06519097?cond=Pancreatic%20Cancer&viewType=Card&page=2&rank=18
Pancreatic Cancer,"Information provided by Liao Hongfan, First Affiliated Hospital of Chongqing Medical University (Responsible Party)",Completed,Study Details | NCT06641947 | Differentiation Benign and Malignant Pancreatic Lesions | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT06641947?cond=Pancreatic%20Cancer&viewType=Card&page=2&rank=19
Pancreatic Cancer,Information provided by Methodist Health System (Responsible Party),Recruiting,Study Details | NCT04637256 | Evaluation of Outcomes from Treatment of Benign or Malignant Gastroesophageal Diseases | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT04637256?cond=Pancreatic%20Cancer&viewType=Card&page=2&rank=20
Pancreatic Cancer,Information provided by The Clatterbridge Cancer Centre NHS Foundation Trust (Responsible Party),Inconnu,Study Details | NCT03610100 | Acelarin First Line Randomised Pancreatic Study | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03610100?cond=Pancreatic%20Cancer&viewType=Card&page=3&rank=21
Pancreatic Cancer,Information provided by GCS Ramsay Santé pour l'Enseignement et la Recherche (Responsible Party),Recruiting,"Study Details | NCT05871164 | Longitudinal, Prospective, French, Multicenter Cohort Study on Pancreatic Radiofrequency | ClinicalTrials.gov",https://clinicaltrials.gov/study/NCT05871164?cond=Pancreatic%20Cancer&viewType=Card&page=3&rank=22
Pancreatic Cancer,Study of Anti-CEA CAR-T + Chemotherapy VS Chemotherapy Alone in Patients With CEA+Pancreatic Cancer & Liver Metastases,Withdrawn,Study Details | NCT04037241 | Study of Anti-CEA CAR,https://clinicaltrials.gov/study/NCT04037241?cond=Pancreatic%20Cancer&viewType=Card&page=3&rank=23
Pancreatic Cancer,"Information provided by Song Cheol Kim, Asan Medical Center (Responsible Party)",Recruiting,Study Details | NCT04357483 | Effect of Thrombin-containing Collagen,https://clinicaltrials.gov/study/NCT04357483?cond=Pancreatic%20Cancer&viewType=Card&page=3&rank=24
Pancreatic Cancer,Information provided by Assistance Publique - Hôpitaux de Paris (Responsible Party),Recruiting,Study Details | NCT05794048 | METabolic PROFILE of Hepatocarcinoma and Pancreatic Tumors | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT05794048?cond=Pancreatic%20Cancer&viewType=Card&page=3&rank=25
Pancreatic Cancer,"Information provided by Qiaofei Liu, Peking Union Medical College Hospital (Responsible Party)",Recruiting,Study Details | NCT05604716 | Cross-sectional Follow,https://clinicaltrials.gov/study/NCT05604716?cond=Pancreatic%20Cancer&viewType=Card&page=3&rank=26
Pancreatic Cancer,"Information provided by JIABIN JIN, Ruijin Hospital (Responsible Party)",Inconnu,Study Details | NCT06573398 | Radiotherapy With Sequential Chemotherapy Combined With PD,https://clinicaltrials.gov/study/NCT06573398?cond=Pancreatic%20Cancer&viewType=Card&page=3&rank=27
Pancreatic Cancer,"Information provided by Zhang Huo Jun, Changhai Hospital (Responsible Party)",Completed,Study Details | NCT02716207 | Phase ǀ Study on Pancreatic Cancer Treated by CyberKnife | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02716207?cond=Pancreatic%20Cancer&viewType=Card&page=3&rank=28
Pancreatic Cancer,"Information provided by John M. Levenick, Milton S. Hershey Medical Center (Responsible Party)",Withdrawn,Study Details | NCT02534246 | Head to Head Comparison of Two Needles EUS Guided FNB | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02534246?cond=Pancreatic%20Cancer&viewType=Card&page=3&rank=29
Pancreatic Cancer,Information provided by Technische Universität Dresden (Responsible Party),Withdrawn,Study Details | NCT02269683 | Robotic vs. Laparoscopic Distal Pancreatectomy for Pancreatic Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02269683?cond=Pancreatic%20Cancer&viewType=Card&page=3&rank=30
Pancreatic Cancer,Information provided by Centre Leon Berard (Responsible Party),Recruiting,Study Details | NCT06211933 | Evaluation of the High Intensity Focused Ultrasound (HIFU) Technique for Patients With Unresectable Pancreatic Tumor Treatment (PULS) | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT06211933?cond=Pancreatic%20Cancer&viewType=Card&page=4&rank=31
Pancreatic Cancer,Information provided by Tianjin Medical University Cancer Institute and Hospital (Responsible Party),Completed,Study Details | NCT05723978 | Selective Extended Dissection in Different Types of Pancreatic Head Cancer: A Retrospective Cohort Study. | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT05723978?cond=Pancreatic%20Cancer&viewType=Card&page=4&rank=32
Pancreatic Cancer,Information provided by National Taiwan University Hospital (Responsible Party),Recruiting,Study Details | NCT01978808 | Efficiency Study of the EUS,https://clinicaltrials.gov/study/NCT01978808?cond=Pancreatic%20Cancer&viewType=Card&page=4&rank=33
Pancreatic Cancer,"Information provided by Wu Xi, Peking Union Medical College Hospital (Responsible Party)",Inconnu,Study Details | NCT05621824 | A Cohort Study on Screening and Follow-up of High,https://clinicaltrials.gov/study/NCT05621824?cond=Pancreatic%20Cancer&viewType=Card&page=4&rank=34
Pancreatic Cancer,"Information provided by BUSQUETS, JULI, Hospital Universitari de Bellvitge (Responsible Party)",Inconnu,Study Details | NCT05489458 | Predictive Factors for Resection and Survival in Type A Borderline Resectable Pancreatic Ductal Adenocarcinoma Patients After Neoadjuvant Therapy | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT05489458?cond=Pancreatic%20Cancer&viewType=Card&page=4&rank=35
Pancreatic Cancer,Information provided by H. Lee Moffitt Cancer Center and Research Institute (Responsible Party),Withdrawn,Study Details | NCT01434550 | Phase II Study of First-line SBRT in Patients With Non,https://clinicaltrials.gov/study/NCT01434550?cond=Pancreatic%20Cancer&viewType=Card&page=4&rank=36
Pancreatic Cancer,Information provided by Mayo Clinic (Responsible Party),Completed,"Study Results | NCT05523154 | ""Answers in Hours"" A Randomized Controlled Trial Using Microbiome Metagenomics for Bile Duct Cultures | ClinicalTrials.gov",https://clinicaltrials.gov/study/NCT05523154?cond=Pancreatic%20Cancer&viewType=Card&page=4&rank=37&tab=results
Pancreatic Cancer,Information provided by Mayo Clinic (Responsible Party),Terminated,"Study Details | NCT05523154 | ""Answers in Hours"" A Randomized Controlled Trial Using Microbiome Metagenomics for Bile Duct Cultures | ClinicalTrials.gov",https://clinicaltrials.gov/study/NCT05523154?cond=Pancreatic%20Cancer&viewType=Card&page=4&rank=37
Pancreatic Cancer,Information provided by St. Olavs Hospital (Responsible Party),Completed,Study Details | NCT04146441 | Ultrasound,https://clinicaltrials.gov/study/NCT04146441?cond=Pancreatic%20Cancer&viewType=Card&page=4&rank=38
Pancreatic Cancer,Information provided by Pfizer,Completed,Study Results | NCT00428597 | A Study Of Sunitinib Compared To Placebo For Patients With Advanced Pancreatic Islet Cell Tumors | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00428597?cond=Pancreatic%20Cancer&viewType=Card&page=4&rank=39&tab=results
Pancreatic Cancer,Information provided by Pfizer,Terminated,Study Details | NCT00428597 | A Study Of Sunitinib Compared To Placebo For Patients With Advanced Pancreatic Islet Cell Tumors | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00428597?cond=Pancreatic%20Cancer&viewType=Card&page=4&rank=39
Pancreatic Cancer,"Information provided by Xian-Jun Yu, Fudan University (Responsible Party)",Inconnu,Study Details | NCT03432624 | Detection of MicroRNA,https://clinicaltrials.gov/study/NCT03432624?cond=Pancreatic%20Cancer&viewType=Card&page=4&rank=40
Pancreatic Cancer,"Information provided by Xian-Jun Yu, Fudan University (Responsible Party)",Recruiting,Study Details | NCT03403101 | The Combination Chemotherapy of SIRIOX as First- or Second,https://clinicaltrials.gov/study/NCT03403101?cond=Pancreatic%20Cancer&viewType=Card&page=5&rank=41
Pancreatic Cancer,"Information provided by J.W. Wilmink, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (Responsible Party)",Recruiting,"Study Details | NCT03500068 | Establishing Organoids From Metastatic Pancreatic Cancer Patients, the OPT",https://clinicaltrials.gov/study/NCT03500068?cond=Pancreatic%20Cancer&viewType=Card&page=5&rank=42
Pancreatic Cancer,"Information provided by M.G. Besselink, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (Responsible Party)",Completed,Study Details | NCT03513705 | Impact of Nationwide Enhanced Implementation of Best Practices in Pancreatic Cancer Care (PACAP,https://clinicaltrials.gov/study/NCT03513705?cond=Pancreatic%20Cancer&viewType=Card&page=5&rank=43
Pancreatic Cancer,Information provided by Oryx GmbH & Co. KG (Responsible Party),Completed,Study Details | NCT02653313 | Parvovirus H,https://clinicaltrials.gov/study/NCT02653313?cond=Pancreatic%20Cancer&viewType=Card&page=5&rank=44
Pancreatic Cancer,"Information provided by University Health Network, Toronto (Responsible Party)",Completed,Study Details | NCT02750657 | Study of Changes and Characteristics of Genes in Patients With Pancreatic Cancer for Better Treatment Selection | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02750657?cond=Pancreatic%20Cancer&viewType=Card&page=5&rank=45
Pancreatic Cancer,"Information provided by Sofia Perea, Director Clinical Trials Unit., Grupo Hospital de Madrid (Responsible Party)",Recruiting,Study Details | NCT01394120 | Chemotherapy Selection Based on Therapeutic Targets for Advanced Pancreatic Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01394120?cond=Pancreatic%20Cancer&viewType=Card&page=5&rank=46
Pancreatic Cancer,"Information provided by Sushanth Reddy, University of Alabama at Birmingham (Responsible Party)",Withdrawn,Study Details | NCT03623984 | Molecular,https://clinicaltrials.gov/study/NCT03623984?cond=Pancreatic%20Cancer&viewType=Card&page=5&rank=47
Pancreatic Cancer,"Information provided by Chen Hongyu, West China Hospital (Responsible Party)",Recruiting,Study Details | NCT02928081 | Standard Versus Extended Lymphadenectomy in Pancreatoduodenectomy for Patients With Pancreatic Head Adenocarcinoma | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02928081?cond=Pancreatic%20Cancer&viewType=Card&page=5&rank=48
Pancreatic Cancer,Information provided by Rambam Health Care Campus (Responsible Party),Recruiting,Study Details | NCT02817308 | Correlation of Serum CA19,https://clinicaltrials.gov/study/NCT02817308?cond=Pancreatic%20Cancer&viewType=Card&page=5&rank=49
Pancreatic Cancer,"Information provided by Zhaoshen Li, Changhai Hospital (Responsible Party)",Recruiting,Study Details | NCT02529579 | Safety and Efficacy Evaluation of iAPA,https://clinicaltrials.gov/study/NCT02529579?cond=Pancreatic%20Cancer&viewType=Card&page=5&rank=50
Pancreatic Cancer,"Information provided by Sheng Yan, Zhejiang University (Responsible Party)",Recruiting,Study Details | NCT06164769 | Enucleation of Pancreatic Tumor by Blocking Abdominal Trunk and Superior Mesenteric Artery | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT06164769?cond=Pancreatic%20Cancer&viewType=Card&page=6&rank=51
Pancreatic Cancer,"Information provided by Do Hyun Park, Asan Medical Center (Responsible Party)",Recruiting,Study Details | NCT07030348 | Early Diagnosis of Pancreatic Cancer Duodenal Fluid,https://clinicaltrials.gov/study/NCT07030348?cond=Pancreatic%20Cancer&viewType=Card&page=6&rank=52
Pancreatic Cancer,Information provided by Assistance Publique Hopitaux De Marseille (Responsible Party),Completed,Study Details | NCT02150408 | Evaluation of PET,https://clinicaltrials.gov/study/NCT02150408?cond=Pancreatic%20Cancer&viewType=Card&page=6&rank=53
Pancreatic Cancer,Information provided by Silence Therapeutics GmbH (Responsible Party),Completed,Study Details | NCT01808638 | Atu027 Plus Gemcitabine in Advanced or Metastatic Pancreatic Cancer (Atu027-I,https://clinicaltrials.gov/study/NCT01808638?cond=Pancreatic%20Cancer&viewType=Card&page=6&rank=54
Pancreatic Cancer,Information provided by University of Florida (Responsible Party),Completed,Study Details | NCT02150746 | Circulating Tumor Cells in Operative Blood | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02150746?cond=Pancreatic%20Cancer&viewType=Card&page=6&rank=55
Pancreatic Cancer,Information provided by Soroka University Medical Center (Responsible Party),Recruiting,Study Details | NCT02682394 | Evaluation of Pancreatic Steatosis in Patients With Cancer of Pancreas | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02682394?cond=Pancreatic%20Cancer&viewType=Card&page=6&rank=56
Pancreatic Cancer,"Information provided by Hani Ashamalla, MD, New York Presbyterian Brooklyn Methodist Hospital (Responsible Party)",Withdrawn,"Study Details | NCT00226746 | Efficacy Study of Gemcitabine, Paclitaxel, and Irradiation in the Treatment of Pancreatic Cancer | ClinicalTrials.gov",https://clinicaltrials.gov/study/NCT00226746?cond=Pancreatic%20Cancer&viewType=Card&page=6&rank=57
Pancreatic Cancer,Information provided by Fred Hutchinson Cancer Center (Responsible Party),Withdrawn,Study Details | NCT06545344 | Palliative Care Consultation to Improve Communication for Patients Considering Surgery for a Pancreatic Neoplasm | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT06545344?cond=Pancreatic%20Cancer&viewType=Card&page=6&rank=58
Pancreatic Cancer,Information provided by National Taiwan University Hospital (Responsible Party),Recruiting,Study Details | NCT06013228 | Trajectories of Fatigue and Quality of Life in People With Both Operable Pancreatic Tumor and Diabetes Mellitus | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT06013228?cond=Pancreatic%20Cancer&viewType=Card&page=6&rank=59
Pancreatic Cancer,Information provided by Pfizer (Responsible Party),Completed,Study Results | NCT00471146 | Study Of Gemcitabine Plus AG,https://clinicaltrials.gov/study/NCT00471146?cond=Pancreatic%20Cancer&viewType=Card&page=6&rank=60&tab=results
Pancreatic Cancer,Information provided by Pfizer (Responsible Party),Completed,Study Details | NCT00471146 | Study Of Gemcitabine Plus AG,https://clinicaltrials.gov/study/NCT00471146?cond=Pancreatic%20Cancer&viewType=Card&page=6&rank=60
Pancreatic Cancer,"Information provided by Sumitomo Pharma America, Inc. (Responsible Party)",Completed,Study Results | NCT02993731 | A Study of Napabucasin Plus Nab,https://clinicaltrials.gov/study/NCT02993731?cond=Pancreatic%20Cancer&viewType=Card&page=7&rank=61&tab=results
Pancreatic Cancer,"Information provided by Sumitomo Pharma America, Inc. (Responsible Party)",Completed,Study Details | NCT02993731 | A Study of Napabucasin Plus Nab,https://clinicaltrials.gov/study/NCT02993731?cond=Pancreatic%20Cancer&viewType=Card&page=7&rank=61
Pancreatic Cancer,"Information provided by Somashekar Krishna, Ohio State University Comprehensive Cancer Center (Responsible Party)",Recruiting,Study Details | NCT05961982 | Evaluation of Endoscopic Ultrasound,https://clinicaltrials.gov/study/NCT05961982?cond=Pancreatic%20Cancer&viewType=Card&page=7&rank=62
Pancreatic Cancer,"Information provided by Zhiqiang Meng, Fudan University (Responsible Party)",Recruiting,Study Details | NCT02635971 | Intra,https://clinicaltrials.gov/study/NCT02635971?cond=Pancreatic%20Cancer&viewType=Card&page=7&rank=63
Pancreatic Cancer,"Information provided by Hao Chen, Fudan University (Responsible Party)",Recruiting,Study Details | NCT02634502 | Radiofrequency Ablation Combined With S,https://clinicaltrials.gov/study/NCT02634502?cond=Pancreatic%20Cancer&viewType=Card&page=7&rank=64
Pancreatic Cancer,"Information provided by Ying Jieer, Zhejiang Cancer Hospital (Responsible Party)",Recruiting,Study Details | NCT07235930 | Firstline Sequential AG and mFOLFOX Combined With Serplulimab and Bevacizumab Versus AG Chemotherapy Alone in Advanced Pancreatic Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT07235930?cond=Pancreatic%20Cancer&viewType=Card&page=7&rank=65
Pancreatic Cancer,Information provided by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (Responsible Party),Completed,Study Details | NCT00714701 | Screening for Early Pancreatic Neoplasia (Cancer of the Pancreas Screening or CAPS4 Study) | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00714701?cond=Pancreatic%20Cancer&viewType=Card&page=7&rank=66
Pancreatic Cancer,"Information provided by Michael Jameson, University of Auckland, New Zealand (Responsible Party)",Inconnu,Study Details | NCT06162468 | Feasibility Trial of EUS,https://clinicaltrials.gov/study/NCT06162468?cond=Pancreatic%20Cancer&viewType=Card&page=7&rank=67
Pancreatic Cancer,Information provided by Fundacion Clinic per a la Recerca Biomédica (Responsible Party),Recruiting,Study Details | NCT05914077 | Aspiration of Duodenopancreatic Juice After Secretin Stimulation vs Endoscopic Aspiration for Molecular Analysis of Intraductal Papillary Mucinous Intraductal Neoplasia. | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT05914077?cond=Pancreatic%20Cancer&viewType=Card&page=7&rank=68
Pancreatic Cancer,"Information provided by University Hospital, Strasbourg, France (Responsible Party)",Recruiting,Study Details | NCT05234450 | Multi,https://clinicaltrials.gov/study/NCT05234450?cond=Pancreatic%20Cancer&viewType=Card&page=7&rank=69
Pancreatic Cancer,"Information provided by Ying Jieer, Zhejiang Cancer Hospital (Responsible Party)",Recruiting,Study Details | NCT06393166 | Sequential AG and mFOLFOX Combined With Serplulimab Injection and Bevacizumab Injection in Untreated Advanced Pancreatic Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT06393166?cond=Pancreatic%20Cancer&viewType=Card&page=7&rank=70
Pancreatic Cancer,"Information provided by KARSENTI, Société Française d'Endoscopie Digestive (Responsible Party)",Completed,Study Details | NCT03444051 | Comparison of Two Endoscopic Biopsic Needles for Pancreatic Tumors | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03444051?cond=Pancreatic%20Cancer&viewType=Card&page=8&rank=71
Pancreatic Cancer,Information provided by Hoffmann-La Roche (Responsible Party),Completed,Study Results | NCT00711191 | A Study On An Immunostimulant Antibody In Combination With Chemotherapy For Advanced Cancer Of The Pancreas | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00711191?cond=Pancreatic%20Cancer&viewType=Card&page=8&rank=72&tab=results
Pancreatic Cancer,Information provided by Hoffmann-La Roche (Responsible Party),Completed,Study Details | NCT00711191 | A Study On An Immunostimulant Antibody In Combination With Chemotherapy For Advanced Cancer Of The Pancreas | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00711191?cond=Pancreatic%20Cancer&viewType=Card&page=8&rank=72
Pancreatic Cancer,Information provided by Yonsei University (Responsible Party),Recruiting,Study Details | NCT07257523 | Carbon Ion Radiotherapy in Frail Patients With Pancreatic Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT07257523?cond=Pancreatic%20Cancer&viewType=Card&page=8&rank=73
Pancreatic Cancer,"Information provided by Baki Topal, University Hospital, Gasthuisberg (Responsible Party)",Withdrawn,Study Details | NCT01712971 | Reduced Intra-operative Blood Loss in Pancreaticoduodenectomy for Pancreatic or Peri,https://clinicaltrials.gov/study/NCT01712971?cond=Pancreatic%20Cancer&viewType=Card&page=8&rank=74
Pancreatic Cancer,Information provided by Institut Paoli-Calmettes (Responsible Party),Recruiting,Study Details | NCT06046794 | Efficacy of First,https://clinicaltrials.gov/study/NCT06046794?cond=Pancreatic%20Cancer&viewType=Card&page=8&rank=75
Pancreatic Cancer,Information provided by University of Central Florida (Responsible Party),Recruiting,Study Details | NCT06148298 | Cell,https://clinicaltrials.gov/study/NCT06148298?cond=Pancreatic%20Cancer&viewType=Card&page=8&rank=76
Pancreatic Cancer,"Information provided by Suayib Yalcin, Hacettepe University (Responsible Party)",Completed,Study Details | NCT03807999 | Nab,https://clinicaltrials.gov/study/NCT03807999?cond=Pancreatic%20Cancer&viewType=Card&page=8&rank=77
Pancreatic Cancer,"Information provided by Nahla Atef Shabaan, Menoufia University (Responsible Party)",Recruiting,Study Details | NCT05566743 | A Study Evaluating Maintenance Therapy After First Line Chemotherapy in Metastatic Cancer Pancreas | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT05566743?cond=Pancreatic%20Cancer&viewType=Card&page=8&rank=78
Pancreatic Cancer,"Information provided by Ahmed Allam Abdelhamed Mohamed, Assiut University (Responsible Party)",Recruiting,"Study Details | NCT02311439 | Induction Chemotherapy, FOLFIRINOX Followed With Concurrent Capecitabine and Radiation Therapy in Inoperable Locally Advanced Cancer of the Pancreas | ClinicalTrials.gov",https://clinicaltrials.gov/study/NCT02311439?cond=Pancreatic%20Cancer&viewType=Card&page=8&rank=79
Pancreatic Cancer,"Information provided by Ehab Abdulkarim Abdulmaksoud, Cairo University (Responsible Party)",Recruiting,Study Details | NCT05163977 | Pancreatico Enteric Anastomosis Post Pancreaticoduodenectomy | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT05163977?cond=Pancreatic%20Cancer&viewType=Card&page=8&rank=80
Pancreatic Cancer,"Information provided by Mezza Teresa, Fondazione Policlinico Universitario Agostino Gemelli IRCCS (Responsible Party)",Active,Study Details | NCT06858631 | IMPact of AerobiC Exercise in Addition to Nutritional Treatment on Quality of Life After Pancreatectomy | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT06858631?cond=Pancreatic%20Cancer&viewType=Card&page=9&rank=81
Pancreatic Cancer,Information provided by Yonsei University (Responsible Party),Completed,Study Details | NCT05745415 | Cancer Stem Cell Specific Aptamer's Ability to Detect Blood Circulating Cancer Stem Cells and Its Role as a Predictor of Prognosis in Pancreatic Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT05745415?cond=Pancreatic%20Cancer&viewType=Card&page=9&rank=82
Pancreatic Cancer,Information provided by Institut Paoli-Calmettes (Responsible Party),Recruiting,Study Details | NCT04677244 | Echo,https://clinicaltrials.gov/study/NCT04677244?cond=Pancreatic%20Cancer&viewType=Card&page=9&rank=83
Pancreatic Cancer,"Information provided by Dr. M.R. Meijerink, Amsterdam UMC, location VUmc (Responsible Party)",Completed,Study Details | NCT02791503 | CROSSFIRE Trial: Comparing the Efficacy of Irreversible Electroporation With Radiotherapy | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02791503?cond=Pancreatic%20Cancer&viewType=Card&page=9&rank=84
Pancreatic Cancer,Information provided by Peking Union Medical College Hospital (Responsible Party),Recruiting,Study Details | NCT05259384 | Robotic Versus Laparoscopic Surgery for Patients With Pancreatic Cystic Neoplasms | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT05259384?cond=Pancreatic%20Cancer&viewType=Card&page=9&rank=85
Pancreatic Cancer,"Information provided by Xian-Jun Yu, Fudan University (Responsible Party)",Completed,Study Details | NCT05222204 | DDP ip Combined With AG in PDAC With Peritoneal Metastasis | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT05222204?cond=Pancreatic%20Cancer&viewType=Card&page=9&rank=86
Pancreatic Cancer,Information provided by University of Sao Paulo General Hospital (Responsible Party),Completed,Study Details | NCT03111368 | EUS-FNA of Solid Pancreatic Mass: Comparison Between Negative Pressure and Slow,https://clinicaltrials.gov/study/NCT03111368?cond=Pancreatic%20Cancer&viewType=Card&page=9&rank=87
Pancreatic Cancer,"Information provided by CCTU- Cancer Theme, Cambridge University Hospitals NHS Foundation Trust (Responsible Party)",Active,Study Details | NCT04128332 | Pre,https://clinicaltrials.gov/study/NCT04128332?cond=Pancreatic%20Cancer&viewType=Card&page=9&rank=88
Pancreatic Cancer,Information provided by Fondation Hôpital Saint-Joseph (Responsible Party),Completed,Study Details | NCT03961646 | Evaluation of the FOCUS Diffusion's Added Clinical Value Compared to Conventional MRI | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03961646?cond=Pancreatic%20Cancer&viewType=Card&page=9&rank=89
Pancreatic Cancer,"Information provided by Dr. med. Hector Eloy Tamez Perez, Hospital Universitario Dr. Jose E. Gonzalez (Responsible Party)",Recruiting,Study Details | NCT04843956 | Comparison of EUS,https://clinicaltrials.gov/study/NCT04843956?cond=Pancreatic%20Cancer&viewType=Card&page=9&rank=90
Pancreatic Cancer,"Information provided by Changhong Miao, Fudan University (Responsible Party)",Inconnu,Study Details | NCT03659292 | Effects of Epidural Block on the Prognosis in Patients With Pancreatic Cancer Undergoing Distal Pancreatectomy | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03659292?cond=Pancreatic%20Cancer&viewType=Card&page=10&rank=91
Pancreatic Cancer,"Information provided by Syed Kazmi, University of Texas Southwestern Medical Center (Responsible Party)",Completed,Study Results | NCT03649321 | Clinical Trial of Chemotherapy and Bemcentinib for Metastatic Pancreatic Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03649321?cond=Pancreatic%20Cancer&viewType=Card&page=10&rank=92&tab=results
Pancreatic Cancer,"Information provided by Syed Kazmi, University of Texas Southwestern Medical Center (Responsible Party)",Terminated,Study Details | NCT03649321 | Clinical Trial of Chemotherapy and Bemcentinib for Metastatic Pancreatic Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03649321?cond=Pancreatic%20Cancer&viewType=Card&page=10&rank=92
Pancreatic Cancer,"Information provided by John DeWitt, Indiana University (Responsible Party)",Inconnu,"Study Details | NCT04693754 | Endoscopic Ultrasound Radiofrequency Ablation, Database Repository | ClinicalTrials.gov",https://clinicaltrials.gov/study/NCT04693754?cond=Pancreatic%20Cancer&viewType=Card&page=10&rank=93
Pancreatic Cancer,"Information provided by Concetta Cacace, University of Pisa (Responsible Party)",Inconnu,Study Details | NCT04662346 | Evaluation of Difficulty Score for Robotic Pancreatoduodenectomy | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT04662346?cond=Pancreatic%20Cancer&viewType=Card&page=10&rank=94
Pancreatic Cancer,"Information provided by Dabin Xu, Chinese PLA General Hospital (Responsible Party)",Inconnu,Study Details | NCT03278015 | Phase 2 Trial of Gemcitabine vs S-1 vs Gemcitabine Plus Nab-paclitaxel as Adjuvant Chemotherapy of Post,https://clinicaltrials.gov/study/NCT03278015?cond=Pancreatic%20Cancer&viewType=Card&page=10&rank=95
Pancreatic Cancer,"Information provided by Changhong Miao, Fudan University (Responsible Party)",Recruiting,Study Details | NCT03245346 | Effects of Epidural Anesthesia and Analgesia on the Prognosis in Patients Undergoing Pancreatic Cancer Surgery | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03245346?cond=Pancreatic%20Cancer&viewType=Card&page=10&rank=96
Pancreatic Cancer,Information provided by University Hospital Plymouth NHS Trust (Responsible Party),Completed,Study Details | NCT02296736 | The Pre-operative Pathway in Pancreatic Head Malignancy,https://clinicaltrials.gov/study/NCT02296736?cond=Pancreatic%20Cancer&viewType=Card&page=10&rank=97
Pancreatic Cancer,"Information provided by Salwan Al Mutar MD MS, University of Texas Southwestern Medical Center (Responsible Party)",Completed,Study Results | NCT02902484 | Study of Nintedanib and Chemotherapy for Advanced Pancreatic Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02902484?cond=Pancreatic%20Cancer&viewType=Card&page=10&rank=98&tab=results
Pancreatic Cancer,"Information provided by Salwan Al Mutar MD MS, University of Texas Southwestern Medical Center (Responsible Party)",Terminated,Study Details | NCT02902484 | Study of Nintedanib and Chemotherapy for Advanced Pancreatic Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02902484?cond=Pancreatic%20Cancer&viewType=Card&page=10&rank=98
Pancreatic Cancer,"Information provided by Joseph Caster, Ph.D., M.D., University of Iowa (Responsible Party)",Withdrawn,Study Details | NCT03541486 | A Clinical Trial Evaluating the Effect of Pharmacological Ascorbate on Radiation Therapy for Pancreatic Cancer Patients | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03541486?cond=Pancreatic%20Cancer&viewType=Card&page=10&rank=99
Pancreatic Cancer,Information provided by Jonsson Comprehensive Cancer Center (Responsible Party),Terminated,Study Details | NCT02681601 | Nutrition Support to Improve Outcomes in Patients With Unresectable Pancreatic Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02681601?cond=Pancreatic%20Cancer&viewType=Card&page=10&rank=100
Pancreatic Cancer,Information provided by Corcept Therapeutics (Responsible Party),Inconnu,Study Details | NCT07259317 | Relacorilant With Nab,https://clinicaltrials.gov/study/NCT07259317?cond=Pancreatic%20Cancer&viewType=Card&page=11&rank=101
Pancreatic Cancer,"Information provided by Carolyn Fang, PhD, Fox Chase Cancer Center (Responsible Party)",Completed,Study Details | NCT02442323 | A Pilot Study of a Home,https://clinicaltrials.gov/study/NCT02442323?cond=Pancreatic%20Cancer&viewType=Card&page=11&rank=102
Pancreatic Cancer,Information provided by Golden Biotechnology Corporation (Responsible Party),Active,Study Details | NCT03310632 | Determine Function of Antroquinonol in Combination With SOC in First Line Metastatic Pancreatic Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03310632?cond=Pancreatic%20Cancer&viewType=Card&page=11&rank=103
Pancreatic Cancer,Information provided by Nantes University Hospital (Responsible Party),Inconnu,Study Details | NCT07178587 | Evaluating the roLe of Multiplexed PET Imaging in the Detection and Staging of hepatocellulaR Carcinoma and gAstro-entero,https://clinicaltrials.gov/study/NCT07178587?cond=Pancreatic%20Cancer&viewType=Card&page=11&rank=104
Pancreatic Cancer,Information provided by AdventHealth (Responsible Party),Completed,Study Details | NCT02910960 | Comparison of Two Fine Needle Biopsy Needles for Solid Pancreatic Masses | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02910960?cond=Pancreatic%20Cancer&viewType=Card&page=11&rank=105
Pancreatic Cancer,Information provided by AdventHealth (Responsible Party),Completed,Study Details | NCT02911974 | Comparing Biopsy Needles for Endoscopic Ultrasound Guided Samples for Pancreatic Masses | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02911974?cond=Pancreatic%20Cancer&viewType=Card&page=11&rank=106
Pancreatic Cancer,"Information provided by Prof. Dr. Thomas Rösch, Universitätsklinikum Hamburg-Eppendorf (Responsible Party)",Completed,Study Results | NCT02181140 | Core Biopsy Endo Sonography Study Evaluation of the Significance of the Pro,https://clinicaltrials.gov/study/NCT02181140?cond=Pancreatic%20Cancer&viewType=Card&page=11&rank=107&tab=results
Pancreatic Cancer,"Information provided by Prof. Dr. Thomas Rösch, Universitätsklinikum Hamburg-Eppendorf (Responsible Party)",Completed,Study Details | NCT02181140 | Core Biopsy Endo Sonography Study Evaluation of the Significance of the Pro,https://clinicaltrials.gov/study/NCT02181140?cond=Pancreatic%20Cancer&viewType=Card&page=11&rank=107
Pancreatic Cancer,Information provided by Centre Hospitalier Universitaire de Nice (Responsible Party),Completed,Study Details | NCT02830620 | Study at the Man of the Profile of Chimiokines in the Anorexia Bound to the Cancerous Cachexy | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02830620?cond=Pancreatic%20Cancer&viewType=Card&page=11&rank=108
Pancreatic Cancer,"Information provided by Yen-I Chen, McGill University Health Centre/Research Institute of the McGill University Health Centre (Responsible Party)",Completed,Study Details | NCT03435588 | Endoscopic Ultrasound (EUS)-Guided Fine Needle Aspiration (FNA) With Rapid On-site Evaluation (ROSE) of Cytopathology vs. EUS,https://clinicaltrials.gov/study/NCT03435588?cond=Pancreatic%20Cancer&viewType=Card&page=11&rank=109
Pancreatic Cancer,Information provided by AdventHealth (Responsible Party),Completed,Study Results | NCT01394159 | 22G FNA Needle vs. 22G ProCore Needle | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01394159?cond=Pancreatic%20Cancer&viewType=Card&page=11&rank=110&tab=results
Pancreatic Cancer,Information provided by AdventHealth (Responsible Party),Completed,Study Details | NCT01394159 | 22G FNA Needle vs. 22G ProCore Needle | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01394159?cond=Pancreatic%20Cancer&viewType=Card&page=11&rank=110
Pancreatic Cancer,Information provided by Università Vita-Salute San Raffaele,Completed,Study Details | NCT01278381 | Prognostic Score To Predict Major Complications After Pancreaticoduodenectomy | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01278381?cond=Pancreatic%20Cancer&viewType=Card&page=12&rank=111
Pancreatic Cancer,Information provided by Institut Curie (Responsible Party),Recruiting,Study Details | NCT05475366 | Personalized First,https://clinicaltrials.gov/study/NCT05475366?cond=Pancreatic%20Cancer&viewType=Card&page=12&rank=112
Pancreatic Cancer,Information provided by Sanofi (Responsible Party),Completed,Study Results | NCT00574275 | Aflibercept Compared to Placebo in Term of Efficacy in Patients Treated With Gemcitabine for Metastatic Pancreatic Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00574275?cond=Pancreatic%20Cancer&viewType=Card&page=12&rank=113&tab=results
Pancreatic Cancer,Information provided by Sanofi (Responsible Party),Terminated,Study Details | NCT00574275 | Aflibercept Compared to Placebo in Term of Efficacy in Patients Treated With Gemcitabine for Metastatic Pancreatic Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00574275?cond=Pancreatic%20Cancer&viewType=Card&page=12&rank=113
Pancreatic Cancer,Information provided by Kochi University,Completed,Study Details | NCT00657995 | Tight Glycemic Control by Artificial Pancreas | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00657995?cond=Pancreatic%20Cancer&viewType=Card&page=12&rank=114
Pancreatic Cancer,Information provided by Eli Lilly and Company (Responsible Party),Completed,Study Results | NCT00267020 | Phase 2 Study of Gemcitabine or Gemcitabine + Enzastaurin in Participants With Advanced or Metastatic Pancreatic Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00267020?cond=Pancreatic%20Cancer&viewType=Card&page=12&rank=115&tab=results
Pancreatic Cancer,Information provided by Eli Lilly and Company (Responsible Party),Completed,Study Details | NCT00267020 | Phase 2 Study of Gemcitabine or Gemcitabine + Enzastaurin in Participants With Advanced or Metastatic Pancreatic Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00267020?cond=Pancreatic%20Cancer&viewType=Card&page=12&rank=115
Pancreatic Cancer,Information provided by University Hospital Tuebingen (Responsible Party),Inconnu,Study Details | NCT07153289 | CD318-targeted CAR,https://clinicaltrials.gov/study/NCT07153289?cond=Pancreatic%20Cancer&viewType=Card&page=12&rank=116
Pancreatic Cancer,"Information provided by Jeong Min Lee, Seoul National University Hospital (Responsible Party)",Active,Study Details | NCT01703650 | Role of Perfusion CT in Pancreatic Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01703650?cond=Pancreatic%20Cancer&viewType=Card&page=12&rank=117
Pancreatic Cancer,Information provided by Hull University Teaching Hospitals NHS Trust (Responsible Party),Recruiting,Study Details | NCT03536793 | Tumour Regulatory Molecules in Early Pancreatic Cancer Detection | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03536793?cond=Pancreatic%20Cancer&viewType=Card&page=12&rank=118
Pancreatic Cancer,"Information provided by Guopei Luo, Fudan University (Responsible Party)",Recruiting,Study Details | NCT06914674 | Tamoxifen for Advanced Solid Pseudopapillary Tumor of the Pancreas | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT06914674?cond=Pancreatic%20Cancer&viewType=Card&page=12&rank=119
Pancreatic Cancer,"Information provided by Second Affiliated Hospital, School of Medicine, Zhejiang University (Responsible Party)",Completed,Study Details | NCT04977596 | Related Studies of Imaging Features and Prognosis Between Pancreatic Neuroendocrine Tumors and Pancreatic Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT04977596?cond=Pancreatic%20Cancer&viewType=Card&page=12&rank=120
Pancreatic Cancer,Information provided by Ipsen (Responsible Party),Completed,Study Results | NCT02651987 | Efficacy and Safety Study in Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel® 120 mg | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02651987?cond=Pancreatic%20Cancer&viewType=Card&page=13&rank=121&tab=results
Pancreatic Cancer,Information provided by Ipsen (Responsible Party),Completed,Study Details | NCT02651987 | Efficacy and Safety Study in Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel® 120 mg | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02651987?cond=Pancreatic%20Cancer&viewType=Card&page=13&rank=121
Pancreatic Cancer,Information provided by Abramson Cancer Center at Penn Medicine (Responsible Party),Recruiting,Study Details | NCT07114939 | FTT PET/CT in Pancreatic Neuroendocrine Tumors | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT07114939?cond=Pancreatic%20Cancer&viewType=Card&page=13&rank=122
Pancreatic Cancer,"Information provided by CHAN SHANNON MELISSA, Chinese University of Hong Kong (Responsible Party)",Recruiting,Study Details | NCT06160323 | Upfront EUS CGN/CPN vs Conventional Step up Approach for Inoperable Painful Pancreatic Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT06160323?cond=Pancreatic%20Cancer&viewType=Card&page=13&rank=123
Pancreatic Cancer,"Information provided by David Ferreras, Hospital Universitario Virgen de la Arrixaca (Responsible Party)",Recruiting,Study Details | NCT04783844 | Usefulness of 3D Digital Reconstruction in the Imaging Diagnosis of Pancreatic Tumors | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT04783844?cond=Pancreatic%20Cancer&viewType=Card&page=13&rank=124
Pancreatic Cancer,"Information provided by Morten Ladekarl, Aalborg University Hospital (Responsible Party)",Recruiting,Study Details | NCT05841420 | Gemcitabine Versus Reduced-dose Combination Chemotherapy in Fragile Patients with Non,https://clinicaltrials.gov/study/NCT05841420?cond=Pancreatic%20Cancer&viewType=Card&page=13&rank=125
Pancreatic Cancer,"Information provided by Yi Miao, Prof., Nanjing Medical University (Responsible Party)",Inconnu,Study Details | NCT04049461 | Heterotopic Ossification in Abdominal Incision and Pancreatic Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT04049461?cond=Pancreatic%20Cancer&viewType=Card&page=13&rank=126
Pancreatic Cancer,"Information provided by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.) (Responsible Party)",Terminated,Study Details | NCT05193604 | A Clinical Trial to Evaluate Tolerability and Security of TQB2858 Injection in Subjects With Advanced Pancreatic Carcinoma | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT05193604?cond=Pancreatic%20Cancer&viewType=Card&page=13&rank=127
Pancreatic Cancer,Information provided by Institut de Cancérologie de Lorraine (Responsible Party),Active,Study Details | NCT02676349 | Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS,https://clinicaltrials.gov/study/NCT02676349?cond=Pancreatic%20Cancer&viewType=Card&page=13&rank=128
Pancreatic Cancer,Information provided by Peking University First Hospital (Responsible Party),Inconnu,Study Details | NCT06833658 | Effects of Aromatherapy with Essential Oils on Anxiety and Depression in Perioperative Patients with Pancreatic Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT06833658?cond=Pancreatic%20Cancer&viewType=Card&page=13&rank=129
Pancreatic Cancer,"Information provided by Charing Chong, MD, Chinese University of Hong Kong (Responsible Party)",Terminated,Study Details | NCT02333409 | Acupuncture for Pain Control in Patients With Inoperable Pancreatic Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02333409?cond=Pancreatic%20Cancer&viewType=Card&page=13&rank=130
Pancreatic Cancer,Information provided by Prima BioMed Ltd (Responsible Party),Withdrawn,Study Details | NCT02310971 | Cvac as Maintenance Treatment Patients With Resected Stage I or Stage II Adenocarcinoma (Cancer) of the Pancreas | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02310971?cond=Pancreatic%20Cancer&viewType=Card&page=14&rank=131
Pancreatic Cancer,"Information provided by CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (Responsible Party)",Recruiting,"Study Details | NCT06505395 | A Trial to Assess Efficacy, Safety, Pharmacokinetics of Octreotide Subcutaneous Injection in Patients With Gastroentero-pancreatic Neuroendocrine Tumor (GEP",https://clinicaltrials.gov/study/NCT06505395?cond=Pancreatic%20Cancer&viewType=Card&page=14&rank=132
Pancreatic Cancer,"Information provided by Peter Vilmann MD, DSc, HC, FASGE, Herlev Hospital (Responsible Party)",Recruiting,Study Details | NCT04687410 | Novel Crown-cut Biopsy Needle (FNB) vs Standard Aspiration Needle (FNA) for EUS,https://clinicaltrials.gov/study/NCT04687410?cond=Pancreatic%20Cancer&viewType=Card&page=14&rank=133
Pancreatic Cancer,Information provided by Institut Paoli-Calmettes (Responsible Party),Recruiting,Study Details | NCT02869581 | Institut Paoli,https://clinicaltrials.gov/study/NCT02869581?cond=Pancreatic%20Cancer&viewType=Card&page=14&rank=134
Pancreatic Cancer,Information provided by HonorHealth Research Institute (Responsible Party),Withdrawn,Study Details | NCT05216120 | Pemigatinib in Subjects With Adenosquamous Carcinoma of the Pancreas | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT05216120?cond=Pancreatic%20Cancer&viewType=Card&page=14&rank=135
Pancreatic Cancer,Information provided by Baylor Research Institute (Responsible Party),Active,Study Details | NCT01771146 | Neoadjuvant FOLFIRINOX Regimen in Patients With Non,https://clinicaltrials.gov/study/NCT01771146?cond=Pancreatic%20Cancer&viewType=Card&page=14&rank=136
Pancreatic Cancer,Information provided by CEBIOTEX (Responsible Party),Recruiting,Study Details | NCT06538857 | CEB,https://clinicaltrials.gov/study/NCT06538857?cond=Pancreatic%20Cancer&viewType=Card&page=14&rank=137
Pancreatic Cancer,Information provided by University of Pennsylvania (Responsible Party),Active,Study Details | NCT03323944 | CAR T Cell Immunotherapy for Pancreatic Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03323944?cond=Pancreatic%20Cancer&viewType=Card&page=14&rank=138
Pancreatic Cancer,Information provided by Mayo Clinic (Responsible Party),Inconnu,Study Details | NCT06744595 | Personalized Education and Genetic Counseling to Increase Genetic Testing in Patients With a Known Family History of Pancreatic Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT06744595?cond=Pancreatic%20Cancer&viewType=Card&page=14&rank=139
Pancreatic Cancer,Information provided by Mayo Clinic (Responsible Party),Recruiting,Study Details | NCT06271291 | Pancreatic Cancer Detection Consortium (PCDC) Prospective Cohorts | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT06271291?cond=Pancreatic%20Cancer&viewType=Card&page=14&rank=140
Pancreatic Cancer,"Information provided by Anthony Teoh, Chinese University of Hong Kong (Responsible Party)",Recruiting,Study Details | NCT03218345 | EUS,https://clinicaltrials.gov/study/NCT03218345?cond=Pancreatic%20Cancer&viewType=Card&page=15&rank=141
Pancreatic Cancer,"Information provided by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.) (Responsible Party)",Recruiting,Study Details | NCT06767813 | Clinical Study of TQB2868 Injection Combined With Anlotinib Capsule and Chemotherapy in the First,https://clinicaltrials.gov/study/NCT06767813?cond=Pancreatic%20Cancer&viewType=Card&page=15&rank=142
Pancreatic Cancer,Information provided by Ramsay Générale de Santé (Responsible Party),Completed,Study Details | NCT05155475 | Endoscopic Ultrasound Evaluation of the Common Bile Duct in Patients With Obstructive Jaundice Due to Bilio,https://clinicaltrials.gov/study/NCT05155475?cond=Pancreatic%20Cancer&viewType=Card&page=15&rank=143
Pancreatic Cancer,Information provided by RenJi Hospital (Responsible Party),Active,Study Details | NCT05141656 | Construction and Evaluation of China's Advanced Pancreatic Tumor Big Data Center | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT05141656?cond=Pancreatic%20Cancer&viewType=Card&page=15&rank=144
Pancreatic Cancer,"Information provided by Stefano Crippa, IRCCS San Raffaele (Responsible Party)",Recruiting,"Study Details | NCT06706700 | Endocrine, Metabolic, Inflammatory Biomarkers to Identify Highgrade Dysplasia/invasive Carcinoma in Patients with IPMN of the Pancreas | ClinicalTrials.gov",https://clinicaltrials.gov/study/NCT06706700?cond=Pancreatic%20Cancer&viewType=Card&page=15&rank=145
Pancreatic Cancer,"Information provided by Tamer.A.A.M.Habeeb, Zagazig University (Responsible Party)",Completed,Study Details | NCT05711433 | Risk Factors for Postoperative Pancreatic Fistula Following Non,https://clinicaltrials.gov/study/NCT05711433?cond=Pancreatic%20Cancer&viewType=Card&page=15&rank=146
Pancreatic Cancer,"Information provided by Natalyn N. Hawk, Emory University (Responsible Party)",Completed,Study Details | NCT01446458 | Phase I Study of Stereotactic Body Radiation Therapy and FOLFIRINOX in the Neoadjuvant Therapy of Pancreatic Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01446458?cond=Pancreatic%20Cancer&viewType=Card&page=15&rank=147
Pancreatic Cancer,Information provided by M.D. Anderson Cancer Center (Responsible Party),Completed,Study Results | NCT01598194 | Comparison of a Novel 22,https://clinicaltrials.gov/study/NCT01598194?cond=Pancreatic%20Cancer&viewType=Card&page=15&rank=148&tab=results
Pancreatic Cancer,Information provided by M.D. Anderson Cancer Center (Responsible Party),Completed,Study Details | NCT01598194 | Comparison of a Novel 22,https://clinicaltrials.gov/study/NCT01598194?cond=Pancreatic%20Cancer&viewType=Card&page=15&rank=148
Pancreatic Cancer,"Information provided by Guoliang Jiang, Shanghai Proton and Heavy Ion Center (Responsible Party)",Recruiting,Study Details | NCT05830019 | Carbon Ion Radiotherapy for Recurrent Pancreatic Cancer Post Surgery | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT05830019?cond=Pancreatic%20Cancer&viewType=Card&page=15&rank=149
Pancreatic Cancer,Information provided by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School (Responsible Party),Inconnu,Study Details | NCT06080854 | AG Combined With Immunotherapy and SBRT in Patients With Potentially Resectable Pancreatic Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT06080854?cond=Pancreatic%20Cancer&viewType=Card&page=15&rank=150
Pancreatic Cancer,"Information provided by Simon Yu, Chinese University of Hong Kong (Responsible Party)",Terminated,Study Details | NCT02822716 | Irreversible Electroporation for Inoperable Hepatic and Pancreatic Malignancy | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02822716?cond=Pancreatic%20Cancer&viewType=Card&page=16&rank=151
Pancreatic Cancer,"Information provided by Patrick J. Worth, M.D., F.A.C.S., F.S.S.O., OHSU Knight Cancer Institute (Responsible Party)",Recruiting,Study Details | NCT06084013 | Use Of Indocyanine Green In Pancreas Surgery | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT06084013?cond=Pancreatic%20Cancer&viewType=Card&page=16&rank=152
Pancreatic Cancer,Information provided by Australasian Gastro-Intestinal Trials Group (Responsible Party),Completed,Study Details | NCT02358356 | Capecitabine ON Temozolomide Radionuclide Therapy Octreotate Lutetium,https://clinicaltrials.gov/study/NCT02358356?cond=Pancreatic%20Cancer&viewType=Card&page=16&rank=153
Pancreatic Cancer,"Information provided by Du Juan, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School (Responsible Party)",Recruiting,Study Details | NCT05634564 | Concurrent Chemoradiotherapy Combined With Immunotherapy in Patients With Potentially Resectable Pancreatic Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT05634564?cond=Pancreatic%20Cancer&viewType=Card&page=16&rank=154
Pancreatic Cancer,"Information provided by University of California, San Francisco (Responsible Party)",Recruiting,Study Details | NCT05058846 | Pilot Study of Pancreatic Cancer Screening | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT05058846?cond=Pancreatic%20Cancer&viewType=Card&page=16&rank=155
Pancreatic Cancer,"Information provided by University Hospital, Montpellier (Responsible Party)",Recruiting,Study Details | NCT03791073 | New Biomarkers in Pancreatic Cancer Using EXPEL Concept | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03791073?cond=Pancreatic%20Cancer&viewType=Card&page=16&rank=156
Pancreatic Cancer,"Information provided by Jeong Min Lee, Seoul National University Hospital (Responsible Party)",Active,Study Details | NCT04592393 | Pancreas Cancer Surveillance Using an Abbreviated MRI | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT04592393?cond=Pancreatic%20Cancer&viewType=Card&page=16&rank=157
Pancreatic Cancer,"Information provided by Charing Chong, MD, Chinese University of Hong Kong (Responsible Party)",Recruiting,Study Details | NCT04841616 | Multicentered Prospective Randomized Controlled Trial For Solid Pancreatic Lesions | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT04841616?cond=Pancreatic%20Cancer&viewType=Card&page=16&rank=158
Pancreatic Cancer,"Information provided by Brett C. Sheppard, M.D., FACS, OHSU Knight Cancer Institute (Responsible Party)",Completed,Study Results | NCT04965311 | Endoscopic Botulinum Toxin Injection in the Prevention of Postoperative Pancreatic Fistula Following Distal Pancreatectomy | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT04965311?cond=Pancreatic%20Cancer&viewType=Card&page=16&rank=159&tab=results
Pancreatic Cancer,"Information provided by Brett C. Sheppard, M.D., FACS, OHSU Knight Cancer Institute (Responsible Party)",Terminated,Study Details | NCT04965311 | Endoscopic Botulinum Toxin Injection in the Prevention of Postoperative Pancreatic Fistula Following Distal Pancreatectomy | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT04965311?cond=Pancreatic%20Cancer&viewType=Card&page=16&rank=159
Pancreatic Cancer,Information provided by Institut Paoli-Calmettes (Responsible Party),Completed,Study Details | NCT04724551 | The Neutrophil-to,https://clinicaltrials.gov/study/NCT04724551?cond=Pancreatic%20Cancer&viewType=Card&page=16&rank=160
Pancreatic Cancer,"Information provided by Guoliang Jiang, Shanghai Proton and Heavy Ion Center (Responsible Party)",Active,Study Details | NCT04082455 | Carbon Ion Radiotherapy for Locally Advanced Pancreatic Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT04082455?cond=Pancreatic%20Cancer&viewType=Card&page=17&rank=161
Pancreatic Cancer,Information provided by SWOG Cancer Research Network (Responsible Party),Recruiting,Study Details | NCT06807437 | Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT06807437?cond=Pancreatic%20Cancer&viewType=Card&page=17&rank=162
Pancreatic Cancer,Information provided by AstraZeneca (Responsible Party),Completed,Study Details | NCT04889404 | LYNPARZA Pancreas Cancer Japan Post,https://clinicaltrials.gov/study/NCT04889404?cond=Pancreatic%20Cancer&viewType=Card&page=17&rank=163
Pancreatic Cancer,"Information provided by Fuda Cancer Hospital, Guangzhou (Responsible Party)",Completed,Study Details | NCT02338752 | Safety and Efficacy Study of Mix Vaccine in Pancreatic Carcinoma Patient | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02338752?cond=Pancreatic%20Cancer&viewType=Card&page=17&rank=164
Pancreatic Cancer,Non spécifié,Inconnu,Study Details | NCT03949933 | | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03949933?cond=Pancreatic%20Cancer&viewType=Card&page=17&rank=165
Pancreatic Cancer,Information provided by Eastern Cooperative Oncology Group (ECOG-ACRIN Cancer Research Group) (Responsible Party),Active,Study Details | NCT04239573 | Comparing Two Methods to Follow Patients With Pancreatic Cysts | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT04239573?cond=Pancreatic%20Cancer&viewType=Card&page=17&rank=166
Pancreatic Cancer,"Information provided by Yingbin Liu, MD, PhD, FACS, Shanghai Jiao Tong University School of Medicine (Responsible Party)",Recruiting,Study Details | NCT07045571 | MSCAN: ctDNA Methylation as Prognostic and Theranostic Tool for Pancreatic Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT07045571?cond=Pancreatic%20Cancer&viewType=Card&page=17&rank=167
Pancreatic Cancer,Information provided by Stanford University (Responsible Party),Withdrawn,Study Details | NCT04833959 | Pilot Study of 89,https://clinicaltrials.gov/study/NCT04833959?cond=Pancreatic%20Cancer&viewType=Card&page=17&rank=168
Pancreatic Cancer,Information provided by M.D. Anderson Cancer Center (Responsible Party),Completed,Study Results | NCT03745794 | Repeat Quadratus Lumborum Block to Reduce Opioid Need in Patients After Pancreatic Surgery | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03745794?cond=Pancreatic%20Cancer&viewType=Card&page=17&rank=169&tab=results
Pancreatic Cancer,Information provided by M.D. Anderson Cancer Center (Responsible Party),Completed,Study Details | NCT03745794 | Repeat Quadratus Lumborum Block to Reduce Opioid Need in Patients After Pancreatic Surgery | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03745794?cond=Pancreatic%20Cancer&viewType=Card&page=17&rank=169
Pancreatic Cancer,Information provided by Hopital Foch (Responsible Party),Recruiting,"Study Details | NCT06757244 | DOVIPA, a Study Evaluating Efficacy and Safety of DOstarlimab and VItamin D3 With mFOLFIRINOX in PAncreatic Cancer | ClinicalTrials.gov",https://clinicaltrials.gov/study/NCT06757244?cond=Pancreatic%20Cancer&viewType=Card&page=17&rank=170
Pancreatic Cancer,Information provided by Gilead Sciences,Completed,Study Details | NCT00041639 | Safety Study of 90Y,https://clinicaltrials.gov/study/NCT00041639?cond=Pancreatic%20Cancer&viewType=Card&page=18&rank=171
Pancreatic Cancer,Information provided by University Medicine Greifswald,Inconnu,Study Details | NCT01330823 | L,https://clinicaltrials.gov/study/NCT01330823?cond=Pancreatic%20Cancer&viewType=Card&page=18&rank=172
Pancreatic Cancer,Information provided by M.D. Anderson Cancer Center (Responsible Party),Recruiting,Study Details | NCT06593431 | Extending Outcomes for Pancreas Cancer Patients With Nominal Oligometastatic Disease (EXPAND): A Randomized Phase III Trial | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT06593431?cond=Pancreatic%20Cancer&viewType=Card&page=18&rank=173
Pancreatic Cancer,Information provided by M.D. Anderson Cancer Center (Responsible Party),Recruiting,"Study Details | NCT06651580 | Biospecimen Collection to Identify Gene Mutations for High Risk Pancreatic Cancer in Pediatric Patients, INSPPIRE 2 Study | ClinicalTrials.gov",https://clinicaltrials.gov/study/NCT06651580?cond=Pancreatic%20Cancer&viewType=Card&page=18&rank=174
Pancreatic Cancer,Information provided by Thomas Jefferson University (Sidney Kimmel Cancer Center at Thomas Jefferson University) (Responsible Party),Completed,Study Results | NCT02517268 | Accelerated Recovery Pathway for Discharge After Surgery in Patients With Pancreatic Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02517268?cond=Pancreatic%20Cancer&viewType=Card&page=18&rank=175&tab=results
Pancreatic Cancer,Information provided by Thomas Jefferson University (Sidney Kimmel Cancer Center at Thomas Jefferson University) (Responsible Party),Completed,Study Details | NCT02517268 | Accelerated Recovery Pathway for Discharge After Surgery in Patients With Pancreatic Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02517268?cond=Pancreatic%20Cancer&viewType=Card&page=18&rank=175
Pancreatic Cancer,"Information provided by Andrew Mokbel, Assiut University (Responsible Party)",Inconnu,Study Details | NCT04768660 | Effects of Chewing Gum Against Postoperative Ileus | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT04768660?cond=Pancreatic%20Cancer&viewType=Card&page=18&rank=176
Pancreatic Cancer,"Information provided by Adenocyte, LLC (Responsible Party)",Inconnu,Study Details | NCT06157671 | The LINFU® U.S. Registry for the Detection of Asymptomatic Pancreatic Ductal Adenocarcinoma | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT06157671?cond=Pancreatic%20Cancer&viewType=Card&page=18&rank=177
Pancreatic Cancer,Information provided by Washington University School of Medicine (Responsible Party),Terminated,Study Details | NCT00732082 | Lag,https://clinicaltrials.gov/study/NCT00732082?cond=Pancreatic%20Cancer&viewType=Card&page=18&rank=178
Pancreatic Cancer,Information provided by Boston Scientific Corporation (Responsible Party),Completed,Study Results | NCT01774019 | Preoperative Biliary Drainage in Resectable Pancreatic or Periampullary Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01774019?cond=Pancreatic%20Cancer&viewType=Card&page=18&rank=179&tab=results
Pancreatic Cancer,Information provided by Boston Scientific Corporation (Responsible Party),Completed,Study Details | NCT01774019 | Preoperative Biliary Drainage in Resectable Pancreatic or Periampullary Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01774019?cond=Pancreatic%20Cancer&viewType=Card&page=18&rank=179
Pancreatic Cancer,"Information provided by National Health Research Institutes, Taiwan (Responsible Party)",Completed,"Study Details | NCT03162510 | Biweekly SOLAR, as First",https://clinicaltrials.gov/study/NCT03162510?cond=Pancreatic%20Cancer&viewType=Card&page=18&rank=180
Pancreatic Cancer,Information provided by Amgen (Responsible Party),Recruiting,"Study Details | NCT06360354 | A Study Evaluating AMG 193 in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)",https://clinicaltrials.gov/study/NCT06360354?cond=Pancreatic%20Cancer&viewType=Card&page=19&rank=181
Pancreatic Cancer,Information provided by AHS Cancer Control Alberta (Responsible Party),Recruiting,Study Details | NCT01411072 | Biomarker Directed Adjuvant Chemotherapy for Resected Pancreas Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01411072?cond=Pancreatic%20Cancer&viewType=Card&page=19&rank=182
Pancreatic Cancer,"Information provided by Mohammed Aly, Assiut University (Responsible Party)",Inconnu,Study Details | NCT05463328 | Open Versus Laparoscopic Assisted Pancreaticoduodenectomy | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT05463328?cond=Pancreatic%20Cancer&viewType=Card&page=19&rank=183
Pancreatic Cancer,"Information provided by Joseph J. Cullen, University of Iowa (Responsible Party)",Completed,Study Details | NCT02905578 | A Phase 2 Trial of High,https://clinicaltrials.gov/study/NCT02905578?cond=Pancreatic%20Cancer&viewType=Card&page=19&rank=184
Pancreatic Cancer,"Information provided by Dong Wan Seo, Asan Medical Center (Responsible Party)",Active,Study Details | NCT00689715 | Long Term Outcomes After EUS,https://clinicaltrials.gov/study/NCT00689715?cond=Pancreatic%20Cancer&viewType=Card&page=19&rank=185
Pancreatic Cancer,Information provided by AdventHealth (Responsible Party),Completed,Study Results | NCT01677312 | Trial Comparing 19 and 25-gauge EUS,https://clinicaltrials.gov/study/NCT01677312?cond=Pancreatic%20Cancer&viewType=Card&page=19&rank=186&tab=results
Pancreatic Cancer,Information provided by AdventHealth (Responsible Party),Completed,Study Details | NCT01677312 | Trial Comparing 19 and 25-gauge EUS,https://clinicaltrials.gov/study/NCT01677312?cond=Pancreatic%20Cancer&viewType=Card&page=19&rank=186
Pancreatic Cancer,Information provided by Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS (Responsible Party),Completed,"Study Details | NCT01996540 | The Role of Early Systematic Best Palliative Care Versus on Request Palliative Care Consultation During Standard Oncologic Treatment for Patients With Advanced Gastric or Pancreatic Cancers: a Randomized, Controlled, Multicenter Trial. | ClinicalTrials.gov",https://clinicaltrials.gov/study/NCT01996540?cond=Pancreatic%20Cancer&viewType=Card&page=19&rank=187
Pancreatic Cancer,"Information provided by Yu Pan, Fujian Medical University Union Hospital (Responsible Party)",Recruiting,Study Details | NCT06310902 | Single,https://clinicaltrials.gov/study/NCT06310902?cond=Pancreatic%20Cancer&viewType=Card&page=19&rank=188
Pancreatic Cancer,Information provided by Peking Union Medical College Hospital (Responsible Party),Recruiting,Study Details | NCT03182270 | Clinical Evaluation Of Needle,https://clinicaltrials.gov/study/NCT03182270?cond=Pancreatic%20Cancer&viewType=Card&page=19&rank=189
Pancreatic Cancer,"Information provided by Francesco De Cobelli, IRCCS San Raffaele (Responsible Party)",Recruiting,Study Details | NCT05714111 | Radiology Registry on Pancreatic Malignancies | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT05714111?cond=Pancreatic%20Cancer&viewType=Card&page=19&rank=190
Pancreatic Cancer,Information provided by H. Lee Moffitt Cancer Center and Research Institute (Responsible Party),Recruiting,Study Details | NCT04275557 | Using Radiogenomics to Predict Malignant Potential of Intraductal Papillary Mucinous Neoplasms of the Pancreas | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT04275557?cond=Pancreatic%20Cancer&viewType=Card&page=20&rank=191
Pancreatic Cancer,"Information provided by Adenocyte, LLC (Responsible Party)",Inconnu,Study Details | NCT06276764 | The LINFU® U.S. Registry in Patients With IPMN (Intraductal Papillary Mucinous Neoplasm of the Pancreas) | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT06276764?cond=Pancreatic%20Cancer&viewType=Card&page=20&rank=192
Pancreatic Cancer,"Information provided by Hao Chen, Fudan University (Responsible Party)",Recruiting,Study Details | NCT05840341 | Clinical Efficacy of QYHJ and Standard Chemotherapy in the Treatment of Advanced Pancreatic Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT05840341?cond=Pancreatic%20Cancer&viewType=Card&page=20&rank=193
Pancreatic Cancer,Information provided by Grupo Espanol de Tumores Neuroendocrinos (Responsible Party),Completed,Study Details | NCT02713763 | Efficacy of Rechallenge With Sunitinib in Metastatic Pancreatic Neuroendocrine Tumor Previously Failed to Sunitinib | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02713763?cond=Pancreatic%20Cancer&viewType=Card&page=20&rank=194
Pancreatic Cancer,"Information provided by Mahmoud Rady, Theodor Bilharz Research Institute (Responsible Party)",Completed,Study Details | NCT06630910 | New Technique of Pancreaticojejunostomy During Whipple Operation | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT06630910?cond=Pancreatic%20Cancer&viewType=Card&page=20&rank=195
Pancreatic Cancer,Information provided by Albert Einstein College of Medicine (Responsible Party),Completed,Study Results | NCT03397342 | MRI Only Radiation Therapy With CPAP | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03397342?cond=Pancreatic%20Cancer&viewType=Card&page=20&rank=196&tab=results
Pancreatic Cancer,Information provided by Albert Einstein College of Medicine (Responsible Party),Terminated,Study Details | NCT03397342 | MRI Only Radiation Therapy With CPAP | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03397342?cond=Pancreatic%20Cancer&viewType=Card&page=20&rank=196
Pancreatic Cancer,"Information provided by Mandana Kamgar, MD, Medical College of Wisconsin (Responsible Party)",Recruiting,Study Details | NCT05914987 | Determining Individualized Cancer Therapy in Pancreatic Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT05914987?cond=Pancreatic%20Cancer&viewType=Card&page=20&rank=197
Pancreatic Cancer,Information provided by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Completed,Study Details | NCT00279292 | Randomized Trial of EUS Neurolysis in Pancreas Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00279292?cond=Pancreatic%20Cancer&viewType=Card&page=20&rank=198
Pancreatic Cancer,Information provided by Hallym University Medical Center (Responsible Party),Completed,Study Details | NCT01693419 | S,https://clinicaltrials.gov/study/NCT01693419?cond=Pancreatic%20Cancer&viewType=Card&page=20&rank=199
Pancreatic Cancer,Information provided by Hospices Civils de Lyon (Responsible Party),Inconnu,Study Details | NCT07144917 | Immunoparalysis After Pancreaticoduodenectomy | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT07144917?cond=Pancreatic%20Cancer&viewType=Card&page=20&rank=200
Pancreatic Cancer,Information provided by University of Ulm,Recruiting,Study Details | NCT00690300 | Docetaxel Plus Oxaliplatin as Therapy in Patients With Pancreatic Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00690300?cond=Pancreatic%20Cancer&viewType=Card&page=21&rank=201
Pancreatic Cancer,"Information provided by Sorrento Therapeutics, Inc. (Responsible Party)",Terminated,Study Details | NCT03818165 | Phase 1b Study of CAR2Anti-CEA CAR,https://clinicaltrials.gov/study/NCT03818165?cond=Pancreatic%20Cancer&viewType=Card&page=21&rank=202
Pancreatic Cancer,Information provided by H. Lee Moffitt Cancer Center and Research Institute (Responsible Party),Completed,Study Details | NCT00985777 | Vitamin E δ,https://clinicaltrials.gov/study/NCT00985777?cond=Pancreatic%20Cancer&viewType=Card&page=21&rank=203
Pancreatic Cancer,Information provided by Xijing Hospital (Responsible Party),Recruiting,Study Details | NCT05187416 | Correlation Between Elastic Modulus of Ultrasonic Shear Wave and Tumor Stromal Component in Pancreatic Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT05187416?cond=Pancreatic%20Cancer&viewType=Card&page=21&rank=204
Pancreatic Cancer,Information provided by Changhai Hospital (Responsible Party),Recruiting,Study Details | NCT06638866 | AI-powered Early Detection for Pancreatic Cancer Via Non,https://clinicaltrials.gov/study/NCT06638866?cond=Pancreatic%20Cancer&viewType=Card&page=21&rank=205
Pancreatic Cancer,"Information provided by University Hospital, Strasbourg, France (Responsible Party)",Completed,Study Details | NCT05546970 | Efficacy of the Transversus Abdominis Plane Block on Analgesia After Cephalic Duodeno,https://clinicaltrials.gov/study/NCT05546970?cond=Pancreatic%20Cancer&viewType=Card&page=21&rank=206
Pancreatic Cancer,Information provided by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (Responsible Party),Withdrawn,Study Details | NCT01784081 | Integrating Palliative Care and Modern Palliative Care Tools Into the Care of Patients With Pancreas Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01784081?cond=Pancreatic%20Cancer&viewType=Card&page=21&rank=207
Pancreatic Cancer,"Information provided by Feifei Wang, The First Hospital of Hebei Medical University (Responsible Party)",Completed,Study Details | NCT07057895 | Diagnostic Consistency of GLIM and PG,https://clinicaltrials.gov/study/NCT07057895?cond=Pancreatic%20Cancer&viewType=Card&page=21&rank=208
Pancreatic Cancer,Information provided by European Institute of Oncology (Responsible Party),Completed,Study Details | NCT02305810 | A Biological Prospective Study in Patients With Metastatic Pancreatic NETs Treated With Everolimus | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02305810?cond=Pancreatic%20Cancer&viewType=Card&page=21&rank=209
Pancreatic Cancer,"Information provided by Ana Ruiz-Casado, Puerta de Hierro University Hospital (Responsible Party)",Completed,Study Details | NCT05722223 | Trimodal Prehabilitation in Pancreatic Cancer Patients Urdergoing Neoadjuvant Treatment | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT05722223?cond=Pancreatic%20Cancer&viewType=Card&page=21&rank=210
Pancreatic Cancer,"Information provided by Zhijun Bao, Fudan University (Responsible Party)",Inconnu,Study Details | NCT06685939 | The Differences of Complications Between LPD(Laparoscopic Pancreaticoduodenectomy) and OPD(Open Pancreaticoduodenectomy) | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT06685939?cond=Pancreatic%20Cancer&viewType=Card&page=22&rank=211
Pancreatic Cancer,Information provided by Institut Paoli-Calmettes (Responsible Party),Inconnu,Study Details | NCT06000553 | Early Detection of Pancreatic Cancer in Patients With Papillary and Mucinous Intracanal Tumours of the Pancreas Papillary and Mucinous Tumours of the Pancreas | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT06000553?cond=Pancreatic%20Cancer&viewType=Card&page=22&rank=212
Pancreatic Cancer,Information provided by Johns Hopkins University (Responsible Party),Completed,Study Details | NCT02703545 | International CAPS Registry: Pancreas Cancer Cases in Surveillance Programs | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02703545?cond=Pancreatic%20Cancer&viewType=Card&page=22&rank=213
Pancreatic Cancer,"Information provided by Jiang Long, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine (Responsible Party)",Recruiting,Study Details | NCT06532617 | Cadonilimab Combined With S-1 or Capecitabine as Second,https://clinicaltrials.gov/study/NCT06532617?cond=Pancreatic%20Cancer&viewType=Card&page=22&rank=214
Pancreatic Cancer,"Information provided by Siya Shi, First Affiliated Hospital, Sun Yat-Sen University (Responsible Party)",Completed,Study Details | NCT06336694 | A Deep Learning Radiomics Model for Predicting Occult Peritoneal Metastases of Pancreatic Adenocarcinoma | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT06336694?cond=Pancreatic%20Cancer&viewType=Card&page=22&rank=215
Pancreatic Cancer,Information provided by National Institutes of Health Clinical Center (CC),Terminated,Study Details | NCT00100321 | Surgery for Pancreatic Tumors and Collection of Tumor Tissue for Study | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00100321?cond=Pancreatic%20Cancer&viewType=Card&page=22&rank=216
Pancreatic Cancer,"Information provided by Baki Topal, University Hospital, Gasthuisberg (Responsible Party)",Completed,Study Details | NCT00936104 | Side Population in Pancreatic Ductal Adenocarcinoma (PDAC) | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00936104?cond=Pancreatic%20Cancer&viewType=Card&page=22&rank=217
Pancreatic Cancer,"Information provided by Sang Myung Woo, National Cancer Center, Korea (Responsible Party)",Inconnu,Study Details | NCT07121478 | Patients With High,https://clinicaltrials.gov/study/NCT07121478?cond=Pancreatic%20Cancer&viewType=Card&page=22&rank=218
Pancreatic Cancer,Information provided by Mayo Clinic (Responsible Party),Recruiting,Study Details | NCT03855800 | Molecular Detection of Advanced Neoplasia in Pancreatic Cysts | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03855800?cond=Pancreatic%20Cancer&viewType=Card&page=22&rank=219
Pancreatic Cancer,Information provided by Institut Paoli-Calmettes (Responsible Party),Completed,Study Details | NCT04422730 | Evolution of Body Connection After Surgery | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT04422730?cond=Pancreatic%20Cancer&viewType=Card&page=22&rank=220
Pancreatic Cancer,"Information provided by Tamer.A.A.M.Habeeb, Zagazig University (Responsible Party)",Completed,Study Details | NCT04747600 | Outcomes of Surgical Resection of Pancreatic Cystic Neoplasms Based on the European Expert Consensus Statement: A Prospective Observational Study. | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT04747600?cond=Pancreatic%20Cancer&viewType=Card&page=23&rank=221
Pancreatic Cancer,Information provided by University of Copenhagen,Recruiting,Study Details | NCT00259532 | Three New Methods for Diagnosing Pancreas Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00259532?cond=Pancreatic%20Cancer&viewType=Card&page=23&rank=222
Pancreatic Cancer,"Information provided by Qi Li, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine (Responsible Party)",Recruiting,Study Details | NCT05795920 | Utidelone Injection Combined With Gemcitabine in First,https://clinicaltrials.gov/study/NCT05795920?cond=Pancreatic%20Cancer&viewType=Card&page=23&rank=223
Pancreatic Cancer,Information provided by University Hospitals Cleveland Medical Center (Responsible Party),Withdrawn,Study Details | NCT01371240 | Secretin,https://clinicaltrials.gov/study/NCT01371240?cond=Pancreatic%20Cancer&viewType=Card&page=23&rank=224
Pancreatic Cancer,Information provided by First Affiliated Hospital Xi'an Jiaotong University (Responsible Party),Recruiting,Study Details | NCT05681390 | Tislelizumab With Anlotinib and Chemotherapy for Second,https://clinicaltrials.gov/study/NCT05681390?cond=Pancreatic%20Cancer&viewType=Card&page=23&rank=225
Pancreatic Cancer,"Information provided by Chin Yung Ka, Singapore General Hospital (Responsible Party)",Inconnu,Study Details | NCT03435770 | Evaluation of Safety and Feasibility of EUS,https://clinicaltrials.gov/study/NCT03435770?cond=Pancreatic%20Cancer&viewType=Card&page=23&rank=226
Pancreatic Cancer,Information provided by Yonsei University (Responsible Party),Recruiting,Study Details | NCT05587387 | Change of Treatment Landscape and Survival in Metastatic Pancreatic Cancer After Nal,https://clinicaltrials.gov/study/NCT05587387?cond=Pancreatic%20Cancer&viewType=Card&page=23&rank=227
Pancreatic Cancer,"Information provided by Benedetto Ielpo, Hospital del Mar (Responsible Party)",Inconnu,Study Details | NCT06981273 | Robotic vs Open Pancreatoduodenectomy | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT06981273?cond=Pancreatic%20Cancer&viewType=Card&page=23&rank=228
Pancreatic Cancer,"Information provided by Du Juan, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School (Responsible Party)",Completed,Study Details | NCT05493995 | A Study of Penpulimab and Anlotinib Plus Nab,https://clinicaltrials.gov/study/NCT05493995?cond=Pancreatic%20Cancer&viewType=Card&page=23&rank=229
Pancreatic Cancer,"Information provided by Francesco Maria Di Matteo, Campus Bio-Medico University (Responsible Party)",Recruiting,Study Details | NCT05549960 | Pre-planning Mathematical Models in EUS,https://clinicaltrials.gov/study/NCT05549960?cond=Pancreatic%20Cancer&viewType=Card&page=23&rank=230
Pancreatic Cancer,"Information provided by Dong sheng Zhang, Sun Yat-sen University (Responsible Party)",Completed,Study Details | NCT05481463 | Surufatinib Combined With TAS-102 in Third-line and Later,https://clinicaltrials.gov/study/NCT05481463?cond=Pancreatic%20Cancer&viewType=Card&page=24&rank=231
Pancreatic Cancer,"Information provided by Dong sheng Zhang, Sun Yat-sen University (Responsible Party)",Active,Study Details | NCT05481476 | Surufatinib Combined With Sintilimab and AG in First,https://clinicaltrials.gov/study/NCT05481476?cond=Pancreatic%20Cancer&viewType=Card&page=24&rank=232
Pancreatic Cancer,Information provided by National Institutes of Health Clinical Center (CC),Completed,"Study Details | NCT00005926 | Gemcitabine, Herceptin and Radiation to Treat Cancer of the Pancreas | ClinicalTrials.gov",https://clinicaltrials.gov/study/NCT00005926?cond=Pancreatic%20Cancer&viewType=Card&page=24&rank=233
Pancreatic Cancer,"Information provided by Renyi Qin, Tongji Hospital (Responsible Party)",Completed,Study Details | NCT05616403 | Textbook Outcome as a Composite Outcome Measure in Laparoscopic Pancreaticoduodenectomy | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT05616403?cond=Pancreatic%20Cancer&viewType=Card&page=24&rank=234
Pancreatic Cancer,"Information provided by Centre Francois Baclesse, Luxembourg (Responsible Party)",Withdrawn,Study Details | NCT03199144 | Neoadjuvant Chemotherapy and Stereotactic Radiosurgery to Pancreatectomy for Patients With Borderline Resectable Pancreatic Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03199144?cond=Pancreatic%20Cancer&viewType=Card&page=24&rank=235
Pancreatic Cancer,"Information provided by Dina Safwat, Assiut University (Responsible Party)",Recruiting,Study Details | NCT03679910 | Evaluation of CEMIP in Pancreatic Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03679910?cond=Pancreatic%20Cancer&viewType=Card&page=24&rank=236
Pancreatic Cancer,Information provided by Georgetown University (Responsible Party),Completed,Study Results | NCT00881621 | Lapatinib and Capecitabine for Second Line Treatment of Pancreas Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00881621?cond=Pancreatic%20Cancer&viewType=Card&page=24&rank=237&tab=results
Pancreatic Cancer,Information provided by Georgetown University (Responsible Party),Terminated,Study Details | NCT00881621 | Lapatinib and Capecitabine for Second Line Treatment of Pancreas Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00881621?cond=Pancreatic%20Cancer&viewType=Card&page=24&rank=237
Pancreatic Cancer,"Information provided by Masonic Cancer Center, University of Minnesota (Responsible Party)",Recruiting,Study Details | NCT06411795 | Rectus Sheath Block With Liposomal Bupivacaine Versus Thoracic Epidural Analgesia for Pain Control Following Pancreatoduodenectomy | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT06411795?cond=Pancreatic%20Cancer&viewType=Card&page=24&rank=238
Pancreatic Cancer,"Information provided by Martin Sillesen, Rigshospitalet, Denmark (Responsible Party)",Recruiting,Study Details | NCT04947696 | Circulating Epigenetics in Pancreatic Surgery | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT04947696?cond=Pancreatic%20Cancer&viewType=Card&page=24&rank=239
Pancreatic Cancer,Information provided by Instituto do Cancer do Estado de São Paulo (Responsible Party),Recruiting,Study Details | NCT04877340 | Comparation Between Needles for EUS,https://clinicaltrials.gov/study/NCT04877340?cond=Pancreatic%20Cancer&viewType=Card&page=24&rank=240
Pancreatic Cancer,Information provided by Tianjin Medical University Cancer Institute and Hospital (Responsible Party),Recruiting,Study Details | NCT04808687 | Neoadjuvant Nab-Paclitaxel and S,https://clinicaltrials.gov/study/NCT04808687?cond=Pancreatic%20Cancer&viewType=Card&page=25&rank=241
Pancreatic Cancer,"Information provided by Sarah Rodriguez, Oregon Health and Science University (Responsible Party)",Completed,Study Details | NCT00680420 | DNA Microarray Study of Pancreas Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00680420?cond=Pancreatic%20Cancer&viewType=Card&page=25&rank=242
Pancreatic Cancer,"Information provided by Tarita Thomas, Loyola University (Responsible Party)",Recruiting,Study Details | NCT02599662 | Intraoperative Radiation Therapy for Resectable Pancreas Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02599662?cond=Pancreatic%20Cancer&viewType=Card&page=25&rank=243
Pancreatic Cancer,"Information provided by Saleh Khairy Saleh MD, Minia University (Responsible Party)",Recruiting,Study Details | NCT07139236 | Preoperative EUS Elastography for Pancreatic Texture and POPF Prediction After PD | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT07139236?cond=Pancreatic%20Cancer&viewType=Card&page=25&rank=244
Pancreatic Cancer,Information provided by Institut Bergonié (Responsible Party),Inconnu,Study Details | NCT06705335 | Convertases and Pancreatic Cancer: Cohort of Patients Treated for Pancreatic Adenocarcinoma | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT06705335?cond=Pancreatic%20Cancer&viewType=Card&page=25&rank=245
Pancreatic Cancer,"Information provided by Ryan Nipp, Massachusetts General Hospital (Responsible Party)",Completed,Study Details | NCT03798769 | Supportive Oncology Care at Home for Patients With Pancreatic Cancer Receiving Preoperative FOLFIRINOX | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03798769?cond=Pancreatic%20Cancer&viewType=Card&page=25&rank=246
Pancreatic Cancer,"Information provided by Dr. M. D'hondt, General Hospital Groeninge (Responsible Party)",Completed,Study Details | NCT05110573 | Single-centre Propensity Score,https://clinicaltrials.gov/study/NCT05110573?cond=Pancreatic%20Cancer&viewType=Card&page=25&rank=247
Pancreatic Cancer,"Information provided by Mehdi Mohamadnejad, University of Tehran (Responsible Party)",Completed,Study Details | NCT04975620 | Comparison of Two Types of Biopsy Needles for EUS,https://clinicaltrials.gov/study/NCT04975620?cond=Pancreatic%20Cancer&viewType=Card&page=25&rank=248
Pancreatic Cancer,"Information provided by An Tai, Medical College of Wisconsin (Responsible Party)",Completed,Study Details | NCT02173353 | Feasibility of Using Ultrasound to Track Respiration Motion | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02173353?cond=Pancreatic%20Cancer&viewType=Card&page=25&rank=249
Pancreatic Cancer,"Information provided by University Hospital, Montpellier (Responsible Party)",Recruiting,Study Details | NCT04370574 | Discovery of Soluble Biomarkers for Pancreatic Cancer Using Innovative All,https://clinicaltrials.gov/study/NCT04370574?cond=Pancreatic%20Cancer&viewType=Card&page=25&rank=250
Pancreatic Cancer,"Information provided by Richard Frank, Nuvance Health (Responsible Party)",Recruiting,Study Details | NCT03250078 | A Pancreatic Cancer Screening Study in Hereditary High Risk Individuals | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03250078?cond=Pancreatic%20Cancer&viewType=Card&page=26&rank=251
Pancreatic Cancer,"Information provided by TingBo Liang, Zhejiang University (Responsible Party)",Recruiting,Study Details | NCT06572813 | Bortezomib Combined with PD,https://clinicaltrials.gov/study/NCT06572813?cond=Pancreatic%20Cancer&viewType=Card&page=26&rank=252
Pancreatic Cancer,"Information provided by Marker Therapeutics, Inc. (Responsible Party)",Inconnu,Study Details | NCT06549751 | MT,https://clinicaltrials.gov/study/NCT06549751?cond=Pancreatic%20Cancer&viewType=Card&page=26&rank=253
Pancreatic Cancer,"Information provided by Benhua Xu, Fujian Medical University Union Hospital (Responsible Party)",Recruiting,Study Details | NCT04289792 | Split,https://clinicaltrials.gov/study/NCT04289792?cond=Pancreatic%20Cancer&viewType=Card&page=26&rank=254
Pancreatic Cancer,Information provided by Aronex Pharmaceuticals,Active,Study Details | NCT00081549 | Aroplatin and Gemcitabine in Patients With Advanced Pancreatic Cancer Resistant to Standard Therapies | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00081549?cond=Pancreatic%20Cancer&viewType=Card&page=26&rank=255
Pancreatic Cancer,"Information provided by carsten palnaes hansen, Rigshospitalet, Denmark (Responsible Party)",Completed,Study Details | NCT04237441 | The Results of Pancreatic Operations After the Implementation of Multidisciplinary Team Conference (MDT): | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT04237441?cond=Pancreatic%20Cancer&viewType=Card&page=26&rank=256
Pancreatic Cancer,Information provided by AdventHealth (Responsible Party),Recruiting,Study Details | NCT04085055 | Fine Needle Biopsy of Solid Pancreatic Mass Lesions | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT04085055?cond=Pancreatic%20Cancer&viewType=Card&page=26&rank=257
Pancreatic Cancer,Information provided by Celgene (Responsible Party),Completed,Study Results | NCT02301143 | Phase 2 Nab®,https://clinicaltrials.gov/study/NCT02301143?cond=Pancreatic%20Cancer&viewType=Card&page=26&rank=258&tab=results
Pancreatic Cancer,Information provided by Celgene (Responsible Party),Completed,Study Details | NCT02301143 | Phase 2 Nab®,https://clinicaltrials.gov/study/NCT02301143?cond=Pancreatic%20Cancer&viewType=Card&page=26&rank=258
Pancreatic Cancer,"Information provided by Mandana Kamgar, MD, Medical College of Wisconsin (Responsible Party)",Recruiting,Study Details | NCT06228599 | Molecular Profile-related Individualized Targeted Therapy in Resected Pancreatic Cancer With High,https://clinicaltrials.gov/study/NCT06228599?cond=Pancreatic%20Cancer&viewType=Card&page=26&rank=259
Pancreatic Cancer,Information provided by UNC Lineberger Comprehensive Cancer Center (Responsible Party),Recruiting,Study Details | NCT06252545 | Promoting CT Engagement for Pancreatic Cancer With App | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT06252545?cond=Pancreatic%20Cancer&viewType=Card&page=26&rank=260
Pancreatic Cancer,"Information provided by NING LI, Cancer Institute and Hospital, Chinese Academy of Medical Sciences (Responsible Party)",Inconnu,Study Details | NCT06255912 | Clinical Trial for Advanced or Metastatic Pancreatic Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT06255912?cond=Pancreatic%20Cancer&viewType=Card&page=27&rank=261
Pancreatic Cancer,"Information provided by Mohamed Othman, Baylor College of Medicine (Responsible Party)",Completed,"Study Details | NCT04165018 | Prospective Study FNB, Is It Time To Abandon Cytological Assessment | ClinicalTrials.gov",https://clinicaltrials.gov/study/NCT04165018?cond=Pancreatic%20Cancer&viewType=Card&page=27&rank=262
Pancreatic Cancer,"Information provided by Mina Melad Boshra Yosef, Assiut University (Responsible Party)",Inconnu,Study Details | NCT06206382 | Surgical Results of Resection of Locally Advanced Pancreatic Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT06206382?cond=Pancreatic%20Cancer&viewType=Card&page=27&rank=263
Pancreatic Cancer,"Information provided by The University of Texas Health Science Center, Houston",Recruiting,Study Details | NCT00178763 | Hyperthermia With Chemotherapy for Locally Advanced or Metastatic Pancreas Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00178763?cond=Pancreatic%20Cancer&viewType=Card&page=27&rank=264
Pancreatic Cancer,"Information provided by Jinbo Yue, Shandong Cancer Hospital and Institute (Responsible Party)",Recruiting,Study Details | NCT06050317 | Sintilimab Combined With Chemotherapy and Radiotherapy in Patients With Inoperable Pancreatic Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT06050317?cond=Pancreatic%20Cancer&viewType=Card&page=27&rank=265
Pancreatic Cancer,Information provided by GlobeImmune (Responsible Party),Completed,"Study Details | NCT00300950 | Safety and Efficacy of the Therapeutic Vaccine GI-4000 in Combination With Gemcitabine Versus Placebo for the Treatment of Non-metastatic, Post",https://clinicaltrials.gov/study/NCT00300950?cond=Pancreatic%20Cancer&viewType=Card&page=27&rank=266
Pancreatic Cancer,Information provided by Assaf-Harofeh Medical Center (Responsible Party),Recruiting,Study Details | NCT03838029 | Perioperative Intervention to Reduce Metastatic Processes in Pancreatic Cancer Patients Undergoing Curative Surgery | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03838029?cond=Pancreatic%20Cancer&viewType=Card&page=27&rank=267
Pancreatic Cancer,"Information provided by Bryan Allen, University of Iowa (Responsible Party)",Terminated,Study Details | NCT01419483 | Ketogenic Diet With Concurrent Chemoradiation for Pancreatic Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01419483?cond=Pancreatic%20Cancer&viewType=Card&page=27&rank=268
Pancreatic Cancer,"Information provided by Jong-Ho Won, Soonchunhyang University Hospital (Responsible Party)",Inconnu,Study Details | NCT06172634 | A Single-center Clinical Study to Evaluate the Safety and Efficacy of Autologous Bone Marrow-derived DCs(CellgramDC-WT1) and Immune Checkpoint Inhibitors in Patients With Metastatic Pancreatic Cancer Who Have Failed First,https://clinicaltrials.gov/study/NCT06172634?cond=Pancreatic%20Cancer&viewType=Card&page=27&rank=269
Pancreatic Cancer,"Information provided by Guilherme Rezende, Universidade Federal do Rio de Janeiro (Responsible Party)",Completed,Study Details | NCT04002778 | Rapid On,https://clinicaltrials.gov/study/NCT04002778?cond=Pancreatic%20Cancer&viewType=Card&page=27&rank=270
Pancreatic Cancer,Information provided by Ipsen (Responsible Party),Completed,Study Results | NCT00842348 | Study of Lanreotide Autogel 120 mg in Patients With Non-functioning Entero,https://clinicaltrials.gov/study/NCT00842348?cond=Pancreatic%20Cancer&viewType=Card&page=28&rank=271&tab=results
Pancreatic Cancer,Information provided by Ipsen (Responsible Party),Completed,Study Details | NCT00842348 | Study of Lanreotide Autogel 120 mg in Patients With Non-functioning Entero,https://clinicaltrials.gov/study/NCT00842348?cond=Pancreatic%20Cancer&viewType=Card&page=28&rank=271
Pancreatic Cancer,Information provided by Case Comprehensive Cancer Center (Responsible Party),Recruiting,Study Details | NCT05720338 | Is Intraperitoneal Drainage Necessary Following Distal Pancreatectomy? | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT05720338?cond=Pancreatic%20Cancer&viewType=Card&page=28&rank=272
Pancreatic Cancer,"Information provided by Tommaso Farolfi, Fondazione Policlinico Universitario Campus Bio-Medico (Responsible Party)",Completed,Study Details | NCT05959213 | Preoperative CA 19.9 Level Predicts Lymph Node Metastasis in Resectable Adenocarcinoma of the Head of the Pancreas. | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT05959213?cond=Pancreatic%20Cancer&viewType=Card&page=28&rank=273
Pancreatic Cancer,"Information provided by Bin Cheng, Huazhong University of Science and Technology (Responsible Party)",Inconnu,Study Details | NCT03803930 | Comparing of a 22G EUS Procore Fine Needle Biopsy Device and a 20G EUS Procore Fine Needle Biopsy Device | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03803930?cond=Pancreatic%20Cancer&viewType=Card&page=28&rank=274
Pancreatic Cancer,"Information provided by University Health Network, Toronto (Responsible Party)",Recruiting,Study Details | NCT05927298 | Province of Ontario Strategy for Personalized Management of Pancreatic Cancer Trial | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT05927298?cond=Pancreatic%20Cancer&viewType=Card&page=28&rank=275
Pancreatic Cancer,Information provided by Azienda USL Reggio Emilia - IRCCS (Responsible Party),Completed,Study Details | NCT01673906 | 68-Ga-labeled Octreotide Analogues PET in Duodenal,https://clinicaltrials.gov/study/NCT01673906?cond=Pancreatic%20Cancer&viewType=Card&page=28&rank=276
Pancreatic Cancer,Information provided by Radboud University Medical Center (Responsible Party),Active,Study Details | NCT05880472 | Percutaneous Holmium Injection in Pancreatic Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT05880472?cond=Pancreatic%20Cancer&viewType=Card&page=28&rank=277
Pancreatic Cancer,"Information provided by Song Cheol Kim, Asan Medical Center (Responsible Party)",Recruiting,Study Details | NCT03665571 | Evaluation of Killing Activity of Expanded Natural Killer Cells From Blood in Patients With Pancreatic Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03665571?cond=Pancreatic%20Cancer&viewType=Card&page=28&rank=278
Pancreatic Cancer,Information provided by Eli Lilly and Company (Responsible Party),Completed,Study Results | NCT00839332 | A Study for Participants With Pancreatic Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00839332?cond=Pancreatic%20Cancer&viewType=Card&page=28&rank=279&tab=results
Pancreatic Cancer,Information provided by Eli Lilly and Company (Responsible Party),Completed,Study Details | NCT00839332 | A Study for Participants With Pancreatic Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00839332?cond=Pancreatic%20Cancer&viewType=Card&page=28&rank=279
Pancreatic Cancer,"Information provided by Charing Chong, MD, Chinese University of Hong Kong (Responsible Party)",Recruiting,Study Details | NCT03766659 | EUS-FNB With MOSE vs EUS,https://clinicaltrials.gov/study/NCT03766659?cond=Pancreatic%20Cancer&viewType=Card&page=28&rank=280
Pancreatic Cancer,Information provided by Abramson Cancer Center at Penn Medicine (Responsible Party),Recruiting,Study Details | NCT05743049 | Collection of Circulating Biomarkers in Pancreatic Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT05743049?cond=Pancreatic%20Cancer&viewType=Card&page=29&rank=281
Pancreatic Cancer,Information provided by Seagen Inc. (Cascadian Therapeutics Inc.) (Responsible Party),Terminated,Study Details | NCT00417287 | Phase II Study of PX,https://clinicaltrials.gov/study/NCT00417287?cond=Pancreatic%20Cancer&viewType=Card&page=29&rank=282
Pancreatic Cancer,Information provided by Institut du Cancer de Montpellier - Val d'Aurelle (Responsible Party),Recruiting,Study Details | NCT06144762 | Precision Imaging for Early Detection and Targeted Treatment Monitoring in Pancreatic Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT06144762?cond=Pancreatic%20Cancer&viewType=Card&page=29&rank=283
Pancreatic Cancer,Information provided by Radboud University Medical Center (Responsible Party),Recruiting,Study Details | NCT03469726 | Contrast-enhanced Diffusion,https://clinicaltrials.gov/study/NCT03469726?cond=Pancreatic%20Cancer&viewType=Card&page=29&rank=284
Pancreatic Cancer,Information provided by RenJi Hospital (Responsible Party),Recruiting,Study Details | NCT06602037 | ImmunoPET Imaging of Pancreatic Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT06602037?cond=Pancreatic%20Cancer&viewType=Card&page=29&rank=285
Pancreatic Cancer,Information provided by Instituto do Cancer do Estado de São Paulo (Responsible Party),Recruiting,Study Details | NCT02896803 | Fluorouracil and Oxaliplatin as First,https://clinicaltrials.gov/study/NCT02896803?cond=Pancreatic%20Cancer&viewType=Card&page=29&rank=286
Pancreatic Cancer,"Information provided by Amany Hamdy Radwan, Assiut University (Responsible Party)",Inconnu,Study Details | NCT05493878 | ITGA2b and SELP Expression in Cancer Pancreas and Biliary Tract Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT05493878?cond=Pancreatic%20Cancer&viewType=Card&page=29&rank=287
Pancreatic Cancer,Information provided by University of Kansas Medical Center (Responsible Party),Active,Study Details | NCT05638698 | Tg01 Vaccine / Qs,https://clinicaltrials.gov/study/NCT05638698?cond=Pancreatic%20Cancer&viewType=Card&page=29&rank=288
Pancreatic Cancer,Information provided by M.D. Anderson Cancer Center (Responsible Party),Active,Study Details | NCT05497778 | A Phase 1b Study of Gemcitabine and Nab,https://clinicaltrials.gov/study/NCT05497778?cond=Pancreatic%20Cancer&viewType=Card&page=29&rank=289
Pancreatic Cancer,Information provided by Johns Hopkins University (Responsible Party),Completed,Study Details | NCT00438906 | Cancer of the Pancreas Screening Study (CAPS 3) | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00438906?cond=Pancreatic%20Cancer&viewType=Card&page=29&rank=290
Pancreatic Cancer,"Information provided by Ismail Gögenur, Zealand University Hospital (Responsible Party)",Terminated,Study Details | NCT05435053 | Irreversible Electroporation + Nivolumab for Patients With Metastatic Pancreatic Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT05435053?cond=Pancreatic%20Cancer&viewType=Card&page=30&rank=291
Pancreatic Cancer,"Information provided by Qure Healthcare, LLC (Responsible Party)",Withdrawn,Study Details | NCT05702385 | Clinical Utility Study for Exo,https://clinicaltrials.gov/study/NCT05702385?cond=Pancreatic%20Cancer&viewType=Card&page=30&rank=292
Pancreatic Cancer,"Information provided by Philip Chang, Cedars-Sinai Medical Center (Responsible Party)",Active,Study Details | NCT05692323 | A Supervised Prehabilitation Program for Patients With Pancreatic Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT05692323?cond=Pancreatic%20Cancer&viewType=Card&page=30&rank=293
Pancreatic Cancer,"Information provided by Mihai Ciocirlan, Carol Davila University of Medicine and Pharmacy (Responsible Party)",Completed,Study Details | NCT03303352 | Connect Your Needle to Your Phone to Increase EUS FNA Diagnostic Yield? | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03303352?cond=Pancreatic%20Cancer&viewType=Card&page=30&rank=294
Pancreatic Cancer,"Information provided by National Cancer Institute, Egypt (Responsible Party)",Recruiting,Study Details | NCT05192044 | Less Than 100 Hours Hospital Stay After Pancreatico,https://clinicaltrials.gov/study/NCT05192044?cond=Pancreatic%20Cancer&viewType=Card&page=30&rank=295
Pancreatic Cancer,Information provided by Case Comprehensive Cancer Center (Responsible Party),Completed,Study Results | NCT02337465 | KV,https://clinicaltrials.gov/study/NCT02337465?cond=Pancreatic%20Cancer&viewType=Card&page=30&rank=296&tab=results
Pancreatic Cancer,Information provided by Case Comprehensive Cancer Center (Responsible Party),Completed,Study Details | NCT02337465 | KV,https://clinicaltrials.gov/study/NCT02337465?cond=Pancreatic%20Cancer&viewType=Card&page=30&rank=296
Pancreatic Cancer,"Information provided by Guido Costamagna, Catholic University of the Sacred Heart (Responsible Party)",Recruiting,"Study Details | NCT05248750 | Genetic, Microenvironmental, and Immunological Factors in Unresectable Pancreatic Ductal Adenocarcinoma | ClinicalTrials.gov",https://clinicaltrials.gov/study/NCT05248750?cond=Pancreatic%20Cancer&viewType=Card&page=30&rank=297
Pancreatic Cancer,Information provided by University of Aarhus (Responsible Party),Inconnu,Study Details | NCT05253313 | Magnetic Resonance Imaging for Better Selection of Pancreatic Cancer Patients for Surgery: A Randomized Clinical Trial | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT05253313?cond=Pancreatic%20Cancer&viewType=Card&page=30&rank=298
Pancreatic Cancer,Information provided by Methodist Health System (Responsible Party),Recruiting,Study Details | NCT05170802 | Pancreatic Cancer & Surgical Resection | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT05170802?cond=Pancreatic%20Cancer&viewType=Card&page=30&rank=299
Pancreatic Cancer,Information provided by Radboud University Medical Center (Responsible Party),Completed,Study Details | NCT05191498 | Intratumoral Holmium Microspheres Brachytherapy for Patients With Pancreatic Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT05191498?cond=Pancreatic%20Cancer&viewType=Card&page=30&rank=300
Leukemia,Information provided by medac GmbH (Responsible Party),Completed,Study Details | NCT02333058 | Treosulfan,https://clinicaltrials.gov/study/NCT02333058?cond=Leukemia&viewType=Card&page=1&rank=1
Leukemia,"Information provided by Lin BioScience, Inc (Responsible Party)",Recruiting,Study Details | NCT05756322 | The Safety and Tolerability of LBS,https://clinicaltrials.gov/study/NCT05756322?cond=Leukemia&viewType=Card&page=1&rank=2
Leukemia,Information provided by Novartis (Novartis Pharmaceuticals) (Responsible Party),Completed,Study Results | NCT01826214 | Study of Efficacy and Safety of LDE225 in Adult Patients With Relapsed/Refractory Acute Leukemia | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01826214?cond=Leukemia&viewType=Card&page=1&rank=3&tab=results
Leukemia,Information provided by Novartis (Novartis Pharmaceuticals) (Responsible Party),Completed,Study Details | NCT01826214 | Study of Efficacy and Safety of LDE225 in Adult Patients With Relapsed/Refractory Acute Leukemia | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01826214?cond=Leukemia&viewType=Card&page=1&rank=3
Leukemia,Information provided by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (Responsible Party),Completed,Study Results | NCT00796562 | Safety Study of Bone Marrow Transplant Using Mismatched Tissue Followed by Chemotherapy | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00796562?cond=Leukemia&viewType=Card&page=1&rank=4&tab=results
Leukemia,Information provided by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (Responsible Party),Completed,Study Details | NCT00796562 | Safety Study of Bone Marrow Transplant Using Mismatched Tissue Followed by Chemotherapy | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00796562?cond=Leukemia&viewType=Card&page=1&rank=4
Leukemia,Information provided by Abramson Cancer Center at Penn Medicine (Responsible Party),Completed,Study Details | NCT00780104 | Sirolimus in Combination With MEC in High Risk Myeloid Leukemias | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00780104?cond=Leukemia&viewType=Card&page=1&rank=5
Leukemia,Information provided by Syndax Pharmaceuticals (Responsible Party),Recruiting,Study Details | NCT06226571 | A Study of SNDX,https://clinicaltrials.gov/study/NCT06226571?cond=Leukemia&viewType=Card&page=1&rank=6
Leukemia,Information provided by Syndax Pharmaceuticals (Responsible Party),Recruiting,Study Details | NCT07211958 | Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT07211958?cond=Leukemia&viewType=Card&page=1&rank=7
Leukemia,"First in Human Testing of Dose-escalation of SAR440234 in Patients With Acute Myeloid Leukemia, Acute Lymphoid Leukemia and Myelodysplastic Syndrome",Completed,Study Results | NCT03594955 | First in Human Testing of Dose,https://clinicaltrials.gov/study/NCT03594955?cond=Leukemia&viewType=Card&page=1&rank=8&tab=results
Leukemia,"First in Human Testing of Dose-escalation of SAR440234 in Patients With Acute Myeloid Leukemia, Acute Lymphoid Leukemia and Myelodysplastic Syndrome",Terminated,Study Details | NCT03594955 | First in Human Testing of Dose,https://clinicaltrials.gov/study/NCT03594955?cond=Leukemia&viewType=Card&page=1&rank=8
Leukemia,"Information provided by Nandita deSouza, Institute of Cancer Research, United Kingdom (Responsible Party)",Recruiting,Study Details | NCT03466944 | PUMA (Paediatric Osseous Marrow Assessment) | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03466944?cond=Leukemia&viewType=Card&page=1&rank=9
Leukemia,Information provided by Novartis (Novartis Pharmaceuticals) (Responsible Party),Completed,Study Results | NCT01313689 | Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine,https://clinicaltrials.gov/study/NCT01313689?cond=Leukemia&viewType=Card&page=1&rank=10&tab=results
Leukemia,Information provided by Novartis (Novartis Pharmaceuticals) (Responsible Party),Completed,Study Details | NCT01313689 | Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine,https://clinicaltrials.gov/study/NCT01313689?cond=Leukemia&viewType=Card&page=1&rank=10
Leukemia,"Information provided by Astex Pharmaceuticals, Inc. (Responsible Party)",Withdrawn,Study Details | NCT01239108 | Study of SGI,https://clinicaltrials.gov/study/NCT01239108?cond=Leukemia&viewType=Card&page=2&rank=11
Leukemia,"Information provided by Cyclacel Pharmaceuticals, Inc. (Responsible Party)",Completed,Study Details | NCT00380653 | Safety and Pharmacology Study of Sapacitabine to Treat Advanced Leukemias or Myelodysplastic Syndromes | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00380653?cond=Leukemia&viewType=Card&page=2&rank=12
Leukemia,Information provided by University Hospital Southampton NHS Foundation Trust (Responsible Party),Completed,Study Details | NCT01334060 | WT1 Immunity Via DNA Fusion Gene Vaccination in Haematological Malignancies by Intramuscular Injection Followed by Intramuscular Electroporation | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01334060?cond=Leukemia&viewType=Card&page=2&rank=13
Leukemia,Information provided by Instituto de Investigación Hospital Universitario La Paz (Responsible Party),Active,"Study Details | NCT05304754 | ""Phase I / II Study on Infusion of Natural Killer Cells After Haploidentical Transplantation in Pediatric Patients"" | ClinicalTrials.gov",https://clinicaltrials.gov/study/NCT05304754?cond=Leukemia&viewType=Card&page=2&rank=14
Leukemia,Information provided by Tel-Aviv Sourasky Medical Center,Inconnu,Study Details | NCT01339988 | Busulfan and Cyclophosphamide Instead of Total Boby Irradiation (TBI) and Cyclophosphamide for Hematological Malignancies Hematocrit (HCT) | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01339988?cond=Leukemia&viewType=Card&page=2&rank=15
Leukemia,"Information provided by Esraa salah sayed gaber, Assiut University (Responsible Party)",Inconnu,Study Details | NCT07200882 | What is the Impact of TKI on Thyroid Function in CML Patients? | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT07200882?cond=Leukemia&viewType=Card&page=2&rank=16
Leukemia,Information provided by GlaxoSmithKline (Responsible Party),Completed,Study Details | NCT01453062 | Phase IV Observational Study in Chronic Lymphocytic Leukemia | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01453062?cond=Leukemia&viewType=Card&page=2&rank=17
Leukemia,Information provided by GlaxoSmithKline (Responsible Party),Completed,Study Results | NCT02177812 | A Phase I Dose Escalation Study of GSK2879552 in Subjects With Acute Myeloid Leukemia (AML) | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02177812?cond=Leukemia&viewType=Card&page=2&rank=18&tab=results
Leukemia,Information provided by GlaxoSmithKline (Responsible Party),Terminated,Study Details | NCT02177812 | A Phase I Dose Escalation Study of GSK2879552 in Subjects With Acute Myeloid Leukemia (AML) | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02177812?cond=Leukemia&viewType=Card&page=2&rank=18
Leukemia,"Information provided by Xiaojun Huang,MD, Peking University People's Hospital (Responsible Party)",Inconnu,"Study Details | NCT04175587 | Randomized,International Multi-center Clinical Trial of RIF Plus RA for Non-high",https://clinicaltrials.gov/study/NCT04175587?cond=Leukemia&viewType=Card&page=2&rank=19
Leukemia,Information provided by Cell Medica Ltd (Responsible Party),Completed,Study Details | NCT01621724 | WT1 TCR Gene Therapy for Leukaemia: A Phase I/II Safety and Toxicity Study | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01621724?cond=Leukemia&viewType=Card&page=2&rank=20
Leukemia,"Information provided by University Hospital, Strasbourg, France",Recruiting,Study Details | NCT00993538 | Leukemia Cell Cultures for Research of New Anti,https://clinicaltrials.gov/study/NCT00993538?cond=Leukemia&viewType=Card&page=3&rank=21
Leukemia,Information provided by GlaxoSmithKline (Responsible Party),Completed,Study Details | NCT01110031 | Ofatumumab Cardiac Repolarization (QTc) Study in Fludarabine,https://clinicaltrials.gov/study/NCT01110031?cond=Leukemia&viewType=Card&page=3&rank=22
Leukemia,Information provided by Novartis (Novartis Pharmaceuticals) (Responsible Party),Completed,Study Results | NCT00748189 | Ofatumumab + Chlorambucil vs Chlorambucil Monotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00748189?cond=Leukemia&viewType=Card&page=3&rank=23&tab=results
Leukemia,Information provided by Novartis (Novartis Pharmaceuticals) (Responsible Party),Terminated,Study Details | NCT00748189 | Ofatumumab + Chlorambucil vs Chlorambucil Monotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00748189?cond=Leukemia&viewType=Card&page=3&rank=23
Leukemia,Information provided by GlaxoSmithKline (Responsible Party),Completed,Study Results | NCT01051063 | Evaluation of a New Anti,https://clinicaltrials.gov/study/NCT01051063?cond=Leukemia&viewType=Card&page=3&rank=24&tab=results
Leukemia,Information provided by GlaxoSmithKline (Responsible Party),Completed,Study Details | NCT01051063 | Evaluation of a New Anti,https://clinicaltrials.gov/study/NCT01051063?cond=Leukemia&viewType=Card&page=3&rank=24
Leukemia,Information provided by GlaxoSmithKline (Responsible Party),Completed,Study Results | NCT00725283 | Evaluation of a New Anti,https://clinicaltrials.gov/study/NCT00725283?cond=Leukemia&viewType=Card&page=3&rank=25&tab=results
Leukemia,Information provided by GlaxoSmithKline (Responsible Party),Completed,Study Details | NCT00725283 | Evaluation of a New Anti,https://clinicaltrials.gov/study/NCT00725283?cond=Leukemia&viewType=Card&page=3&rank=25
Leukemia,Information provided by Novartis (Novartis Pharmaceuticals) (Responsible Party),Completed,Study Results | NCT01890746 | A Safety and Efficacy Study of Eltrombopag in Subjects With AML | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01890746?cond=Leukemia&viewType=Card&page=3&rank=26&tab=results
Leukemia,Information provided by Novartis (Novartis Pharmaceuticals) (Responsible Party),Completed,Study Details | NCT01890746 | A Safety and Efficacy Study of Eltrombopag in Subjects With AML | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01890746?cond=Leukemia&viewType=Card&page=3&rank=26
Leukemia,Information provided by Novartis (Novartis Pharmaceuticals) (Responsible Party),Completed,Study Results | NCT00824265 | Ofatumumab Added to Fludarabine-Cyclophosphamide vs Fludarabine,https://clinicaltrials.gov/study/NCT00824265?cond=Leukemia&viewType=Card&page=3&rank=27&tab=results
Leukemia,Information provided by Novartis (Novartis Pharmaceuticals) (Responsible Party),Completed,Study Details | NCT00824265 | Ofatumumab Added to Fludarabine-Cyclophosphamide vs Fludarabine,https://clinicaltrials.gov/study/NCT00824265?cond=Leukemia&viewType=Card&page=3&rank=27
Leukemia,Information provided by GlaxoSmithKline (Responsible Party),Completed,"Study Results | NCT01563055 | A Phase I/II, Open",https://clinicaltrials.gov/study/NCT01563055?cond=Leukemia&viewType=Card&page=3&rank=28&tab=results
Leukemia,Information provided by GlaxoSmithKline (Responsible Party),Completed,"Study Details | NCT01563055 | A Phase I/II, Open",https://clinicaltrials.gov/study/NCT01563055?cond=Leukemia&viewType=Card&page=3&rank=28
Leukemia,Information provided by GlaxoSmithKline (Responsible Party),Completed,"Study Results | NCT01077622 | A Phase I/II, a Single Arm, Open",https://clinicaltrials.gov/study/NCT01077622?cond=Leukemia&viewType=Card&page=3&rank=29&tab=results
Leukemia,Information provided by GlaxoSmithKline (Responsible Party),Completed,"Study Details | NCT01077622 | A Phase I/II, a Single Arm, Open",https://clinicaltrials.gov/study/NCT01077622?cond=Leukemia&viewType=Card&page=3&rank=29
Leukemia,Information provided by GlaxoSmithKline (Responsible Party),Completed,"Study Results | NCT01808326 | A Phase II, Open Label, Single Arm, Multicenter Study of Chlorambucil in Japanese Previously Untreated Patients With Chronic Lymphocytic Leukemia | ClinicalTrials.gov",https://clinicaltrials.gov/study/NCT01808326?cond=Leukemia&viewType=Card&page=3&rank=30&tab=results
Leukemia,Information provided by GlaxoSmithKline (Responsible Party),Completed,"Study Details | NCT01808326 | A Phase II, Open Label, Single Arm, Multicenter Study of Chlorambucil in Japanese Previously Untreated Patients With Chronic Lymphocytic Leukemia | ClinicalTrials.gov",https://clinicaltrials.gov/study/NCT01808326?cond=Leukemia&viewType=Card&page=3&rank=30
Leukemia,Information provided by GlaxoSmithKline (Responsible Party),Completed,Study Results | NCT00349349 | HuMax-CD20 in B-Cell Chronic Lymphocytic Leukemia (B,https://clinicaltrials.gov/study/NCT00349349?cond=Leukemia&viewType=Card&page=4&rank=31&tab=results
Leukemia,Information provided by GlaxoSmithKline (Responsible Party),Completed,Study Details | NCT00349349 | HuMax-CD20 in B-Cell Chronic Lymphocytic Leukemia (B,https://clinicaltrials.gov/study/NCT00349349?cond=Leukemia&viewType=Card&page=4&rank=31
Leukemia,Information provided by GlaxoSmithKline (Responsible Party),Completed,Study Results | NCT00802737 | Efficacy and Safety of Ofatumumab Retreatment and Maintenance Treatment in Patients With B,https://clinicaltrials.gov/study/NCT00802737?cond=Leukemia&viewType=Card&page=4&rank=32&tab=results
Leukemia,Information provided by GlaxoSmithKline (Responsible Party),Completed,Study Details | NCT00802737 | Efficacy and Safety of Ofatumumab Retreatment and Maintenance Treatment in Patients With B,https://clinicaltrials.gov/study/NCT00802737?cond=Leukemia&viewType=Card&page=4&rank=32
Leukemia,"Information provided by dr. luyue, Sun Yat-sen University (Responsible Party)",Recruiting,Study Details | NCT02660762 | Modified MRCUKALLⅫ/ECOGE2993 Regimen for ALL | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02660762?cond=Leukemia&viewType=Card&page=4&rank=33
Leukemia,"Information provided by Antonio Pierini, University Of Perugia (Responsible Party)",Recruiting,Study Details | NCT06845592 | Safely Delivered Targeted High-dose Irradiation Followed by Adoptive Immunotherapy with Regulatory and Conventional T Cells to Increase Potency of Hematopoietic Stem Cell Transplantation in High,https://clinicaltrials.gov/study/NCT06845592?cond=Leukemia&viewType=Card&page=4&rank=34
Leukemia,Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy (PROLONG),Completed,Study Results | NCT01039376 | Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01039376?cond=Leukemia&viewType=Card&page=4&rank=35&tab=results
Leukemia,Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy (PROLONG),Terminated,Study Details | NCT01039376 | Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01039376?cond=Leukemia&viewType=Card&page=4&rank=35
Leukemia,"Information provided by Casey McAtee, Baylor College of Medicine (Responsible Party)",Recruiting,Study Details | NCT06928909 | Leukemia Adapted Protocol | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT06928909?cond=Leukemia&viewType=Card&page=4&rank=36
Leukemia,Information provided by GlaxoSmithKline (Responsible Party),Completed,Study Results | NCT00410163 | Ofatumumab With Fludarabine and Cyclophosphamide in B,https://clinicaltrials.gov/study/NCT00410163?cond=Leukemia&viewType=Card&page=4&rank=37&tab=results
Leukemia,Information provided by GlaxoSmithKline (Responsible Party),Completed,Study Details | NCT00410163 | Ofatumumab With Fludarabine and Cyclophosphamide in B,https://clinicaltrials.gov/study/NCT00410163?cond=Leukemia&viewType=Card&page=4&rank=37
Leukemia,"Information provided by Sebastian Giebel, Maria Sklodowska-Curie National Research Institute of Oncology (Responsible Party)",Completed,Study Details | NCT02452099 | Impact of DMSO Concentrations on Hematopoietic Recovery After Autologous HSC Transplantation. | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02452099?cond=Leukemia&viewType=Card&page=4&rank=38
Leukemia,Information provided by Servier (Institut de Recherches Internationales Servier) (Responsible Party),Completed,Study Results | NCT04629443 | Phase I/II Trial of S64315 Plus Azacitidine in Acute Myeloid Leukaemia | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT04629443?cond=Leukemia&viewType=Card&page=4&rank=39&tab=results
Leukemia,Information provided by Servier (Institut de Recherches Internationales Servier) (Responsible Party),Completed,Study Details | NCT04629443 | Phase I/II Trial of S64315 Plus Azacitidine in Acute Myeloid Leukaemia | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT04629443?cond=Leukemia&viewType=Card&page=4&rank=39
Leukemia,Information provided by GlaxoSmithKline (Responsible Party),Completed,Study Details | NCT01428427 | Combination Study of GSK1120212 With Gemcitabine in Subjects With Solid Tumors | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01428427?cond=Leukemia&viewType=Card&page=4&rank=40
Leukemia,Information provided by Novartis (Novartis Pharmaceuticals) (Responsible Party),Completed,Study Details | NCT05893836 | Real,https://clinicaltrials.gov/study/NCT05893836?cond=Leukemia&viewType=Card&page=5&rank=41
Leukemia,Information provided by National Institutes of Health Clinical Center (CC) (National Cancer Institute (NCI)) (Responsible Party),Completed,Study Details | NCT01031641 | Refinement of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO,https://clinicaltrials.gov/study/NCT01031641?cond=Leukemia&viewType=Card&page=5&rank=42
Leukemia,"Information provided by Iben Husted Nielsen, Rigshospitalet, Denmark (Responsible Party)",Recruiting,Study Details | NCT07062250 | Feasibility and Safety of Home Blood Count Measurement and Transfusions in Patients With Acute Myeloid Leukemia | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT07062250?cond=Leukemia&viewType=Card&page=5&rank=43
Leukemia,"Information provided by Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd (Responsible Party)",Recruiting,Study Details | NCT07036250 | Clinical Study of U32 in Patients With Acute Myeloid Leukemia | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT07036250?cond=Leukemia&viewType=Card&page=5&rank=44
Leukemia,Information provided by AstraZeneca,Completed,Study Details | NCT00502385 | Phase I AZD2171 in Patients With Relapsed or Refractory AML and Elderly Patients With DeNovo or Secondary AML | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00502385?cond=Leukemia&viewType=Card&page=5&rank=45
Leukemia,Information provided by Hikma Pharmaceuticals LLC (Responsible Party),Completed,Study Details | NCT06326697 | Bioequivalence of Azacitidine 300 mg Film,https://clinicaltrials.gov/study/NCT06326697?cond=Leukemia&viewType=Card&page=5&rank=46
Leukemia,Information provided by Nantes University Hospital (Responsible Party),Inconnu,Study Details | NCT07249476 | Study of NK Cells in the Monitoring of Patients With Acute Leukemia or Myelodysplasia | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT07249476?cond=Leukemia&viewType=Card&page=5&rank=47
Leukemia,"Information provided by Jin Wang, Ruijin Hospital (Responsible Party)",Active,Study Details | NCT07238907 | A Multi-center Retrospective Study of INO Treating B,https://clinicaltrials.gov/study/NCT07238907?cond=Leukemia&viewType=Card&page=5&rank=48
Leukemia,Information provided by Zhongnan Hospital (Responsible Party),Recruiting,Study Details | NCT06345365 | MA+AZA Regimen for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT06345365?cond=Leukemia&viewType=Card&page=5&rank=49
Leukemia,"Information provided by Dr. Matthias Willmann, University Hospital Tuebingen (Responsible Party)",Completed,Study Details | NCT02058888 | Amplification and Selection of Antimicrobial Resistance in the Intestine | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02058888?cond=Leukemia&viewType=Card&page=5&rank=50
Leukemia,Information provided by PETHEMA Foundation,Completed,Study Details | NCT00464217 | Treatment of the Acute Myeloblastic Leukaemia in Patients Over 65 Years | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00464217?cond=Leukemia&viewType=Card&page=6&rank=51
Leukemia,Information provided by Hospices Civils de Lyon (Responsible Party),Completed,Study Details | NCT02844257 | Transfusion Dependency at Diagnosis and Transfusion Intensity During Initial Chemotherapy Are Associated With Poorer Outcomes in Adult Acute Myeloid Leukaemia | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02844257?cond=Leukemia&viewType=Card&page=6&rank=52
Leukemia,Information provided by Hospital de Clinicas de Porto Alegre (Responsible Party),Inconnu,Study Details | NCT06783478 | NK Cell Infusion for Remission Consolidation in AML: A Phase II Trial | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT06783478?cond=Leukemia&viewType=Card&page=6&rank=53
Leukemia,Information provided by Cellectis S.A. (Responsible Party),Withdrawn,Study Details | NCT04106076 | Phase I Study of UCART123 in Patient With Adverse Genetic Risk Acute Myeloid Leukemia | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT04106076?cond=Leukemia&viewType=Card&page=6&rank=54
Leukemia,Information provided by University Hospital Southampton NHS Foundation Trust (Responsible Party),Completed,Study Details | NCT01521611 | Targeted Radiotherapy in HSCT for Poor Risk Haematological Malignancy | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01521611?cond=Leukemia&viewType=Card&page=6&rank=55
Leukemia,Information provided by University of Birmingham (Responsible Party),Recruiting,Study Details | NCT02724163 | International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02724163?cond=Leukemia&viewType=Card&page=6&rank=56
Leukemia,Information provided by Sanofi (Responsible Party),Terminated,Study Details | NCT05712278 | A Study to Investigate Use of Off-the,https://clinicaltrials.gov/study/NCT05712278?cond=Leukemia&viewType=Card&page=6&rank=57
Leukemia,Information provided by AstraZeneca (Responsible Party),Terminated,"Study Details | NCT03217838 | Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticles as Monotherapy or in Combination in Acute Myeloid Leukemia Participants. | ClinicalTrials.gov",https://clinicaltrials.gov/study/NCT03217838?cond=Leukemia&viewType=Card&page=6&rank=58
Leukemia,"Information provided by Prof. Christina Peters, St. Anna Kinderspital, Austria (Responsible Party)",Recruiting,Study Details | NCT01949129 | Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01949129?cond=Leukemia&viewType=Card&page=6&rank=59
Leukemia,Information provided by Servier (Institut de Recherches Internationales Servier) (Responsible Party),Completed,Study Details | NCT03672695 | Phase I Dose Escalation Study of Intravenously Administered S64315 in Combination With Orally Administered Venetoclax in Patients With Acute Myeloid Leukaemia. | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03672695?cond=Leukemia&viewType=Card&page=6&rank=60
Leukemia,Information provided by AstraZeneca,Completed,"Study Details | NCT00530699 | Safety, Tolerability and PK of AZD1152 in Patients With Relapsed Acute Myeloid Leukaemia (AML) | ClinicalTrials.gov",https://clinicaltrials.gov/study/NCT00530699?cond=Leukemia&viewType=Card&page=7&rank=61
Leukemia,Information provided by Samara State Medical University (Responsible Party),Recruiting,Study Details | NCT05682924 | Condition Vasoregulation Function Endothelium in Patients With CML Getting TKI II Generation Bosutinib | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT05682924?cond=Leukemia&viewType=Card&page=7&rank=62
Leukemia,Information provided by PETHEMA Foundation,Completed,Study Details | NCT00840346 | Panobinostat in Combination With Idarubicin and Cytarabine in Patients Aged 65 Years or Older With Newly Diagnosed Acute Myeloblastic Leukaemia (AML) | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00840346?cond=Leukemia&viewType=Card&page=7&rank=63
Leukemia,Information provided by AstraZeneca,Completed,"Study Details | NCT01019161 | An Open Label, Single Centre Mass Balance C14 Study in Patients With Acute Myeloid Leukaemia (AML) | ClinicalTrials.gov",https://clinicaltrials.gov/study/NCT01019161?cond=Leukemia&viewType=Card&page=7&rank=64
Leukemia,"Information provided by University Hospital, Brest (Responsible Party)",Recruiting,"Study Details | NCT03294980 | Chronic Lymphoid Leukaemia Observatory in Finistere Area, France | ClinicalTrials.gov",https://clinicaltrials.gov/study/NCT03294980?cond=Leukemia&viewType=Card&page=7&rank=65
Leukemia,Information provided by Gilead Sciences (Responsible Party),Completed,Study Details | NCT03582098 | Clinical Outcomes and Routine Management of Adults With Chronic Lymphocytic Leukaemia Treated With Idelalisib and Rituximab in the United Kingdom (UK) and Ireland | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03582098?cond=Leukemia&viewType=Card&page=7&rank=66
Leukemia,"Information provided by University College, London (Responsible Party)",Completed,Study Details | NCT01616238 | A Study for Older Adults With Acute Lymphoblastic Leukaemia | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01616238?cond=Leukemia&viewType=Card&page=7&rank=67
Leukemia,Information provided by Pfizer (Responsible Party),Completed,Study Results | NCT05286528 | Study to Evaluate Chronic Myeloid Leukemia Treatment Landscape and Real,https://clinicaltrials.gov/study/NCT05286528?cond=Leukemia&viewType=Card&page=7&rank=68&tab=results
Leukemia,Information provided by Pfizer (Responsible Party),Completed,Study Details | NCT05286528 | Study to Evaluate Chronic Myeloid Leukemia Treatment Landscape and Real,https://clinicaltrials.gov/study/NCT05286528?cond=Leukemia&viewType=Card&page=7&rank=68
Leukemia,"Information provided by Moleculin Biotech, Inc. (Responsible Party)",Recruiting,Study Details | NCT06788756 | L,https://clinicaltrials.gov/study/NCT06788756?cond=Leukemia&viewType=Card&page=7&rank=69
Leukemia,"Information provided by University Hospital, Bordeaux (Responsible Party)",Completed,Study Details | NCT01343173 | Multicenter Trial Estimating the Persistence of Molecular Remission in Chronic Myeloid Leukaemia in Long Term After Stopping Imatinib | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01343173?cond=Leukemia&viewType=Card&page=7&rank=70
Leukemia,Information provided by medac GmbH,Completed,Study Details | NCT01063660 | Treosulfan Based Conditioning Acute Myeloid Leukaemia (AML) | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01063660?cond=Leukemia&viewType=Card&page=8&rank=71
Leukemia,Information provided by Tempus AI (Responsible Party),Inconnu,Study Details | NCT07154823 | A Longitudinal Multi,https://clinicaltrials.gov/study/NCT07154823?cond=Leukemia&viewType=Card&page=8&rank=72
Leukemia,Information provided by University of Liverpool (Responsible Party),Completed,Study Details | NCT01804985 | De,https://clinicaltrials.gov/study/NCT01804985?cond=Leukemia&viewType=Card&page=8&rank=73
Leukemia,Information provided by PETHEMA Foundation,Completed,"Study Details | NCT00390897 | Glivec® (Imatinib Mesylate, STI571) in Monotherapy Versus Glivec®-Interferon Alpha in the Treatment of Chronic",https://clinicaltrials.gov/study/NCT00390897?cond=Leukemia&viewType=Card&page=8&rank=74
Leukemia,"Information provided by Eman Ibrahim Abdelshakour, Sohag University (Responsible Party)",Recruiting,Study Details | NCT07244367 | Maintenance Venetoclax in AML Fit Patients | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT07244367?cond=Leukemia&viewType=Card&page=8&rank=75
Leukemia,Information provided by Hospices Civils de Lyon (Responsible Party),Completed,Study Details | NCT02631811 | Early Palliative Care in Patient With Acute Leukaemia | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02631811?cond=Leukemia&viewType=Card&page=8&rank=76
Leukemia,Information provided by Australasian Leukaemia and Lymphoma Group (Responsible Party),Completed,Study Details | NCT02001818 | Pegylated Interferon Alfa,https://clinicaltrials.gov/study/NCT02001818?cond=Leukemia&viewType=Card&page=8&rank=77
Leukemia,Information provided by Gruppo Italiano Malattie EMatologiche dell'Adulto (Responsible Party),Completed,Study Details | NCT01475110 | Observational Study in Adults With Imatinib,https://clinicaltrials.gov/study/NCT01475110?cond=Leukemia&viewType=Card&page=8&rank=78
Leukemia,Information provided by University of Liverpool,Recruiting,Study Details | NCT01678430 | A Trial Looking at Ofatumumab for People With Chronic Lymphocytic Leukaemia Who Cannot Have More Intensive Treatment | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01678430?cond=Leukemia&viewType=Card&page=8&rank=79
Leukemia,Information provided by medac GmbH (Responsible Party),Terminated,Study Details | NCT01251809 | Trial of Oncaspar® and Three Doses of Pegylated Recombinant Asparaginase in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukaemia | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01251809?cond=Leukemia&viewType=Card&page=8&rank=80
Leukemia,Information provided by Abbott,Completed,Study Details | NCT00743028 | Assess the Oral Bioavailability of New ABT,https://clinicaltrials.gov/study/NCT00743028?cond=Leukemia&viewType=Card&page=9&rank=81
Leukemia,Information provided by Sanofi (Responsible Party),Terminated,Study Details | NCT01440179 | SAR3419 in Acute Lymphoblastic Leukemia | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01440179?cond=Leukemia&viewType=Card&page=9&rank=82
Leukemia,"Information provided by University Health Network, Toronto (Responsible Party)",Completed,"Study Results | NCT00751296 | Study of Lenalidomide in Previously Untreated, Symptomatic Chronic Lymphocytic Leukemia (CLL) | ClinicalTrials.gov",https://clinicaltrials.gov/study/NCT00751296?cond=Leukemia&viewType=Card&page=9&rank=83&tab=results
Leukemia,"Information provided by University Health Network, Toronto (Responsible Party)",Terminated,"Study Details | NCT00751296 | Study of Lenalidomide in Previously Untreated, Symptomatic Chronic Lymphocytic Leukemia (CLL) | ClinicalTrials.gov",https://clinicaltrials.gov/study/NCT00751296?cond=Leukemia&viewType=Card&page=9&rank=83
Leukemia,"Information provided by Louise Tram Henriksen, Aarhus University Hospital (Responsible Party)",Recruiting,Study Details | NCT01272440 | A Drug Monitoring Study on PEG,https://clinicaltrials.gov/study/NCT01272440?cond=Leukemia&viewType=Card&page=9&rank=84
Leukemia,Information provided by AstraZeneca (Responsible Party),Active,Study Details | NCT05645172 | Retention Rate of Acalabrutinib in a Non,https://clinicaltrials.gov/study/NCT05645172?cond=Leukemia&viewType=Card&page=9&rank=85
Leukemia,Information provided by The Christie NHS Foundation Trust,Terminated,Study Details | NCT01127542 | RESPeCT: Revlimid Early Stage Poor Prognosis Chronic Lymphocytic Leukaemia (CLL) Trial | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01127542?cond=Leukemia&viewType=Card&page=9&rank=86
Leukemia,Information provided by King's College Hospital NHS Trust,Completed,Study Details | NCT01279252 | CLL Empirical Antibiotic Regimen | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01279252?cond=Leukemia&viewType=Card&page=9&rank=87
Leukemia,Information provided by Pfizer (Responsible Party),Completed,Study Results | NCT02546375 | A Study To Describe The Real World Use Of Bosutinib In The UK And Netherlands | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02546375?cond=Leukemia&viewType=Card&page=9&rank=88&tab=results
Leukemia,Information provided by Pfizer (Responsible Party),Completed,Study Details | NCT02546375 | A Study To Describe The Real World Use Of Bosutinib In The UK And Netherlands | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02546375?cond=Leukemia&viewType=Card&page=9&rank=88
Leukemia,Information provided by GlaxoSmithKline (Responsible Party),Completed,Study Details | NCT00866671 | Observational Study of Nelarabine in Children and Young Adults | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00866671?cond=Leukemia&viewType=Card&page=9&rank=89
Leukemia,Information provided by University of Leipzig,Recruiting,Study Details | NCT01414231 | Comparison of the OSHO Protocol to a Standard Arm Protocol of the German AML Intergroup in Patients With AML<60a | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01414231?cond=Leukemia&viewType=Card&page=9&rank=90
Leukemia,"Information provided by Prof. Dr. Dominik Wolf, University of Bonn (Responsible Party)",Recruiting,Study Details | NCT03205267 | Phase II Study Testing the Tolerability and the Efficacy of Bosutinib in Chronic Phase CML Patients | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03205267?cond=Leukemia&viewType=Card&page=10&rank=91
Leukemia,Information provided by University of Sydney (Responsible Party),Recruiting,Study Details | NCT02189824 | Chemotherapy Followed by Infusion of Partially HLA Matched Unrelated Donor Cells for Patients With AML Who Are Ineligible for Stem Cell Transplantation | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02189824?cond=Leukemia&viewType=Card&page=10&rank=92
Leukemia,Information provided by Gruppo Italiano Studio Linfomi (Responsible Party),Completed,Study Details | NCT01832597 | Efficacy and Safety Study of Bendamustine With or Without Rituximab in Chronic Lymphoproliferative Disorders | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01832597?cond=Leukemia&viewType=Card&page=10&rank=93
Leukemia,Information provided by University of Leipzig (Responsible Party),Completed,Study Details | NCT01497002 | Comparison of the OSHO Protocol to a Standard Arm Protocol of the German AML Intergroup in Patients With AML>60a | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01497002?cond=Leukemia&viewType=Card&page=10&rank=94
Leukemia,Information provided by PETHEMA Foundation (Responsible Party),Completed,Study Details | NCT02445742 | CML Treated With Bosutinib After Relapse | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02445742?cond=Leukemia&viewType=Card&page=10&rank=95
Leukemia,Information provided by Royal Marsden NHS Foundation Trust,Completed,Study Details | NCT00292760 | A Single-arm Phase II Study of Alemtuzumab in Combination With High,https://clinicaltrials.gov/study/NCT00292760?cond=Leukemia&viewType=Card&page=10&rank=96
Leukemia,Information provided by Novartis (Novartis Pharmaceuticals) (Responsible Party),Completed,Study Results | NCT02108951 | Study to Assess Efficacy and Safety of Nilotinib 300mg Twice Daily in Patients With Philadelphia Positive Chronic Myeloid Leukaemia (CML) in Chronic Phase Who Are Intolerant to Prior Tyrosine Kinase Inhibitors. | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02108951?cond=Leukemia&viewType=Card&page=10&rank=97&tab=results
Leukemia,Information provided by Novartis (Novartis Pharmaceuticals) (Responsible Party),Terminated,Study Details | NCT02108951 | Study to Assess Efficacy and Safety of Nilotinib 300mg Twice Daily in Patients With Philadelphia Positive Chronic Myeloid Leukaemia (CML) in Chronic Phase Who Are Intolerant to Prior Tyrosine Kinase Inhibitors. | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02108951?cond=Leukemia&viewType=Card&page=10&rank=97
Leukemia,"Information provided by University College, London (Responsible Party)",Recruiting,Study Details | NCT04678869 | CiproPAL (Ciprofloxacin Prophylaxis in Acute Leukaemia) | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT04678869?cond=Leukemia&viewType=Card&page=10&rank=98
Leukemia,Information provided by University of Pennsylvania (Responsible Party),Recruiting,Study Details | NCT02650414 | CD22 Redirected Autologous T Cells for ALL | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02650414?cond=Leukemia&viewType=Card&page=10&rank=99
Leukemia,Information provided by Ain Shams University (Responsible Party),Recruiting,Study Details | NCT06918054 | Hepatoprotective for Children and Adolescent With Acute Lymphoblastic Leukemia | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT06918054?cond=Leukemia&viewType=Card&page=10&rank=100
Leukemia,Information provided by Fundació Sant Joan de Déu (Responsible Party),Completed,Study Results | NCT01615809 | Nebulized Amphotericin B Lipid Complex in Invasive Pulmonary Aspergillosis in Paediatric Patients With Acute Leukaemia | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01615809?cond=Leukemia&viewType=Card&page=11&rank=101&tab=results
Leukemia,Information provided by Fundació Sant Joan de Déu (Responsible Party),Completed,Study Details | NCT01615809 | Nebulized Amphotericin B Lipid Complex in Invasive Pulmonary Aspergillosis in Paediatric Patients With Acute Leukaemia | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01615809?cond=Leukemia&viewType=Card&page=11&rank=101
Leukemia,"Information provided by Supachai Ekwattanakit, Lai Corporation Pty. Ltd. (Responsible Party)",Recruiting,Study Details | NCT03825146 | The Effects of AMPC in the Treatments of Refractory or Relapsed AML | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03825146?cond=Leukemia&viewType=Card&page=11&rank=102
Leukemia,Information provided by University Hospital Southampton NHS Foundation Trust (Responsible Party),Completed,Study Details | NCT01422603 | Clofarabine Pre,https://clinicaltrials.gov/study/NCT01422603?cond=Leukemia&viewType=Card&page=11&rank=103
Leukemia,Information provided by AstraZeneca (Responsible Party),Inconnu,"Study Details | NCT07155226 | Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression | ClinicalTrials.gov",https://clinicaltrials.gov/study/NCT07155226?cond=Leukemia&viewType=Card&page=11&rank=104
Leukemia,Information provided by University Hospital Center of Martinique (Responsible Party),Completed,Study Details | NCT01941680 | High Risk Adult T-cell Leukemia/Lymphoma (ATLL,https://clinicaltrials.gov/study/NCT01941680?cond=Leukemia&viewType=Card&page=11&rank=105
Leukemia,Information provided by Great Ormond Street Hospital for Children NHS Foundation Trust (Responsible Party),Recruiting,Study Details | NCT05942599 | Base Edited CAR T Cells Against AML: Deep Conditioning Ahead of Allogeneic Stem Cell Transplantation | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT05942599?cond=Leukemia&viewType=Card&page=11&rank=106
Leukemia,Information provided by Assistance Publique Hopitaux De Marseille (Responsible Party),Recruiting,Study Details | NCT01756599 | Multi-centre Prospective Cohort of Childhood Leukaemia: Determinants of Health and Quality of Life of the Patients After Treatment for an Acute Leukaemia During Childhood or Adolescence,https://clinicaltrials.gov/study/NCT01756599?cond=Leukemia&viewType=Card&page=11&rank=107
Leukemia,"Information provided by Prof. Dr S Fadilah Abdul Wahid, National University of Malaysia (Responsible Party)",Recruiting,Study Details | NCT03937544 | Intravenous Autologous CD19 CAR-T Cells for R/R B,https://clinicaltrials.gov/study/NCT03937544?cond=Leukemia&viewType=Card&page=11&rank=108
Leukemia,"Information provided by National University Hospital, Singapore (Responsible Party)",Recruiting,Study Details | NCT02123836 | Natural Killer Cells in Acute Leukaemia and Myelodysplastic Syndrome | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02123836?cond=Leukemia&viewType=Card&page=11&rank=109
Leukemia,Information provided by Universidade do Porto (Responsible Party),Inconnu,Study Details | NCT06848270 | Effectiveness of Early Intervention in Palliative Care for Acute Myeloid Leukemia Patients Comparing to Standard of Care | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT06848270?cond=Leukemia&viewType=Card&page=11&rank=110
Leukemia,Information provided by Novartis (Novartis Pharmaceuticals) (Responsible Party),Completed,Study Results | NCT01520922 | Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL) | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01520922?cond=Leukemia&viewType=Card&page=12&rank=111&tab=results
Leukemia,Information provided by Novartis (Novartis Pharmaceuticals) (Responsible Party),Completed,Study Details | NCT01520922 | Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL) | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01520922?cond=Leukemia&viewType=Card&page=12&rank=111
Leukemia,Information provided by AstraZeneca (Responsible Party),Recruiting,Study Details | NCT06651970 | Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT06651970?cond=Leukemia&viewType=Card&page=12&rank=112
Leukemia,Information provided by medac GmbH (Responsible Party),Active,"Study Details | NCT03156790 | PK, PD, Safety and Immunogenicity of Spectrila in Adults With Acute B",https://clinicaltrials.gov/study/NCT03156790?cond=Leukemia&viewType=Card&page=12&rank=113
Leukemia,"Information provided by Janssen Research & Development, LLC (Responsible Party)",Recruiting,Study Details | NCT04811560 | A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot,https://clinicaltrials.gov/study/NCT04811560?cond=Leukemia&viewType=Card&page=12&rank=114
Leukemia,"Information provided by Philippe ROUSSELOT, Versailles Hospital (Responsible Party)",Recruiting,Study Details | NCT03895671 | PONAZA : A COMBINATION OF PONATINIB AND 5,https://clinicaltrials.gov/study/NCT03895671?cond=Leukemia&viewType=Card&page=12&rank=115
Leukemia,"Information provided by Masonic Cancer Center, University of Minnesota (Responsible Party)",Completed,Study Results | NCT02145039 | Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic Diseases | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02145039?cond=Leukemia&viewType=Card&page=12&rank=116&tab=results
Leukemia,"Information provided by Masonic Cancer Center, University of Minnesota (Responsible Party)",Terminated,Study Details | NCT02145039 | Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic Diseases | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02145039?cond=Leukemia&viewType=Card&page=12&rank=116
Leukemia,"Information provided by University College, London (Responsible Party)",Terminated,Study Details | NCT02310997 | Myloablative Cord Blood Transplant in Haematological Malignancies (MAC UCBT) | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02310997?cond=Leukemia&viewType=Card&page=12&rank=117
Leukemia,"Information provided by Jing Pan, Beijing GoBroad Hospital (Responsible Party)",Recruiting,Study Details | NCT06326021 | Optimised CD33 (FL,https://clinicaltrials.gov/study/NCT06326021?cond=Leukemia&viewType=Card&page=12&rank=118
Leukemia,Information provided by Servier (Institut de Recherches Internationales Servier) (Responsible Party),Completed,Study Details | NCT02979366 | Phase I Study of S64315 Administred Intravenously in Patients With Acute Myeloid Leukaemia or Myelodysplastic Syndrome | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02979366?cond=Leukemia&viewType=Card&page=12&rank=119
Leukemia,"Information provided by University of Colorado, Denver (Responsible Party)",Recruiting,Study Details | NCT06429449 | Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT06429449?cond=Leukemia&viewType=Card&page=12&rank=120
Leukemia,Information provided by Servier (Institut de Recherches Internationales Servier) (Responsible Party),Completed,Study Details | NCT02920541 | Dose,https://clinicaltrials.gov/study/NCT02920541?cond=Leukemia&viewType=Card&page=13&rank=121
Leukemia,Information provided by Gruppo Italiano Trapianto di Midollo Osseo (Responsible Party),Completed,Study Details | NCT06790680 | GITMO AML/MDS,https://clinicaltrials.gov/study/NCT06790680?cond=Leukemia&viewType=Card&page=13&rank=122
Leukemia,"Information provided by Andrew Hantel, MD, Dana-Farber Cancer Institute (Responsible Party)",Recruiting,Study Details | NCT06907797 | Tools for Reducing Inequity in Acute Leukemia (TRIAL): Beta Testing | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT06907797?cond=Leukemia&viewType=Card&page=13&rank=123
Leukemia,"Information provided by Peter MacCallum Cancer Centre, Australia (Responsible Party)",Completed,"Study Details | NCT01488565 | A Single Arm Pilot Study of Azacitidine in Myelodysplastic Syndromes (MDS) / Acute Myeloid Leukaemia (AML), With Eltrombopag Support for Thrombocytopenia | ClinicalTrials.gov",https://clinicaltrials.gov/study/NCT01488565?cond=Leukemia&viewType=Card&page=13&rank=124
Leukemia,Information provided by The Methodist Hospital Research Institute (Responsible Party),Inconnu,Study Details | NCT07060001 | Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood,https://clinicaltrials.gov/study/NCT07060001?cond=Leukemia&viewType=Card&page=13&rank=125
Leukemia,"Information provided by Ipsen (Epizyme, Inc.) (Responsible Party)",Completed,Study Details | NCT02141828 | A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ,https://clinicaltrials.gov/study/NCT02141828?cond=Leukemia&viewType=Card&page=13&rank=126
Leukemia,"Information provided by Kun-Hsing Yu, Harvard Medical School (HMS and HSDM) (Responsible Party)",Completed,Study Details | NCT07203885 | AI-Assisted Acute Myeloid Leukemia Evaluation With the Leukemia End-to-End Analysis Platform (LEAP) Versus Clinician,https://clinicaltrials.gov/study/NCT07203885?cond=Leukemia&viewType=Card&page=13&rank=127
Leukemia,Information provided by GlaxoSmithKline (Responsible Party),Completed,Study Details | NCT00742144 | Ofatumumab in Japanese Patients With CD20 Positive Follicular Lymphoma or Chronic Lymphocytic Leukemia | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00742144?cond=Leukemia&viewType=Card&page=13&rank=128
Leukemia,Information provided by AstraZeneca (Responsible Party),Completed,Study Details | NCT01955668 | AZD6738 First Time in Patient Multiple Ascending Dose Study | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01955668?cond=Leukemia&viewType=Card&page=13&rank=129
Leukemia,"Information provided by Yana Pikman, MD, Dana-Farber Cancer Institute (Responsible Party)",Completed,Study Results | NCT02670525 | Matched Targeted Therapy For High,https://clinicaltrials.gov/study/NCT02670525?cond=Leukemia&viewType=Card&page=13&rank=130&tab=results
Leukemia,"Information provided by Yana Pikman, MD, Dana-Farber Cancer Institute (Responsible Party)",Active,Study Details | NCT02670525 | Matched Targeted Therapy For High,https://clinicaltrials.gov/study/NCT02670525?cond=Leukemia&viewType=Card&page=13&rank=130
Leukemia,Information provided by Stanford University (Responsible Party),Completed,Study Details | NCT05282459 | Enasidenib in MDS &Non,https://clinicaltrials.gov/study/NCT05282459?cond=Leukemia&viewType=Card&page=14&rank=131
Leukemia,"Information provided by Prof Nigel Russell, Cardiff University (Responsible Party)",Recruiting,Study Details | NCT02272478 | Trial to Test the Effects of Adding 1 of 2 New Treatment Agents to Commonly Used Chemotherapy Combinations | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02272478?cond=Leukemia&viewType=Card&page=14&rank=132
Leukemia,"Information provided by Ehab L Atallah, Medical College of Wisconsin (Responsible Party)",Recruiting,Study Details | NCT07117136 | Blinatumomab Consolidation in Real World | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT07117136?cond=Leukemia&viewType=Card&page=14&rank=133
Leukemia,Information provided by Cell Medica Ltd (Responsible Party),Completed,Study Details | NCT02550535 | A Phase I/II Study of Gene,https://clinicaltrials.gov/study/NCT02550535?cond=Leukemia&viewType=Card&page=14&rank=134
Leukemia,Information provided by OHSU Knight Cancer Institute (Responsible Party),Inconnu,Study Details | NCT01549548 | Compassionate Use Ponatinib | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01549548?cond=Leukemia&viewType=Card&page=14&rank=135
Leukemia,Information provided by M.D. Anderson Cancer Center (Responsible Party),Completed,"Study Details | NCT01396499 | Study to Assess Safety, Tolerability and Preliminary Efficacy of BKM120, PI3K Kinase Inhibitor, With Advanced Leukemias | ClinicalTrials.gov",https://clinicaltrials.gov/study/NCT01396499?cond=Leukemia&viewType=Card&page=14&rank=136
Leukemia,"Information provided by Gesine Bug, Goethe University (Responsible Party)",Terminated,Study Details | NCT04326764 | Panobinostat Maintenance After HSCT fo High,https://clinicaltrials.gov/study/NCT04326764?cond=Leukemia&viewType=Card&page=14&rank=137
Leukemia,"Information provided by Sheng-Li Xue, MD, The First Affiliated Hospital of Soochow University (Responsible Party)",Recruiting,Study Details | NCT05901974 | Venetoclax Combined With Azactidine in the Treatment of ALAL | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT05901974?cond=Leukemia&viewType=Card&page=14&rank=138
Leukemia,Information provided by Gilead Sciences (Responsible Party),Completed,Study Results | NCT01659255 | Study to Evaluate the Safety and Tolerability of Tirabrutinib (ONO/GS,https://clinicaltrials.gov/study/NCT01659255?cond=Leukemia&viewType=Card&page=14&rank=139&tab=results
Leukemia,Information provided by Gilead Sciences (Responsible Party),Completed,Study Details | NCT01659255 | Study to Evaluate the Safety and Tolerability of Tirabrutinib (ONO/GS,https://clinicaltrials.gov/study/NCT01659255?cond=Leukemia&viewType=Card&page=14&rank=139
Leukemia,Information provided by Astellas Pharma Inc (Astellas Pharma International B.V.) (Responsible Party),Terminated,Study Details | NCT02273856 | Multicentre Registry of Treatments and Outcomes in Patients With Chronic Lymphocytic Leukaemia (CLL) Or Indolent Non Hodgkin's Lymphoma (iNHL) | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02273856?cond=Leukemia&viewType=Card&page=14&rank=140
Leukemia,"Information provided by Peter Lang, University Children's Hospital Tuebingen (Responsible Party)",Recruiting,Study Details | NCT01919866 | Safety Study of CD3/CD19 Depleted Haploidentical Stem Cells | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01919866?cond=Leukemia&viewType=Card&page=15&rank=141
Leukemia,"Information provided by Antonio Pérez Martínez, Hospital Universitario La Paz (Responsible Party)",Completed,"Study Details | NCT02074657 | ""LANK",https://clinicaltrials.gov/study/NCT02074657?cond=Leukemia&viewType=Card&page=15&rank=142
Leukemia,Information provided by Assistance Publique - Hôpitaux de Paris,Completed,Study Details | NCT00339196 | 5,https://clinicaltrials.gov/study/NCT00339196?cond=Leukemia&viewType=Card&page=15&rank=143
Leukemia,Information provided by Saglik Bilimleri Universitesi (Responsible Party),Completed,Study Details | NCT06357585 | Providing Web,https://clinicaltrials.gov/study/NCT06357585?cond=Leukemia&viewType=Card&page=15&rank=144
Leukemia,Information provided by Bristol-Myers Squibb (Responsible Party),Completed,Study Results | NCT00777036 | A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML) or With Ph+ Leukemias Resistant or Intolerant to Imatinib | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00777036?cond=Leukemia&viewType=Card&page=15&rank=145&tab=results
Leukemia,Information provided by Bristol-Myers Squibb (Responsible Party),Recruiting,Study Details | NCT00777036 | A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML) or With Ph+ Leukemias Resistant or Intolerant to Imatinib | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00777036?cond=Leukemia&viewType=Card&page=15&rank=145
Leukemia,Information provided by Takeda (Responsible Party),Active,Study Details | NCT05886491 | A Study of GDX012 in Adults With Relapsed or Refractory Acute Myeloid Leukemia | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT05886491?cond=Leukemia&viewType=Card&page=15&rank=146
Leukemia,Information provided by European Institute of Oncology (Responsible Party),Terminated,Study Details | NCT01446900 | R,https://clinicaltrials.gov/study/NCT01446900?cond=Leukemia&viewType=Card&page=15&rank=147
Leukemia,Information provided by Children's Oncology Group (Responsible Party),Completed,Study Details | NCT01150656 | Obatoclax Mesylate in Samples From Young Patients With Acute Myeloid Leukemia | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01150656?cond=Leukemia&viewType=Card&page=15&rank=148
Leukemia,Information provided by M.D. Anderson Cancer Center (Responsible Party),Terminated,Study Details | NCT01029509 | Study to Assess OPB,https://clinicaltrials.gov/study/NCT01029509?cond=Leukemia&viewType=Card&page=15&rank=149
Leukemia,"Information provided by David F. Claxton, MD, Milton S. Hershey Medical Center (Responsible Party)",Terminated,"Study Details | NCT00882076 | Clofarabine, Etoposide, and Mitoxantrone for Relapsed and Refractory Acute Leukemias | ClinicalTrials.gov",https://clinicaltrials.gov/study/NCT00882076?cond=Leukemia&viewType=Card&page=15&rank=150
Leukemia,Information provided by Centre Hospitalier Universitaire de Nīmes (Responsible Party),Recruiting,Study Details | NCT05793801 | Study of the Impact of Frequency of Changing PICCline Dressings in Patients With Acute Leukemia | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT05793801?cond=Leukemia&viewType=Card&page=16&rank=151
Leukemia,Information provided by Royal Marsden NHS Foundation Trust (Responsible Party),Recruiting,Study Details | NCT03233763 | Laboratory Studies Into the Pathology of Leukaemia | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03233763?cond=Leukemia&viewType=Card&page=16&rank=152
Leukemia,"Information provided by Andrew Hantel, MD, Dana-Farber Cancer Institute (Responsible Party)",Active,Study Details | NCT06795139 | Pilot of a Trial Enrollment Diversity Dashboard | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT06795139?cond=Leukemia&viewType=Card&page=16&rank=153
Leukemia,Information provided by M.D. Anderson Cancer Center (Responsible Party),Completed,Study Results | NCT05464836 | Phase II Study to Evaluate Safety and Efficacy of CB-103 With Venetoclax in Adolescent and Young Adult Patients With Relapsed/Refractory T-ALL or T,https://clinicaltrials.gov/study/NCT05464836?cond=Leukemia&viewType=Card&page=16&rank=154&tab=results
Leukemia,Information provided by M.D. Anderson Cancer Center (Responsible Party),Terminated,Study Details | NCT05464836 | Phase II Study to Evaluate Safety and Efficacy of CB-103 With Venetoclax in Adolescent and Young Adult Patients With Relapsed/Refractory T-ALL or T,https://clinicaltrials.gov/study/NCT05464836?cond=Leukemia&viewType=Card&page=16&rank=154
Leukemia,"Information provided by Xiaoyu Zhu, Anhui Provincial Hospital (Responsible Party)",Inconnu,Study Details | NCT07120607 | Allogeneic CD7 CAR γδ T Cells Therapy Recurrent/Refractory Leukemia | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT07120607?cond=Leukemia&viewType=Card&page=16&rank=155
Leukemia,"Information provided by Heba Ahmed Ali Abdeen, Cairo University (Responsible Party)",Completed,Study Details | NCT03876834 | Respiratory Training in Patients With Leukemia | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03876834?cond=Leukemia&viewType=Card&page=16&rank=156
Leukemia,"Information provided by Mikalai Katsin, Vitebsk Regional Clinical Cancer Centre (Responsible Party)",Inconnu,Study Details | NCT06762431 | Phase I/II Open-label Study Evaluating The Safety And Efficacy of Concomitant Administration of Anti-CD19 CAR T,https://clinicaltrials.gov/study/NCT06762431?cond=Leukemia&viewType=Card&page=16&rank=157
Leukemia,"Information provided by Peter Paschka, University of Ulm (Responsible Party)",Recruiting,Study Details | NCT02310243 | Study of Palbociclib in MLL,https://clinicaltrials.gov/study/NCT02310243?cond=Leukemia&viewType=Card&page=16&rank=158
Leukemia,Information provided by Children's Oncology Group (Responsible Party),Completed,Study Details | NCT01395628 | Cell Samples From Patients With Leukemia | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01395628?cond=Leukemia&viewType=Card&page=16&rank=159
Leukemia,"Information provided by Prof DDr Thomas Lion, St. Anna Kinderkrebsforschung (Responsible Party)",Recruiting,Study Details | NCT02643888 | Pre-existing Kinase Domain Mutations in Ph,https://clinicaltrials.gov/study/NCT02643888?cond=Leukemia&viewType=Card&page=16&rank=160
Leukemia,"Information provided by University College, London (Responsible Party)",Completed,Study Details | NCT01597219 | Trial of Haploidentical Stem Cell Transplantation for Haematological Cancers | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01597219?cond=Leukemia&viewType=Card&page=17&rank=161
Leukemia,Information provided by Great Ormond Street Hospital for Children NHS Foundation Trust (Responsible Party),Recruiting,Study Details | NCT04856215 | 90Y-labelled Anti,https://clinicaltrials.gov/study/NCT04856215?cond=Leukemia&viewType=Card&page=17&rank=162
Leukemia,Information provided by Eli Lilly and Company (Responsible Party),Completed,Study Results | NCT01214603 | A Study in Participants With Acute Leukemia | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01214603?cond=Leukemia&viewType=Card&page=17&rank=163&tab=results
Leukemia,Information provided by Eli Lilly and Company (Responsible Party),Completed,Study Details | NCT01214603 | A Study in Participants With Acute Leukemia | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01214603?cond=Leukemia&viewType=Card&page=17&rank=163
Leukemia,Information provided by M.D. Anderson Cancer Center (Responsible Party),Completed,"Study Results | NCT02089230 | MEK Inhibitor 162 Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Poor Prognosis, Not Suitable for or Unwilling to Receive Standard Therapy | ClinicalTrials.gov",https://clinicaltrials.gov/study/NCT02089230?cond=Leukemia&viewType=Card&page=17&rank=164&tab=results
Leukemia,Information provided by M.D. Anderson Cancer Center (Responsible Party),Terminated,"Study Details | NCT02089230 | MEK Inhibitor 162 Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Poor Prognosis, Not Suitable for or Unwilling to Receive Standard Therapy | ClinicalTrials.gov",https://clinicaltrials.gov/study/NCT02089230?cond=Leukemia&viewType=Card&page=17&rank=164
Leukemia,"Information provided by Ferdaush Ahmed Sojib, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh (Responsible Party)",Completed,Study Details | NCT03593304 | Evaluate the Neuroprotective Effect of Vitamin B6 and Vitamin B12 Against Vincristine Induced Neurotoxicity in Acute Lymphoblastic Leukaemia Patients | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03593304?cond=Leukemia&viewType=Card&page=17&rank=165
Leukemia,"Information provided by Children's Hospital Medical Center, Cincinnati (Responsible Party)",Recruiting,Study Details | NCT03826992 | Venetoclax Combined With Vyxeos (CPX,https://clinicaltrials.gov/study/NCT03826992?cond=Leukemia&viewType=Card&page=17&rank=166
Leukemia,Information provided by Alexandria University (Responsible Party),Completed,Study Details | NCT06095726 | Peppermint Inhalation Versus Swedish Massage on Chemotherapy Induced,https://clinicaltrials.gov/study/NCT06095726?cond=Leukemia&viewType=Card&page=17&rank=167
Leukemia,"Information provided by Chongqing Precision Biotech Co., Ltd (Responsible Party)",Recruiting,Study Details | NCT04272125 | Safety and Efficacy of CD123-Targeted CAR,https://clinicaltrials.gov/study/NCT04272125?cond=Leukemia&viewType=Card&page=17&rank=168
Leukemia,"Information provided by Jing Pan, Beijing GoBroad Hospital (Responsible Party)",Recruiting,Study Details | NCT06890494 | Clinical Study on the Safety and Efficacy of BiTE-EV in Relapsed/Refractory Acute B,https://clinicaltrials.gov/study/NCT06890494?cond=Leukemia&viewType=Card&page=17&rank=169
Leukemia,Information provided by Affiliated Hospital of Nantong University (Responsible Party),Recruiting,Study Details | NCT06643962 | Venetoclax Combined with Intensive Therapy for Acute Myeloid Leukemia Patients with Lower Early Peripheral Blast Clearance Rate After Standard Induction Therapy | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT06643962?cond=Leukemia&viewType=Card&page=17&rank=170
Leukemia,Information provided by Kecellitics Biotech Company Ltd (Responsible Party),Inconnu,Study Details | NCT04100187 | Immunotherapy With CD19 CAR T-cells for B,https://clinicaltrials.gov/study/NCT04100187?cond=Leukemia&viewType=Card&page=18&rank=171
Leukemia,Information provided by M.D. Anderson Cancer Center (Responsible Party),Withdrawn,Study Details | NCT06522373 | Phase I Trial of MT,https://clinicaltrials.gov/study/NCT06522373?cond=Leukemia&viewType=Card&page=18&rank=172
Leukemia,Information provided by Institut Paoli-Calmettes (Responsible Party),Completed,Study Details | NCT02860793 | Role of PTK,https://clinicaltrials.gov/study/NCT02860793?cond=Leukemia&viewType=Card&page=18&rank=173
Leukemia,Information provided by Children's Oncology Group (Responsible Party),Completed,Study Details | NCT01500499 | Role of Biomarkers in Disease Progression in Samples From Patients With Acute Myeloid Leukemia | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01500499?cond=Leukemia&viewType=Card&page=18&rank=174
Leukemia,Information provided by National Cancer Institute (NCI),Active,Study Details | NCT00003437 | Hormone Therapy Plus Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00003437?cond=Leukemia&viewType=Card&page=18&rank=175
Leukemia,"Information provided by Erin Shields, Children's Hospital Los Angeles (Responsible Party)",Recruiting,"Study Details | NCT06360718 | Effects of Using a Storybook, to Explain Leukemia to Children Versus the Standard Child Life Intervention, on Parental Stress. | ClinicalTrials.gov",https://clinicaltrials.gov/study/NCT06360718?cond=Leukemia&viewType=Card&page=18&rank=176
Leukemia,Information provided by Swedish Orphan Biovitrum (Responsible Party),Completed,Study Results | NCT00460421 | A Phase 1 Dose,https://clinicaltrials.gov/study/NCT00460421?cond=Leukemia&viewType=Card&page=18&rank=177&tab=results
Leukemia,Information provided by Swedish Orphan Biovitrum (Responsible Party),Completed,Study Details | NCT00460421 | A Phase 1 Dose,https://clinicaltrials.gov/study/NCT00460421?cond=Leukemia&viewType=Card&page=18&rank=177
Leukemia,Information provided by University of Rochester (Responsible Party),Completed,"Study Details | NCT00258271 | Cladribine, Cytarabine, and Imatinib Mesylate in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Blastic Phase Chronic Myelogenous Leukemia | ClinicalTrials.gov",https://clinicaltrials.gov/study/NCT00258271?cond=Leukemia&viewType=Card&page=18&rank=178
Leukemia,"Information provided by Nanfang Hospital, Southern Medical University (Responsible Party)",Inconnu,"Study Details | NCT07264010 | Sorafenib Combined With Venetoclax as Pre-emptive Therapy Strategy for MRD+ AML: a Prospective, Single",https://clinicaltrials.gov/study/NCT07264010?cond=Leukemia&viewType=Card&page=18&rank=179
Leukemia,Information provided by Daiichi Sankyo (Responsible Party),Recruiting,Study Details | NCT06578247 | Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3,https://clinicaltrials.gov/study/NCT06578247?cond=Leukemia&viewType=Card&page=18&rank=180
Leukemia,Information provided by Children's Oncology Group (Responsible Party),Completed,Study Details | NCT00083070 | Temozolomide in Treating Young Patients With Refractory or Recurrent Leukemia | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00083070?cond=Leukemia&viewType=Card&page=19&rank=181
Leukemia,Information provided by Alliance for Clinical Trials in Oncology (Responsible Party),Active,Study Details | NCT00898092 | Genetics Study of Tissue Collected From Patients With Acute Myeloid Leukemia | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00898092?cond=Leukemia&viewType=Card&page=19&rank=182
Leukemia,Information provided by M.D. Anderson Cancer Center (Responsible Party),Completed,"Study Results | NCT01794702 | Decitabine Followed by Clofarabine, Idarubicin, and Cytarabine in Acute Leukemia | ClinicalTrials.gov",https://clinicaltrials.gov/study/NCT01794702?cond=Leukemia&viewType=Card&page=19&rank=183&tab=results
Leukemia,Information provided by M.D. Anderson Cancer Center (Responsible Party),Completed,"Study Details | NCT01794702 | Decitabine Followed by Clofarabine, Idarubicin, and Cytarabine in Acute Leukemia | ClinicalTrials.gov",https://clinicaltrials.gov/study/NCT01794702?cond=Leukemia&viewType=Card&page=19&rank=183
Leukemia,Information provided by Sanofi (Responsible Party),Terminated,"Study Details | NCT05086315 | First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR",https://clinicaltrials.gov/study/NCT05086315?cond=Leukemia&viewType=Card&page=19&rank=184
Leukemia,Information provided by Alliance for Clinical Trials in Oncology (Responsible Party),Active,Study Details | NCT00898456 | Multidrug Resistance Genes in Patients With Acute Myeloid Leukemia | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00898456?cond=Leukemia&viewType=Card&page=19&rank=185
Leukemia,Information provided by Wake Forest University Health Sciences (Responsible Party),Completed,Study Results | NCT01656031 | A Phase II Open-Label Study of High,https://clinicaltrials.gov/study/NCT01656031?cond=Leukemia&viewType=Card&page=19&rank=186&tab=results
Leukemia,Information provided by Wake Forest University Health Sciences (Responsible Party),Completed,Study Details | NCT01656031 | A Phase II Open-Label Study of High,https://clinicaltrials.gov/study/NCT01656031?cond=Leukemia&viewType=Card&page=19&rank=186
Leukemia,"Information provided by University of Maryland, Baltimore (Responsible Party)",Completed,Study Details | NCT00004009 | R115777 in Treating Patients With Refractory or Recurrent Acute Leukemia or Chronic Myelogenous Leukemia | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00004009?cond=Leukemia&viewType=Card&page=19&rank=187
Leukemia,Information provided by M.D. Anderson Cancer Center (Responsible Party),Completed,Study Results | NCT00509600 | Etanercept (Enbrel) for Juvenile Myelomonocytic Leukemia | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00509600?cond=Leukemia&viewType=Card&page=19&rank=188&tab=results
Leukemia,Information provided by M.D. Anderson Cancer Center (Responsible Party),Terminated,Study Details | NCT00509600 | Etanercept (Enbrel) for Juvenile Myelomonocytic Leukemia | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00509600?cond=Leukemia&viewType=Card&page=19&rank=188
Leukemia,Information provided by National Cancer Institute (NCI),Completed,Study Details | NCT01235117 | Azacitidine in Treating Patients With Chronic Myelomonocytic Leukemia | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01235117?cond=Leukemia&viewType=Card&page=19&rank=189
Leukemia,Information provided by M.D. Anderson Cancer Center (Responsible Party),Completed,Study Results | NCT01786343 | Decitabine for Older or Unfit Patients With Acute Myeloid Leukemia (AML) | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01786343?cond=Leukemia&viewType=Card&page=19&rank=190&tab=results
Leukemia,Information provided by M.D. Anderson Cancer Center (Responsible Party),Completed,Study Details | NCT01786343 | Decitabine for Older or Unfit Patients With Acute Myeloid Leukemia (AML) | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01786343?cond=Leukemia&viewType=Card&page=19&rank=190
Leukemia,Information provided by M.D. Anderson Cancer Center (Responsible Party),Completed,"Study Details | NCT02652871 | LY2510924, Idarubicin and Cytarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia | ClinicalTrials.gov",https://clinicaltrials.gov/study/NCT02652871?cond=Leukemia&viewType=Card&page=20&rank=191
Leukemia,Information provided by Cancer Research UK (Responsible Party),Completed,Study Details | NCT01431664 | AT9283 in Treating Young Patients With Relapsed or Refractory Acute Leukemia | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01431664?cond=Leukemia&viewType=Card&page=20&rank=192
Leukemia,Information provided by M.D. Anderson Cancer Center (Responsible Party),Active,Study Details | NCT00503256 | Genetic Study of Chronic Lymphocytic Leukemia Families | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00503256?cond=Leukemia&viewType=Card&page=20&rank=193
Leukemia,Information provided by M.D. Anderson Cancer Center (Responsible Party),Terminated,Study Details | NCT02141477 | Omacetaxine and Decitabine in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS) | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02141477?cond=Leukemia&viewType=Card&page=20&rank=194
Leukemia,Information provided by M.D. Anderson Cancer Center (Responsible Party),Terminated,"Study Details | NCT02225574 | An Open-Label, Phase I/II Study of Nilotinib (Tasigna) and MEK-162 (ARRY",https://clinicaltrials.gov/study/NCT02225574?cond=Leukemia&viewType=Card&page=20&rank=195
Leukemia,Information provided by National Cancer Institute (NCI),Completed,Study Details | NCT00967057 | Combination Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00967057?cond=Leukemia&viewType=Card&page=20&rank=196
Leukemia,Information provided by Children's Oncology Group (Responsible Party),Completed,Study Details | NCT01057199 | Studying Biomarkers in Cell Samples From Patients With Acute Myeloid Leukemia | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01057199?cond=Leukemia&viewType=Card&page=20&rank=197
Leukemia,Information provided by M.D. Anderson Cancer Center (Responsible Party),Withdrawn,Study Details | NCT02028039 | IPI,https://clinicaltrials.gov/study/NCT02028039?cond=Leukemia&viewType=Card&page=20&rank=198
Leukemia,Information provided by Swiss Cancer Institute (Responsible Party),Completed,Study Details | NCT00003230 | Paclitaxel in Treating Patients With Refractory or Recurrent Acute Leukemia or Chronic Myelogenous Leukemia | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00003230?cond=Leukemia&viewType=Card&page=20&rank=199
Leukemia,Information provided by Memorial Sloan Kettering Cancer Center,Completed,Study Details | NCT00002534 | Bone Marrow Transplantation in Treating Patients With Acute Leukemia in First or Second Remission | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00002534?cond=Leukemia&viewType=Card&page=20&rank=200
Leukemia,Information provided by National Cancer Institute (NCI),Completed,Study Details | NCT00003305 | Aminopterin in Treating Patients With Refractory Leukemia | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00003305?cond=Leukemia&viewType=Card&page=21&rank=201
Leukemia,"Information provided by Jerome Ritz, MD, Dana-Farber Cancer Institute (Responsible Party)",Completed,Study Details | NCT00429910 | Natural History Study of Patients With Chronic Myelogenous Leukemia | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00429910?cond=Leukemia&viewType=Card&page=21&rank=202
Leukemia,Information provided by Daiichi Sankyo (Responsible Party),Recruiting,Study Details | NCT06824168 | Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3,https://clinicaltrials.gov/study/NCT06824168?cond=Leukemia&viewType=Card&page=21&rank=203
Leukemia,Information provided by National Cancer Institute (NCI),Completed,Study Details | NCT00004905 | Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia or Acute Leukemia | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00004905?cond=Leukemia&viewType=Card&page=21&rank=204
Leukemia,Information provided by Washington University School of Medicine (Responsible Party),Completed,Study Details | NCT01137747 | Carfilzomib in Patients With Relapsed Acute Myeloid or Acute Lymphoblastic Leukemia | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01137747?cond=Leukemia&viewType=Card&page=21&rank=205
Leukemia,Information provided by M.D. Anderson Cancer Center (Responsible Party),Completed,Study Details | NCT01092741 | Late Chronic Phase Chronic Myelogenous Leukemia | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01092741?cond=Leukemia&viewType=Card&page=21&rank=206
Leukemia,Information provided by M.D. Anderson Cancer Center (Responsible Party),Completed,Study Results | NCT01251965 | Phase l/II Study of Ruxolitinib for Acute Leukemia | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01251965?cond=Leukemia&viewType=Card&page=21&rank=207&tab=results
Leukemia,Information provided by M.D. Anderson Cancer Center (Responsible Party),Terminated,Study Details | NCT01251965 | Phase l/II Study of Ruxolitinib for Acute Leukemia | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01251965?cond=Leukemia&viewType=Card&page=21&rank=207
Leukemia,Information provided by Children's Oncology Group (Responsible Party),Completed,"Study Details | NCT00003735 | Chemotherapy in Treating Children With Relapsed Acute Leukemia, Acute Myeloid Leukemia, or Blastic Phase Chronic Myelogenous Leukemia | ClinicalTrials.gov",https://clinicaltrials.gov/study/NCT00003735?cond=Leukemia&viewType=Card&page=21&rank=208
Leukemia,Information provided by Wake Forest University Health Sciences (Responsible Party),Completed,Study Details | NCT00295841 | Cytarabine and Clofarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00295841?cond=Leukemia&viewType=Card&page=21&rank=209
Leukemia,Information provided by Alliance for Clinical Trials in Oncology (Responsible Party),Completed,Study Details | NCT01005368 | Study of Biomarkers in Blood and Bone Marrow Samples From Patients With Previously Untreated Chronic Lymphocytic Leukemia | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01005368?cond=Leukemia&viewType=Card&page=21&rank=210
Leukemia,Information provided by M.D. Anderson Cancer Center (Responsible Party),Completed,Study Results | NCT02302846 | Study of MLN9708 as Maintenance Therapy for Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) in Remission | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02302846?cond=Leukemia&viewType=Card&page=22&rank=211&tab=results
Leukemia,Information provided by M.D. Anderson Cancer Center (Responsible Party),Terminated,Study Details | NCT02302846 | Study of MLN9708 as Maintenance Therapy for Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) in Remission | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02302846?cond=Leukemia&viewType=Card&page=22&rank=211
Leukemia,Information provided by Children's Oncology Group (Responsible Party),Completed,Study Details | NCT00006462 | Gemcitabine in Treating Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00006462?cond=Leukemia&viewType=Card&page=22&rank=212
Leukemia,"Information provided by Hongsheng Zhou. M.D., Ph.D, Nanfang Hospital, Southern Medical University (Responsible Party)",Recruiting,Study Details | NCT03564470 | Precision Diagnosis Directing HDACi and TKI Target Therapy for Adult Ph,https://clinicaltrials.gov/study/NCT03564470?cond=Leukemia&viewType=Card&page=22&rank=213
Leukemia,Information provided by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,Completed,Study Details | NCT00276601 | Combination Chemotherapy in Treating Patients With Acute Promyelocytic Leukemia | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00276601?cond=Leukemia&viewType=Card&page=22&rank=214
Leukemia,Information provided by Children's Oncology Group (Responsible Party),Completed,Study Details | NCT00899652 | DNA Analysis of Bone Marrow and Blood Samples From Young Patients With Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00899652?cond=Leukemia&viewType=Card&page=22&rank=215
Leukemia,Information provided by Children's Oncology Group (Responsible Party),Completed,Study Details | NCT00021242 | Docetaxel in Treating Children With Relapsed or Refractory Acute Lymphoblastic or Acute Myeloid Leukemia | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00021242?cond=Leukemia&viewType=Card&page=22&rank=216
Leukemia,Information provided by National Cancer Institute (NCI) (Responsible Party),Completed,Study Details | NCT00004862 | Augmerosen Plus Fludarabine and Cytarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00004862?cond=Leukemia&viewType=Card&page=22&rank=217
Leukemia,Information provided by Children's Oncology Group (Responsible Party),Completed,Study Details | NCT01229124 | RNA Biomarkers in Tissue Samples From Infants With Acute Myeloid Leukemia | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01229124?cond=Leukemia&viewType=Card&page=22&rank=218
Leukemia,Information provided by National Cancer Institute (NCI),Completed,Study Details | NCT00015860 | STI571 Plus Combination Chemotherapy in Treating Patients With Chronic Myelogenous Leukemia or Acute Lymphocytic Leukemia | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00015860?cond=Leukemia&viewType=Card&page=22&rank=219
Leukemia,"Information provided by Colleen Annesley, Seattle Children's Hospital (Responsible Party)",Active,Study Details | NCT03244306 | A Phase 1 Study of CD22,https://clinicaltrials.gov/study/NCT03244306?cond=Leukemia&viewType=Card&page=22&rank=220
Leukemia,Information provided by M.D. Anderson Cancer Center (Responsible Party),Active,Study Details | NCT00502983 | Molecular Epidemiology of Acute Myelogenous Leukemia | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00502983?cond=Leukemia&viewType=Card&page=23&rank=221
Leukemia,Information provided by M.D. Anderson Cancer Center (Responsible Party),Completed,"Study Results | NCT02481297 | Lirilumab With Rituximab for Relapsed, Refractory or High",https://clinicaltrials.gov/study/NCT02481297?cond=Leukemia&viewType=Card&page=23&rank=222&tab=results
Leukemia,Information provided by M.D. Anderson Cancer Center (Responsible Party),Completed,"Study Details | NCT02481297 | Lirilumab With Rituximab for Relapsed, Refractory or High",https://clinicaltrials.gov/study/NCT02481297?cond=Leukemia&viewType=Card&page=23&rank=222
Leukemia,Information provided by M.D. Anderson Cancer Center (Responsible Party),Withdrawn,Study Details | NCT02194374 | Autologous ROR1R-CAR,https://clinicaltrials.gov/study/NCT02194374?cond=Leukemia&viewType=Card&page=23&rank=223
Leukemia,Information provided by SWOG Cancer Research Network (Responsible Party),Completed,Study Details | NCT01059734 | S9031-S9126-S9333-S9500,https://clinicaltrials.gov/study/NCT01059734?cond=Leukemia&viewType=Card&page=23&rank=224
Leukemia,Information provided by City of Hope Medical Center (Responsible Party),Completed,Study Details | NCT00816283 | Dasatinib and Vorinostat in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Acute Lymphoblastic Leukemia | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00816283?cond=Leukemia&viewType=Card&page=23&rank=225
Leukemia,"Information provided by Beijing Immunochina Medical Science & Technology Co., Ltd. (Responsible Party)",Recruiting,Study Details | NCT05480501 | Clinical Trial to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) B,https://clinicaltrials.gov/study/NCT05480501?cond=Leukemia&viewType=Card&page=23&rank=226
Leukemia,Information provided by Eastern Cooperative Oncology Group (Responsible Party),Completed,Study Details | NCT01385150 | Biomarkers in Blood Samples From Patients With Acute Myeloid Leukemia | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01385150?cond=Leukemia&viewType=Card&page=23&rank=227
Leukemia,Information provided by M.D. Anderson Cancer Center (Responsible Party),Completed,Study Results | NCT00940342 | Rituximab Plus Sargramostim (GM,https://clinicaltrials.gov/study/NCT00940342?cond=Leukemia&viewType=Card&page=23&rank=228&tab=results
Leukemia,Information provided by M.D. Anderson Cancer Center (Responsible Party),Completed,Study Details | NCT00940342 | Rituximab Plus Sargramostim (GM,https://clinicaltrials.gov/study/NCT00940342?cond=Leukemia&viewType=Card&page=23&rank=228
Leukemia,Information provided by Gruppo Italiano Malattie EMatologiche dell'Adulto (Responsible Party),Completed,Study Details | NCT01156883 | Combination Chemotherapy in Treating Young Adult Patients With Acute Lymphoblastic Leukemia | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01156883?cond=Leukemia&viewType=Card&page=23&rank=229
Leukemia,Information provided by Alliance for Clinical Trials in Oncology (Responsible Party),Completed,Study Details | NCT00003931 | Diagnostic Study of Gene Alterations in Patients With Acute Myeloid Leukemia | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00003931?cond=Leukemia&viewType=Card&page=23&rank=230
Leukemia,Information provided by National Cancer Institute (NCI),Completed,Study Details | NCT00458523 | Alemtuzumab in Treating Patients With B,https://clinicaltrials.gov/study/NCT00458523?cond=Leukemia&viewType=Card&page=24&rank=231
Leukemia,Information provided by Takeda (Responsible Party),Completed,"Study Details | NCT05743465 | A Study to Evaluate Available Treatment Information of Ponatinib, Bosutinib, Imatinib, Dasatinib and Nilotinib in Adults With Chronic Myeloid Leukemia | ClinicalTrials.gov",https://clinicaltrials.gov/study/NCT05743465?cond=Leukemia&viewType=Card&page=24&rank=232
Leukemia,Information provided by M.D. Anderson Cancer Center (Responsible Party),Completed,Study Results | NCT00506597 | Erwinase Study in Patients With Acute Lymphoblastic Leukemia | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00506597?cond=Leukemia&viewType=Card&page=24&rank=233&tab=results
Leukemia,Information provided by M.D. Anderson Cancer Center (Responsible Party),Completed,Study Details | NCT00506597 | Erwinase Study in Patients With Acute Lymphoblastic Leukemia | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00506597?cond=Leukemia&viewType=Card&page=24&rank=233
Leukemia,Information provided by Alliance for Clinical Trials in Oncology (Responsible Party),Completed,Study Details | NCT01284010 | Biomarkers in Blood and Bone Marrow Samples From Patients With Acute Lymphoblastic Leukemia | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01284010?cond=Leukemia&viewType=Card&page=24&rank=234
Leukemia,"Information provided by Ivan S Moiseev, St. Petersburg State Pavlov Medical University (Responsible Party)",Completed,Study Details | NCT02799147 | GVHD Prophylaxis With Post,https://clinicaltrials.gov/study/NCT02799147?cond=Leukemia&viewType=Card&page=24&rank=235
Leukemia,Information provided by Children's Oncology Group (Responsible Party),Completed,Study Details | NCT01407757 | Study of Gemtuzumab Ozogamicin Therapy in DNA Samples From Patients With Acute Myeloid Leukemia Treated on COG,https://clinicaltrials.gov/study/NCT01407757?cond=Leukemia&viewType=Card&page=24&rank=236
Leukemia,Information provided by City of Hope Medical Center (Responsible Party),Completed,Study Results | NCT00723203 | Panobinostat in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00723203?cond=Leukemia&viewType=Card&page=24&rank=237&tab=results
Leukemia,Information provided by City of Hope Medical Center (Responsible Party),Terminated,Study Details | NCT00723203 | Panobinostat in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00723203?cond=Leukemia&viewType=Card&page=24&rank=237
Leukemia,Information provided by Roswell Park Cancer Institute,Completed,Study Details | NCT00053131 | Combination Chemotherapy Followed By Filgrastim or Sargramostim in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00053131?cond=Leukemia&viewType=Card&page=24&rank=238
Leukemia,"Information provided by Chongqing Precision Biotech Co., Ltd (Responsible Party)",Recruiting,Study Details | NCT04265963 | CD123-Targeted CAR,https://clinicaltrials.gov/study/NCT04265963?cond=Leukemia&viewType=Card&page=24&rank=239
Leukemia,"Information provided by University Hospital, Montpellier (Responsible Party)",Terminated,Study Details | NCT04136665 | Physical Activity Adapted at Home Supervised by Videoconferencing in Post,https://clinicaltrials.gov/study/NCT04136665?cond=Leukemia&viewType=Card&page=24&rank=240
Leukemia,Information provided by M.D. Anderson Cancer Center (Responsible Party),Terminated,Study Details | NCT00514189 | Feasibility Study of Acute Myelogenous Leukemia mRNA Plus Lysate Loaded Dendritic Cell Vaccines | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00514189?cond=Leukemia&viewType=Card&page=25&rank=241
Leukemia,Information provided by Gruppo Italiano Malattie EMatologiche dell'Adulto (Responsible Party),Completed,Study Details | NCT00482833 | Phase III Trial in Acute Promyelocytic Leukemia Patients | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00482833?cond=Leukemia&viewType=Card&page=25&rank=242
Leukemia,Information provided by Northwestern University (Responsible Party),Completed,Study Details | NCT00005795 | Arsenic Trioxide in Treating Patients With Acute Myeloid Leukemia | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00005795?cond=Leukemia&viewType=Card&page=25&rank=243
Leukemia,Information provided by Children's Oncology Group (Responsible Party),Completed,Study Details | NCT00004932 | STI571 in Treating Patients With Recurrent Leukemia | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00004932?cond=Leukemia&viewType=Card&page=25&rank=244
Leukemia,Information provided by Dutch Childhood Oncology Group (Responsible Party),Recruiting,Study Details | NCT00550992 | Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00550992?cond=Leukemia&viewType=Card&page=25&rank=245
Leukemia,Information provided by Children's Oncology Group (Responsible Party),Completed,Study Details | NCT01150058 | Drug Biomarkers in Cell Samples From Patients With Acute Myeloid Leukemia | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01150058?cond=Leukemia&viewType=Card&page=25&rank=246
Leukemia,Information provided by Children's Oncology Group (Responsible Party),Completed,Study Results | NCT00372619 | Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00372619?cond=Leukemia&viewType=Card&page=25&rank=247&tab=results
Leukemia,Information provided by Children's Oncology Group (Responsible Party),Completed,Study Details | NCT00372619 | Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00372619?cond=Leukemia&viewType=Card&page=25&rank=247
Leukemia,"Information provided by Beijing Immunochina Medical Science & Technology Co., Ltd. (Responsible Party)",Inconnu,Study Details | NCT05309213 | Clinical Trial to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) B,https://clinicaltrials.gov/study/NCT05309213?cond=Leukemia&viewType=Card&page=25&rank=248
Leukemia,Information provided by Boston Medical Center,Completed,Study Details | NCT00006097 | Chemotherapy in Treating Patients With Chronic Lymphocytic Leukemia | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00006097?cond=Leukemia&viewType=Card&page=25&rank=249
Leukemia,Information provided by Children's Oncology Group (Responsible Party),Completed,Study Details | NCT01016379 | Studying DNA in Blood and Bone Marrow Samples From Young Patients With Acute Lymphoblastic Leukemia | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01016379?cond=Leukemia&viewType=Card&page=25&rank=250
Leukemia,Information provided by M.D. Anderson Cancer Center (Responsible Party),Withdrawn,"Study Details | NCT02420938 | Urelumab (CD137 mAb) With Rituximab for Relapsed, Refractory or High",https://clinicaltrials.gov/study/NCT02420938?cond=Leukemia&viewType=Card&page=26&rank=251
Leukemia,Information provided by Alliance for Clinical Trials in Oncology (Responsible Party),Completed,Study Details | NCT00896701 | Relationship Between Natural Killer Cells' Ability to Kill Leukemia Cells and the Outcome of Patients With Acute Myeloid Leukemia Previously Treated With Interleukin,https://clinicaltrials.gov/study/NCT00896701?cond=Leukemia&viewType=Card&page=26&rank=252
Leukemia,Information provided by National Cancer Institute (NCI),Completed,Study Details | NCT00963521 | Vaccine Therapy in Treating Patients With Acute Myeloid Leukemia in Complete Remission | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00963521?cond=Leukemia&viewType=Card&page=26&rank=253
Leukemia,Information provided by M.D. Anderson Cancer Center (Responsible Party),Terminated,Study Details | NCT01891981 | Study of Moxetumomab Pasudotox in Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL) | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01891981?cond=Leukemia&viewType=Card&page=26&rank=254
Leukemia,Information provided by Children's Oncology Group (Responsible Party),Completed,Study Details | NCT01295476 | Biomarker Study in Bone Marrow Samples From Patients With T,https://clinicaltrials.gov/study/NCT01295476?cond=Leukemia&viewType=Card&page=26&rank=255
Leukemia,Information provided by Children's Oncology Group (Responsible Party),Completed,Study Details | NCT01581528 | Studying Samples From Patients With T,https://clinicaltrials.gov/study/NCT01581528?cond=Leukemia&viewType=Card&page=26&rank=256
Leukemia,Information provided by University of New Mexico (Responsible Party),Terminated,Study Details | NCT00277056 | Dysregulated Tyrosine Kinase Signaling in Leukemia | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00277056?cond=Leukemia&viewType=Card&page=26&rank=257
Leukemia,Information provided by Cancer Research UK (Responsible Party),Completed,Study Results | NCT02933320 | BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B,https://clinicaltrials.gov/study/NCT02933320?cond=Leukemia&viewType=Card&page=26&rank=258&tab=results
Leukemia,Information provided by Cancer Research UK (Responsible Party),Completed,Study Details | NCT02933320 | BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B,https://clinicaltrials.gov/study/NCT02933320?cond=Leukemia&viewType=Card&page=26&rank=258
Leukemia,Information provided by Roswell Park Cancer Institute,Completed,Study Details | NCT00053144 | Irinotecan and Cytarabine in Treating Patients With Refractory or Recurrent Acute Myeloid Leukemia or Chronic Myelogenous Leukemia | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00053144?cond=Leukemia&viewType=Card&page=26&rank=259
Leukemia,Information provided by Memorial Sloan Kettering Cancer Center,Completed,Study Details | NCT00002609 | Monoclonal Antibody Therapy and Chemotherapy in Treating Patients With Acute Promyelocytic Leukemia in Remission | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00002609?cond=Leukemia&viewType=Card&page=26&rank=260
Leukemia,Information provided by M.D. Anderson Cancer Center (Responsible Party),Recruiting,"Study Details | NCT05536349 | Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment",https://clinicaltrials.gov/study/NCT05536349?cond=Leukemia&viewType=Card&page=27&rank=261
Leukemia,Information provided by National Cancer Institute (NCI) (Eastern Cooperative Oncology Group),Inconnu,Study Details | NCT01653613 | Studying Genes in Samples From Younger Patients With Acute Lymphoblastic Leukemia | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01653613?cond=Leukemia&viewType=Card&page=27&rank=262
Leukemia,Information provided by M.D. Anderson Cancer Center (Responsible Party),Completed,Study Results | NCT01570868 | Ponatinib,https://clinicaltrials.gov/study/NCT01570868?cond=Leukemia&viewType=Card&page=27&rank=263&tab=results
Leukemia,Information provided by M.D. Anderson Cancer Center (Responsible Party),Terminated,Study Details | NCT01570868 | Ponatinib,https://clinicaltrials.gov/study/NCT01570868?cond=Leukemia&viewType=Card&page=27&rank=263
Leukemia,Information provided by Alliance for Clinical Trials in Oncology (Responsible Party),Completed,Study Details | NCT00005829 | Gemcitabine in Treating Patients With Recurrent Chronic Lymphocytic Leukemia | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00005829?cond=Leukemia&viewType=Card&page=27&rank=264
Leukemia,Information provided by SWOG Cancer Research Network (Responsible Party),Completed,"Study Results | NCT00551460 | S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia | ClinicalTrials.gov",https://clinicaltrials.gov/study/NCT00551460?cond=Leukemia&viewType=Card&page=27&rank=265&tab=results
Leukemia,Information provided by SWOG Cancer Research Network (Responsible Party),Completed,"Study Details | NCT00551460 | S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia | ClinicalTrials.gov",https://clinicaltrials.gov/study/NCT00551460?cond=Leukemia&viewType=Card&page=27&rank=265
Leukemia,Information provided by Swiss Cancer Institute (Responsible Party),Completed,Study Details | NCT00003746 | Daily or Weekly Cladribine in Treating Patients With Hairy Cell Leukemia | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00003746?cond=Leukemia&viewType=Card&page=27&rank=266
Leukemia,Information provided by M.D. Anderson Cancer Center (Responsible Party),Completed,Study Results | NCT01893320 | Study of Vosaroxin and Decitabine in Older Patients With Acute Myeloid Leukemia and High,https://clinicaltrials.gov/study/NCT01893320?cond=Leukemia&viewType=Card&page=27&rank=267&tab=results
Leukemia,Information provided by M.D. Anderson Cancer Center (Responsible Party),Completed,Study Details | NCT01893320 | Study of Vosaroxin and Decitabine in Older Patients With Acute Myeloid Leukemia and High,https://clinicaltrials.gov/study/NCT01893320?cond=Leukemia&viewType=Card&page=27&rank=267
Leukemia,Information provided by M.D. Anderson Cancer Center (Responsible Party),Completed,Study Results | NCT02441803 | Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML) | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02441803?cond=Leukemia&viewType=Card&page=27&rank=268&tab=results
Leukemia,Information provided by M.D. Anderson Cancer Center (Responsible Party),Completed,Study Details | NCT02441803 | Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML) | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02441803?cond=Leukemia&viewType=Card&page=27&rank=268
Leukemia,Information provided by Memorial Sloan Kettering Cancer Center (Responsible Party),Completed,Study Results | NCT00528450 | Tretinoin and Arsenic Trioxide With or Without Idarubicin in Treating Patients With Acute Promyelocytic Leukemia | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00528450?cond=Leukemia&viewType=Card&page=27&rank=269&tab=results
Leukemia,Information provided by Memorial Sloan Kettering Cancer Center (Responsible Party),Terminated,Study Details | NCT00528450 | Tretinoin and Arsenic Trioxide With or Without Idarubicin in Treating Patients With Acute Promyelocytic Leukemia | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00528450?cond=Leukemia&viewType=Card&page=27&rank=269
Leukemia,Information provided by M.D. Anderson Cancer Center (Responsible Party),Active,Study Details | NCT01046305 | Symptom Burden in Chronic Myeloid Leukemia (CML) | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01046305?cond=Leukemia&viewType=Card&page=27&rank=270
Leukemia,"Information provided by Masonic Cancer Center, University of Minnesota (Responsible Party)",Terminated,Study Details | NCT00643240 | Yttrium Y 90 Anti-CD19 Antibody BU,https://clinicaltrials.gov/study/NCT00643240?cond=Leukemia&viewType=Card&page=28&rank=271
Leukemia,Information provided by M.D. Anderson Cancer Center (Responsible Party),Completed,Study Results | NCT02096042 | Phase I/II - Brentuximab/5,https://clinicaltrials.gov/study/NCT02096042?cond=Leukemia&viewType=Card&page=28&rank=272&tab=results
Leukemia,Information provided by M.D. Anderson Cancer Center (Responsible Party),Terminated,Study Details | NCT02096042 | Phase I/II - Brentuximab/5,https://clinicaltrials.gov/study/NCT02096042?cond=Leukemia&viewType=Card&page=28&rank=272
Leukemia,Information provided by National Cancer Institute (NCI),Recruiting,Study Details | NCT00343369 | Combination Chemotherapy in Treating Young Patients With Acute Lymphoblastic Leukemia | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00343369?cond=Leukemia&viewType=Card&page=28&rank=273
Leukemia,Information provided by M.D. Anderson Cancer Center (Responsible Party),Completed,Study Details | NCT00002844 | Bone Marrow Transplantation in Treating Patients With Chronic Lymphocytic Leukemia | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00002844?cond=Leukemia&viewType=Card&page=28&rank=274
Leukemia,Information provided by Novartis (Novartis Pharmaceuticals) (Responsible Party),Completed,Study Results | NCT02272777 | A Study of Imatinib and Nilotinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02272777?cond=Leukemia&viewType=Card&page=28&rank=275&tab=results
Leukemia,Information provided by Novartis (Novartis Pharmaceuticals) (Responsible Party),Completed,Study Details | NCT02272777 | A Study of Imatinib and Nilotinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02272777?cond=Leukemia&viewType=Card&page=28&rank=275
Leukemia,Information provided by Hospices Civils de Lyon (Responsible Party),Completed,Study Details | NCT02981784 | Comparative Evaluation of Results of Allogeneic Hematopoietic Stem Cells Versus Ponatinib in CML Patients Carrying a Mutation T315I | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02981784?cond=Leukemia&viewType=Card&page=28&rank=276
Leukemia,Information provided by National Cancer Institute (NCI),Completed,Study Details | NCT00006223 | flt3L in Treating Patients With Acute Myeloid Leukemia | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00006223?cond=Leukemia&viewType=Card&page=28&rank=277
Leukemia,Information provided by Washington University School of Medicine (Responsible Party),Completed,Study Details | NCT00008697 | Arsenic Trioxide in Treating Patients With Refractory or Recurrent Acute Promyelocytic Leukemia | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00008697?cond=Leukemia&viewType=Card&page=28&rank=278
Leukemia,Information provided by Memorial Sloan Kettering Cancer Center,Completed,Study Details | NCT00016159 | Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00016159?cond=Leukemia&viewType=Card&page=28&rank=279
Leukemia,"Information provided by Masonic Cancer Center, University of Minnesota (Responsible Party)",Completed,Study Results | NCT00609739 | Cytosine Arabinoside and Mitoxantrone for Patients With Juvenile Myelomonocytic Leukemia Receiving Repeat Stem Cell Transplantation | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00609739?cond=Leukemia&viewType=Card&page=28&rank=280&tab=results
Leukemia,"Information provided by Masonic Cancer Center, University of Minnesota (Responsible Party)",Terminated,Study Details | NCT00609739 | Cytosine Arabinoside and Mitoxantrone for Patients With Juvenile Myelomonocytic Leukemia Receiving Repeat Stem Cell Transplantation | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00609739?cond=Leukemia&viewType=Card&page=28&rank=280
Leukemia,Information provided by National Cancer Institute (NCI) (Responsible Party),Completed,Study Details | NCT00002705 | Topotecan in Treating Children With Refractory Leukemia | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00002705?cond=Leukemia&viewType=Card&page=29&rank=281
Leukemia,Information provided by Children's Oncology Group (Responsible Party),Completed,Study Details | NCT00899899 | Resistance to Methotrexate in Patients With Acute Lymphoblastic Leukemia in Relapse or Remission | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00899899?cond=Leukemia&viewType=Card&page=29&rank=282
Leukemia,Information provided by Alliance for Clinical Trials in Oncology (Responsible Party),Completed,Study Details | NCT00003255 | Carboplatin Plus Topotecan in Treating Patients With Relapsed Acute Myelogenous Leukemia | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00003255?cond=Leukemia&viewType=Card&page=29&rank=283
Leukemia,Information provided by Memorial Sloan Kettering Cancer Center (Responsible Party),Completed,Study Details | NCT00462787 | Combination Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Leukemia | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00462787?cond=Leukemia&viewType=Card&page=29&rank=284
Leukemia,Information provided by M.D. Anderson Cancer Center (Responsible Party),Completed,Study Results | NCT01319981 | Hyper,https://clinicaltrials.gov/study/NCT01319981?cond=Leukemia&viewType=Card&page=29&rank=285&tab=results
Leukemia,Information provided by M.D. Anderson Cancer Center (Responsible Party),Completed,Study Details | NCT01319981 | Hyper,https://clinicaltrials.gov/study/NCT01319981?cond=Leukemia&viewType=Card&page=29&rank=285
Leukemia,Information provided by Memorial Sloan Kettering Cancer Center,Completed,Study Details | NCT00004052 | Vaccine Therapy in Treating Patients With Chronic Myelogenous Leukemia | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00004052?cond=Leukemia&viewType=Card&page=29&rank=286
Leukemia,Information provided by Children's Oncology Group (Responsible Party),Completed,Study Details | NCT01247584 | Biomarkers in Samples From Young Patients With Acute Myeloid Leukemia | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01247584?cond=Leukemia&viewType=Card&page=29&rank=287
Leukemia,Information provided by Eastern Cooperative Oncology Group (ECOG-ACRIN Cancer Research Group) (Responsible Party),Completed,Study Details | NCT00900380 | Studying Tissue Samples to Learn More About Drug Resistance in Patients With Acute Myeloid Leukemia | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00900380?cond=Leukemia&viewType=Card&page=29&rank=288
Leukemia,Information provided by Eastern Cooperative Oncology Group (Responsible Party),Completed,Study Results | NCT00003910 | Methotrexate With or Without Cyclophosphamide in Treating Patients With Lymphocytic Leukemia | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00003910?cond=Leukemia&viewType=Card&page=29&rank=289&tab=results
Leukemia,Information provided by Eastern Cooperative Oncology Group (Responsible Party),Terminated,Study Details | NCT00003910 | Methotrexate With or Without Cyclophosphamide in Treating Patients With Lymphocytic Leukemia | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00003910?cond=Leukemia&viewType=Card&page=29&rank=289
Leukemia,"Information provided by Shelly Brown, Ohio State University Comprehensive Cancer Center (Responsible Party)",Completed,"Study Details | NCT04597086 | Bright White Light Therapy for the Improvement of Sleep, Fatigue, Distress, Depression, and Anxiety in Hospitalized Leukemia Patients | ClinicalTrials.gov",https://clinicaltrials.gov/study/NCT04597086?cond=Leukemia&viewType=Card&page=29&rank=290
Leukemia,Information provided by Massachusetts General Hospital,Completed,Study Details | NCT00505700 | VELCADE in Combination With Idarubicin and Cytosine Arabinoside in Patients With Acute Myelogenous Leukemia | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00505700?cond=Leukemia&viewType=Card&page=30&rank=291
Leukemia,Information provided by Canadian Cancer Trials Group (NCIC Clinical Trials Group) (Responsible Party),Completed,Study Details | NCT00049075 | Fludarabine in Treating Patients With Chronic Lymphocytic Leukemia | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00049075?cond=Leukemia&viewType=Card&page=30&rank=292
Leukemia,"Information provided by Reuven Schore, Children's National Research Institute (Responsible Party)",Terminated,Study Details | NCT02484261 | Monitoring and Treatment of Relapsed Leukemia Following Allogeneic Hematopoietic Stem Cell Transplantation in Children | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02484261?cond=Leukemia&viewType=Card&page=30&rank=293
Leukemia,Information provided by M.D. Anderson Cancer Center (Responsible Party),Completed,Study Results | NCT01752426 | Pilot Study to Determine Effects of the Btk Inhibitor PCI,https://clinicaltrials.gov/study/NCT01752426?cond=Leukemia&viewType=Card&page=30&rank=294&tab=results
Leukemia,Information provided by M.D. Anderson Cancer Center (Responsible Party),Completed,Study Details | NCT01752426 | Pilot Study to Determine Effects of the Btk Inhibitor PCI,https://clinicaltrials.gov/study/NCT01752426?cond=Leukemia&viewType=Card&page=30&rank=294
Leukemia,Information provided by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,Terminated,Study Details | NCT00265915 | Rituximab and GM,https://clinicaltrials.gov/study/NCT00265915?cond=Leukemia&viewType=Card&page=30&rank=295
Leukemia,Information provided by National Cancer Institute (NCI),Completed,Study Details | NCT00021983 | Immunotoxin Therapy in Treating Patients With Hairy Cell Leukemia | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00021983?cond=Leukemia&viewType=Card&page=30&rank=296
Leukemia,Information provided by Eastern Cooperative Oncology Group,Completed,"Study Details | NCT00003808 | Theophylline in Treating Patients With In Situ, Stage I, or Stage II Chronic Lymphocytic Leukemia | ClinicalTrials.gov",https://clinicaltrials.gov/study/NCT00003808?cond=Leukemia&viewType=Card&page=30&rank=297
Leukemia,Information provided by M.D. Anderson Cancer Center (Responsible Party),Completed,Study Results | NCT02196857 | Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3,https://clinicaltrials.gov/study/NCT02196857?cond=Leukemia&viewType=Card&page=30&rank=298&tab=results
Leukemia,Information provided by M.D. Anderson Cancer Center (Responsible Party),Completed,Study Details | NCT02196857 | Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3,https://clinicaltrials.gov/study/NCT02196857?cond=Leukemia&viewType=Card&page=30&rank=298
Leukemia,Information provided by National Cancer Institute (NCI),Completed,Study Details | NCT00004218 | Chemotherapy in Treating Patients With Newly Diagnosed Chronic Lymphocytic Leukemia | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00004218?cond=Leukemia&viewType=Card&page=30&rank=299
Leukemia,Information provided by M.D. Anderson Cancer Center (Responsible Party),Terminated,"Study Details | NCT00038805 | Nonmyeloablative Preparative Regimen Using Mylotarg for Patients With High Risk Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myeloid Leukemia (CML) and Myelodysplastic Syndrome (MDS) | ClinicalTrials.gov",https://clinicaltrials.gov/study/NCT00038805?cond=Leukemia&viewType=Card&page=30&rank=300
Prostate Cancer,"Information provided by Aliaa Bakr Ahmed, Sohag University (Responsible Party)",Inconnu,Study Details | NCT05428319 | Expression of STEAP,https://clinicaltrials.gov/study/NCT05428319?cond=Prostate%20Cancer&viewType=Card&page=1&rank=1
Prostate Cancer,"Information provided by Marianne Jensen Hjermstad, Oslo University Hospital (Responsible Party)",Completed,Study Details | NCT03088202 | PALLiON,https://clinicaltrials.gov/study/NCT03088202?cond=Prostate%20Cancer&viewType=Card&page=1&rank=2
Prostate Cancer,"Information provided by David A. Woodrum, Mayo Clinic (Responsible Party)",Withdrawn,Study Details | NCT01743638 | MR,https://clinicaltrials.gov/study/NCT01743638?cond=Prostate%20Cancer&viewType=Card&page=1&rank=3
Prostate Cancer,"Information provided by David A. Woodrum, Mayo Clinic (Responsible Party)",Active,Study Details | NCT01727284 | MR,https://clinicaltrials.gov/study/NCT01727284?cond=Prostate%20Cancer&viewType=Card&page=1&rank=4
Prostate Cancer,Information provided by Ottawa Hospital Research Institute (Responsible Party),Terminated,Study Details | NCT02177526 | Imaging of High Grade Prostate Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02177526?cond=Prostate%20Cancer&viewType=Card&page=1&rank=5
Prostate Cancer,"Information provided by Bradley (Brad) Stish, Mayo Clinic (Responsible Party)",Active,Study Details | NCT05830838 | Daily Adaptive Post,https://clinicaltrials.gov/study/NCT05830838?cond=Prostate%20Cancer&viewType=Card&page=1&rank=6
Prostate Cancer,Information provided by Yonsei University (Responsible Party),Completed,Study Details | NCT06093971 | Remimazolam Versus Propofol for General Anesthesia Induction in Patients on Renin-angiotensin System Blockers Undergoing Robot,https://clinicaltrials.gov/study/NCT06093971?cond=Prostate%20Cancer&viewType=Card&page=1&rank=7
Prostate Cancer,"Information provided by Dr. Gerard Morton, Sunnybrook Health Sciences Centre (Responsible Party)",Active,Study Details | NCT01890096 | A Phase II Trial of High Dose,https://clinicaltrials.gov/study/NCT01890096?cond=Prostate%20Cancer&viewType=Card&page=1&rank=8
Prostate Cancer,"Information provided by Alfredo Berruti, Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (Responsible Party)",Completed,Study Details | NCT05265988 | Multiparametric Assessment of Bone Response in mCRPC Patients Treated With Cabozantinib | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT05265988?cond=Prostate%20Cancer&viewType=Card&page=1&rank=9
Prostate Cancer,"Information provided by University Health Network, Toronto (Responsible Party)",Active,Study Details | NCT03535831 | PSMA PET Registry (18F,https://clinicaltrials.gov/study/NCT03535831?cond=Prostate%20Cancer&viewType=Card&page=1&rank=10
Prostate Cancer,Information provided by Sunnybrook Health Sciences Centre (Responsible Party),Terminated,Study Details | NCT03323879 | Combined LDR Boost and HDR Whole Gland | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03323879?cond=Prostate%20Cancer&viewType=Card&page=2&rank=11
Prostate Cancer,"Information provided by Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (Responsible Party)",Completed,Study Details | NCT03103724 | A Phase II Study Evaluating the Efficacy of Enzalutamide and the Role of ARv7 in Metastatic Castration Resistant Prostate Cancer (mCRPC) Patients With Visceral Disease. | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03103724?cond=Prostate%20Cancer&viewType=Card&page=2&rank=12
Prostate Cancer,"Information provided by Naveed Haroon, Aga Khan University (Responsible Party)",Completed,Study Details | NCT01939743 | Efficacy of Diclofenac Suppository for Pain Control in Ultrasound Guided Biopsy of Prostate | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01939743?cond=Prostate%20Cancer&viewType=Card&page=2&rank=13
Prostate Cancer,Information provided by Tomsk National Research Medical Center of the Russian Academy of Sciences (Responsible Party),Completed,Study Details | NCT06641219 | Clinical Evaluation of [177Lu]Lu-BQ7876 for Targeting of Prostate,https://clinicaltrials.gov/study/NCT06641219?cond=Prostate%20Cancer&viewType=Card&page=2&rank=14
Prostate Cancer,"Information provided by Rui Yang, Qianfoshan Hospital (Responsible Party)",Active,"Study Details | NCT06929884 | Effectiveness, Safety, and Economic Evaluation of Goserelin Microspheres for Injection and Goserelin Sustained-Release Implants in Prostate Cancer Patients: A Real",https://clinicaltrials.gov/study/NCT06929884?cond=Prostate%20Cancer&viewType=Card&page=2&rank=15
Prostate Cancer,Information provided by Gold Standard Phantoms (Responsible Party),Inconnu,Study Details | NCT06607783 | PRostate Cancer Enhanced Diagnosis by Calibration Technology | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT06607783?cond=Prostate%20Cancer&viewType=Card&page=2&rank=16
Prostate Cancer,Information provided by Jules Bordet Institute (Responsible Party),Withdrawn,Study Details | NCT02810886 | Prospective Evaluation of 68Ga-PSMA PET,https://clinicaltrials.gov/study/NCT02810886?cond=Prostate%20Cancer&viewType=Card&page=2&rank=17
Prostate Cancer,Information provided by Curium US LLC (Responsible Party),Active,Study Details | NCT05204927 | 177Lu-PSMA-I&T for Metastatic Castration,https://clinicaltrials.gov/study/NCT05204927?cond=Prostate%20Cancer&viewType=Card&page=2&rank=18
Prostate Cancer,"Information provided by David M. Schuster, MD, Emory University (Responsible Party)",Completed,Study Results | NCT00917865 | FACBC Positron Emission Tomography/Computed Tomography(PET/CT) Used in the Diagnosis of Primary Prostate Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00917865?cond=Prostate%20Cancer&viewType=Card&page=2&rank=19&tab=results
Prostate Cancer,"Information provided by David M. Schuster, MD, Emory University (Responsible Party)",Terminated,Study Details | NCT00917865 | FACBC Positron Emission Tomography/Computed Tomography(PET/CT) Used in the Diagnosis of Primary Prostate Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00917865?cond=Prostate%20Cancer&viewType=Card&page=2&rank=19
Prostate Cancer,Information provided by First Affiliated Hospital of Fujian Medical University (Responsible Party),Recruiting,Study Details | NCT06437496 | 68Ga-AAZTA-093 PET/CT: First-in,https://clinicaltrials.gov/study/NCT06437496?cond=Prostate%20Cancer&viewType=Card&page=2&rank=20
Prostate Cancer,Information provided by Hopital Foch (Responsible Party),Completed,Study Details | NCT02235142 | Prostatic Cancer Versus Androgen Deficiency | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02235142?cond=Prostate%20Cancer&viewType=Card&page=3&rank=21
Prostate Cancer,Information provided by Case Comprehensive Cancer Center (Responsible Party),Withdrawn,Study Details | NCT04765423 | Fluciclovine (Axumin) PET/CT vs. NaF PET/CT in Prostate Cancer Osseous Metastatic Disease | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT04765423?cond=Prostate%20Cancer&viewType=Card&page=3&rank=22
Prostate Cancer,Information provided by Case Comprehensive Cancer Center (Responsible Party),Withdrawn,Study Details | NCT04696263 | Single-Port Versus Multi,https://clinicaltrials.gov/study/NCT04696263?cond=Prostate%20Cancer&viewType=Card&page=3&rank=23
Prostate Cancer,Information provided by Case Comprehensive Cancer Center (Responsible Party),Recruiting,Study Details | NCT04556045 | Exercise Therapy and Radiation Therapy (EXERT) for Metastatic Prostate Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT04556045?cond=Prostate%20Cancer&viewType=Card&page=3&rank=24
Prostate Cancer,Information provided by Wake Forest University Health Sciences (Responsible Party),Withdrawn,Study Details | NCT03987568 | Characterize Tumor Hypoxia by Magnetic Resonance Imaging | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03987568?cond=Prostate%20Cancer&viewType=Card&page=3&rank=25
Prostate Cancer,Information provided by Fondazione del Piemonte per l'Oncologia (Responsible Party),Recruiting,Study Details | NCT06318559 | Artificial Intelligence 3D Augmented Reality Robot-Assisted-Radical,https://clinicaltrials.gov/study/NCT06318559?cond=Prostate%20Cancer&viewType=Card&page=3&rank=26
Prostate Cancer,Information provided by National Institutes of Health Clinical Center (CC) (National Cancer Institute (NCI)) (Responsible Party),Recruiting,Study Details | NCT05361798 | T-Cell Clonality After Stereotactic Body Radiation Therapy Alone and in Combination With the Immunocytokine M9241 in Localized High- and Intermediate,https://clinicaltrials.gov/study/NCT05361798?cond=Prostate%20Cancer&viewType=Card&page=3&rank=27
Prostate Cancer,Information provided by Case Comprehensive Cancer Center (Responsible Party),Recruiting,Study Details | NCT06150417 | MDRT in Prostate Cancer Treated With Long,https://clinicaltrials.gov/study/NCT06150417?cond=Prostate%20Cancer&viewType=Card&page=3&rank=28
Prostate Cancer,Information provided by Maastricht University Medical Center (Responsible Party),Inconnu,Study Details | NCT06406803 | The Impact of Physical Activity Versus Dietary Energy Restriction on Tumour and Muscle Protein Synthesis in Prostate Cancer Patients | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT06406803?cond=Prostate%20Cancer&viewType=Card&page=3&rank=29
Prostate Cancer,"Information provided by Giuseppe Sanguineti, Regina Elena Cancer Institute (Responsible Party)",Completed,Study Details | NCT04703543 | Evaluating the Role of Both PSMA and 64Cu,https://clinicaltrials.gov/study/NCT04703543?cond=Prostate%20Cancer&viewType=Card&page=3&rank=30
Prostate Cancer,Information provided by Medtechtomarket Consulting Ltd (Responsible Party),Recruiting,Study Details | NCT06554587 | Investigation of Three Biomarkers for the Detection of Prostate Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT06554587?cond=Prostate%20Cancer&viewType=Card&page=4&rank=31
Prostate Cancer,Information provided by Curium US LLC (Responsible Party),Completed,Study Results | NCT05653856 | Cu-64-PSMA,https://clinicaltrials.gov/study/NCT05653856?cond=Prostate%20Cancer&viewType=Card&page=4&rank=32&tab=results
Prostate Cancer,Information provided by Curium US LLC (Responsible Party),Completed,Study Details | NCT05653856 | Cu-64-PSMA,https://clinicaltrials.gov/study/NCT05653856?cond=Prostate%20Cancer&viewType=Card&page=4&rank=32
Prostate Cancer,"Information provided by EDGAR BELTRAN-SUAREZ, Instituto Mexicano del Seguro Social (Responsible Party)",Completed,Study Details | NCT03442075 | Pain Comparison Whit Visual Analog Scale (EVA) Between Four Analgesic Methods During Trans Rectal Prostatic Biopsy | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03442075?cond=Prostate%20Cancer&viewType=Card&page=4&rank=33
Prostate Cancer,"Information provided by Ding-Wei Ye, Fudan University (Responsible Party)",Recruiting,Study Details | NCT05577689 | Novel Therapy Target in Metastatic Prostate Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT05577689?cond=Prostate%20Cancer&viewType=Card&page=4&rank=34
Prostate Cancer,"Information provided by Ted Skolarus, University of Michigan (Responsible Party)",Completed,Study Results | NCT03579680 | De,https://clinicaltrials.gov/study/NCT03579680?cond=Prostate%20Cancer&viewType=Card&page=4&rank=35&tab=results
Prostate Cancer,"Information provided by Ted Skolarus, University of Michigan (Responsible Party)",Completed,Study Details | NCT03579680 | De,https://clinicaltrials.gov/study/NCT03579680?cond=Prostate%20Cancer&viewType=Card&page=4&rank=35
Prostate Cancer,Information provided by Mayo Clinic (Responsible Party),Recruiting,Study Details | NCT06315595 | Improvements in Dynamic Contrast-Enhanced MR Angiography and Perfusion and Non,https://clinicaltrials.gov/study/NCT06315595?cond=Prostate%20Cancer&viewType=Card&page=4&rank=36
Prostate Cancer,Information provided by Cancer Research Antwerp (Responsible Party),Recruiting,Study Details | NCT03899077 | Radiotherapy Combined With a LHRH (Ant)Agonist Versus Apalutamide in Patients With Biochemical Recurrence After RP | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03899077?cond=Prostate%20Cancer&viewType=Card&page=4&rank=37
Prostate Cancer,Information provided by EDAP TMS S.A. (Responsible Party),Active,Study Details | NCT03632980 | Dynamic Focusing Evaluation for Prostate Cancer Treatment | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03632980?cond=Prostate%20Cancer&viewType=Card&page=4&rank=38
Prostate Cancer,Information provided by Luye Pharma Group Ltd. (Responsible Party),Completed,Study Details | NCT03450109 | A Study to Assess LY01005 Versus Goserelin Comparator (ZOLADEX®) in Patients With Prostate Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03450109?cond=Prostate%20Cancer&viewType=Card&page=4&rank=39
Prostate Cancer,"Information provided by Janssen Research & Development, LLC (Responsible Party)",Completed,Study Results | NCT01695135 | A Study of Abiraterone Acetate Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel,https://clinicaltrials.gov/study/NCT01695135?cond=Prostate%20Cancer&viewType=Card&page=4&rank=40&tab=results
Prostate Cancer,"Information provided by Janssen Research & Development, LLC (Responsible Party)",Completed,Study Details | NCT01695135 | A Study of Abiraterone Acetate Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel,https://clinicaltrials.gov/study/NCT01695135?cond=Prostate%20Cancer&viewType=Card&page=4&rank=40
Prostate Cancer,"Information provided by Janssen Research & Development, LLC (Responsible Party)",Completed,"Study Results | NCT01715285 | A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone",https://clinicaltrials.gov/study/NCT01715285?cond=Prostate%20Cancer&viewType=Card&page=5&rank=41&tab=results
Prostate Cancer,"Information provided by Janssen Research & Development, LLC (Responsible Party)",Completed,"Study Details | NCT01715285 | A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone",https://clinicaltrials.gov/study/NCT01715285?cond=Prostate%20Cancer&viewType=Card&page=5&rank=41
Prostate Cancer,"Information provided by Janssen Research & Development, LLC (Responsible Party)",Inconnu,Study Details | NCT01834209 | A Study of Abiraterone Acetate Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration,https://clinicaltrials.gov/study/NCT01834209?cond=Prostate%20Cancer&viewType=Card&page=5&rank=42
Prostate Cancer,Post-marketing Surveillance Study on the Safety and Effectiveness of Abiraterone Acetate Among Adult Filipino Male Patients With Advanced Metastatic Castration Resistant Prostate Cancer,Withdrawn,Study Details | NCT01692483 | Post,https://clinicaltrials.gov/study/NCT01692483?cond=Prostate%20Cancer&viewType=Card&page=5&rank=43
Prostate Cancer,"Information provided by Exosome Diagnostics, Inc. (Responsible Party)",Completed,Study Details | NCT03031418 | Clinical Evaluation of the 'ExoDx Prostate IntelliScore' (EPI) | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03031418?cond=Prostate%20Cancer&viewType=Card&page=5&rank=44
Prostate Cancer,"Information provided by Janssen Research & Development, LLC (Responsible Party)",Completed,Study Details | NCT01664728 | An Expanded Access Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer Who Have Completed Clinical Study COU-AA,https://clinicaltrials.gov/study/NCT01664728?cond=Prostate%20Cancer&viewType=Card&page=5&rank=45
Prostate Cancer,Information provided by Fox Chase Cancer Center (Responsible Party),Completed,Study Results | NCT02614859 | Bicalutamide With or Without Metformin for Biochemical Recurrence in Overweight or Obese Prostate Cancer Patients | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02614859?cond=Prostate%20Cancer&viewType=Card&page=5&rank=46&tab=results
Prostate Cancer,Information provided by Fox Chase Cancer Center (Responsible Party),Completed,Study Details | NCT02614859 | Bicalutamide With or Without Metformin for Biochemical Recurrence in Overweight or Obese Prostate Cancer Patients | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02614859?cond=Prostate%20Cancer&viewType=Card&page=5&rank=46
Prostate Cancer,"Information provided by Janssen Research & Development, LLC (Responsible Party)",Completed,Study Details | NCT00910754 | A QT/QTc and Multi-Dose Pharmacokinetic Study of Abiraterone Acetate Plus Prednisone in Patients With Metastatic Castration,https://clinicaltrials.gov/study/NCT00910754?cond=Prostate%20Cancer&viewType=Card&page=5&rank=47
Prostate Cancer,"Information provided by Cougar Biotechnology, Inc. (Responsible Party)",Completed,Study Details | NCT00600535 | A Pharmacokinetics Study to Assess Abiraterone Acetate Capsule and Tablet Formulations in Patients With Prostate Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00600535?cond=Prostate%20Cancer&viewType=Card&page=5&rank=48
Prostate Cancer,"Information provided by Janssen Research & Development, LLC (Responsible Party)",Completed,Study Details | NCT01017939 | A Drug-Drug Interaction Study of Abiraterone Acetate Plus Prednisone With Dextromethorphan and Theophylline in Patients With Metastatic Castration,https://clinicaltrials.gov/study/NCT01017939?cond=Prostate%20Cancer&viewType=Card&page=5&rank=49
Prostate Cancer,"Information provided by David A. Woodrum, Mayo Clinic (Responsible Party)",Recruiting,Study Details | NCT04797039 | MRI,https://clinicaltrials.gov/study/NCT04797039?cond=Prostate%20Cancer&viewType=Card&page=5&rank=50
Prostate Cancer,"Information provided by Cougar Biotechnology, Inc. (Responsible Party)",Completed,Study Results | NCT00474383 | An Safety and Efficacy Study of Abiraterone Acetate in Participants With Advanced Prostate Cancer Who Failed Androgen Deprivation and Docetaxel,https://clinicaltrials.gov/study/NCT00474383?cond=Prostate%20Cancer&viewType=Card&page=6&rank=51&tab=results
Prostate Cancer,"Information provided by Cougar Biotechnology, Inc. (Responsible Party)",Completed,Study Details | NCT00474383 | An Safety and Efficacy Study of Abiraterone Acetate in Participants With Advanced Prostate Cancer Who Failed Androgen Deprivation and Docetaxel,https://clinicaltrials.gov/study/NCT00474383?cond=Prostate%20Cancer&viewType=Card&page=6&rank=51
Prostate Cancer,Information provided by UNICANCER (Responsible Party),Active,Study Details | NCT03438552 | Efficacy of Repeat Stereotactic Radiation in Patients With Intraprostatic Tumor Recurrence | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03438552?cond=Prostate%20Cancer&viewType=Card&page=6&rank=52
Prostate Cancer,"Information provided by Janssen Research & Development, LLC (Responsible Party)",Completed,Study Results | NCT00473746 | Abiraterone Acetate Dose,https://clinicaltrials.gov/study/NCT00473746?cond=Prostate%20Cancer&viewType=Card&page=6&rank=53&tab=results
Prostate Cancer,"Information provided by Janssen Research & Development, LLC (Responsible Party)",Completed,Study Details | NCT00473746 | Abiraterone Acetate Dose,https://clinicaltrials.gov/study/NCT00473746?cond=Prostate%20Cancer&viewType=Card&page=6&rank=53
Prostate Cancer,"Information provided by Mustafa Serdar CAGLAYAN, Hitit University (Responsible Party)",Inconnu,Study Details | NCT06836271 | Cleaning the Biopsy Needle in TRUS Bx | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT06836271?cond=Prostate%20Cancer&viewType=Card&page=6&rank=54
Prostate Cancer,"Information provided by Janssen Research & Development, LLC (Responsible Party)",Completed,Study Results | NCT00544440 | An Observational Study of Continuous Oral Dosing of Abiraterone Acetate in Castration,https://clinicaltrials.gov/study/NCT00544440?cond=Prostate%20Cancer&viewType=Card&page=6&rank=55&tab=results
Prostate Cancer,"Information provided by Janssen Research & Development, LLC (Responsible Party)",Completed,Study Details | NCT00544440 | An Observational Study of Continuous Oral Dosing of Abiraterone Acetate in Castration,https://clinicaltrials.gov/study/NCT00544440?cond=Prostate%20Cancer&viewType=Card&page=6&rank=55
Prostate Cancer,"Information provided by Hongqian Guo, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School (Responsible Party)",Completed,Study Details | NCT04376008 | A Prospective Study Of Free,https://clinicaltrials.gov/study/NCT04376008?cond=Prostate%20Cancer&viewType=Card&page=6&rank=56
Prostate Cancer,"Information provided by Hongqian Guo, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School (Responsible Party)",Inconnu,Study Details | NCT04124107 | Unfavorable MRI But Favorable 68Ga,https://clinicaltrials.gov/study/NCT04124107?cond=Prostate%20Cancer&viewType=Card&page=6&rank=57
Prostate Cancer,Information provided by Hospices Civils de Lyon (Responsible Party),Completed,Study Details | NCT01639859 | Assessment of Supersonic Imagine Aixplorer for the Detection and Localisation of Prostate Cancer Foci | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01639859?cond=Prostate%20Cancer&viewType=Card&page=6&rank=58
Prostate Cancer,"Information provided by Albert DeNittis, Main Line Health (Responsible Party)",Recruiting,Study Details | NCT01581749 | Evaluation of Truebeam for Low,https://clinicaltrials.gov/study/NCT01581749?cond=Prostate%20Cancer&viewType=Card&page=6&rank=59
Prostate Cancer,Information provided by Radboud University Medical Center (Responsible Party),Completed,Study Details | NCT03828838 | | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03828838?cond=Prostate%20Cancer&viewType=Card&page=6&rank=60
Prostate Cancer,Information provided by Imperial College London (Responsible Party),Completed,Study Results | NCT03702439 | Prostate Cancer Screening Trial Using Imaging | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03702439?cond=Prostate%20Cancer&viewType=Card&page=7&rank=61&tab=results
Prostate Cancer,Information provided by Imperial College London (Responsible Party),Completed,Study Details | NCT03702439 | Prostate Cancer Screening Trial Using Imaging | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03702439?cond=Prostate%20Cancer&viewType=Card&page=7&rank=61
Prostate Cancer,"Information provided by Hongqian Guo, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School (Responsible Party)",Recruiting,Study Details | NCT03572946 | Targeted Biopsy or Standard Biopsy for Clinical Significant Prostate Cancer Detection | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03572946?cond=Prostate%20Cancer&viewType=Card&page=7&rank=62
Prostate Cancer,Information provided by Astellas Pharma Inc (Responsible Party),Completed,Study Details | NCT01228760 | A Study to Determine the Maximum Tolerated Dose of ASG-5ME in Subjects With Castration,https://clinicaltrials.gov/study/NCT01228760?cond=Prostate%20Cancer&viewType=Card&page=7&rank=63
Prostate Cancer,Information provided by Samsung Medical Center (Responsible Party),Active,Study Details | NCT03241537 | COHORT Trial in Clinical Pelivc Lymph Node Metastatic Prostate Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03241537?cond=Prostate%20Cancer&viewType=Card&page=7&rank=64
Prostate Cancer,"Information provided by University Health Network, Toronto",Completed,Study Details | NCT00805883 | MRI Targeted Focal Laser Thermal Therapy of Prostate Cancer Followed by Radical Prostatectomy | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00805883?cond=Prostate%20Cancer&viewType=Card&page=7&rank=65
Prostate Cancer,"Information provided by Jennifer Allen, Tufts University (Responsible Party)",Completed,Study Details | NCT02787434 | Addressing Prostate Cancer Information Disparities With eHealth Technology | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02787434?cond=Prostate%20Cancer&viewType=Card&page=7&rank=66
Prostate Cancer,Information provided by National Institutes of Health Clinical Center (CC),Completed,Study Details | NCT00001266 | A Phase II Trial of Leuprolide + Flutamide + Suramin in Untreated Poor Prognosis Prostate Carcinoma | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00001266?cond=Prostate%20Cancer&viewType=Card&page=7&rank=67
Prostate Cancer,Information provided by Advanced Accelerator Applications (Responsible Party),Terminated,Study Details | NCT03490838 | 177Lu-PSMA,https://clinicaltrials.gov/study/NCT03490838?cond=Prostate%20Cancer&viewType=Card&page=7&rank=68
Prostate Cancer,Information provided by University of Southern California (Responsible Party),Terminated,Study Details | NCT02809690 | 18F,https://clinicaltrials.gov/study/NCT02809690?cond=Prostate%20Cancer&viewType=Card&page=7&rank=69
Prostate Cancer,"Information provided by Teresa Hayes, Baylor College of Medicine (Responsible Party)",Completed,Study Results | NCT00425503 | PS,https://clinicaltrials.gov/study/NCT00425503?cond=Prostate%20Cancer&viewType=Card&page=7&rank=70&tab=results
Prostate Cancer,"Information provided by Teresa Hayes, Baylor College of Medicine (Responsible Party)",Completed,Study Details | NCT00425503 | PS,https://clinicaltrials.gov/study/NCT00425503?cond=Prostate%20Cancer&viewType=Card&page=7&rank=70
Prostate Cancer,Information provided by San Bernardino Urological Associates Medical Group Inc,Completed,"Study Details | NCT00220194 | A Six-Month, Open",https://clinicaltrials.gov/study/NCT00220194?cond=Prostate%20Cancer&viewType=Card&page=8&rank=71
Prostate Cancer,Information provided by Yonsei University (Responsible Party),Recruiting,Study Details | NCT06236789 | Observation Study to Evaluate the Efficacy and Safety of Ifosfamide/Mesna in Patients With Metastatic Castration,https://clinicaltrials.gov/study/NCT06236789?cond=Prostate%20Cancer&viewType=Card&page=8&rank=72
Prostate Cancer,Information provided by Centre Henri Becquerel (Responsible Party),Inconnu,Study Details | NCT06439784 | Contribution of the VERITON,https://clinicaltrials.gov/study/NCT06439784?cond=Prostate%20Cancer&viewType=Card&page=8&rank=73
Prostate Cancer,Information provided by Steba Biotech S.A. (Responsible Party),Completed,Study Details | NCT04017325 | European Randomised Study of TOOKAD® Soluble for Prostate Cancer vs Active Surveillance. Post Study Follow,https://clinicaltrials.gov/study/NCT04017325?cond=Prostate%20Cancer&viewType=Card&page=8&rank=74
Prostate Cancer,"Information provided by Veeru Kasivisvanathan, University College, London (Responsible Party)",Completed,Study Details | NCT02380027 | PRostate Evaluation for Clinically Important Disease: Sampling Using Image,https://clinicaltrials.gov/study/NCT02380027?cond=Prostate%20Cancer&viewType=Card&page=8&rank=75
Prostate Cancer,Information provided by CMX Research (Responsible Party),Completed,Study Details | NCT04057859 | PCa Patients Managed With ADT to Examine the Effect of Nutritional Guidance and Aerobic/Resistance Fitness Training | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT04057859?cond=Prostate%20Cancer&viewType=Card&page=8&rank=76
Prostate Cancer,Information provided by VA Office of Research and Development (Responsible Party),Completed,Study Results | NCT00255125 | Role of Soy Supplementation in Prostate Cancer Development | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00255125?cond=Prostate%20Cancer&viewType=Card&page=8&rank=77&tab=results
Prostate Cancer,Information provided by VA Office of Research and Development (Responsible Party),Completed,Study Details | NCT00255125 | Role of Soy Supplementation in Prostate Cancer Development | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00255125?cond=Prostate%20Cancer&viewType=Card&page=8&rank=77
Prostate Cancer,Information provided by European Institute of Oncology (Responsible Party),Recruiting,Study Details | NCT06059859 | Impact of Augmented Reality During Robot,https://clinicaltrials.gov/study/NCT06059859?cond=Prostate%20Cancer&viewType=Card&page=8&rank=78
Prostate Cancer,"Information provided by Ahmed Mohamed Shebl Mehanna, Menoufia University (Responsible Party)",Completed,Study Details | NCT05969704 | Fusion Versus Cognitive MRI Targeted Prostatic Biopsy | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT05969704?cond=Prostate%20Cancer&viewType=Card&page=8&rank=79
Prostate Cancer,Information provided by Novartis (Novartis Pharmaceuticals) (Responsible Party),Recruiting,Study Details | NCT05849298 | A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT05849298?cond=Prostate%20Cancer&viewType=Card&page=8&rank=80
Prostate Cancer,"Information provided by William Barrett, University of Cincinnati (Responsible Party)",Active,Study Details | NCT03564275 | Proton Boost in Prostate Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03564275?cond=Prostate%20Cancer&viewType=Card&page=9&rank=81
Prostate Cancer,Information provided by Centre Hospitalier Universitaire de Besancon (Responsible Party),Recruiting,Study Details | NCT05612841 | A Study on Drug,https://clinicaltrials.gov/study/NCT05612841?cond=Prostate%20Cancer&viewType=Card&page=9&rank=82
Prostate Cancer,"Information provided by Giuseppe Sanguineti, Regina Elena Cancer Institute (Responsible Party)",Recruiting,Study Details | NCT05667636 | Early Salvage Stereotactic Radiotherapy for Biochemical Failure After RP | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT05667636?cond=Prostate%20Cancer&viewType=Card&page=9&rank=83
Prostate Cancer,Information provided by University of Nebraska (Responsible Party),Recruiting,Study Details | NCT05754580 | High,https://clinicaltrials.gov/study/NCT05754580?cond=Prostate%20Cancer&viewType=Card&page=9&rank=84
Prostate Cancer,"Information provided by Rete Oncologica Piemonte, Valle d'Aosta (Responsible Party)",Completed,"Study Details | NCT03348722 | Active Surveillance or Radical Treatment for Newly Diagnosed Patients With a Localized, Low Risk, Prostate Cancer START | ClinicalTrials.gov",https://clinicaltrials.gov/study/NCT03348722?cond=Prostate%20Cancer&viewType=Card&page=9&rank=85
Prostate Cancer,Information provided by Cleveland BioLabs (Responsible Party),Completed,Study Results | NCT00417274 | Quinacrine Treatment in Patients With Androgen,https://clinicaltrials.gov/study/NCT00417274?cond=Prostate%20Cancer&viewType=Card&page=9&rank=86&tab=results
Prostate Cancer,Information provided by Cleveland BioLabs (Responsible Party),Completed,Study Details | NCT00417274 | Quinacrine Treatment in Patients With Androgen,https://clinicaltrials.gov/study/NCT00417274?cond=Prostate%20Cancer&viewType=Card&page=9&rank=86
Prostate Cancer,"Information provided by Konstantinos Pikramenos, Sismanoglio General Hospital (Responsible Party)",Completed,Study Details | NCT05566405 | The Effects of Method of Anaesthesia on the Safety and Effectiveness of Radical Retropubic Prostatectomy | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT05566405?cond=Prostate%20Cancer&viewType=Card&page=9&rank=87
Prostate Cancer,Information provided by Guy's and St Thomas' NHS Foundation Trust (Responsible Party),Active,Study Details | NCT03238170 | MR,https://clinicaltrials.gov/study/NCT03238170?cond=Prostate%20Cancer&viewType=Card&page=9&rank=88
Prostate Cancer,"Information provided by Kim Chi, British Columbia Cancer Agency (Responsible Party)",Inconnu,Study Details | NCT01630967 | Efficacy Study of Switching to a Lutenizing Hormone,https://clinicaltrials.gov/study/NCT01630967?cond=Prostate%20Cancer&viewType=Card&page=9&rank=89
Prostate Cancer,Information provided by Singapore General Hospital (Responsible Party),Completed,Study Details | NCT03124433 | Neoadjuvant Apalutamide (ARN509) and Radical Prostatectomy in Treatment of Intermediate to High Risk Prostate Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03124433?cond=Prostate%20Cancer&viewType=Card&page=9&rank=90
Prostate Cancer,"Information provided by Exosome Diagnostics, Inc. (Responsible Party)",Active,Study Details | NCT03235687 | Decision Impact Trial of the ExoDx Prostate (IntelliScore) | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03235687?cond=Prostate%20Cancer&viewType=Card&page=10&rank=91
Prostate Cancer,Information provided by The Netherlands Cancer Institute (Responsible Party),Completed,Study Details | NCT05162573 | EBRT + Lu,https://clinicaltrials.gov/study/NCT05162573?cond=Prostate%20Cancer&viewType=Card&page=10&rank=92
Prostate Cancer,"Information provided by Chunjing Yu, Affiliated Hospital of Jiangnan University (Responsible Party)",Recruiting,Study Details | NCT05623878 | 68Ga,https://clinicaltrials.gov/study/NCT05623878?cond=Prostate%20Cancer&viewType=Card&page=10&rank=93
Prostate Cancer,Information provided by University of Michigan Rogel Cancer Center (Responsible Party),Completed,Study Results | NCT02958787 | Vessel Sparing Prostate Radiation Therapy | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02958787?cond=Prostate%20Cancer&viewType=Card&page=10&rank=94&tab=results
Prostate Cancer,Information provided by University of Michigan Rogel Cancer Center (Responsible Party),Completed,Study Details | NCT02958787 | Vessel Sparing Prostate Radiation Therapy | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02958787?cond=Prostate%20Cancer&viewType=Card&page=10&rank=94
Prostate Cancer,"Information provided by Karen Kurdziel, M.D., National Institutes of Health Clinical Center (CC) (Responsible Party)",Completed,Study Results | NCT01240551 | F,https://clinicaltrials.gov/study/NCT01240551?cond=Prostate%20Cancer&viewType=Card&page=10&rank=95&tab=results
Prostate Cancer,"Information provided by Karen Kurdziel, M.D., National Institutes of Health Clinical Center (CC) (Responsible Party)",Completed,Study Details | NCT01240551 | F,https://clinicaltrials.gov/study/NCT01240551?cond=Prostate%20Cancer&viewType=Card&page=10&rank=95
Prostate Cancer,Information provided by University Hospitals of North Midlands NHS Trust (Responsible Party),Completed,Study Details | NCT02939456 | Comparison Of DIR-MRI And DCE,https://clinicaltrials.gov/study/NCT02939456?cond=Prostate%20Cancer&viewType=Card&page=10&rank=96
Prostate Cancer,Information provided by Hospices Civils de Lyon (Responsible Party),Recruiting,Study Details | NCT02879851 | Evaluation of the Accuracy of the Elastic Fusion MRI,https://clinicaltrials.gov/study/NCT02879851?cond=Prostate%20Cancer&viewType=Card&page=10&rank=97
Prostate Cancer,"Information provided by Giuseppe Sanguineti, Regina Elena Cancer Institute (Responsible Party)",Recruiting,Study Details | NCT04774133 | The Immunodynamic Effect of Radiotherapy in Prostate Cancer Patients. | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT04774133?cond=Prostate%20Cancer&viewType=Card&page=10&rank=98
Prostate Cancer,Information provided by Blue Earth Diagnostics (Responsible Party),Completed,Study Results | NCT02578940 | Fluciclovine (18F) PET/CT in biochemicAL reCurrence Of Prostate caNcer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02578940?cond=Prostate%20Cancer&viewType=Card&page=10&rank=99&tab=results
Prostate Cancer,Information provided by Blue Earth Diagnostics (Responsible Party),Completed,Study Details | NCT02578940 | Fluciclovine (18F) PET/CT in biochemicAL reCurrence Of Prostate caNcer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02578940?cond=Prostate%20Cancer&viewType=Card&page=10&rank=99
Prostate Cancer,"Information provided by David Büchser, Biocruces Bizkaia Health Research Institute (Responsible Party)",Recruiting,Study Details | NCT04523896 | HDR Brachytherapy Plus Stereotactic Ablative Prostate Radiotherapy for Patients With Intermediate and High,https://clinicaltrials.gov/study/NCT04523896?cond=Prostate%20Cancer&viewType=Card&page=10&rank=100
Prostate Cancer,"Information provided by Anders Frey, Herlev Hospital (Responsible Party)",Recruiting,Study Details | NCT02274350 | The Herlev Hospital Post Radiation Therapy for Localized Prostate Cancer Database for Sexual Side Effects | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02274350?cond=Prostate%20Cancer&viewType=Card&page=11&rank=101
Prostate Cancer,Information provided by Fondazione del Piemonte per l'Oncologia (Responsible Party),Completed,Study Details | NCT04398173 | Detection Rate of Prostate Cancer in Men Undergoing MRI | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT04398173?cond=Prostate%20Cancer&viewType=Card&page=11&rank=102
Prostate Cancer,"Information provided by BHR Pharma, LLC (Responsible Party)",Completed,Study Results | NCT02349386 | Maintaining Suppression of Testosterone With Transdermal Estradiol Gel | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02349386?cond=Prostate%20Cancer&viewType=Card&page=11&rank=103&tab=results
Prostate Cancer,"Information provided by BHR Pharma, LLC (Responsible Party)",Terminated,Study Details | NCT02349386 | Maintaining Suppression of Testosterone With Transdermal Estradiol Gel | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02349386?cond=Prostate%20Cancer&viewType=Card&page=11&rank=103
Prostate Cancer,"Information provided by Farrokh Dehdashti, Washington University School of Medicine (Responsible Party)",Inconnu,Study Details | NCT02355054 | Detecting Recurrent Prostate Cancer With C,https://clinicaltrials.gov/study/NCT02355054?cond=Prostate%20Cancer&viewType=Card&page=11&rank=104
Prostate Cancer,Information provided by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (Responsible Party),Completed,Study Details | NCT04266431 | EMPOWER Men to Reduce Weight and Inhibit Prostate Cancer Progression | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT04266431?cond=Prostate%20Cancer&viewType=Card&page=11&rank=105
Prostate Cancer,"Information provided by Professor Thomas Eade, Royal North Shore Hospital (Responsible Party)",Completed,Study Details | NCT02212548 | Prostate,https://clinicaltrials.gov/study/NCT02212548?cond=Prostate%20Cancer&viewType=Card&page=11&rank=106
Prostate Cancer,Information provided by Hospices Civils de Lyon (Responsible Party),Completed,Study Details | NCT04421781 | Salvage HIFU for Local Recurrence in the Prostatic Bed After Prostatectomy and External Beam Radiation Therapy : Preliminary Results | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT04421781?cond=Prostate%20Cancer&viewType=Card&page=11&rank=107
Prostate Cancer,"Information provided by Prof. Dr. Silke Gillessen, Cantonal Hospital of St. Gallen (Responsible Party)",Completed,Study Details | NCT01897207 | Phase I/II Study of Vaccination With Antigen Loaded Dendritic Cells (DCs) in Hormone,https://clinicaltrials.gov/study/NCT01897207?cond=Prostate%20Cancer&viewType=Card&page=11&rank=108
Prostate Cancer,Information provided by Centre Hospitalier Universitaire de Nice (Responsible Party),Completed,Study Details | NCT03947515 | Urinary and Prostate Microbiotes and Prostate Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03947515?cond=Prostate%20Cancer&viewType=Card&page=11&rank=109
Prostate Cancer,Information provided by British Columbia Cancer Agency (Responsible Party),Withdrawn,Study Details | NCT04495959 | Dynamic Whole Body PET/ MRI | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT04495959?cond=Prostate%20Cancer&viewType=Card&page=11&rank=110
Prostate Cancer,Information provided by Centre Antoine Lacassagne (Responsible Party),Terminated,Study Details | NCT03952793 | Organoids From Metastases of Prostate Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03952793?cond=Prostate%20Cancer&viewType=Card&page=12&rank=111
Prostate Cancer,"Information provided by Dmitriy Akselrod, MD, University of Vermont (Responsible Party)",Terminated,"Study Details | NCT04234399 | Determination of the Diagnostic Detection Rate of Axumin (Fluciclovine) Digital PET/CT, Post",https://clinicaltrials.gov/study/NCT04234399?cond=Prostate%20Cancer&viewType=Card&page=12&rank=112
Prostate Cancer,Information provided by Fondazione del Piemonte per l'Oncologia (Responsible Party),Completed,Study Details | NCT03693703 | Comparison of Multi-parametric and Bi,https://clinicaltrials.gov/study/NCT03693703?cond=Prostate%20Cancer&viewType=Card&page=12&rank=113
Prostate Cancer,"Information provided by Jarle Jakobsen, Norwegian Institute of Public Health (Responsible Party)",Active,Study Details | NCT03893123 | Prostate Cancer Risk in Firefighters | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03893123?cond=Prostate%20Cancer&viewType=Card&page=12&rank=114
Prostate Cancer,"Information provided by Anders Widmark, Umeå University (Responsible Party)",Active,Study Details | NCT01787630 | To Evaluate the Technique and Effects of Separating the Prostate and Rectum With Hyaluronic Acid During Radiotherapy | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01787630?cond=Prostate%20Cancer&viewType=Card&page=12&rank=115
Prostate Cancer,"Information provided by Susan Steck, University of South Carolina (Responsible Party)",Completed,Study Details | NCT03289130 | Dietary Factors and Racial Disparities in Prostate Cancer Aggressiveness | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03289130?cond=Prostate%20Cancer&viewType=Card&page=12&rank=116
Prostate Cancer,Information provided by CMX Research (Responsible Party),Completed,Study Details | NCT00992251 | Eligard Observational Registry for Patients With Prostate Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00992251?cond=Prostate%20Cancer&viewType=Card&page=12&rank=117
Prostate Cancer,Information provided by The University of Texas Health Science Center at San Antonio (Responsible Party),Completed,Study Details | NCT03397030 | Impact of Exercise on Prognostic Biomarkers Related to Prostate Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03397030?cond=Prostate%20Cancer&viewType=Card&page=12&rank=118
Prostate Cancer,Information provided by Cliniques universitaires Saint-Luc- Université Catholique de Louvain (Responsible Party),Completed,Study Details | NCT03183544 | Dosimetry and Safety Phase 1 Study With 68Ga-PSMA,https://clinicaltrials.gov/study/NCT03183544?cond=Prostate%20Cancer&viewType=Card&page=12&rank=119
Prostate Cancer,"Information provided by Flemming Forsberg, Thomas Jefferson University (Responsible Party)",Completed,"Study Results | NCT02967458 | Detection of High Grade Prostate Cancer With Subharmonic Ultrasound Imaging, A Pilot Study | ClinicalTrials.gov",https://clinicaltrials.gov/study/NCT02967458?cond=Prostate%20Cancer&viewType=Card&page=12&rank=120&tab=results
Prostate Cancer,"Information provided by Flemming Forsberg, Thomas Jefferson University (Responsible Party)",Completed,"Study Details | NCT02967458 | Detection of High Grade Prostate Cancer With Subharmonic Ultrasound Imaging, A Pilot Study | ClinicalTrials.gov",https://clinicaltrials.gov/study/NCT02967458?cond=Prostate%20Cancer&viewType=Card&page=12&rank=120
Prostate Cancer,Information provided by Pantarhei Oncology B.V. (Responsible Party),Completed,Study Details | NCT03361969 | Evaluation of Effects of Estetrol on Testosterone Suppression and Quality of Life in Prostate Cancer Patients Treated With an LHRH Agonist. | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03361969?cond=Prostate%20Cancer&viewType=Card&page=13&rank=121
Prostate Cancer,Information provided by University of Minnesota (Responsible Party),Completed,Study Results | NCT03343093 | Restore: Improving Sexual Outcomes of Gay and Bisexual Prostate Cancer Survivors | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03343093?cond=Prostate%20Cancer&viewType=Card&page=13&rank=122&tab=results
Prostate Cancer,Information provided by University of Minnesota (Responsible Party),Completed,Study Details | NCT03343093 | Restore: Improving Sexual Outcomes of Gay and Bisexual Prostate Cancer Survivors | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03343093?cond=Prostate%20Cancer&viewType=Card&page=13&rank=122
Prostate Cancer,Information provided by Samsung Medical Center,Completed,Study Details | NCT01171729 | Autologous Dendritic Cell Therapy for Hormone,https://clinicaltrials.gov/study/NCT01171729?cond=Prostate%20Cancer&viewType=Card&page=13&rank=123
Prostate Cancer,"Information provided by Park, Se-Hoon, Samsung Medical Center (Responsible Party)",Active,Study Details | NCT03061643 | An Open Label Phase II Study of Biweekly Docetaxel Plus Androgen-Deprivation Therapy in Patients With Previously,https://clinicaltrials.gov/study/NCT03061643?cond=Prostate%20Cancer&viewType=Card&page=13&rank=124
Prostate Cancer,Information provided by Bayer (Responsible Party),Completed,Study Details | NCT02729103 | Treatment Patterns in Metastatic Prostate Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02729103?cond=Prostate%20Cancer&viewType=Card&page=13&rank=125
Prostate Cancer,Information provided by Yonsei University,Completed,Study Details | NCT01086956 | Effect of Adding Sufentanil to Epidural Ropivacaine on Perioperative Metabolic and Stress Responses in Combined General/Epidural Anaesthesia for Geriatric Radical Retropubic Prostatectomy | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01086956?cond=Prostate%20Cancer&viewType=Card&page=13&rank=126
Prostate Cancer,"Information provided by Peter Gann, University of Illinois at Chicago (Responsible Party)",Completed,Study Results | NCT01443026 | The Effects of Lycopene on High Risk Prostatic Tissue | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01443026?cond=Prostate%20Cancer&viewType=Card&page=13&rank=127&tab=results
Prostate Cancer,"Information provided by Peter Gann, University of Illinois at Chicago (Responsible Party)",Completed,Study Details | NCT01443026 | The Effects of Lycopene on High Risk Prostatic Tissue | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01443026?cond=Prostate%20Cancer&viewType=Card&page=13&rank=127
Prostate Cancer,Information provided by Assistance Publique - Hôpitaux de Paris (Responsible Party),Recruiting,Study Details | NCT00502723 | Multicentric Study Comparing Carcinological and Functional Results of Surgery | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00502723?cond=Prostate%20Cancer&viewType=Card&page=13&rank=128
Prostate Cancer,"Information provided by José Luis Ponce Díaz-Reixa, Complexo Hospitalario Universitario de A Coruña (Responsible Party)",Completed,Study Details | NCT02909049 | Clinical Trial to Examine Individual Pain Tolerance in the Use of Two Anesthetic Techniques to Perform Saturation Prostate Biopsy | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02909049?cond=Prostate%20Cancer&viewType=Card&page=13&rank=129
Prostate Cancer,"Information provided by Aurelius Omlin, Cantonal Hospital of St. Gallen (Responsible Party)",Terminated,Study Details | NCT02311764 | Carboplatin in Castration,https://clinicaltrials.gov/study/NCT02311764?cond=Prostate%20Cancer&viewType=Card&page=13&rank=130
Prostate Cancer,Information provided by AstraZeneca (Responsible Party),Completed,Study Details | NCT01284608 | Metabolic Changes in Prostate Cancer Patients With Androgen,https://clinicaltrials.gov/study/NCT01284608?cond=Prostate%20Cancer&viewType=Card&page=14&rank=131
Prostate Cancer,"Information provided by Ove Andrén, Örebro University, Sweden (Responsible Party)",Completed,Study Details | NCT01696539 | Steps for PRosTAte Cancer Health and Survival (SPaRTACuS): Pilot Study of a Walking Intervention to Improve Health and Quality of Life in Prostate Cancer Patients | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01696539?cond=Prostate%20Cancer&viewType=Card&page=14&rank=132
Prostate Cancer,Information provided by AHS Cancer Control Alberta (Responsible Party),Terminated,Study Details | NCT01996696 | Prevention of Metabolic Syndrome and Increased Weight Using Metformin Concurrent to Androgen Deprivation Therapy and Radiotherapy for Locally Advanced Adenocarcinoma of the Prostate | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01996696?cond=Prostate%20Cancer&viewType=Card&page=14&rank=133
Prostate Cancer,Information provided by Abbott (Responsible Party),Completed,Study Results | NCT01081873 | Study to Document Treatment Patterns and to Evaluate Leuprolide and Alternative Therapeutic Approaches to the Treatments of Advanced Prostate Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01081873?cond=Prostate%20Cancer&viewType=Card&page=14&rank=134&tab=results
Prostate Cancer,Information provided by Abbott (Responsible Party),Completed,Study Details | NCT01081873 | Study to Document Treatment Patterns and to Evaluate Leuprolide and Alternative Therapeutic Approaches to the Treatments of Advanced Prostate Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01081873?cond=Prostate%20Cancer&viewType=Card&page=14&rank=134
Prostate Cancer,Information provided by Maria Sklodowska-Curie National Research Institute of Oncology (Responsible Party),Recruiting,Study Details | NCT06201078 | Stereotactic Re,https://clinicaltrials.gov/study/NCT06201078?cond=Prostate%20Cancer&viewType=Card&page=14&rank=135
Prostate Cancer,Information provided by Mayo Clinic,Completed,Study Details | NCT00956228 | Study of Radioimmunoguided Intensity Modulated Radiotherapy (IMRT) for Prostate Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00956228?cond=Prostate%20Cancer&viewType=Card&page=14&rank=136
Prostate Cancer,"Information provided by Geoffrey Weinstein, M.D., Sharp HealthCare (Responsible Party)",Completed,Study Results | NCT01540994 | Stereotactic Body Radiation Therapy (SBRT) for Prostate Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01540994?cond=Prostate%20Cancer&viewType=Card&page=14&rank=137&tab=results
Prostate Cancer,"Information provided by Geoffrey Weinstein, M.D., Sharp HealthCare (Responsible Party)",Completed,Study Details | NCT01540994 | Stereotactic Body Radiation Therapy (SBRT) for Prostate Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01540994?cond=Prostate%20Cancer&viewType=Card&page=14&rank=137
Prostate Cancer,Information provided by Debiopharm International SA (Responsible Party),Completed,Study Results | NCT00751790 | Efficacy and Safety of a Triptorelin 6,https://clinicaltrials.gov/study/NCT00751790?cond=Prostate%20Cancer&viewType=Card&page=14&rank=138&tab=results
Prostate Cancer,Information provided by Debiopharm International SA (Responsible Party),Completed,Study Details | NCT00751790 | Efficacy and Safety of a Triptorelin 6,https://clinicaltrials.gov/study/NCT00751790?cond=Prostate%20Cancer&viewType=Card&page=14&rank=138
Prostate Cancer,"Information provided by Enzon Pharmaceuticals, Inc. (Responsible Party)",Inconnu,"Study Details | NCT01337518 | A Phase 1a/1b Study to Evaluate the Safety of EZN-4176, in Adult Patients With Castration",https://clinicaltrials.gov/study/NCT01337518?cond=Prostate%20Cancer&viewType=Card&page=14&rank=139
Prostate Cancer,"Information provided by University Health Network, Toronto (Responsible Party)",Completed,Study Details | NCT00252460 | CT/MRI Co,https://clinicaltrials.gov/study/NCT00252460?cond=Prostate%20Cancer&viewType=Card&page=14&rank=140
Prostate Cancer,"Information provided by Gregory Merrick, M.D., Schiffler Cancer Center (Responsible Party)",Completed,Study Details | NCT00247312 | Pd-103 Dose De,https://clinicaltrials.gov/study/NCT00247312?cond=Prostate%20Cancer&viewType=Card&page=15&rank=141
Prostate Cancer,Information provided by Sanofi,Completed,Study Details | NCT00174863 | Evaluation of SR 31747A Versus Placebo in Androgen,https://clinicaltrials.gov/study/NCT00174863?cond=Prostate%20Cancer&viewType=Card&page=15&rank=142
Prostate Cancer,"Information provided by University Health Network, Toronto",Completed,Study Details | NCT00252447 | Preop Conformal Radiotherapy,https://clinicaltrials.gov/study/NCT00252447?cond=Prostate%20Cancer&viewType=Card&page=15&rank=143
Prostate Cancer,Information provided by AHS Cancer Control Alberta (Responsible Party),Completed,Study Details | NCT00126854 | High Field Magnetic Resonance Spectroscopy Imaging for Follow Up of Prostate Cancer Post Brachytherapy Implantation | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00126854?cond=Prostate%20Cancer&viewType=Card&page=15&rank=144
Prostate Cancer,Information provided by National Institutes of Health Clinical Center (CC),Completed,Study Details | NCT00001446 | A Randomized Phase II Study of Oral Thalidomide in Patients With Hormone,https://clinicaltrials.gov/study/NCT00001446?cond=Prostate%20Cancer&viewType=Card&page=15&rank=145
Prostate Cancer,Information provided by University of Pittsburgh,Completed,Study Details | NCT00178113 | A Pilot Study of Lycopene Supplementation in Prostatic Intraepithelial Neoplasia | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00178113?cond=Prostate%20Cancer&viewType=Card&page=15&rank=146
Prostate Cancer,Information provided by Technical University of Munich (Responsible Party),Recruiting,"Study Details | NCT06859203 | A Prospective, Bicentric Evaluation of Fluciclovine PET-imaging in Patients with Prior Negative or Inconclusive PSMA",https://clinicaltrials.gov/study/NCT06859203?cond=Prostate%20Cancer&viewType=Card&page=15&rank=147
Prostate Cancer,"Information provided by Sylvie Lambert, St. Mary's Research Center, Canada (Responsible Party)",Completed,"Study Details | NCT04304196 | Tailored, wEb-based, Psychosocial and Physical Activity Self",https://clinicaltrials.gov/study/NCT04304196?cond=Prostate%20Cancer&viewType=Card&page=15&rank=148
Prostate Cancer,"Information provided by Fan Feng, Nanjing University School of Medicine (Responsible Party)",Completed,Study Details | NCT06020287 | The Robot,https://clinicaltrials.gov/study/NCT06020287?cond=Prostate%20Cancer&viewType=Card&page=15&rank=149
Prostate Cancer,"Information provided by Christoffer Johansen, Danish Cancer Society (Responsible Party)",Completed,Study Details | NCT03444532 | Feasibility Study Testing a Sleep Intervention in Prostate Cancer Patients With Insomnia | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03444532?cond=Prostate%20Cancer&viewType=Card&page=15&rank=150
Prostate Cancer,Information provided by National Taiwan University Hospital (Responsible Party),Recruiting,Study Details | NCT05048537 | 18F,https://clinicaltrials.gov/study/NCT05048537?cond=Prostate%20Cancer&viewType=Card&page=16&rank=151
Prostate Cancer,"Information provided by Sylvie Lambert, St. Mary's Research Center, Canada (Responsible Party)",Recruiting,Study Details | NCT06363266 | A SMART Design to Optimize the Delivery of TEMPO for Men With Prostate Cancer and Their Caregivers | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT06363266?cond=Prostate%20Cancer&viewType=Card&page=16&rank=152
Prostate Cancer,Information provided by Quadram Institute Bioscience,Completed,"Study Details | NCT00535977 | Broccoli, Peas and PIN | ClinicalTrials.gov",https://clinicaltrials.gov/study/NCT00535977?cond=Prostate%20Cancer&viewType=Card&page=16&rank=153
Prostate Cancer,Information provided by National Institutes of Health Clinical Center (CC) (National Cancer Institute (NCI)) (Responsible Party),Recruiting,Study Details | NCT04633252 | M9241 in Combination With Docetaxel in Adults With Metastatic Castration Sensitive and Castration Resistant Prostate Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT04633252?cond=Prostate%20Cancer&viewType=Card&page=16&rank=154
Prostate Cancer,Information provided by AstraZeneca (Responsible Party),Completed,Study Details | NCT04801186 | Retrospective Study to Describe the Real-world Treatment Patterns and Associated Clinical Outcomes in Patients With Metastatic Castration,https://clinicaltrials.gov/study/NCT04801186?cond=Prostate%20Cancer&viewType=Card&page=16&rank=155
Prostate Cancer,Information provided by AHS Cancer Control Alberta (Responsible Party),Terminated,Study Details | NCT05712174 | A Study of [18]F-PSMA,https://clinicaltrials.gov/study/NCT05712174?cond=Prostate%20Cancer&viewType=Card&page=16&rank=156
Prostate Cancer,Information provided by Clarity Pharmaceuticals Ltd (Responsible Party),Completed,Study Results | NCT05407311 | 64Cu-SAR,https://clinicaltrials.gov/study/NCT05407311?cond=Prostate%20Cancer&viewType=Card&page=16&rank=157&tab=results
Prostate Cancer,Information provided by Clarity Pharmaceuticals Ltd (Responsible Party),Completed,Study Details | NCT05407311 | 64Cu-SAR,https://clinicaltrials.gov/study/NCT05407311?cond=Prostate%20Cancer&viewType=Card&page=16&rank=157
Prostate Cancer,Information provided by Clarity Pharmaceuticals Ltd (Responsible Party),Completed,Study Results | NCT05249127 | 64Cu-SAR,https://clinicaltrials.gov/study/NCT05249127?cond=Prostate%20Cancer&viewType=Card&page=16&rank=158&tab=results
Prostate Cancer,Information provided by Clarity Pharmaceuticals Ltd (Responsible Party),Completed,Study Details | NCT05249127 | 64Cu-SAR,https://clinicaltrials.gov/study/NCT05249127?cond=Prostate%20Cancer&viewType=Card&page=16&rank=158
Prostate Cancer,"Information provided by Bruce Montgomery, University of Washington (Responsible Party)",Completed,Study Results | NCT00298155 | Maximal Suppression of the Androgen Axis in Clinically Localized Prostate Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00298155?cond=Prostate%20Cancer&viewType=Card&page=16&rank=159&tab=results
Prostate Cancer,"Information provided by Bruce Montgomery, University of Washington (Responsible Party)",Completed,Study Details | NCT00298155 | Maximal Suppression of the Androgen Axis in Clinically Localized Prostate Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00298155?cond=Prostate%20Cancer&viewType=Card&page=16&rank=159
Prostate Cancer,"Information provided by Sung Kyu Hong, Seoul National University Hospital (Responsible Party)",Recruiting,Study Details | NCT02436122 | Impact of Preoperative HbA1c Levels on Pathologic Features and Oncological Outcomes in the Patients With Prostate Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02436122?cond=Prostate%20Cancer&viewType=Card&page=16&rank=160
Prostate Cancer,Information provided by University of Washington,Completed,Study Details | NCT00167648 | Neoadjuvant Estradiol or Androgen Deprivation in Clinically Localized Prostate Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00167648?cond=Prostate%20Cancer&viewType=Card&page=17&rank=161
Prostate Cancer,Information provided by GTx,Completed,Study Details | NCT00028353 | A Chemoprevention Study of an Investigational Drug in Men With High Grade Prostate Intraepithelial Neoplasia (PIN) | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00028353?cond=Prostate%20Cancer&viewType=Card&page=17&rank=162
Prostate Cancer,Information provided by Jonsson Comprehensive Cancer Center (Responsible Party),Active,Study Details | NCT04457232 | Prospective Exploratory Study of FAPi PET/CT in Prostate Cancer With Histopathology Validation | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT04457232?cond=Prostate%20Cancer&viewType=Card&page=17&rank=163
Prostate Cancer,"Information provided by University Hospital, Basel, Switzerland (Responsible Party)",Recruiting,Study Details | NCT06776172 | Extended vs. No Pelvic Lymph Node Dissection During Radical Prostatectomy. DISSECTION 2.0. | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT06776172?cond=Prostate%20Cancer&viewType=Card&page=17&rank=164
Prostate Cancer,Information provided by Yale University (Responsible Party),Completed,Study Details | NCT03285048 | Cognitive Remediation Therapy (CRT) for Adults Treated for Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03285048?cond=Prostate%20Cancer&viewType=Card&page=17&rank=165
Prostate Cancer,"Information provided by Thomas Zilli, University Hospital, Geneva (Responsible Party)",Active,Study Details | NCT01764646 | Hypofractionated Radiation Therapy in Prostate Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01764646?cond=Prostate%20Cancer&viewType=Card&page=17&rank=166
Prostate Cancer,Information provided by Taipei Medical University (Responsible Party),Completed,Study Details | NCT03475433 | An Observational Prospective Cohort Study Using an Actigraphy Device. | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03475433?cond=Prostate%20Cancer&viewType=Card&page=17&rank=167
Prostate Cancer,Information provided by ATGen Canada Inc (Responsible Party),Terminated,Study Details | NCT03242265 | Measurement of Natural Killer Cell Activity in Whole Blood in Men Being Screened for Prostate Cancer With Biopsy | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03242265?cond=Prostate%20Cancer&viewType=Card&page=17&rank=168
Prostate Cancer,Information provided by Tampere University Hospital (Responsible Party),Completed,Study Details | NCT02526589 | Does Bloody Urine Predict Urethrovesical Anastomosis Leakage After Radical Prostatectomy | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02526589?cond=Prostate%20Cancer&viewType=Card&page=17&rank=169
Prostate Cancer,"Information provided by Christer Ericsson, Sormland County Council, Sweden (Responsible Party)",Inconnu,Study Details | NCT04101305 | Measurement of Circulating Tumor Cells in Prostate Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT04101305?cond=Prostate%20Cancer&viewType=Card&page=17&rank=170
Prostate Cancer,Information provided by University Hospital Tuebingen (Responsible Party),Recruiting,Study Details | NCT04104607 | The Bispecific PSMAxCD3 Antibody CC,https://clinicaltrials.gov/study/NCT04104607?cond=Prostate%20Cancer&viewType=Card&page=18&rank=171
Prostate Cancer,"Information provided by Ester Forastiere, Regina Elena Cancer Institute (Responsible Party)",Completed,Study Details | NCT01998685 | Prothrombotic Factors and Anaesthesia in Prostate Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01998685?cond=Prostate%20Cancer&viewType=Card&page=18&rank=172
Prostate Cancer,Information provided by Radboud University Medical Center (Responsible Party),Recruiting,Study Details | NCT06223295 | Effectiveness of Focal Therapy in Men With Prostate Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT06223295?cond=Prostate%20Cancer&viewType=Card&page=18&rank=173
Prostate Cancer,Information provided by British Columbia Cancer Agency (Responsible Party),Active,Study Details | NCT04484701 | [68Ga]Ga-PSMA,https://clinicaltrials.gov/study/NCT04484701?cond=Prostate%20Cancer&viewType=Card&page=18&rank=174
Prostate Cancer,"Information provided by Volkan Selmi, Bozok University (Responsible Party)",Completed,Study Details | NCT07006779 | Effects of Music and Conversation in Prostate Biopsy | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT07006779?cond=Prostate%20Cancer&viewType=Card&page=18&rank=175
Prostate Cancer,"Information provided by Fabricio Borges Carrerette, Rio de Janeiro State University (Responsible Party)",Completed,Study Details | NCT02687308 | Open Anterograde Radical Prostatectomy Compared to Open Retrograde Technique | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02687308?cond=Prostate%20Cancer&viewType=Card&page=18&rank=176
Prostate Cancer,"Information provided by Fuda Cancer Hospital, Guangzhou (Responsible Party)",Withdrawn,Study Details | NCT02430649 | Irreversible Electroporation(IRE) For Unresectable Prostatic Neoplasms | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02430649?cond=Prostate%20Cancer&viewType=Card&page=18&rank=177
Prostate Cancer,Information provided by Washington University School of Medicine (Responsible Party),Recruiting,Study Details | NCT04887935 | Neoadjuvant SGLT2 Inhibition in Localized Prostate Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT04887935?cond=Prostate%20Cancer&viewType=Card&page=18&rank=178
Prostate Cancer,"Information provided by Stephen Langley, Royal Surrey County Hospital NHS Foundation Trust (Responsible Party)",Completed,Study Details | NCT02632669 | Hemi,https://clinicaltrials.gov/study/NCT02632669?cond=Prostate%20Cancer&viewType=Card&page=18&rank=179
Prostate Cancer,"Information provided by University Health Network, Toronto",Completed,Study Details | NCT00152789 | Normal Prostate: Oxygenation of the Prostate Gland in Men Undergoing Prostate Biopsy | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00152789?cond=Prostate%20Cancer&viewType=Card&page=18&rank=180
Prostate Cancer,Information provided by OHSU Knight Cancer Institute (Responsible Party),Completed,Study Details | NCT00660686 | Exercise for Physical Health in Men With Prostate Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00660686?cond=Prostate%20Cancer&viewType=Card&page=19&rank=181
Prostate Cancer,Information provided by Hospices Civils de Lyon (Responsible Party),Recruiting,Study Details | NCT05714774 | Evaluation of Different Methods of Ultrasound Image Analysis for Real,https://clinicaltrials.gov/study/NCT05714774?cond=Prostate%20Cancer&viewType=Card&page=19&rank=182
Prostate Cancer,"Information provided by Janssen Research & Development, LLC (Responsible Party)",Completed,Study Details | NCT05441501 | A Study of JNJ,https://clinicaltrials.gov/study/NCT05441501?cond=Prostate%20Cancer&viewType=Card&page=19&rank=183
Prostate Cancer,"Information provided by University Hospital, Brest (Responsible Party)",Completed,Study Details | NCT06836154 | Prostate Hyperfixation on PET-choline in Patients With Prostate Cancer: Correlation With MRI and Pathological Data (LOC,https://clinicaltrials.gov/study/NCT06836154?cond=Prostate%20Cancer&viewType=Card&page=19&rank=184
Prostate Cancer,"Information provided by Andrea DeCensi, Ente Ospedaliero Ospedali Galliera (Responsible Party)",Completed,Study Details | NCT06601205 | Finasteride and Flutamide in Pre,https://clinicaltrials.gov/study/NCT06601205?cond=Prostate%20Cancer&viewType=Card&page=19&rank=185
Prostate Cancer,Information provided by Imperial College London (Responsible Party),Active,Study Details | NCT05228197 | Imperial Prostate 6,https://clinicaltrials.gov/study/NCT05228197?cond=Prostate%20Cancer&viewType=Card&page=19&rank=186
Prostate Cancer,Information provided by Pfizer (Responsible Party),Completed,Study Details | NCT06072196 | A Study to Learn About Novel Hormonal Therapies in People With Metastatic Castration,https://clinicaltrials.gov/study/NCT06072196?cond=Prostate%20Cancer&viewType=Card&page=19&rank=187
Prostate Cancer,"Information provided by University of Wisconsin, Madison (Responsible Party)",Completed,Study Details | NCT03232164 | PSMA-based 18F,https://clinicaltrials.gov/study/NCT03232164?cond=Prostate%20Cancer&viewType=Card&page=19&rank=188
Prostate Cancer,"Information provided by Linda Trinh, University of Toronto (Responsible Party)",Recruiting,Study Details | NCT05214937 | A Intervention for Reducing Sedentary Behaviour Among Prostate Cancer Survivors | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT05214937?cond=Prostate%20Cancer&viewType=Card&page=19&rank=189
Prostate Cancer,Information provided by Washington University School of Medicine (Responsible Party),Inconnu,Study Details | NCT07221825 | Low-Count Quantitative SPECT for Men Treated With Radium,https://clinicaltrials.gov/study/NCT07221825?cond=Prostate%20Cancer&viewType=Card&page=19&rank=190
Prostate Cancer,Information provided by Celgene (Responsible Party),Recruiting,Study Details | NCT04428788 | Study to Evaluate the Safety and Tolerability of CC-94676 in Participants With Metastatic Castration,https://clinicaltrials.gov/study/NCT04428788?cond=Prostate%20Cancer&viewType=Card&page=20&rank=191
Prostate Cancer,"Information provided by Janssen Research & Development, LLC (Responsible Party)",Completed,Study Details | NCT02230059 | Study to Assess the Treatment Patterns in Metastatic Castration,https://clinicaltrials.gov/study/NCT02230059?cond=Prostate%20Cancer&viewType=Card&page=20&rank=192
Prostate Cancer,"Information provided by Janssen Research & Development, LLC (Responsible Party)",Recruiting,Study Details | NCT07082920 | A Study of JNJ-78278343 in Combination With JNJ,https://clinicaltrials.gov/study/NCT07082920?cond=Prostate%20Cancer&viewType=Card&page=20&rank=193
Prostate Cancer,Information provided by Universitaire Ziekenhuizen KU Leuven (Responsible Party),Recruiting,Study Details | NCT03819751 | MRI,https://clinicaltrials.gov/study/NCT03819751?cond=Prostate%20Cancer&viewType=Card&page=20&rank=194
Prostate Cancer,"Information provided by Aalaa Wael Hussein, Assiut University (Responsible Party)",Recruiting,Study Details | NCT06209853 | Correlation Between PSA Levels and F,https://clinicaltrials.gov/study/NCT06209853?cond=Prostate%20Cancer&viewType=Card&page=20&rank=195
Prostate Cancer,Information provided by Washington University School of Medicine (Responsible Party),Recruiting,Study Details | NCT07109427 | Impact of an Electronic Health Record Maintenance Alert on PSA Screening Rates in a 10,https://clinicaltrials.gov/study/NCT07109427?cond=Prostate%20Cancer&viewType=Card&page=20&rank=196
Prostate Cancer,Information provided by Tulane University (Responsible Party),Inconnu,Study Details | NCT04854369 | 68Ga-PSMA,https://clinicaltrials.gov/study/NCT04854369?cond=Prostate%20Cancer&viewType=Card&page=20&rank=197
Prostate Cancer,Information provided by Bayer (Responsible Party),Completed,Study Details | NCT02702908 | Second Primary Cancers in Patients With Castration Resistant Prostate Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02702908?cond=Prostate%20Cancer&viewType=Card&page=20&rank=198
Prostate Cancer,"Information provided by Marijo Bilusic, M.D., National Cancer Institute (NCI) (Responsible Party)",Completed,Study Results | NCT03481816 | Treatment of Castration Resistant Prostate Cancer Using Multi,https://clinicaltrials.gov/study/NCT03481816?cond=Prostate%20Cancer&viewType=Card&page=20&rank=199&tab=results
Prostate Cancer,"Information provided by Marijo Bilusic, M.D., National Cancer Institute (NCI) (Responsible Party)",Completed,Study Details | NCT03481816 | Treatment of Castration Resistant Prostate Cancer Using Multi,https://clinicaltrials.gov/study/NCT03481816?cond=Prostate%20Cancer&viewType=Card&page=20&rank=199
Prostate Cancer,Information provided by First Affiliated Hospital Xi'an Jiaotong University (Responsible Party),Completed,Study Details | NCT05958004 | The Application Value of Prostate Specific Membrane Antigen PET/CT in Biopsy Free of PSA Grey Area Prostate Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT05958004?cond=Prostate%20Cancer&viewType=Card&page=20&rank=200
Prostate Cancer,"Information provided by Lars Boesen, Herlev Hospital (Responsible Party)",Inconnu,Study Details | NCT03648359 | Multiparametric MRI in Men With Prostate Cancer Enrolled in Active Surveillance | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03648359?cond=Prostate%20Cancer&viewType=Card&page=21&rank=201
Prostate Cancer,Information provided by Janssen Inc. (Responsible Party),Completed,Study Details | NCT02364531 | A Canadian Observational Study in Metastatic Cancer of the Prostate: A Study of ZYTIGA Use in the Community Urology Setting | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02364531?cond=Prostate%20Cancer&viewType=Card&page=21&rank=202
Prostate Cancer,"Information provided by Primo Biotechnology Co., Ltd (Responsible Party)",Recruiting,Study Details | NCT05422105 | Diagnostic Performance of 18F-PSMA,https://clinicaltrials.gov/study/NCT05422105?cond=Prostate%20Cancer&viewType=Card&page=21&rank=203
Prostate Cancer,Information provided by First Affiliated Hospital Xi'an Jiaotong University (Responsible Party),Recruiting,Study Details | NCT04521894 | The Application Value of 18F-prostate,https://clinicaltrials.gov/study/NCT04521894?cond=Prostate%20Cancer&viewType=Card&page=21&rank=204
Prostate Cancer,Information provided by Pfizer (Responsible Party),Completed,Study Results | NCT06151418 | A Study to Learn About Novel Hormonal Therapies (NHTs) for Metastatic Castration,https://clinicaltrials.gov/study/NCT06151418?cond=Prostate%20Cancer&viewType=Card&page=21&rank=205&tab=results
Prostate Cancer,Information provided by Pfizer (Responsible Party),Completed,Study Details | NCT06151418 | A Study to Learn About Novel Hormonal Therapies (NHTs) for Metastatic Castration,https://clinicaltrials.gov/study/NCT06151418?cond=Prostate%20Cancer&viewType=Card&page=21&rank=205
Prostate Cancer,Information provided by Tethis S.p.A. (Responsible Party),Active,Study Details | NCT04964271 | Identification of Prostate Cancer Specific Markers in Patients Compared to Healthy Participants | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT04964271?cond=Prostate%20Cancer&viewType=Card&page=21&rank=206
Prostate Cancer,Information provided by Radboud University Medical Center (Responsible Party),Inconnu,Study Details | NCT05373316 | Addition of a Focal Boost in External Beam Radiotherapy for Locally Advanced Prostate Cancer by Online Adaptive MR,https://clinicaltrials.gov/study/NCT05373316?cond=Prostate%20Cancer&viewType=Card&page=21&rank=207
Prostate Cancer,Information provided by AstraZeneca (Responsible Party),Withdrawn,Study Details | NCT06457854 | Real-life Experience in Brazil in Patients With Castration,https://clinicaltrials.gov/study/NCT06457854?cond=Prostate%20Cancer&viewType=Card&page=21&rank=208
Prostate Cancer,Information provided by Wonju Severance Christian Hospital (Responsible Party),Recruiting,Study Details | NCT04248621 | Androgen Deprivation Therapy on Bone Mineral Density Change in Prostate Cancer Patients | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT04248621?cond=Prostate%20Cancer&viewType=Card&page=21&rank=209
Prostate Cancer,"Information provided by Qilu Pharmaceutical Co., Ltd. (Responsible Party)",Inconnu,Study Details | NCT07104110 | Study of QLH12016 in Combination With Novel Hormonal Agent in Subjects With Advanced Prostate Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT07104110?cond=Prostate%20Cancer&viewType=Card&page=21&rank=210
Prostate Cancer,Information provided by Norwegian University of Science and Technology (Responsible Party),Completed,Study Details | NCT04298112 | PSMA,https://clinicaltrials.gov/study/NCT04298112?cond=Prostate%20Cancer&viewType=Card&page=22&rank=211
Prostate Cancer,Information provided by National Institutes of Health Clinical Center (CC) (Responsible Party),Inconnu,Study Details | NCT02759744 | Fusion Guided Focal Laser Ablation of Prostate Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02759744?cond=Prostate%20Cancer&viewType=Card&page=22&rank=212
Prostate Cancer,Information provided by Swiss Cancer Institute (Responsible Party),Active,Study Details | NCT04024475 | Prostate Cancer Biobank | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT04024475?cond=Prostate%20Cancer&viewType=Card&page=22&rank=213
Prostate Cancer,"Information provided by Rajender Kumar, Post Graduate Institute of Medical Education and Research, Chandigarh (Responsible Party)",Completed,Study Details | NCT05137561 | Robotic,https://clinicaltrials.gov/study/NCT05137561?cond=Prostate%20Cancer&viewType=Card&page=22&rank=214
Prostate Cancer,Information provided by Eli Lilly and Company (Responsible Party),Active,Study Details | NCT05999968 | Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT05999968?cond=Prostate%20Cancer&viewType=Card&page=22&rank=215
Prostate Cancer,Information provided by Royal North Shore Hospital (Responsible Party),Inconnu,Study Details | NCT06547398 | Prostate Adaptive Radiation Therapy | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT06547398?cond=Prostate%20Cancer&viewType=Card&page=22&rank=216
Prostate Cancer,"Information provided by Janssen Research & Development, LLC (Responsible Party)",Recruiting,"Study Details | NCT04898634 | A Study of JNJ-78278343, a T-Cell",https://clinicaltrials.gov/study/NCT04898634?cond=Prostate%20Cancer&viewType=Card&page=22&rank=217
Prostate Cancer,"Information provided by Ching-Hui Chien, National Taipei University of Nursing and Health Sciences (Responsible Party)",Completed,Study Details | NCT04693910 | Multimedia,https://clinicaltrials.gov/study/NCT04693910?cond=Prostate%20Cancer&viewType=Card&page=22&rank=218
Prostate Cancer,Information provided by University of Nebraska (Responsible Party),Completed,"Study Details | NCT04852224 | Strength, Aging, and Memory in Prostate Cancer | ClinicalTrials.gov",https://clinicaltrials.gov/study/NCT04852224?cond=Prostate%20Cancer&viewType=Card&page=22&rank=219
Prostate Cancer,Information provided by GAAD Medical Research Institute Inc.,Active,Study Details | NCT00573820 | Far Infrared Radiation Treatment for Prostate Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00573820?cond=Prostate%20Cancer&viewType=Card&page=22&rank=220
Prostate Cancer,"Information provided by Anna Bruynzeel, Amsterdam UMC, location VUmc (Responsible Party)",Completed,Study Details | NCT03961321 | Stereotactic MR,https://clinicaltrials.gov/study/NCT03961321?cond=Prostate%20Cancer&viewType=Card&page=23&rank=221
Prostate Cancer,Information provided by Washington University School of Medicine (Responsible Party),Active,Study Details | NCT05628363 | Adaptive Stereotactic Body Radiation Therapy to the Prostate and Pelvic Nodes With Simultaneous Integrated Boost to the MR-detected Nodule for Patients With High-risk and Unfavorable Intermediate,https://clinicaltrials.gov/study/NCT05628363?cond=Prostate%20Cancer&viewType=Card&page=23&rank=222
Prostate Cancer,"Information provided by University College, London (Responsible Party)",Recruiting,Study Details | NCT04792138 | Learning MRI and Histology Image Mappings for Cancer Diagnosis and Prognosis. | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT04792138?cond=Prostate%20Cancer&viewType=Card&page=23&rank=223
Prostate Cancer,Information provided by Bayer (Responsible Party),Completed,Study Results | NCT04736199 | Darolutamide in Addition to ADT Versus ADT in Metastatic Hormone,https://clinicaltrials.gov/study/NCT04736199?cond=Prostate%20Cancer&viewType=Card&page=23&rank=224&tab=results
Prostate Cancer,Information provided by Bayer (Responsible Party),Active,Study Details | NCT04736199 | Darolutamide in Addition to ADT Versus ADT in Metastatic Hormone,https://clinicaltrials.gov/study/NCT04736199?cond=Prostate%20Cancer&viewType=Card&page=23&rank=224
Prostate Cancer,"Information provided by Urological Research Network, LLC (Responsible Party)",Recruiting,Study Details | NCT05241236 | MRI/Ultrasound Fusion Guided Laser Ablation of Prostate Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT05241236?cond=Prostate%20Cancer&viewType=Card&page=23&rank=225
Prostate Cancer,"Information provided by Lars Boesen, Herlev Hospital (Responsible Party)",Inconnu,Study Details | NCT02526797 | Multiparametric MRI in Men With Prostate Cancer Undergoing Active Surveillance | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02526797?cond=Prostate%20Cancer&viewType=Card&page=23&rank=226
Prostate Cancer,Information provided by Universität Münster (Responsible Party),Active,Study Details | NCT04295447 | Adjuvant Apalutamide in Subjects With High,https://clinicaltrials.gov/study/NCT04295447?cond=Prostate%20Cancer&viewType=Card&page=23&rank=227
Prostate Cancer,"Information provided by Janssen Research & Development, LLC (Responsible Party)",Completed,Study Details | NCT02546908 | A Registry of Participants With Prostate Cancer in Asia | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02546908?cond=Prostate%20Cancer&viewType=Card&page=23&rank=228
Prostate Cancer,Information provided by Yonsei University (Responsible Party),Inconnu,Study Details | NCT04836949 | Verification of Shear Wave Elastography for DEtection of Prostate Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT04836949?cond=Prostate%20Cancer&viewType=Card&page=23&rank=229
Prostate Cancer,"Information provided by University Health Network, Toronto (Responsible Party)",Completed,Study Details | NCT00160979 | Transrectal Tumour Oxygen,https://clinicaltrials.gov/study/NCT00160979?cond=Prostate%20Cancer&viewType=Card&page=23&rank=230
Prostate Cancer,"Information provided by Foresee Pharmaceuticals Co., Ltd. (Responsible Party)",Completed,"Study Results | NCT03261999 | Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate (LMIS 25 mg) in Subjects With Prostate Cancer | ClinicalTrials.gov",https://clinicaltrials.gov/study/NCT03261999?cond=Prostate%20Cancer&viewType=Card&page=24&rank=231&tab=results
Prostate Cancer,"Information provided by Foresee Pharmaceuticals Co., Ltd. (Responsible Party)",Completed,"Study Details | NCT03261999 | Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate (LMIS 25 mg) in Subjects With Prostate Cancer | ClinicalTrials.gov",https://clinicaltrials.gov/study/NCT03261999?cond=Prostate%20Cancer&viewType=Card&page=24&rank=231
Prostate Cancer,"Information provided by Rahul Aggarwal, University of California, San Francisco (Responsible Party)",Completed,Study Details | NCT02391025 | Gallium,https://clinicaltrials.gov/study/NCT02391025?cond=Prostate%20Cancer&viewType=Card&page=24&rank=232
Prostate Cancer,Information provided by Montefiore Medical Center (Responsible Party),Active,Study Details | NCT03565835 | Abiraterone With Discontinuation of Gonadotropin,https://clinicaltrials.gov/study/NCT03565835?cond=Prostate%20Cancer&viewType=Card&page=24&rank=233
Prostate Cancer,"Information provided by Liu Cheng, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine (Responsible Party)",Inconnu,Study Details | NCT06707974 | Prognostic Study of Via Dynamic Change of dT,https://clinicaltrials.gov/study/NCT06707974?cond=Prostate%20Cancer&viewType=Card&page=24&rank=234
Prostate Cancer,Information provided by Seoul National University Hospital,Completed,Study Details | NCT01347476 | Aggressive Prostate Cancers in Elderly Patients | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01347476?cond=Prostate%20Cancer&viewType=Card&page=24&rank=235
Prostate Cancer,Information provided by Bayer (Responsible Party),Completed,Study Details | NCT02788409 | Incidence of Second Primary Malignancies in Castration,https://clinicaltrials.gov/study/NCT02788409?cond=Prostate%20Cancer&viewType=Card&page=24&rank=236
Prostate Cancer,Information provided by Bayer (Responsible Party),Completed,Study Details | NCT02963675 | Incidence of Second Primary Malignancies in Prostate Cancer Patients With Bone Metastases,https://clinicaltrials.gov/study/NCT02963675?cond=Prostate%20Cancer&viewType=Card&page=24&rank=237
Prostate Cancer,"Information provided by University Health Network, Toronto (Responsible Party)",Recruiting,Study Details | NCT05364229 | MR,https://clinicaltrials.gov/study/NCT05364229?cond=Prostate%20Cancer&viewType=Card&page=24&rank=238
Prostate Cancer,Information provided by Celgene (Responsible Party),Recruiting,Study Details | NCT04628988 | A Study of CC,https://clinicaltrials.gov/study/NCT04628988?cond=Prostate%20Cancer&viewType=Card&page=24&rank=239
Prostate Cancer,"Information provided by University Health Network, Toronto (Responsible Party)",Completed,Study Details | NCT00188708 | Effect of Casodex on Tumour Hypoxia,https://clinicaltrials.gov/study/NCT00188708?cond=Prostate%20Cancer&viewType=Card&page=24&rank=240
Prostate Cancer,Information provided by Novartis (Novartis Pharmaceuticals) (Responsible Party),Completed,Study Results | NCT04689828 | 177Lu-PSMA-617 vs. Androgen Receptor,https://clinicaltrials.gov/study/NCT04689828?cond=Prostate%20Cancer&viewType=Card&page=25&rank=241&tab=results
Prostate Cancer,Information provided by Novartis (Novartis Pharmaceuticals) (Responsible Party),Active,Study Details | NCT04689828 | 177Lu-PSMA-617 vs. Androgen Receptor,https://clinicaltrials.gov/study/NCT04689828?cond=Prostate%20Cancer&viewType=Card&page=25&rank=241
Prostate Cancer,"Information provided by Jun Qi, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine (Responsible Party)",Recruiting,Study Details | NCT02940977 | Establishment and Clinical Assessment of a Prostate Cancer (PCa) Risk Model Based on the Updated Circulating Tumor Cell (CTC) Detection Technique | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02940977?cond=Prostate%20Cancer&viewType=Card&page=25&rank=242
Prostate Cancer,Information provided by Bayer (Responsible Party),Completed,Study Details | NCT02363855 | Phase 1 Dose Escalation Study of BAY 1841788 in Japanese Metastatic Castration,https://clinicaltrials.gov/study/NCT02363855?cond=Prostate%20Cancer&viewType=Card&page=25&rank=243
Prostate Cancer,"Information provided by Cougar Biotechnology, Inc. (Responsible Party)",Completed,Study Details | NCT01400555 | A Safety Study of Abiraterone Acetate Administered in Combination With Docetaxel in Patients With Metastatic Castration,https://clinicaltrials.gov/study/NCT01400555?cond=Prostate%20Cancer&viewType=Card&page=25&rank=244
Prostate Cancer,"Information provided by Janssen Research & Development, LLC (Responsible Party)",Active,Study Details | NCT05022849 | A Study of JNJ-75229414 for Metastatic Castration,https://clinicaltrials.gov/study/NCT05022849?cond=Prostate%20Cancer&viewType=Card&page=25&rank=245
Prostate Cancer,"Information provided by Janssen-Ortho Inc., Canada (Responsible Party)",Completed,Study Results | NCT01424930 | A Study to Determine the Short-Term Safety of Continuous Dosing of Abiraterone Acetate and Prednisone in Modified Fasting and Fed States to Patients With Metastatic Castration,https://clinicaltrials.gov/study/NCT01424930?cond=Prostate%20Cancer&viewType=Card&page=25&rank=246&tab=results
Prostate Cancer,"Information provided by Janssen-Ortho Inc., Canada (Responsible Party)",Completed,Study Details | NCT01424930 | A Study to Determine the Short-Term Safety of Continuous Dosing of Abiraterone Acetate and Prednisone in Modified Fasting and Fed States to Patients With Metastatic Castration,https://clinicaltrials.gov/study/NCT01424930?cond=Prostate%20Cancer&viewType=Card&page=25&rank=246
Prostate Cancer,"Information provided by Yinghao Sun, Changhai Hospital (Responsible Party)",Inconnu,Study Details | NCT04126915 | Precise Therapy for mCRPC Patients Through Whole Exome Sequencing(PTtWES) | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT04126915?cond=Prostate%20Cancer&viewType=Card&page=25&rank=247
Prostate Cancer,Information provided by UNICANCER (Responsible Party),Recruiting,Study Details | NCT06276465 | Treatment With Darolutamide +/,https://clinicaltrials.gov/study/NCT06276465?cond=Prostate%20Cancer&viewType=Card&page=25&rank=248
Prostate Cancer,"Information provided by Olof Akre, Karolinska University Hospital (Responsible Party)",Recruiting,Study Details | NCT02102477 | Surgery Versus Radiotherapy for Locally Advanced Prostate Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02102477?cond=Prostate%20Cancer&viewType=Card&page=25&rank=249
Prostate Cancer,Information provided by CancerCare Manitoba (Responsible Party),Terminated,Study Details | NCT01976962 | Functional MR,https://clinicaltrials.gov/study/NCT01976962?cond=Prostate%20Cancer&viewType=Card&page=25&rank=250
Prostate Cancer,Information provided by Astellas Pharma Inc (Responsible Party),Completed,Study Details | NCT00568516 | Phase II Study of ASP3550 in Patients With Prostate Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00568516?cond=Prostate%20Cancer&viewType=Card&page=26&rank=251
Prostate Cancer,"Information provided by Baowei Fei, PhD, EngD, Emory University (Responsible Party)",Completed,Study Results | NCT02744534 | Targeted Fusion Biopsy of the Prostate | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02744534?cond=Prostate%20Cancer&viewType=Card&page=26&rank=252&tab=results
Prostate Cancer,"Information provided by Baowei Fei, PhD, EngD, Emory University (Responsible Party)",Completed,Study Details | NCT02744534 | Targeted Fusion Biopsy of the Prostate | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02744534?cond=Prostate%20Cancer&viewType=Card&page=26&rank=252
Prostate Cancer,Information provided by University of Sydney (Responsible Party),Active,Study Details | NCT02446405 | Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02446405?cond=Prostate%20Cancer&viewType=Card&page=26&rank=253
Prostate Cancer,"Information provided by Janssen Research & Development, LLC (Responsible Party)",Completed,Study Results | NCT02854436 | An Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA,https://clinicaltrials.gov/study/NCT02854436?cond=Prostate%20Cancer&viewType=Card&page=26&rank=254&tab=results
Prostate Cancer,"Information provided by Janssen Research & Development, LLC (Responsible Party)",Completed,Study Details | NCT02854436 | An Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA,https://clinicaltrials.gov/study/NCT02854436?cond=Prostate%20Cancer&viewType=Card&page=26&rank=254
Prostate Cancer,"Information provided by Songtao Xiang, Guangzhou University of Traditional Chinese Medicine (Responsible Party)",Active,Study Details | NCT03587285 | A Pilot Study of Hormonal Therapy Combined With Central Memory T Cells (Tcm) for Patients With Advanced Prostate Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03587285?cond=Prostate%20Cancer&viewType=Card&page=26&rank=255
Prostate Cancer,Information provided by Lantheus Medical Imaging (Responsible Party),Inconnu,Study Details | NCT06033001 | Expanded Access Treatment with [Lu-177]-PNT2002 for Adult Patients with Prostate-Specific Membrane Antigen (PSMA)-Positive Metastatic Castration,https://clinicaltrials.gov/study/NCT06033001?cond=Prostate%20Cancer&viewType=Card&page=26&rank=256
Prostate Cancer,"Information provided by David Thurtle, Cambridge University Hospitals NHS Foundation Trust (Responsible Party)",Inconnu,Study Details | NCT03321864 | Capture of Prostatic Trans,https://clinicaltrials.gov/study/NCT03321864?cond=Prostate%20Cancer&viewType=Card&page=26&rank=257
Prostate Cancer,Non spécifié,Inconnu,Study Details | NCT04093375 | | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT04093375?cond=Prostate%20Cancer&viewType=Card&page=26&rank=258
Prostate Cancer,Information provided by Swiss Cancer Institute (Responsible Party),Completed,Study Details | NCT02640534 | Investigation of Metformin in Patients With Castration Resistant Prostate Cancer in Combination With Enzalutamide vs. Enzalutamide Alone | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02640534?cond=Prostate%20Cancer&viewType=Card&page=26&rank=259
Prostate Cancer,Non spécifié,Inconnu,Study Details | NCT03424850 | | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03424850?cond=Prostate%20Cancer&viewType=Card&page=26&rank=260
Prostate Cancer,Non spécifié,Inconnu,Study Details | NCT02869594 | | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02869594?cond=Prostate%20Cancer&viewType=Card&page=27&rank=261
Prostate Cancer,Non spécifié,Inconnu,Study Details | NCT02531516 | | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02531516?cond=Prostate%20Cancer&viewType=Card&page=27&rank=262
Prostate Cancer,Information provided by City of Hope Medical Center (Responsible Party),Recruiting,"Study Details | NCT07202247 | Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT",https://clinicaltrials.gov/study/NCT07202247?cond=Prostate%20Cancer&viewType=Card&page=27&rank=263
Prostate Cancer,Information provided by Clarity Pharmaceuticals Ltd (Responsible Party),Completed,Study Details | NCT04839367 | Positron Emission Tomography (PET) Imaging of Participants With Confirmed Prostate Cancer Using 64Cu-SAR,https://clinicaltrials.gov/study/NCT04839367?cond=Prostate%20Cancer&viewType=Card&page=27&rank=264
Prostate Cancer,Information provided by Medical University of Graz (Responsible Party),Active,Study Details | NCT03677414 | Analysis of Androgene Receptors Axis and DNA Damage Repair Genes in Patients With Prostate Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03677414?cond=Prostate%20Cancer&viewType=Card&page=27&rank=265
Prostate Cancer,Information provided by Centre Hospitalier Universitaire de Saint Etienne (Responsible Party),Withdrawn,Study Details | NCT02260349 | Interest of Indocyanine Green in Neoplastic Prostatic Tissue | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02260349?cond=Prostate%20Cancer&viewType=Card&page=27&rank=266
Prostate Cancer,"Information provided by University Hospital, Lille (Responsible Party)",Recruiting,Study Details | NCT03421015 | Genetic Analysis of Prostate Cancer to Identify Predictive Markers of Disease Relapse or Metastatic Evolution | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03421015?cond=Prostate%20Cancer&viewType=Card&page=27&rank=267
Prostate Cancer,Information provided by Copenhagen University Hospital at Herlev (Responsible Party),Completed,Study Details | NCT01640262 | Evaluation of Modern MRI in the Diagnosis of Prostate Cancer in a Danish Setup | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01640262?cond=Prostate%20Cancer&viewType=Card&page=27&rank=268
Prostate Cancer,"Information provided by Aragon Pharmaceuticals, Inc. (Responsible Party)",Completed,Study Results | NCT01946204 | A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration,https://clinicaltrials.gov/study/NCT01946204?cond=Prostate%20Cancer&viewType=Card&page=27&rank=269&tab=results
Prostate Cancer,"Information provided by Aragon Pharmaceuticals, Inc. (Responsible Party)",Active,Study Details | NCT01946204 | A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration,https://clinicaltrials.gov/study/NCT01946204?cond=Prostate%20Cancer&viewType=Card&page=27&rank=269
Prostate Cancer,Information provided by Janssen Inc. (Responsible Party),Completed,Study Details | NCT03501173 | A Study of Participants With Advanced Prostate Cancer in Canada | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03501173?cond=Prostate%20Cancer&viewType=Card&page=27&rank=270
Prostate Cancer,Information provided by Ottawa Hospital Research Institute (Responsible Party),Recruiting,Study Details | NCT05851547 | Dose Escalation For INtraprostatic LEsions | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT05851547?cond=Prostate%20Cancer&viewType=Card&page=28&rank=271
Prostate Cancer,"Information provided by University of Wisconsin, Madison (Responsible Party)",Inconnu,Study Details | NCT06675357 | Using FAPI PET/MRI to Evaluate Prostate Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT06675357?cond=Prostate%20Cancer&viewType=Card&page=28&rank=272
Prostate Cancer,"Information provided by Matthew Dallos, Columbia University (Responsible Party)",Active,Study Details | NCT03824275 | 18F,https://clinicaltrials.gov/study/NCT03824275?cond=Prostate%20Cancer&viewType=Card&page=28&rank=273
Prostate Cancer,Information provided by National Institutes of Health Clinical Center (CC) (National Cancer Institute (NCI)) (Responsible Party),Recruiting,Study Details | NCT03805919 | Men at High Genetic Risk for Prostate Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03805919?cond=Prostate%20Cancer&viewType=Card&page=28&rank=274
Prostate Cancer,Information provided by The Netherlands Cancer Institute (Responsible Party),Terminated,Study Details | NCT03066154 | Oral Docetaxel (ModraDoc/r) in Combination With Hormonal Treatment and Radiation Therapy in High,https://clinicaltrials.gov/study/NCT03066154?cond=Prostate%20Cancer&viewType=Card&page=28&rank=275
Prostate Cancer,Information provided by Novartis (Novartis Pharmaceuticals) (Responsible Party),Completed,Study Details | NCT00035113 | EPO906 Therapy in Patients With Prostate Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT00035113?cond=Prostate%20Cancer&viewType=Card&page=28&rank=276
Prostate Cancer,"Information provided by Janssen Research & Development, LLC (Responsible Party)",Active,Study Details | NCT04577833 | A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT04577833?cond=Prostate%20Cancer&viewType=Card&page=28&rank=277
Prostate Cancer,"Information provided by Robert J Amato, The University of Texas Health Science Center, Houston (Responsible Party)",Completed,Study Results | NCT02560051 | Hormone Therapy Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02560051?cond=Prostate%20Cancer&viewType=Card&page=28&rank=278&tab=results
Prostate Cancer,"Information provided by Robert J Amato, The University of Texas Health Science Center, Houston (Responsible Party)",Terminated,Study Details | NCT02560051 | Hormone Therapy Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02560051?cond=Prostate%20Cancer&viewType=Card&page=28&rank=278
Prostate Cancer,Information provided by Institut Mutualiste Montsouris (Responsible Party),Inconnu,Study Details | NCT03533998 | Biomarkers in Prostate Cancer Treated With SRP Following Failure of FAT | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT03533998?cond=Prostate%20Cancer&viewType=Card&page=28&rank=279
Prostate Cancer,"Information provided by Ofer Gofrit, Hadassah Medical Organization (Responsible Party)",Inconnu,Study Details | NCT02631616 | Treatment With Sandostatin in Patients With Castrate Resistance Prostate Cancer Showing Uptake of 68Ga,https://clinicaltrials.gov/study/NCT02631616?cond=Prostate%20Cancer&viewType=Card&page=28&rank=280
Prostate Cancer,Information provided by AstraZeneca (Responsible Party),Completed,Study Details | NCT04425200 | Prevalence of HRR,https://clinicaltrials.gov/study/NCT04425200?cond=Prostate%20Cancer&viewType=Card&page=29&rank=281
Prostate Cancer,"Information provided by Teemu Murtola, Tampere University Hospital (Responsible Party)",Completed,Study Details | NCT01821404 | Atorvastatin Before Prostatectomy and Prostate Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01821404?cond=Prostate%20Cancer&viewType=Card&page=29&rank=282
Prostate Cancer,"Information provided by Lawrence Fong, University of California, San Francisco (Responsible Party)",Completed,Study Results | NCT02506114 | Neoadjuvant PROSTVAC,https://clinicaltrials.gov/study/NCT02506114?cond=Prostate%20Cancer&viewType=Card&page=29&rank=283&tab=results
Prostate Cancer,"Information provided by Lawrence Fong, University of California, San Francisco (Responsible Party)",Terminated,Study Details | NCT02506114 | Neoadjuvant PROSTVAC,https://clinicaltrials.gov/study/NCT02506114?cond=Prostate%20Cancer&viewType=Card&page=29&rank=283
Prostate Cancer,"Information provided by Dr. Patrick Cheung, Sunnybrook Health Sciences Centre (Responsible Party)",Active,Study Details | NCT02563691 | Stereotactic Radiotherapy for Oligometastatic Prostate Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02563691?cond=Prostate%20Cancer&viewType=Card&page=29&rank=284
Prostate Cancer,Information provided by Janssen Pharmaceutical K.K. (Responsible Party),Completed,Study Details | NCT04034095 | A Registry Study to Observe Clinical Outcomes of Participants With High-risk Metastatic Hormone,https://clinicaltrials.gov/study/NCT04034095?cond=Prostate%20Cancer&viewType=Card&page=29&rank=285
Prostate Cancer,"Information provided by Janssen Research & Development, LLC (Responsible Party)",Completed,Study Results | NCT04108208 | A Study of Apalutamide in Chinese Participants With Non Metastatic Castration Resistant Prostate Cancer (NM,https://clinicaltrials.gov/study/NCT04108208?cond=Prostate%20Cancer&viewType=Card&page=29&rank=286&tab=results
Prostate Cancer,"Information provided by Janssen Research & Development, LLC (Responsible Party)",Active,Study Details | NCT04108208 | A Study of Apalutamide in Chinese Participants With Non Metastatic Castration Resistant Prostate Cancer (NM,https://clinicaltrials.gov/study/NCT04108208?cond=Prostate%20Cancer&viewType=Card&page=29&rank=286
Prostate Cancer,Information provided by University of Sydney (Responsible Party),Active,"Study Details | NCT02446444 | Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer | ClinicalTrials.gov",https://clinicaltrials.gov/study/NCT02446444?cond=Prostate%20Cancer&viewType=Card&page=29&rank=287
Prostate Cancer,"Information provided by Inge Marie Svane, Herlev Hospital (Responsible Party)",Completed,Study Results | NCT01446731 | Dendritic Cell Vaccination and Docetaxel for Patients With Prostate Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01446731?cond=Prostate%20Cancer&viewType=Card&page=29&rank=288&tab=results
Prostate Cancer,"Information provided by Inge Marie Svane, Herlev Hospital (Responsible Party)",Completed,Study Details | NCT01446731 | Dendritic Cell Vaccination and Docetaxel for Patients With Prostate Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01446731?cond=Prostate%20Cancer&viewType=Card&page=29&rank=288
Prostate Cancer,"Information provided by Janssen Research & Development, LLC (Responsible Party)",Completed,"Study Results | NCT02217566 | Study of Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC), Chemo",https://clinicaltrials.gov/study/NCT02217566?cond=Prostate%20Cancer&viewType=Card&page=29&rank=289&tab=results
Prostate Cancer,"Information provided by Janssen Research & Development, LLC (Responsible Party)",Completed,"Study Details | NCT02217566 | Study of Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC), Chemo",https://clinicaltrials.gov/study/NCT02217566?cond=Prostate%20Cancer&viewType=Card&page=29&rank=289
Prostate Cancer,Information provided by Centre Antoine Lacassagne (Responsible Party),Completed,Study Details | NCT01796028 | Metformin-Docetaxel Association in Metastatic Hormone,https://clinicaltrials.gov/study/NCT01796028?cond=Prostate%20Cancer&viewType=Card&page=29&rank=290
Prostate Cancer,Information provided by Australian and New Zealand Urogenital and Prostate Cancer Trials Group (Responsible Party),Terminated,Study Details | NCT04918810 | Biomarker-driven Intermittent Docetaxel in Metastatic Castration,https://clinicaltrials.gov/study/NCT04918810?cond=Prostate%20Cancer&viewType=Card&page=30&rank=291
Prostate Cancer,"Information provided by Yueqing Tang, Qilu Hospital of Shandong University (Responsible Party)",Recruiting,"Study Details | NCT04699344 | A Prospective, Single-centre，Single",https://clinicaltrials.gov/study/NCT04699344?cond=Prostate%20Cancer&viewType=Card&page=30&rank=292
Prostate Cancer,"Information provided by Foresee Pharmaceuticals Co., Ltd. (Responsible Party)",Completed,"Study Results | NCT02234115 | Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate in Subjects With Advanced Prostate Carcinoma | ClinicalTrials.gov",https://clinicaltrials.gov/study/NCT02234115?cond=Prostate%20Cancer&viewType=Card&page=30&rank=293&tab=results
Prostate Cancer,"Information provided by Foresee Pharmaceuticals Co., Ltd. (Responsible Party)",Completed,"Study Details | NCT02234115 | Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate in Subjects With Advanced Prostate Carcinoma | ClinicalTrials.gov",https://clinicaltrials.gov/study/NCT02234115?cond=Prostate%20Cancer&viewType=Card&page=30&rank=293
Prostate Cancer,"Information provided by Janssen Pharmaceutica N.V., Belgium (Responsible Party)",Active,Study Details | NCT04557059 | A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone,https://clinicaltrials.gov/study/NCT04557059?cond=Prostate%20Cancer&viewType=Card&page=30&rank=294
Prostate Cancer,Information provided by Bayer (Responsible Party),Completed,Study Details | NCT01618370 | Radium(223) Dichloride (Alpharadin) in Castration-Resistant (Hormone,https://clinicaltrials.gov/study/NCT01618370?cond=Prostate%20Cancer&viewType=Card&page=30&rank=295
Prostate Cancer,Information provided by Bayer (Responsible Party),Inconnu,Study Details | NCT01516762 | Radium-223 Dichloride (BAY88-8223) in Castration-Resistant (Hormone,https://clinicaltrials.gov/study/NCT01516762?cond=Prostate%20Cancer&viewType=Card&page=30&rank=296
Prostate Cancer,"Information provided by Aragon Pharmaceuticals, Inc. (Responsible Party)",Inconnu,Study Details | NCT03523338 | An Expanded Access Protocol for Apalutamide Treatment of Participants With Non-Metastatic Castration,https://clinicaltrials.gov/study/NCT03523338?cond=Prostate%20Cancer&viewType=Card&page=30&rank=297
Prostate Cancer,"Information provided by Peter Gann, University of Illinois at Chicago (Responsible Party)",Completed,Study Details | NCT02668276 | Engaging Newly Diagnosed Men About Cancer Treatment Options | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT02668276?cond=Prostate%20Cancer&viewType=Card&page=30&rank=298
Prostate Cancer,Information provided by Bastyr University (Responsible Party),Withdrawn,Study Details | NCT01685489 | A Phase 1b Dose Escalation Trial of PSK®/Placebo With Docetaxel to Treat Metastatic Castration,https://clinicaltrials.gov/study/NCT01685489?cond=Prostate%20Cancer&viewType=Card&page=30&rank=299
Prostate Cancer,Information provided by Astellas Pharma Inc (Responsible Party),Completed,Study Results | NCT01288911 | A Study of Enzalutamide Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01288911?cond=Prostate%20Cancer&viewType=Card&page=30&rank=300&tab=results
Prostate Cancer,Information provided by Astellas Pharma Inc (Responsible Party),Completed,Study Details | NCT01288911 | A Study of Enzalutamide Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer | ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01288911?cond=Prostate%20Cancer&viewType=Card&page=30&rank=300
